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The best APC for tumour immunotherapy is yet to be defined. The dendritic cell (DC) 
is well established as the key professional antigen-presenting cell (APC) for priming 
naïve T cells against tumours and for this reason it is the APC of choice in adoptive 
cell therapy (ACT) for cancer. However, robust clinical results with DC ACT remain 
disappointing and researchers are beginning to investigate the utility of alternative 
APCs, particularly B cells. DCs have been used as vaccines clinically to present 
tumour antigens in the form of tumour cell lysates, also with limited success. Tumour 
cell lysates represent an attractive source of tumour-associated antigens (TAAs) for 
cancer immunotherapy as their defined and undefined TAAs have the potential for 
simultaneous activation of CD4+ and CD8+ cytotoxic T lymphocytes (CTLs). 
Although their self-antigenic nature requires overcoming of inherent tolerance 
mechanisms as well as caution with regards to induction of autoimmunity. 
 
METHODS 
In this study the ability of three professional APCs, DCs, macrophages (MΦs) and B 
cells, to stimulate an anti-tumour T cell response against tumour lysate (TL) antigens 
was compared. The activation profile and IL-12 response of the APCs to soluble 
freeze-thaw lysate (s-L) and oxidized whole freeze-thaw lysate (ox-L) was examined. 
Also investigated was the lysate-loaded APCs’ ability to induce T cell proliferation 
and effector functions, whether individually or in combination. 
 
RESULTS 
The three APCs displayed differing responses to the two TLs indicative of differing T 
cell activation capacities.  
MHC-II and CD40 were upregulated on DCs in response to s-L and ox-L while 
MHC-II and CD86 were upregulated on B cells in response to s-L and ox-L. A 
synergistic increase in IL-12 production was observed in the lysate-loaded DC+B cell 
groups. No proliferation response was observed in lysate-primed CD4+ T cells. 
However, significant increases in CD8+ T cell proliferation were observed when T 
cells were primed with combinations of s-L-loaded APCs compared to a DC alone. 
The greatest proliferation was observed when CD8+ T cells were primed by the ox-L-
loaded DC+B cell combination. The greatest IFN-γ levels were also observed in 
CD8+ T cells primed with lysate-loaded DC+B cells. The greatest in vivo cytotoxicity 
was achieved by ox-L-primed CD8+ T cells activated by the DC+B cell combination. 
 
SIGNIFICANCE 
Both DCs and B cells are currently being investigated as APCs in adoptive cell 
therapy for cancer. This study demonstrates that combining DCs and B cells yields an 
improved CD8+ T cell response in a pre-clinical model of melanoma. Given that, in 
vivo, DCs do not present TAA in isolation, these results suggest that a single APC 
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“Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the 
most effective treatment for patients with metastatic melanoma and can mediate objective cancer 
regression in approximately 50% of patients”  
Rosenberg et al, 20081 
1.1 Melanoma in the New Zealand Context 
New Zealand’s incidence of melanoma is the highest in the world2. With early 
diagnosis and surgical removal, melanoma has a 50% cure rate and an 80-100% 5-
year survival expectation3. However, in cases of advanced melanoma, the 5-year life 
expectancy drops to 10% with most patients surviving 6-8.5 months4. Advanced 
melanoma is refractory to chemotherapy treatment5,6, but owing to a lack of suitable 
alternatives, treatment with Dacarbazine (DTIC) remains the ‘gold standard’7, in spite 
of DTIC  receiving ‘placebo’ results in recent clinical trials and having a very low 
overall response (OR) and overall survival (OS) rates. Combinations of different 
chemotherapeutic agents are no more effective than DTIC8, but currently alternative 
options are limited.  
1.2 Current Cancer Therapies 
From the 1950s until very recently the standard treatments for cancer fell broadly into 
the three categories of surgery, chemotherapy and radiation therapy. In the context of 
melanoma, surgical excision of the primary tumour is the first treatment. Lymph node 
mapping, sentinel node biopsies, and sometimes lymph node removal depending on 
the level of lymph node involvement, follow excision of the primary. 
 
Metastatic melanoma is treated with regional lymph node therapy, which, if 
unsuccessful is followed up with chemotherapy with drugs such as Dacarbazine. The 
outlook for Stage IV melanoma patients is poor with a 6 – 9 month median survival 
and a 5-year survival of 5 – 10% depending on various prognostic factors, serum 
LDH levels, sites and number of metastases9. DTIC treatment results in short duration 
response rates of 5 – 20%, with only 5% complete responses9. Combination 
chemotherapies in metastatic melanoma do not increase survival. Radiotherapy only 
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improves local symptoms and is not curative9. There is a real need for therapeutics 
that can complement current approaches and target metastases not removed by 
surgery, drugs or radiation. 
 
Recent advances in our understanding have identified that, rather than simple 
elimination of rapidly dividing cells, one of the reasons for the success of 
chemotherapy and radiotherapy is their capacity to generate non-targeted innate and 
adaptive immune activation via immunologic tumour cell death and disruption of 
immune suppression and tolerance (reviewed in10,11). Immunoadjuvant pathways, such 
as the binding of high mobility group box protein 1 (HMGB1) to TLR4, or 
translocation of calreticulin to the cell surface, can be triggered by chemotherapeutic 
tumour cell death12–14. Cyclophosphamide has been observed to lift immune 
suppression by selectively depleting regulatory T cells (TREGs)15, while a comparative 
study identified the immune-enhancing role of DNA-damaging alkylating 
chemotherapeutic agents and the reduced immunostimulatory capacity of cytarabine, 
an inhibitor of DNA polymerase16. Radiotherapy’s success in cancer eradication can 
also be attributed to its induction of immunogenic forms of cell death and destruction 
of immune barriers, which results in increased immune cell infiltration, increased 
tumour associated antigen (TAA) presentation and T cell activation17–21. Thus, in 
addition to their roles as debulking and cytotoxic agents, certain chemotherapies as 
well as radiotherapy, are increasingly viewed as potentially useful primers or adjuncts 
for immunotherapy for cancer10,22.  
 
The immune-stimulating features of chemotherapy and radiotherapy23,24 have been 
documented (reviewed in10,11,17,25–27) Chemotherapy and radiotherapy can essentially 
create a form of tumour lysate in situ, exposing the entire range of tumour-associated 
elements to the attentions of the immune system. However, chemotherapy and 
radiotherapy are non-specific treatments, resulting in side effects that bring about 
significant patient suffering. A more targeted approach that minimises collateral 
damage to healthy tissue is required.  
 
The advent of new immunotherapies for cancer has introduced treatments that are able 
to fulfill these criteria to varying degrees. Checkpoint blockade inhibitors such as 
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monoclonal antibodies (mABs) against the T cell inhibiting molecules CTLA-4 and 
PD-1 are enhancing survival rates, and in many cases the suffering experienced by 
patients is greatly reduced compared to standard treatments28. Several of these 
immune modulators have been approved for the treatment of different cancers, usually 
in combination, and often in conjunction with standard therapies17,29,30. The use of 
chimeric antigen receptor (CAR) T cells with hybrid monoclonal antibody (mAB) T 
cell receptors (TCRs) has also entered the clinic as important tools for the treatment of 
certain lymphocyte malignancies and will be discussed further under Immunotherapy 
for Cancer. 
 
The introduction of these new treatments has only been possible due to advances in 
understanding of how the immune system responds to malignant cells and how 
tumour cells modulate the immune response. It is now well understood that cancer is a 
highly heterogeneous disease (31, reviewed in32), of varying and complex etiology. The 
cancer of each patient is likely to be unique to the point that the possibility of a 
generic ‘one size fits all’ approach to treatment is highly improbable11. Given that 
cancer is a highly individual disease an individualised approach to treatment is 
required. Thus any cancer therapy must address the cancer threat in a manner that is 
responsive to the uniqueness of the cancer in each patient. 
1.3 Antigen Presenting Cells: Initiating the Adaptive Immune Response to 
Tumours 
Antigen presenting cells (APC) stand at the interface between innate and adaptive 
immunity, directing key decision-making processes in the immune response 
repertoire, from tolerance of self-antigens, to rejection of anything foreign or 
dangerous.  They guide the response to a wide range of threats including infectious 
organisms, potential allergens, autoimmunity, graft rejection and cancer. 
 
Major Histocompatibility Complex (MHC) is also called the human leukocyte antigen 
(HLA) in humans. HLA complexes A, B and C correspond to MHC Class I and are 
the molecules used for endogenous peptide presentation. HLA DR, DP and DQ are 
MHC Class II. Cells with antigen-presentation capacity process exogenous antigen 
into peptides and load them into MHC Class II molecules for presentation to CD4+ T 
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cells. APCs possessing cross-priming ability can also present exogenous antigen on 
Class I molecules to CD8+ T cells.  All nucleated cells express MHC Class I (MHC-
I), therefore MHC-I-expressing tumours can also be targeted directly by antigen-
specific class I-restricted CD8+ T cells33–35.  
 
A  paper by the Restifo group reporting on adoptive cell therapy (ACT) for melanoma 
demonstrates the crucial role of APCs36 in the anti-tumour response. Beta2 
microglobulin (β2m) is a component of the MHC class I molecule on the surface of 
cells. In order to assess whether the MHC-I+ tumours or APCs were providing the 
antigen source to T cells, β2m-/- and β2m WT chimeric mice were generated and the 
effect of adoptively transferred early effector  T cells observed. In the mice with 
ineffective MHC-I on the surface of the tumour cells the effect of ACT was ablated, 
showing that APC antigen presentation was necessary for the anti-tumour response.  
 
Three cell types, dendritic cells (DCs), macrophages (MΦs) and B cells, are known as 
professional APCs. DCs are the foremost APC and they have been utilised in most 
APC-mediated immune-based cancer therapies. However the success of these 
treatments has been limited. Therefore this thesis has examined whether or not 
combining the three professional APCs can augment the presentation of lysate tumour 
antigens to T cells.  
1.3.1 Antigen Acquisition  
Endocytosis is the general term for intake of material from the extracellular 
environment. Endocytotic mechanisms fall into the broad categories of phagocytosis 
(‘cell eating’, or the acquisition of larger particles) and pinocytosis (‘cell drinking’, 
which refers to uptake of liquid and solutes). Phagocytosis occurs in phagocytes, 
while virtually all cells conduct some form of pinocytosis37. Pinocytosis is further 
subdivided into at least four mechanisms, including macropinocytosis, clathrin-
dependent endocytosis, caveolae-dependent endocytosis and clathrin- and caveolae-
independent endocytosis. These mechanisms have been extensively reviewed38. 
 
Immature DCs efficiently endocytose material via receptor-mediated endocytosis and 
non-specific phagocytosis and macropinocytosis39. Apoptotic cells, soluble proteins, 
bacterial or viral particles can all be taken up by non-specific sampling of the 
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environment, or triggered by engagement of specific receptors. Many receptors have 
been described that specifically mediate antigen endocytosis, including Fc receptors, 
heat shock protein receptors, scavenger receptors and C-type lectin receptors. These 
receptors internalize antigen into endosomes where their outcome varies according to 
the receptor involved40. DCs excel at receptor-mediated endocytosis, whereas MΦ 
appear to be superior at phagocytosis149.  
 
DCs, MΦs38 and B cells all take in particles and macromolecules via phagocytosis, 
pinocytosis and receptor-dependent endocytosis. MΦs, like DC, express a variety of 
phagocytic receptors rendering them highly efficient at clearance of pathogens, and 
infected or stressed cells. These include the mannose receptor, C-type lectin receptors, 
NOD-like receptors, scavenger receptors, retinoic-acid-inducible gene 1 (RIG1)-like 
helicase receptors (RLRs) and toll-like receptors (TLRs)41,42.  
 
TLRs on MΦs recognise the extracellular presence of molecules normally 
encountered intracellularly, such as ATP43, high-mobility box group box 1 protein 
(HMGB1)44, which increases their phagocytic clearance of necrotic cell debris. 
Complement receptors42,45 and Fc receptors, which bind complement- and Ig-
opsonised antigens respectively, are also avidly phagocytosed by MΦs42, while 
phosphatidyl serine on the cell surface triggers MΦs to engulf apoptotic cells46.  
 
The common misconception that mature DCs downregulate all forms of antigen 
uptake has been clarified recently. While macropinocytosis is briefly 
upregulated47.and then downregulated following inflammatory signaling48, mature 
DCs retain the capacity to form clathrin-coated vesicles48, and clathrin-dependent 
acquisition of viral antigen49 and immune complexes50 demonstrating that inward 
transport of surface molecules continues51. Platt and colleagues also demonstrated that 
Fcγ-receptor and DEC-205-mediated endocytic internalization continued, as did 
phagocytosis, in the face of abrogated macropinocytosis51.  
 
1.3.2 Antigen Processing  
Loading of exogenous peptides onto MHC-II molecules is the result of degradation of 
acquired exogenous proteins by proteolytic and other enzymatic processes. 
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Extracellular antigen is taken up into endocytic vesicles that fuse with lysosomes to 
form endolysosomes or phagolysosomes. Protein degradation into peptides occurs 
inside the phagolysosome. 
 
MHC-II molecules are formed in the endoplasmic reticulum (ER), and complexes 
with the invariant chain (CD74) in the Golgi. CD74 assists trafficking of the MHC-II 
molecule to the endolysosomal path, resulting in cathepsin-mediated degradation of 
CD74 that leaves only the peptide-binding portion of CD74 (the CLIP peptide) 
attached to MHC-II. Fusion of the phagolysosome with the MHC-II-vesicle results in 
CLIP being replaced with an antigenic peptide with the assistance of the chaperone 
HLA-DM40,52. Finally the vesicle containing peptide-loaded MHC-II traffics to the 
plasma membrane for presentation to CD4+ T cells. 
 
MHC Class I is expressed on all nucleated cells, allowing the presentation of 
intracellular antigens to CD8+ T cells. Six steps leading to presentation on Class I 
have been well-characterised. One: antigen acquisition; 2: ubiquitin-tagging of 
peptides for destruction; 3: proteolytic degradation; 4: peptide delivery to the ER; 5: 
peptide-loading into MHC-I molecules; and 6: traffic of the MHC-I-peptide complex 
to the cell surface40,53. During normal homeostatic processes intracellular proteins 
destined for destruction are tagged with ubiquitin molecules, which targets them for 
break down into short peptide sequences inside the barrel-shaped proteasome54. 
 
Like the MHC-II chains, MHC-I heavy chains are also synthesized in the ER. 
Peptides translocated from the cytosol into the ER lumen via Transport Associated 
with Antigen Processing (TAP)-mediated transport bind to MHC-I in the ER during 
assemblage of the heavy chain β2m dimer (reviewed in53). TAP connects with tapasin 
and calreticulin to form the Peptide Loading Complex (PLC), which, in conjunction 
with other molecules, chaperones and edits the loading of peptides onto MHC-I, 
stabilizing the MHC-I-β2m complex53. Competition for high affinity binding occurs, 
and only stable MHC-I-peptide complexes traffic to the surface for presentation to 
CD8+ T cells. 
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1.3.3 Cross-presentation 
DC have the capacity to present exogenous antigen on MHC class I molecules, a 
process termed cross-presentation, enabling them to activate CD8+ T cells with 
exogenous antigen that has accessed the MHC Class I pathway. One of the key 
challenges in cancer therapy design is orchestrating the delivery of exogenous tumour 
antigen into the DC cross-presentation machinery.  
 
Cross-presentation allows exogenous antigens to cross from the MHC Class II 
presentation pathway in to the MHC-I pathway for presentation to CD8+ T cells 
(Figure 1). Our current understanding of cross-presentation mechanisms comes 
primarily from in vitro experiments that have demonstrated diverse means of antigen 
transfer from tumours to DCs to for Class I presentation. These include antigens from 
dead (apoptotic or necrotic) tumour cells; soluble antigens; scavenger-receptor-
mediated uptake of chaperone-bound soluble antigens; uptake of tumour-derived 
exosomes; gap junction transfer of peptides; and “nibbling” of plasma membranes of 
live tumour cells by DCs (reviewed in26).  
 
CD8+ DCs are recognised as superior to CD8- DCs at cross-presentation55, and are 
also the superior DCs in the anti-tumour response56. Cross-presentation is 
constitutively active in CD8+ DCs due to their low degradation endosomes which 
have been shown to be responsible for the increased cross-presentation efficiency 
compared to CD8- DCs57. In addition CD8+ DCs possess phagosome to cytosol 
transport that permits antigen entry to the cytosol, which enables loading onto MHC-
I58,59, and other mechanisms that foster antigen entry to the cytosol have also been 
described59,60. 
 
While the majority of researchers argue that cross-presentation of tumour antigens is 
the “only important natural mode of presentation”26,61–64 the question has been asked 
whether or not the importance of physiological cross-presentation may have been 
overstated65. Zinkernagel argues that the importance of cross-presentation has been 
overemphasized. He views cross-presentation as an experimental artefact of in vitro 
experiments, which use higher than physiologically-achievable amounts of antigen, 
and of in vivo experiments using artificially high numbers of antigen-specific T cells 
in TCR transgenic mice65,66. An alternative view to cross-priming suggests that any 
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“antigen-expressing cell”, including tumour cells, that arrive at peripheral lymphatic 
organs can induce effector T cells65,67,68. These views are supported by studies 
demonstrating both TAP-dependent and TAP-independent mechanisms of cross-
presentation69–73. 
  
 Figure 1 Molecular Pathways Leading to Cross-Presentation in DCs. DCs take up Ag by three general 
mechanisms, receptor-mediated endocytosis, phagocytosis, or macropinocytosis. Once the Ag reaches the 
endolysosomal pathway, depending of the specific routing, it may be degraded by the concourse of the mild pH and 
different types of cathepsins and other proteases. At this point, properly degraded Ag can be directly loaded into 
recycling MHC-I in the phagosome (Vacuolar pathway). Ag that still needs further processing must be transported to 
the cytosol (Cytosolic pathway) where it is degraded, together with endogenous proteins and DRiPs, by the 
proteasome. The peptides generated by the proteasome are transported by TAP or a yet uncharacterized transporter 
into the ER where they are loaded into MHC-I with the help of the peptide-loading complex. Further trimming in the 
ER prior to loading, it is possible by the presence of ER-localized endopeptidases (ERAP1 and 2). R, ribosome; CNX, 
calnexin; CRT, calreticulin; b2m, b2microglobulin; UGT1, UDP-glucose:glycoprotein glucosyltransferase 1; 
ERAP1/2, ER-aminopeptidases 1/2; PLC, peptide-loading complex; ERp57, protein disulfide isomerase 3; TAP1/2, 
transporter associated with antigen-presenting 1/2; DRiPs, defective ribosomal products; ROS, reactive oxygen 
species; NOX2, NADPH oxidase 2; CLR, C-type lectins; FcR, Fc receptors; SR, scavenger receptors. Understanding 
the biology of antigen cross-presentation for the design of vaccines against cancer, Fehres et al, Frontiers in 
Immunology, 2014. Reprint permitted under the terms of the Creative Commons Attribution License (CC BY). 
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In vivo cross-presentation of tumour antigens is much less understood and relies on 
work with model antigens outside the cancer field. Studies in autoimmune diabetes, 
for example, demonstrated that while high OVA expression resulted in cross-
presentation, low OVA expression resulted in a lack of cross-presentation74, pointing 
to the amount of antigen as being important45. Furthermore the maturation state of the 
cross-presenting DC is also critical. DC maturation during stimulation of a primary 
immune response includes upregulation of MHC and costimulatory molecules, and 
migration of the DCs to secondary lymphoid organs. In the lymph nodes interactions 
with naïve T cell clones results in T cell activation and clonal expansion. The 
maturation status of the DC determines the outcome of cross-presentation with 
activated DCs activating strong CTL responses26,64,75 and immature DCs stimulating 
tolerance76. In the absence of DC activation the cross-presentation of OVA as a model 
self-antigen in autoimmune diabetes resulted in deletion of OVA-specific (self-
reactive) CD8+ T cells77.  
 
While pathogens induce strong DC activation, cancer cells are likely to lead to weaker 
DC activation, in spite of the presence of tumour associated inflammation and danger 
signals78. The PRR pentraxin 3 has been shown to suppress CD8+ T cell activation 
initiated by DCs cross-presenting TAAs, but not pathogenic antigens79 and the amount 
of apoptosis occurring in growing tumours has been described as too low to generate 
sufficient uric acid or hsp-bound tumour antigens to effectively prime DCs26. This 
may explain the immature, tolerising DCs associated with many cancers. 
1.3.4 Cross dressing 
Cross-dressing differs from cross-presentation in that peptide-MHC-I (p-MHC-I) 
complexes acquired from dead cells are attached to the outside of the DC and have 
not been generated via uptake and processing mechanisms80. Cross-dressed DCs can 
activate CD8+ T cells in the absence of antigen processing80 and can drive anti-viral 
effector and memory T cell activation in vivo81,82. In the context of tumour lysate that 
consisting of dead cell components this may be an important mode of CD8+ T cell 
priming. 
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1.3.5 Antigen Presentation  
The final step in the antigen uptake and presentation process is the cell-cell contact 
between APCs and T cells, in which the T cell receptor (TCR) complex recognises 
peptide bound to MHC on the DC surface. This forms “Signal 1”, which initiates the 
process that determines whether or not the T cell will react to or ignore the antigen 
being presented. “Signal 2” comprises co-stimulation by molecules on the surface of 
the antigen-presenting cell, initially CD28 on the T cell binding to CD80 and CD86 
on the APC. CD4+ T cells “license” DCs to present antigen to CD8+ T cells, and this 
licensing is dependent in part on further costimulation in the form of CD40-CD40L 
and 4-1BB-4-1BBL interactions, which stimulate upregulation of “Signal 3” 
cytokines, such as IL-12, by APCs83–85. Successful interactions between APCs and T 
cells form an immunological synapse, or supramolecule activation cluster (SMAC)86 
the initiation event in T cell proliferation. The T cell response to presentation is 
discussed under “T Cells”.  
1.4 Dendritic Cells  
In humans, dendritic cells (DCs) are the best known and most potent of the antigen 
presenting cells87,88.  Immature DC (iDC), widely, but sparsely, dispersed throughout 
the tissues and in circulation, are highly phagocytic, constantly sampling the 
environment by taking up and processing antigen. The ability to generate large 
numbers of DCs from bone marrow and blood89–91 greatly facilitated the study of DCs 
and they have been well established as the most proficient presenters of antigen69,89–92.  
 
Immature DC (iDC) can be differentiated in vitro into mature DC (mDC) by exposure 
to stimuli such as bacterial lipopolysaccharide (LPS), interleukin 1 (IL-1), 
polyinosinic polycytidylic acid, CD40L or tumour necrosing factor alpha (TNF-
alpha)93,94 . DCs are well equipped with receptors that recognise both pathogen-
associated molecular patterns (PAMPs) and damage-associated molecular patterns 
(DAMPs)95,96. Their receptor repertoire includes TLRs, RLRs, nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs) and receptor for advanced 
glycation end products (RAGE) receptors for recognition of a wide range of 
pathogenic and danger-associated molecules. When iDC encounter an appropriate 
stimulus, such as pathogenic antigens, they undergo a maturation process during 
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which cell surface markers such as CD40, CD80, CD86 and migration markers such 
as CCR7 are up-regulated, along with IL-12 production. The immunostimulatory or 
immunoregulatory outcome of antigen presentation by DC depends on the maturation 
state of the DC presenting the antigen, and that state is mediated by inflammatory 
signals that accompany antigen acquisition and processing. Thus the maturation status 
of the TAA-presenting DC is critical due to its role in directing the immune response 
stimulated, and ensuring that DCs presenting undefined tumour antigens are properly 
activated is one of the goals of tumour immunotherapy. 
 
Maturation enables the DC to migrate efficiently to the site of antigen presentation 
(most commonly the lymph node or spleen) and proficiently activate cognate naïve 
CD4+ and CD8+ T cells via presentation of antigenic peptide on MHC class II and 
class I molecules respectively97–99. In this regard DCs are key initiators of the innate 
immune response.  They also regulate the T cell response, polarizing the T cell 
response into a Type 1 or Type 2 helper T cell response. This polarization may be 
mediated by distinct DC subsets100. The differentiation of CD4+ T cells into T helper 
1 and T helper 2 cells is discussed under CD4+ T cell differentiation. 
 
1.4.1 Peripheral Myeloid DC 
There are several populations of DCs. In mice, myeloid or conventional DC (cDC) are 
found in both peripheral and lymphoid tissue and are broadly grouped into CD11bHI 
and CD11bLO cells. CD11b+CD11c+ antigen-presenting Langerhans cells (LC) are 
found in the external, epidermal layer of the skin and their primary role may be one of 
immunoregulation in the skin101. In the next layer down, the dermis, CD11c+ dermal 
DC (dDC) are distinguished from LC by their expression of CD103102,103. Only the 
CD11bLO dDC subset demonstrate cross-presentation104. In the pulmonary setting 
CD11b-CD103+ DCs migrate with lung-derived antigen to the LNs to initiate antigen 
responses and are able to cross-present antigen105, but their presence is also required in 
the lung for the maintenance of CD8+ T cell function106. CD11b+ lung DC on the 
other hand primarily present to CD4+ T cells on MHC-II and foster antibody 
production112. 
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1.4.2 Lymph Tissue DC 
Two subpopulations of DC are encountered in murine lymph tissue: those DCs such 
as mature LC that migrate into lymph tissue from the periphery, and the permanent 
residents. Whereas peripheral DC are discriminated by their CD11b expression, in 
lymph tissue they are grouped by CD4 and CD8α expression (reviewed in 107). Four 
subpopulations are found in the spleen on their basis of CD4, CD8, CD11b and 
DEC205 expression107. These populations are also found in the LNs along with two 
more groups that are CD8LODEC205INT, and CD8LODEC205HI108. CD8+ and CD8- DC 
can both present antigens but the CD8+ DCs are the primary subset that cross-present 
antigen to CD8+ T cells75,109–112. Two exceptions appear to be the migratory 
CD8+langerin-CX3CR1 plasmacytoid DC-related subgroup that are unable to cross-
present113 and migratory CD103+ lung and dermal DC, which cross-present antigens 
in the LNs104,114.  
 
Each of these DC subsets possess varying antigen presentation capabilities. CD8+ DC 
efficiently cross-present antigen to CD8+ T cells55 while marginal zone CD8- DC 
preferentially present on Class II to CD4+ T cells115115, for example the presentation of 
Sacchromyces cerivisiae antigen116. However it is the CD8+ DCs with cross-
presenting capacity that are the target in DC-mediated immunotherapies. In the clinic 
the focus is on harnessing the human equivalents of murine peripheral CD103+ and 
lymph-resident CD8+ DCs for their CTL-stimulating capacity. 
1.4.3 Plasmacytoid (pDC) 
CD11cLOB220HI pDC are best-known for their Type I IFN-α response in viral 
infections (reviewed in117). TLR ligation by viruses upregulates pDCs powerful, 
TRAIL-mediated cytotoxic functions and cross-presentation machinery118. The role of 
pDC in cancer has generally shown an association with poorer outcomes119,120 
however work with the adjuvant CpG has shown that this TLR9 agonist can be 
harnessed to activate anti-tumour immunity in these cells121. 
1.4.4 Human DCs 
The divisions of pDC and cDC exist in murine and human systems, though human 
DC do not express CD8α. In humans the Type I IFN anti-viral function of pDC is 
conserved122, as are the tolerogenic functions of epidermal LC123. However the easy 
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categorisations end there with correspondences between mouse and human peripheral 
and lymph-resident DC less well defined. Blood-derived human cDC are normally 
identified as CD11cHIMHC-IIHI lineage marker negative cells. This group is further 
partitioned into 3 sub-populations: CD1c+, CD16+ or CD141+124. 
 
CD11c+CD141+ were recently defined as the equivalent of murine CD8α+ cross-
presenting cells125,126, with further characterization adding XCR1127 and Clec9A 
(DNGR-1)128,129 to their surface markers. However some differences still exist 
between CD141+ human DC and murine CD8α+ DC. The latter express TLR4 and 
TLR9 whereas CD141+ huDC do not. CD1c+ DCs express all TLR except TLR9, 
whereas CD141+ DCs diplay a restricted TLR configuration with high expression of 
TLR3 and TLR10, some expression of TLRs 1,2, 6 and 8, and absence of TLRs 4, 5, 
7 and 9130. All activated huDC subsets can produce IL-12 and cross-present antigen124, 
whereas in mice only the CD8+ DC have demonstrated superior IL-12 and cross-
presentation capacity131. However the current consensus is that the CD141+ huDC 
compartment possess potent CTL activating capacities and are the appropriate target 
for immunotherapies. 
1.5 Macrophages  
Metchnikoff identified and named these cells ‘Big Eaters’ due to their high 
phagocytic capacity132, but they are much more than mere scavengers or garbage 
disposal cells. MΦ activities are numerous due to the various roles they play in 
different tissues. They possess a full complement of pattern recognition receptors133 to 
defend against threats including infection, toxins, ischaemia, tissue trauma and sterile 
wounds. They carry out tissue remodeling and remove dead or dying cells and cell 
components. They can be cytotoxic in their own right and secrete an extensive range 
of cytokines, growth factors, coagulation factors, lysozymes, proteases, complement 
components and prostaglandins134.  They are found in high numbers at sites of 
infection, trauma or inflammation and, like DC, they are able to present antigen and 
express co-stimulatory molecules. However it has been suggested that the panoply of 
MΦ functions can be summarised under four headings denoted with the acronym 



















Tissue-resident MΦs are yolk-sac derived, tissue-based, and primarily self-regenerate 
in situ, except in cases of inflammation136. Myeloid-derived MΦs are generated in the 
bone marrow as immature monocytes and migrate to the periphery where they 
differentiate into lymph and non-lymph, tissue-resident MΦs.  In vivo MΦs, and 
certain DC subsets, can be replenished from circulating monocytes under both steady 
state and inflammatory conditions137.  
 
Tissue-specific MΦs include liver-resident Kupfer cells138, longer-lived alveolar 
MΦs139, and shorter-lived interstitial MΦs in the lung, bone-resorptive osteoclasts140, 
migroglia in the brain141, histiocytes of connective tissue, gastrointestinal, splenic, 
lymph node and peritoneal MΦs142,143 . At least four types of MΦ have been identified 
in the mouse spleen based on their location and combinations of surface markers: red 
pulp MΦs (F4/80++CD11b+), marginal zone MΦs (CD209b+F4/80-), marginal zone 
metalophilic MΦs (CD169+F4/80-) and monocyte-derived MΦs (F4/80+CD11b+)144. 
CD169+CD11c+ subcapsular MΦs in the lymph nodes are positioned to sample 
afferent lymph flow and capture dead tumour cell antigens that accumulate in the 
subcapsular and paracortical sinuses. Meanwhile lymph node medullary MΦs cluster 
around lymphatic endothelium145. In the peritoneal cavity large 
 Figure 2 Macrophages have four basic SHIP functions [sample, heal, inhibit and present 
(antigen] that allow them to recognize pathogens or injury, and respond directly (or indirectly by 
presenting antigens) to engender responses that provide optimal host protection. From Ref. (1) 
with permission from S. Karger AG, Basel. Anatomy of a Discovery: M1 and M2 Macrophages, 
Charles Dudley Mills, Front Immunol. 2015; 6: 212. Published online 2015 May. doi:  
10.3389/fimmu.2015.00212 PMCID: PMC4419847. Reproduction permitted with acknowledgement. 
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F4/80++CD11b+MHC-II- MΦs and small F4/80+CD11b+MHC-II+ MΦs have been 
described146. Thus MΦs with a variety of surface markers have been described among 
peripheral and lymph tissues. 
 
In cancer, and in other fields147 there has been a tendency to broadly vilify MΦs as 
pro-tumourigenic and their role in tumour development was seen as inherently 
negative. Over the years this view merged to a more ambiguous position however the 
consensus is now one of distinct MΦ subsets (just like DCs), which may be pro- or 
anti-tumourigenic in nature depending on polarization. The three broad subsets are 
classically activated M1 inflammatory MΦ; the alternatively activated 
immunosuppressive or tolerising M2 MΦ, and the more recently described regulatory 
MΦs148. In addition another subpopulation of immature myeloid cells known as 
myeloid derived suppressor cells (MDSCs) comprise innately suppressive monocyte- 
or granulocyte-derived cells whose role in tumour suppression has been extensively 
reviewed149,150. MDSCs directly impact on the progression of tumours by promoting 
angiogenesis, inhibiting T cell activation and proliferation, disrupting T cell homing 
to LNs and intratumoural CTL penetration. Their cytokine profile also promotes 
expansion of naturally occurring TREGs and the differentiation of inducible TREGs 
(reviewed in149). The tumour-promoting nature of MDSCs has brought them to the 
attention of investigators as therapeutic targets in cancer treatment150. 
1.5.1 M1 Versus M2 Macrophages 
MΦs are broadly polarized as M1 or M2151–153 with the former having a pro-
inflammatory phenotype and the latter having an anti-inflammatory, healing 
phenotype (Figure 3). The M1/M2 concept stems from the ability of MΦs to use a 
single amino acid, arginine, to conduct polar-opposite functions (Figure 4).  
Conversion of arginine to growth-stimulating ornithine and growth-regulating nitric 
oxid (NO) is achieved by the same cell, via nitric oxide synthase or arginase 
conversion of this substrate153–158. The combination of IFN-y with a TLR agonist 
provides canonical induction of MΦ activation159,160 and induces enhanced antigen 
presentation via exchange of three proteasome subunits228,229161,162. IFN-γ produced by 
TH1 activation downregulates M2 activity, while TH2- or tumour-induced IL-4 
ameliorates M1 actions. 
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Culture of bone-marrow precursor cells with granulocyte-macrophage-colony 
stimulating factor (GM-CSF) and interleukin-3 (IL-3) induces differentiation of M1-
type MΦs with a CD11cLOW-INTIL-12HIIL-23HIIL-10LO phenotype151. Culture of the 
same precursors with macrophage-colony stimulating factor (M-CSF) generates anti-
inflammatory M2-type MΦs (IL-12 LOIL-23 LOIL-10HI)152.  
 
The M1/M2 paradigm is a debated area with many saying this concept oversimplifies 
the immunological context of stimuli source, and the fact that polarising stimuli exist 
together in tissues163. Opponents of the M1/M2 concept contend that simplified 
representations of macrophage active states can’t account for the degree of 
heterogeneity observed in vivo. Although distinct macrophage subsets with unique 
functional abilities have been described, it is generally believed that macrophages 
represent a spectrum of activated phenotypes rather than discrete stable 
subpopulations143. They adopt context-dependent phenotypes that either promote or 
inhibit host antimicrobial defence, antitumour immune responses and inflammatory 
responses. 
 
However it has also been argued that the classification of MΦs into numerous 
subpopulations41 on the basis of surface markers, many of which are observed in vitro 
and not in vivo, is an over complication, which clouds the fact that MΦs possess two 
prime activities. They ‘inhibit’ the progress of pathogens, and cancer, and cause tissue 
damage, (M1-type). And they ‘heal’, repair and maintain tissue integrity and promote 
cell proliferation (M2-type)153. While acknowledging the on-going debate, for the 







 Figure 3 The M1/M2 paradigm, origin, and molecular basis (A) 4 years after Mills proposed the M1/M2 
macrophage model Mantovani and colleagues published this M1-M2 macrophage model, in which M1 included 
interferon-gamma (IFN-γ) + lipopolysaccharide (LPS) or tumour necrosis factor (TNF) and M2 was subdivided 
to accommodate similarities and differences between interleukin-4 (IL-4) (M2a), immune complex + Toll-like 
receptor (TLR) ligands (M2b), and IL-10 and glucocorticoids (M2c). Diagram reproduced with the permission of 
Elsevier. (B) The signaling behind the effects of M1 and M2 stimuli in macrophages has gained clarity in recent 
years. Here, we highlight receptors and key signaling mediators in common and distinct pathways, explained in 
the text. The diagram includes granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage 
colony-stimulating factor (M-CSF) as M1 and M2 stimuli. From: The M1 and M2 paradigm of macrophage 
activation: time for reassessment, Fernando O. Martinez and Siamon Gordon. Permission to reprint in thesis 
granted by Martinez, email correspondance 5.11.15 All F1000Prime Reports articles are distributed under the 
terms of the Creative Commons Attribution-Non Commercial License, which permits non-commercial use, 













Although murine M1- and M2-polarized macrophage subsets are relatively easy to 
distinguish on the basis of combinatorial gene expression profiles, the identification of 
equivalent subsets in humans has been less clear. Much progress has been made in 
unraveling MΦ and DC subsets with the use of lineage-specific genes41,59,164–166 which 
may lead to more refined use of surface markers in future. However currently the 
issue remains complex, particularly for the neophyte to MΦ DC research. 
1.5.2 Antigen processing by Macrophages 
MΦ antigen processing follows the same trafficking patterns described under Antigen 
Processing (1.3.2), with transfer of ingested items transitioning from early through 
late endosomes and lysosomes, or early phagosomes through to phagolysosomes167. 
One key difference between DCs and MΦs lies in the increased degradative potential 
of the MΦ processing pathway. While DCs have both degradative and non-
degradative machinery168,169MΦs have higher lysosomal protease activity and degrade 
internalized antigen more rapidly compared to DC and B cells169,170.  
1.5.3 Antigen Presentation By Macrophages 
The phagocytic ability of MΦs, combined with their antigen presentation capacity, 
allows them to link innate with adaptive immunity. MΦs bearing internalized antigen 
have been shown to stimulate T cell microtubule organizing centres and repositioning 
of F-actin cytoskeletal fragments to the point of contact with the MΦ42. When loaded 
with the same dose of antigen (1 μM) MΦs bearing phagocytized antigen formed 
productive immune synapses with T cells with greater efficiency than peptide-loaded 
 Figure 4 Macrophages have both iNOS and arginase enzymes that can convert arginine to NO or 
ornithine, respectively. Products of each reaction inhibit the opposing reaction, promoting preferential 
NO or ornithine production. Anatomy of a Discovery: M1 and M2 Macrophages, Charles Dudley Mills, 
Front Immunol. 2015; 6: 212. Published online 2015 May. doi:  10.3389/fimmu.2015.00212 PMCID: 
PMC4419847. Reproduction permitted with acknowledgement. 
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MΦs42. These data suggest that lysate antigen-loaded MΦs may have the potential to 
stimulate effective T cell responses from lysate antigens.  
 
However another study found that uptake of apoptotic cells by MΦs did not result in 
presentation to T cells171. Inhibition of MΦ antigen presentation was the result of 
apoptotic DNA binding to MHC-II, which led to TGF-β production, and which also 
inhibited antigen presentation by DCs in the immediate vicinity. Freeze-thaw lysate is 
usually described as generating necrotic-type cell death172–174, however some have 
argued that freeze-thaw lysis does not mimic in vivo necrotic death175, therefore we 
were interested to see whether or not MΦs loaded with TAAs generated from freeze-
thaw-generated lysate could activate T cells. 
 
The consensus appears to be that MΦs are excellent scavenger cells in many 
situations but that while they possess antigen presenting ability167, and can even 
generate T cell epitopes248, their T cell stimulation capacity is limited176–179. 
Nevertheless some researchers have shown in both humans and mice, in vivo, that 
MΦs and DCs can have equal effects on T cell activation180,181. These data 
demonstrate the ability for MΦ function to be modulated, such as has been shown in 
other models in which IFN-γ and TNF-α have been shown to overcome the effects of 
suppressive molecules such as prostaglandin E2182. 
1.5.4 Cross-presentation By Macrophages 
Their steady-state role as regulators of inflammatory-mediated tissue damage means 
that unactivated MΦs do not produce meaningful quantities of inflammatory factors. 
This changes upon exposure to activation stimuli such as LPS binding to TLR4, 
which activates the MyD88 signal path, triggering Type 1 interferons and leads to the 
production of various pro-inflammatory cytokines152. In addition to cytokines, the 
uptake of necrotic or apoptotic cell components exerts differential activation 
programming on MΦs, with phagocytosis of apoptotic cells leading to a non-
inflammatory, non-immunogenic response and phagocytosis of necrotic cells resulting 
in tumour cell cytotoxicity183, the release of inflammatory cytokines and upregulation 
of costimulatory molecules179,184,185. 
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Just as the value of MΦs in the tumour environment is debated so too is the value of 
using MΦs to generate anti-cancer T cell responses. Nonetheless the ability of MΦs 
to present tumour antigen and prime naïve CD8+ T cells has been 
demonstrated42,180,181. Efficient MΦ cross-presentation of OVA has been demonstrated 
in murine models177, and the ability of human MΦs to cross-present naturally 
occurring TAAs taken from apoptotic or necrotic cells has also been investigated 180. 
 
Dead cells from the periphery are one source of tumour antigen26 but prior to 2011 
little was known about the role of APCs in the clearance of dead cells and the 
presentation of dead cell-associated antigens in peripheral tissues or LNs. A study by 
Asano et al suggests that apoptotic cells in the periphery are cleared and processed 
differently from blood-borne apoptotic cells in the spleen. Dead cells accumulate in 
the sinuses of draining LNs where resident CD169+ MΦs phagocytose and cross-
present dead cell-associated antigens to CD8+ T cells177. Mice that were depleted of 
CD169+ MΦs failed to cross-prime CD8+ T cells, demonstrating that these MΦs 
played a key role in the induction of antitumour immunity via cross-presentation of 
dead tumour cell antigens. Asano’s work showed that migratory DCs were not 
primarily involved in delivery and cross-presentation of dead cell antigens. CD169+ 
MΦs residing in the LN sinus took up dead tumour cells and cross-presented this 
source of TAAs to CTLs. By contrast, CD8α+CD103+ DCs phagocytosing dead cell 
antigen entering the spleen via blood flow after i.v. injection induced a tolerogenic 
response after cross-presenting these antigens.  
 
Continuing with the CD169+ MΦ theme, Bernhard et al showed in 2015 that these 
APCs were able to prime CTLs against epitopes that cross-priming DCs had failed to 
present178. Using adenoviral vectors that do not infect DCs but accumulate specifically 
in CD169+ MΦs, they demonstrated that, in the absence of DCs, CD169+ MΦs were 
able to prime CTLs against all epitopes tested. When DCs alone were used to prime 
CTLs the only epitopes selected were strong-binding MHC-I peptides, demonstrating 
that DCs prime CTLs against a more restricted repertoire. These two studies were 
important since they question the absolute necessity of DC-mediated cross-
presentation and highlighted the role of particular MΦ subsets in T cell priming, 
which can generate CTLs with broader repertoires. These may be precisely the kinds 
 21 
of APCs that are ideal for use in ACT for cancer to minimise the possibility of escape 
variants due to the failure of DCs to prime T cells against the full range of the 
patient’s TAAs. 
1.6 A Comment On Dendritic Cell and Macrophage Generation and 
Classification 
Arising as they do from common myeloid precursors, MΦs and DCs inevitably share 
surface marker expression. It has been a common practice to distinguish solely DCs 
on the basis of CD11c expression, or the combination of CD11c and MHC-II 
expression. However, as described in the following section, most if not all MΦs also 
express CD11c, to differing degrees, just like DCs, and this has led to obfuscated 
experimental conclusions. In a similar manner F4/80 has been over-utilised as a single 
MΦ marker when certain DC populations express F4/80186 and some MΦ subsets lack 
F4/80 expression (for example marginal zone and white pulp MΦs in the spleen, and 
subcapsular sinus and cortical MΦs in the LNs145). Therefore it has been noted that 
identifying APCs on the basis of their cell surface markers merely identifies 
mononuclear phagocytes with the functional characteristics of DCs or MΦs, which 
may stimulate naïve T cells to the same degree41,186. 
 
Adding to the confusion are more recent acknowledgements in the literature that the 
ubiquitous differentiation of murine bone-marrow precursors in GM-CSF results in a 
heterogeneous population of MΦs, DCs and other granulocytes187,188. This has led to 
some passionate debate in the literature about what constitutes a ‘real DC’189,190. Due 
to their complexity and heterogeneity classifying MΦ on the basis of gene expression 
profiles and surface markers has been described as “genuinely futile and misleading” 
(D Hume, personal correspondence). Jenkins and Hume argue that MΦs and DCs 
arise from separate lineages and are distinct functional entities. Moreover, they take 
the position that the name DC should be applied to cells arising from Flt3+ pre-DCs, 
and that a monocyte-derived cell is a MΦ irrespective of its ability to conduct antigen 
presentation191. Hume, Summers and Rehli divide bone marrow-derived cells in to 
monocyte-derived MΦs (if cultured in CSF1); monocytes (if cultured in GM-CSF, +/-
IL-4); and DCs (if cultured in Flt-3 ligand)192. Thus according to that argument this 
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thesis has not compared MΦs and DCs but rather two different populations of 
antigen-presenting MΦs. 
1.7 B cells  
The B cell is the third, and least-recognised, member of the professional APC 
triumvirate. Anyone with a rudimentary knowledge of B cell biology may be 
surprised by the selection of B cells as an APC for comparison with DCs given the 
DCs’ reputation of superior antigen presentation. Naïve B lymphocytes are, as a rule, 
thought to be inadequate APCs and there is incomplete understanding of their role in 
activation of CD8+ T cells. However B cells, which recognise native protein antigen 
as well as peptide fragments, take up protein antigen comparably to176, or better than 
DCs193 and since this study is looking at protein-packed tumour lysate it was 
important to compare B cell ability to present tumour lysate antigen.  
 
B cells are best known for their antibody-production role but early studies failed to 
identify their antigen-presenting capabilities and this aspect of their biology has been 
underappreciated. This led to the misunderstanding, which persists today, that 
antibody production is their primary immune function. However, under the right 
conditions B cells efficiently present, and even cross-present, antigen to CD4+ and 
CD8+ T cells respectively. In this way cytokine-secreting, antigen-presenting B cells 
actively direct and regulate immune responses. 
 
B cells arise from lymphoid progenitors known as haematopoietic stem cells in the 
bone-marrow and undergo a transitional maturation and functional rearrangement of 
immunoglobulin (Ig) loci194 before exiting to the periphery as mature, naïve, IgM-
expressing B cells. Activation occurs in secondary lymphoid tissue when antigen-
induced somatic hypermutation, or “class switching”, genetic rearrangement that 
leads to production of antibodies with the same specificity but of a different class195, 
results in IgM and IgD-expressing B cells196. The classes IgA, IgE and IgG can also 
arise from class switching, depending on the immune response required. B cell VJD 
gene rearrangements and somatic hypermutation that result in the generation of single 
specificity B cell receptors (BCRs) have been extensively reviewed and will not be 
discussed in this thesis (reviewed in197,198).  
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In secondary lymphoid organs hubs of proliferating B cells, known as germinal 
centres, develop along the interface of the T cell zone in B cell-populated regions 
called follicles. It is here that B cells differentiate into high affinity, antibody- 
secreting plasma cells and memory B cells of the primary humoral response. B cells 
are broadly categorized as being either B-1 or B-2199, or as B-1, B-2 and marginal 
zone B cells (MZB)200. B-1 and MZB cells are described as innate-like B cells with 
regulatory functions (BREGs) including secretion of IgM and IL10200. They recognise 
self-antigen and produce immunoglobulins (Ig) in response to repetitive epitope 
patterns associated with specific pathogens199. The germline-encoded, semi-invariant 
BCRs of innate-like B cells recognise a limited range of epitopes. They provide a link 
between rapid immune responses and the more protracted T cell-dependent adaptive 
response with their prompt T cell-independent production of low affinity 
antibodies200–202. MZB can undergo rapid, short-lived T-independent responses to 
antigenic stimuli, for example in response to the TLR4 ligand, LPS203,204. 
 
Resident B cells of the secondary lymphoid organs that mediate adaptive immunity 
include the B-2 follicular B cells (fB cell), which make up the majority of the LN- and 
spleen-resident B cells, and the less populous marginal zone (MZ) B cells. Blood flow 
into the spleen brings blood borne antigens and T cells into contact with MZB, as well 
as MZMΦs and metalophilic MZMΦs, facilitating the initiation of T cell-dependent 
and independent immune responses205. Lymph flow into the LNs is an alternative 
source of circulating lymphocytes, as well as tissue-derived antigens and cellular 
debris. Cancer cells also flow in via afferent lymphatics, allowing for potential 
recognition by immune cells, but also mediating metastasis206.  
 
Both fB cells and MZ B cells can undertake Ig class switching and transition into 
memory cells199. B2 cells generate immune responses against T cell-dependent 
antigens and require T cell help to undergo germinal centre formation that results in 
the production of high-affinity antibodies200.  
 
The observation that B cell-deficient mice display aberrant secondary lymphoid 
structure led to understanding of the importance of B cells in both development as 
well as maintenance of these tissue structures and their associated cell 
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populations205,207. Thus, in addition to antibody production B cells are key players in 
immune development, maintenance, antigen presentation and regulation of T-
dependent and T-independent immune responses. Their presence has been shown to 
be a positive prognostic factor in colorectal cancer208, while in a melanoma model 
their absence results in loss of tumour control209. In addition to antibody-dependent 
cell-mediated cytotoxicity (ADCC), the fact that B cells can kill tumour cells directly 
via antibody-independent mechanisms has also been under-recognised. Activated B 
cells express a variety of the death receptor ligands including Fas-L, tumour necrosis 
factor-related apoptosis-inducing ligand (TRAIL), as well as the granzyme 
system(reviewed in210,211). Li has shown that tumour-primed CD40-activated B cells 
can mediate primary and metastatic tumour regression in a model of ACT212,213. 
1.7.1 Antigen Acquisition by B cells 
Like DCs and MΦs, B cells also utilise phagocytosis, pinocytosis and possess 
numerous receptors for conducting receptor-mediated endocytosis. They include the B 
cell receptor (BCR), as well as Fc receptors, heat shock protein receptors, scavenger 
receptors and C-type lectin receptors.  
 
The BCR comprises surface-bound immunoglobulin heavy (IgH) Ig light (IgL) chains 
complexed with the Igα and Igβ signaling chains214. Antigen cross-linking is the first 
step in breaking quiescence in a B cell215. It activates signaling through the 
immunoreceptor tyrosine-based activation motifs (ITAMs) on the BCR, which leads 
to the B cell to progress from G0 to G1 phase, making the B cell ‘competent’. Antigen 
binding to the BCR triggers endocytosis and an activation-inducing signal cascade216. 
Interaction with T cell ligands and cytokines is the second signal that pushes the B 
cell from G1 to S phase217. The BCR has specificity, and high affinity, for a single 
antigen, which allows concentration and efficient presentation of small amounts of 
antigen218,219. The high affinity nature of BCR-peptide binding also means that 
processing of antigen sequences that have interacted with the BCR is limited, leading 
to enhanced presentation of particular epitopes219–221.  
 
Different subpopulations of B cells express distinct TLR profiles222, allowing B cells 
to recognise various PAMPs and DAMPs. The combination of BCR signaling and 
TLR ligation facilitates their cytokine production, induces upregulation of surface 
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molecules and enhances their presentation of antigen (reviewed in223). The binding of 
CpG to TLR9 is particularly relevant to this thesis due to our use of CpG as an 
immune stimulant. IL-12p70 production by human B cells has been reported to only 
occur in the presence of both TLR9 ligation and CD40 signaling, and interestingly 
this occurred in the absence of BCR cross-linking224. The carbohydrate-binding C-
type lectin DEC205 is a surface receptor specific for CpG Class B, though not for the 
CpG motif that binds to intracellular TLR9225. DEC205 facilitates CpG uptake by B 
cells and DCs, and transport to the internally located TLR9225. The CpG TLR9 
interaction is strongly mitogenic and induces costimulatory molecule upregulation in 
B cells, along with increased levels of the Fcγ receptor226–228. Human B cells 
upregulate expression of not only CD80 and CD86 but also CD40 and CD54 in 
response to CpG229. Certain CpG motifs (CpG-A) are especially potent at activating 
NK cells and inducing IFN-alpha production by pDCs, while other motifs (CpG-B) 
are especially potent B cell activators227,230, inducing production of TH1-like 
proinflammatory cytokines, interferons, and chemokines231. In mature peripheral B 
cells, low concentrations of CpG DNA binding to TLR9 strongly synergize with 
signals through the BCR, leading to an approximate tenfold increase in B cell 
proliferation and antigen-specific Ig secretion and IL-6 secretion228. While CpG is a 
known immune stimulant tumour lysate also contains other unspecified immune-
stimulating DAMPs, such as heat shock proteins and intracellular components that 
alert immune cells when encountered in the extracellular setting. These will contribute 
to APC activation in ways that were not specifically measured in this study. 
 
Cross-linking of antigen on the BCR triggers internalisation219,232 and rapid 
reorganisation of antigen presentation vesicles233. The BCR-antigen complex enters 
the endocytic trafficking pathway to commence peptide-MHC-II loading in MHC-II-
rich compartments234–237. B cell processing machinery is coupled to BCR-mediated 
antigen recognition in a manner that mediates its preferential presentation over that of 
non-specifically pinocytosed material219,234. This feature results in T cell presentation 




Finally, expression of the non-classical MHC-II molecule HLA-DO (H-20 in mice) 
distinguishes B cells from other APCs240. Another non-classical MHC-II molecule 
HLA-DM mediates peptide-MHC-II loading in all APC. HLA-DM operates in acidic 
lysosomes whereas HLA-DO is active in the more basic pH of the endosomes. It is 
postulated that HLA-DO inhibition of HLA-DM at higher pH also serves to favour 
presentation of BCR-antigenic material, and to limit B cell-mediated autoimmunity 
induced by presentation of pinocytosed self antigen241. 
 
T cell-independent (TI) antigens do not require contact with TH cells in order to 
activate the B-lymphocytes. TI-1 antigens, such as bacterial lipopolysaccharides are 
polyclonal activators of B cells. They are capable of non-specific activation of B cells 
at high concentrations and stimulating both transitional and naïve B cells. TI-2 
antigens require cytokines secreted by T helper cells for their activation, but not direct 
contact with them. Bacterial polysaccharides can also be TI-2 antigens as can 
polymeric bacterial flagellin, which have repeating antigenic determinants. The 
response to a TI antigen is weak, usually produces only IgM and a poor recall 
response (reviewed in217). 
 
With T-dependent antigens interactions between B cells and TH cells cause maturation 
of primary follicles into secondary follicles. Germinal centres arise from secondary 
follicles and it is in these germinal centres that B cells go through massive 
proliferation217. During proliferation genetic mutations in the variable region of the Ig 
gene sees the formation of B cells with low, medium and high affinity for the antigen 
that was encountered by the originating cell. These cells migrate to areas of high 
follicular DC (fDC) density where those with high-affinity BCRs will bind antigen-
antibody complexes on fDCs, receiving survival signals from fDC and TH cells. Thus 
T cell-dependent antigen recognition by the BCR also initiates differentiation into 
antibody-secreting plasmocytes and initiation of germinal centre (GC) formation for 
high affinity antibody production. However the presentation of antigen to CD4+ T 
cells is required for GC formation to proceed (reviewed in242). For the purposes of this 
thesis we will focus on the B cells’ antigen presentation role, rather than antibody 
production. 
 27 
1.7.2 Antigen Presentation by B Cells 
Despite B cell antigen presentation being less widely known, the ability of B cells to 
activate antigen specific T cells has been recognised by immunologists since the early 
1980s243–248. While resting B cells are poor at antigen presentation238,249–251 , or induce T 
cell tolerance252, properly activated B cells upregulate expression of MHC-II and 
costimulatory molecules253 after BCR cross-linking with antigen254, and consequently 
act as effective APCs249. In a similar manner to DCs and MΦs antigen-stimulated B 
cells activated under certain circumstances also play regulatory roles inducing 
tolerance and TREGs255.  
 
The ability of B cells, MΦs and DC to stimulate Class-II-restricted T cell responses in 
vivo was compared in an early study employing a mouse chimera model256. That work 
appeared to demonstrate that antigen presenting B cells were not involved in T cell 
priming but could reactivate previously primed T cells. Those data suggested that in 
an immune response DCs first present antigen to naive T cells, and only afterwards 
can primed T cells be activated by antigen presented by B cells. However it was 
shown shortly thereafter that naïve CD4+ T cells can be primed in vivo by activated B 
cells193,219,257–259, though this concept was initially not fully understood and remained 
controversial for some time. 
 
B cells encounter both their specific antigen and T cells specific for that same antigen 
in the spleen and LNs219. The epitopes on the same antigen recognized by the T and B 
cells are very different217. After antigen encounter B cells participate early in T cell 
priming. Following chemokine gradients, they traffic toward T cell zones where 
antigen-specific B cell-CD4+ T cell interactions occur soon after the entrance of 
antigen into the lymph tissue204,219,260–262. 
 
Expression of CD86, one of the two CD28 ligands, is induced following cross-linking 
of the BCR257,263 thus the Signal 1 and Signal 2 criteria for inducing CD40L 
expression on T cells are met by B cells encountering antigen. Rodríguez-Pinto 
demonstrated that during activation B cells can induce CD40L expression on T cells 
enabling full CD4+ T cell activation219. CD40-CD40L interactions play a vital role in 
T cell priming264. CD40 signals also effect multiple functions in B cells including 
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sustaining activation, enhancing antigen processing264, increasing MHC-II 
upregulation, inducing CD80 expression and sustaining CD86 on the cell surface219,265–
268. Inhibition of CD40L-CD40 signaling with mABs or genetic deletion abolishes B 
cell antigen presentation or renders the B cells tolerogenic261,269–272.  
 
In addition to T-independent functions, MZB have been shown to have increased T 
cell presentation and activation capacity by virtue of greater MHC-II, CD80 and 
CD86 expression, relative to follicular B cells273. MZB have also been observed to 
traffic blood-borne antigen from the marginal zone sinus to follicular B cells and DC 
in a manner suggestive of enhancing antigen presentation274. 
 
The final requirement for complete T cell activation is Signal 3, cytokine production, 
which is also ably fulfilled by B cells. Immune stimulatory B cells and BREGs secrete 
distinct cytokine profiles in response to antigen encounter. B cells participating in TH1 
T cell responses produce IL-12, which assists in escalating the Type 1 response. B 
cells can also drive TH2 responses by their secretion of IL-4 and IL-13, while BREGs 
secrete elevated IL-10 to regulate immunity275,276. During T-dependent B cell 
activation cytokines secreted by T helper cells direct the B cell response. IL-4 known 
previously as B cell differentiation factor 1, induces B cell activation and 
differentiation, as well as TH2 differentiation. IL-2 and IFN-γ secreted by TH1 cells 
drives a feedback loop that enhances TH1 activities217. 
 
Many studies delineated the current understanding, which is that the type and form of 
antigen dictates the degree of B cell participation in T cell priming (reviewed in219). 
Two studies confirmed that B cells can prime naïve CD4+ T cells in the absence of 
other APC277,278. Rodríguez-Pinto suggests that each circumstance of antigen 
presentation involves the different APCs to varying degrees but we can now be 
assured that B cells are indeed major players in particular instances285. 
1.7.3 Cross-Presentation by B cells 
The B cell role as cross-presenters to CD8+ CTLs is an underappreciated fact279. 
While B cell ability to prime CD4+ cells and drive a TH2 response was established in 
the 1980s and 1990s193,245,280 little was known about B cell priming of TH1 responses 
until a 2002 study established that when exposed to CpG-conjugated antigen B cells 
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can also carry out this function, which was previously uniquely assigned to DCs231. 
Since then further studies have confirmed the ability of conjugated and unconjugated 
CpG to induce cross-presentation by both murine and human B cells281–283. 
 
B cell cross-presentation to CD8+ T cells is required for the clearance of Salmonella 
infection279. Clearance is mediated in the absence of DC and in the absence of 
antibody but not in the absence of B cells. B cell cross-presentation has also been 
observed in the pathogenesis of diabetes284, after uptake of OVA and immune-
stimulating complexes incorporating OVA285, and after gene gun vaccination with 
influenza and CMV DNA286. Jiang et al has shown that CpG-activated B cells can 
cross-present soluble tetanus toxoid and MV antigen282. Heit et al also demonstrated 
upregulation of costimulatory molecules and IL-12 production in B cells, 
accompanied by cross-presentation of SIINFEKL to CD8+ T cells, after uptake of 
CpG-conjugated OVA, albeit at a reduced efficiency compared to DC281. The cross-
presentation of viral particles has been variously shown to occur287,288 and not to 
occur289. However these different examples probably reinforce Rodriguez-Pinto’s 
view that the role of B cells in antigen presentation, cross or otherwise, varies 
according to the circumstances219.  
 
Using a recombinant E-3-defective human adenovirus type 7 (HAdV7) vector 
transduced to express the colorectal cancer carcinoembryonic antigen (CEA) Peng 
and colleagues demonstrated transduction of naïve human B cells and presentation to 
CEA-specific CD8+ autologous T cells with accompanying B cell signal transduction, 
cytokine production and T cell cytotoxic capabilities290. These effects were eliminated 
in the presence of TLR9 inhibition. Castiglioni et al had demonstrated similar 
findings earlier with CD8+ CTL-mediated immunity to influenza generated by B cells 
transduced to express influenza epitopes291. Finally, CD40-activated B cells have been 
used to activate human CD8+ T cells in the cancer immunotherapy setting292,293. 
Interestingly, in LaPointe’s study using CD40-activated B cells to present undefined 
TL antigens CD4+ T cell expansion was limited whereas successful induction of 
CD8+ T cells occurred in more than 80% of patients in two other studies294,295. These 
studies demonstrate significant possibilities for increased use of B cells in the cancer 
vaccine and immunotherapy fields to activate both T helper and CTL responses. 
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1.8 Evidence For APC Cooperation 
While it is important to isolate individual cell types, especially in the initial period of 
research, to tease out their various qualities and capabilities, it hardly needs to be 
stated that in vivo individual cell types involved in immune responses do not operate 
in isolation. As such, work remains to be done on groups or combinations of cells in 
order to gain a better understanding of how these cells work together – the systems 
biology approach. The cooperative nature of the anti-tumour response is not 
surprising given the complexity of systems biology, however that very complexity 
makes defining the relationships and interactions painstakingly difficult. 
 
Another factor to be considered is that antigen presentation does not always occur in 
the secondary lymphoid organs, and this brings other cells into the antigen 
presentation scenario. A key observation of Ma’s 2013 study was that effective anti-
tumour presentation may take place in the tumour bed itself, rather than in tertiary 
lymph structures of spleen or nodes296. They observed that ablation or removal of 
draining lymph nodes (dLNs) or abolition of tertiary lymphoid structures did not 
impact on the activation of tumour-infiltrating CD8+ T cells or adoptively transferred 
tumour-antigen-specific T cells. In addition, chemotherapy did not increase the 
numbers of CD11c+MHC-II+ cells in the dLNs. They observed accumulation of both 
CD169+F4/80+ MΦs and CD11b+Ly6C+ granulocytes in tumours after treatment 
with the anthracycline-based chemotherapies doxorubicin or mitoxantrone. This 
recruitment was driven by myeloid cells attracted by ATP released from dying cancer 
cells, which then stimulated local differentiation of CD11b+CD11c+Ly6CHIcells. 
These cells then presented tumour antigens to T cells296. Thus significant levels of T 
cell activation was occurring externally to the secondary lymph tissue. 
 
Campisano et al sorted CD11c+ and CD11c- cells from their heterogeneous GM-
CSF-differentiated bone marrow cultures and showed that the CD11c+ cells alone 
were insufficient to generate an anti-tumour response in mice. They found that all the 
cell types present in the heterogeneous mix were necessary for in vivo anti-tumour 
protection187. In recent years an increasing number of studies have reported that cells 
such as neutrophils, basophils and eosinophils, previously thought to be exclusively 
involved in innate immunity, in fact play an accessory role in adaptive immunity297–301. 
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The Parish group also found that eosinophil degranulation inside the tumour was 
required for OVA-specific CD4+ TH2 cells to clear tumours, but interestingly not 
TH1302.  
 
Some clinical investigators are also widening the net and looking beyond DCs and T 
cells. A Phase I trial in metastatic melanoma utilising autologous dying tumour cells 
transduced to express GM-CSF analysed the DC, MΦ, B cell, eosinophil and T cell 
infiltrates in patients303. DCs MΦs and eosinophils quickly infiltrated vaccination sites 
and high concentrations of CTLs, B cells and Ig-secreting plasma cells entered 
tumour tissues. 
 
While acknowledging that other cell types all play a part in the anti-cancer response, 
this study focused on the ability of the three professional APCs to activate T cells 
against the TAAs found in tumour lysate. An orchestrated set of responses among 
DCs, MΦs and B cells results in the proliferation and differentiation of a variety of 
mature effector T cells. These responses are mediated by intercellular 
communications including cell-to-cell contact, cytokines and antigen presentation. 
Each APC conducts particular functions via their distinct APC uptake and processing 
machinery. The varying temporal and spatial dynamics of each APC trigger diverse 
signaling information that is integrated to coordinate the final immune outcome.  
 
In one case of multi-APC cooperation Näslund et al, reported that tumour protein-
loaded DC-derived exosomes (dexosomes) were superior to peptide-loaded 
dexosomes304. They showed that the CTL response was totally dependent on CD4+ T 
cells and, interestingly, also on B cells, suggesting that proper activation of CD4+ T 
cells and B cells needs to be considered, in addition to the activation of DCs and 
CTLs, when designing cancer vaccines to ensure full potential of the treatment.  
 
In an effort to delineate the relative contributions of two APCs Kleindienst and 
Brocker used a transgenic mouse model in which B cells or DCs or both expressed 
MHC Class II. They showed that DCs alone are sufficient to prime naïve T cells in 
vivo after immunization with a peptide antigen. In their hands, neither naïve nor 
activated B cells alone could activate naïve CD4+ T cells with peptide antigen, 
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however if DCs were present B cells supported and enhanced CD4+ T cell priming. 
While antigen presentation by DC was sufficient for in vivo CD4+ T cell activation, 
DC and B cell together produced enhanced T cell proliferation, expansion and 
cytokine production305. Interestingly, despite documented examples demonstrating 
divergent T cell activation by B cells and DCs delivering peptide versus protein193,306, 
Kleindeinst and Brocker did not observe T cell activation after B cell-mediated 
protein presentation in their system. Once again, the type of antigen dictated the 
immunological outcome. 
 
DC uptake machinery comprises both degradative and non-degradative pathways, 
enabling them to present antigen to both B and T cells168. Native antigen is presented 
to the BCR by DCs that have endocytosed material via the FcγRIIB receptor, which 
enters a non-degradative vesicle that subsequently returns to the plasma membrane. 
DCs can thus present antigen to B cells in the splenic marginal zone. Additional work 
has shown that migratory DCs store antigen acquired by macropinocytosis and after 
entry into LNs transfer antigen from late endocytic vesicles to B cells169. Certain B 
cell subsets also respond to T-independent antigens and this requires interactions with 
particular DC populations201,307,308. 
 
On the other hand, B cells have been shown to inhibit DC-induced CD8+ T cell 
effector function via a mechanism that depends on B cell MHC-II expression309. The 
results of this and the studies described above was the basis of our interest in 
examining whether the addition of B cells could enhance DC-mediated presentation 
of lysate antigens to T cells, particularly since those studies imply MHC-II-dependent 
and independent outcomes.  
 
Cooperative interactions between B cells and MΦs have also been described in the 
literature. B cells are essential for protection against VSV infection due to their 
provision of lymphotoxin α1β2 signals to MΦs310. When B cells were excluded the 
MΦ protection was lost. Conversely, when MΦs were eliminated, there was likewise 
no protection from B cells. Antibodies, an adaptive immune response, were not 
required; it was the lymphotoxin activating the MΦs that led to the protection. Thus B 
cells play multiple roles and understanding of this is required when analysing B cell-
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mediated disease responses. Indeed, studies of cancer have also demonstrated B cell-
mediated responses in the absence of ABs in the patient sera311.  
 
In the presence of antigen-specific B cells MΦs have been shown to acquire more 
antigen than in their absence312. MΦ activation of OVA-specific T cells occurred after 
MHC-independent transfer of B cell-captured antigen. The transfer of BCR-acquired 
antigen to other APCs escalates the frequency of antigen presentation and in this 
manner B cells amplify or regulate the immune response to specific antigen377. The 
transfer of antigen from B cells to DC, and subsequent DC-mediated presentation of B 
cell-captured antigen has also been described313. 
 
As with the DC-B cell interaction negative outcomes in the anti-cancer response have 
also been described for MΦ-B cell collaborations. B cell-derived antibodies and 
immune complexes can also drive MΦ polarization via ligation of FCγ receptors on 
the surface of MΦs379 leading to malignant progression and carcinoma development 
in a murine model of inflammation-driven squamous carcinoma314. 
 
As can be seen some combinatorial studies have been conducted, which highlight 
inter-cell cooperation and provide a basis for examination of the ability of combined 
APCs to present undefined TAAs to T cells. We are not aware of any studies that 
have combined three APCs, or of any combinatorial studies using tumour lysate as the 
source of TAA. 
1.9 T cells  
T cells are implicated in all aspects of immune responses to pathogens or transformed 
cells, and as such are indispensable in the adaptive immune response to cancer. The 
three main subsets, CD4+ CD8+ and NK T cells are discussed in the context of 
cancer. 
1.9.1 Self Antigen and Immunological Tolerance  
Our immune systems are finely tuned to distinguish ‘self’ from ‘non-self’. During 
development in the thymus T cells undergo selection processes that lead to central 
tolerance against self antigens. Developing T cells first undergo “positive” selection 
to eliminate T cells that fail to bind MHC Class I or II molecules315. This step is 
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followed by “negative” selection to eliminate those T cells that bind with high affinity 
to self-antigen peptide in the MHC molecule316. T cells that react to self antigen 
become anergic317, or are eliminated by apoptosis,318 and the mature non-self-reactive 
T cells complete development into single positive CD4 T helper cells (TH) or CD8 
positive cytotoxic T lymphocytes (CTLs).  
 
These selection processes are not perfect and low frequencies of self-reactive T cells 
may be found in the periphery319. However, peripheral tolerance mechanisms also 
exist as a second layer of protection against inappropriate immune responses by 
mature T and B lymphocytes to benign antigens such as foods and gut microflora. 
Peripheral tolerance mechanisms include immunologically privileged sites such as the 
eye, the testes, the female reproductive tract and the central nervous system (Shirai, 
1921, Murphy and Sturm 1923, Medawar 1948320), that restrict entry of lymphocytes 
by mechanisms such as FasL-induced apoptosis321. Other peripheral tolerance 
mechanisms include anergic T cell responses when MHC-peptide is encountered 
without accompanying costimulation322. Immune regulation also occurs via naturally 
arising or induced regulatory T cells (TREGs)323, whose regulatory systems target both 
T cells and APCs (reviewed in324). TREGs secrete TGF-β and IL-10, suppressive 
cytokines that lead to T cell cycle arrest324,325. TREGs also bind via CTLA4 to CD80 and 
CD86 on TEFF cells, switching off the effector T cell response. Activated TREGs are 
also capable of direct cell-cell granzyme-mediated cytolysis of activated CD4+ and 
CD8+ T cells326. 
 
Finally there is also presentation of antigen by tolerogenic DCs327. Cross-presentation 
of tumour peptides by DCs that are insufficiently activated, either due to immune-
suppressive factors in the tumour environment, or due to the fact that tumour cells are 
self cells, will not lead to a robust anti-tumour T cell response, but rather to T cell 
anergy or activation induced cell death (AICD)328, resulting in immune tolerance to 
these antigens. 
1.9.2 CD4+ T Cells Priming: Activation Signals 1 & 2  
Priming refers to the first time a naïve T cell encounters its cognate antigen in the 
context of the MHC molecule and becomes activated against that antigen. Antigens in 
the body, self or otherwise, flow through blood and lymphatic channels. Antigen 
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entering secondary lymphoid tissue and presented by APCs are ceaselessly surveyed 
by TCRs. CD4+ T cells interact with APCs via the peptide-MHC-II complex on the 
surface of mature APC such as DCs, macrophages (MΦ) and B cells. Recognition of 
the peptide-MHC complex (p-MHC) constitutes Signal 1 of T cell activation and 
triggers intracellular phosphorylation-mediated signaling cascades329.  
 
The duration of the TCR connection with the antigen-MHC complex is 
important330,331, with long engagements of the TCR, approximately 20 hours in the 
case of naïve CD4+ T cells, required for the T cell to commit to proliferation332. This 
commitment time, and the amount of antigen required, are both reduced in the 
presence of CD28 costimulation333. By contrast, primed effector TH cells have reduced 
activation requirements (reviewed in 334) and are able to begin proliferating and 
secreting cytokines after TCR engagement of approximately 30 minutes, even in the 
absence of CD28.  
 
A CD4+ T cell that recognises antigen in the context of the MHC-II molecule, and 
also receives Signal 2 - co-stimulation - will become activated against that specific 
antigen, including TAAs. Initial co-stimulation involves ligation of the T cell’s CD28 
molecule253,335 with CD80 (B7.1)336 and, or CD86 (B7.2)335,337, which are upregulated 
on APCs after PAMP or DAMP receptor or inflammatory cytokine engagement. 
CD28 binding to CD80 and CD86 delivers a costimulation signal necessary for naïve 
T cell activation and survival338–341. 
 
The importance of costimulation was demonstrated by experiments in which antigen 
presentation in the absence of costimulation resulted in T cell anergy342,343. 
Diminished CD4+ T cell proliferation in CD28-deficient mice demonstrated the 
critical role of this co-stimulatory molecule, but also identified redundancy in the 
pathway that allows for other co-stimulatory paths. Ligation of CD28 and the T cell 
receptor (TCR) delivers a potent signal for proliferation and production of cytokines, 
especially IL-2340 and IL-6344. 
 
One of the additional costimulatory mechanisms involves CD40L on T cells ligating 
with CD40 on activated APC345,346. This sends a potent activating signal to DC that, in 
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combination with IL-1, mediates pro-inflammatory cytokine production, which in turn 
drives TH1 differentiation of naïve T cells.  
 
CD27 is another of the costimulatory molecules involved in T cell activation347–350 and 
is required for the generation and long-term maintenance of T cell immunity351. CD27 
stimulates both growth signals for naïve T cell antigen-specific proliferation as well as 
pro-apoptotic signals, such as binding to Siva protein, the proapoptotic intracellular 
ligand of CD4347–353. CD70 on DCs binding to CD27 on CD4+ T cells indirectly 
promotes TH1 differentiation354. Furthermore, CD27 binding to CD70 on B cells plays 
a key role in regulating B cell activation and immunoglobulin synthesis352. CD27 
ligation leads to the activation of NF-κB and MAPK8/JNK signaling. Finally, the 
CD28 homologue inducible T cell costimulator (ICOS)355, along with 4-1BB and OX-
40 (all members of the TNF receptor family), also provide further, less powerful 
costimulation.  
 
Inhibitory molecules are also upregulated in response to T cell activation. CTLA-4 is 
another homologue of CD28 and functions to switch off the T cell response once the 
pathogenic condition has been resolved. CTLA4 binds with higher affinity than CD28 
to CD80 and CD86, inhibiting IL-2 production and proliferation356. It is for this reason 
that mABs against CTLA4 have seen success in the treatment of some cancers 
(reviewed in 357).  
 
1.9.3 CD4+ T cell Proliferation and Cytokine Secretion 
Clonal expansion of the antigen-experienced T cell is the result of a successful 
priming interaction. In addition to proliferating, activated T cells integrate the signals 
received via TCR ligation, co-stimulation and the cytokine milieu to differentiate into 
different subpopulations capable of addressing the threat that has been identified. 
Differentiation provides the T cells with effector functions358,359, mediated primarily 
via the secretion of immune-modulatory chemokines and cytokines360.  
 
Cytokines, secreted by APCs and the T cells themselves, comprise Signal 3 in T cell 
activation361 and their requirement has been demonstrated for T cell proliferation, 
differentiation into effector and memory cells362, as well as T cell survival83–85. IL-2 is 
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a pleiotropic growth factor that drives T cell proliferation363. Successful resolution of 
tumours have been observed in mice364–368 and humans369,370 after treatment with IL-2, 
highlighting the important role of this cytokine in the immune system’s anti-tumour 
arsenal. The clinical use of IL-2 is constrained by dose-limiting toxicities in patients, 
though more than twenty years of clinical experience has resulted in refined 
administration and patient care which can ameliorate the morbidity observed in early 
years of IL-2 treatment371,372. 
 
IL-12, secreted by APCs, drives TH1 differentiation and the IL-12 IFN-α/β 
combination has been identified as the key third signal for CD8+ T cells373. Cytokines 
from activated APCs and innate immune cells provide preliminary information to the 
T cells. Cytokines from T cells provide feedback to the APCs, inducing positive and 
regulatory feedback loops that amplify, direct and ultimately switch off the immune 
response. The nature of the presented antigen along with the cytokine setting in which 
presentation occurs dictates the phenotype that the CD4+ T cell will develop as well 
as the type of immune response337,374,375. The cytokine messages received by the T 
cells control the expression of transcription factors that dictate differentiation and 
lymphokine production. 
 
IL-12’s T cell-independent mechanism of MΦ activation was first delineated in L. 
monocytogenes-infected SCID mice that lack functional T and B cells, but whose 
APCs produce IL-12. This cytokine is responsible for inducing IFN-γ production 
from activated T cells, which in turn drives phagocytic cell activation, increasing their 
cytokine production and bacteriocidal properties376. Shortly after the SCID mice 
experiments IL-12’s production by APCs and its polarizing effects on CD4+ T cells 
were demonstrated377,378. The importance of IL-12 in driving T cell proliferation and 
directing CD4+ T cells toward the TH1 phenotype was confirmed in an artificial in 
vitro system using MHC-peptide complexes immobilized on microspheres in the 
absence of confounding APC cytokines83 (reviewed in). IL-12 from activated APCs 
and innate cells promotes activation of Tbet, driving the production of IFN-γ, but not 
IL-4 or IL-17, resulting in a TH1 phenotype379. By contrast high levels of IL-4 in the 
activation environment switches on GATA-3, sending the cells into TH2 mode 
resulting in the production of more IL-4 but not IFN-γ or IL-17380. Paracrine IFN-γ 
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feedback381, along with signaling from IL-15382 and CD40-CD40L exchanges383, 
amplify IL-12-mediated responses (reviewed in 378).  
 
As with the costimulatory molecules of Signal 2, the balance of cytokines helps 
determine the differentiation fate of naïve T cells, and the ultimate effector functions, 
of the differentiated cell84,384. Understanding of IL-12’s role in the anti-tumour 
response was enhanced with the observation that mice deficient in IL-12 or IL-12 
receptors showed induced susceptibility to chemically –induced carcinomas and 
lymphoma385–387, while in humans IL-12 deficiency endows a genetic predisposition to 
glioma388. While IL-12’s anti-tumour capacity has been clearly demonstrated in pre-
clinical models (reviewed in378), and vector-mediated co-delivery of antigen and IL-12 
has been shown to enhance anti-tumour effects389, as with IL-2, dose-limiting 
toxicities and low response rates have plagued clinical trials of IL-12 as an adjuvant 
therapy for cancer immunotherapy. 
 
Our interest in IL-12 lies in its polarization of naïve CD4+ T cells toward the TH1 
differentiation cycle390, primarily via its role in the induction of IFN-γ391–394. 
Unmodified freeze-thaw lysates have been reported to suppress DC IL-12 
production175,395. By contrast studies with appropriately activated, lysate-loaded DCs 
have demonstrated effective IL-12 productio395–398, therefore we hypothesized that 
with the appropriate activation our lysate-loaded APCs would produce IL-12 and 
drive a TH1 response in the lysate-primed T cells. 
 
Early studies of the Type II interferon IFN-γ indicated that it was secreted only by T 
cells399 but it is now known that this cytokine is produced by innate NK cells400, as 
well as adaptive TH1 CD4+, CD8+ T cells and APCs, including activated B cells401,402. 
IFN-γ further directs the immune response by aiding IL-12-mediated promotion of 
CD4+ T cell differentiation into TH1 cells403 and by blocking IL-4-mediated B cell 
isotype switching404.  
 
The critical functions of IFN-γ in the anti-tumour immune response were revealed in 
mouse studies that demonstrated elevated risk of spontaneous and chemically-
stimulated tumours in IFN-γ-/- or IFN receptor -/- mice405–407. Radiation-induced 
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intratumoural IFN-γ production has been shown to cause upregulation of MHC-I on 
tumour cells that aided T cell tumour infiltration and tumour cell targeting408. In 
addition to direct killing of tumour cells by CD8+ and CD4+ T cells409, IFN-y 
mediates other anti-tumoural effects such as inhibition of tumour-promoted 
angiogenesis409–413, and migration of T cells to tumour sites414.  
 
IFN-γ-treated melanoma cells have been characterised as a way of enhancing whole 
tumour vaccines for use in DC-based immunotherapy415. In a Phase II clinical trial 
patients received a vaccine of DCs that were loaded with surgically excised melanoma 
cells that had been briefly grown as cells lines and treated with IFN-γ prior to loading 
onto DCs. Patients also received adjuvant GM-CSF. The vaccine was safe and 
effective and resulted in a “remarkable 5-year survival rate of more than 50%”. 
Reduced MHC-II expression is one method tumours use to evade the immune 
response. In this study pre-treatment of the patient melanoma cells with IFN-γ 
resulted in increased MHC-II, MHC-I and ICAM-1 expression, but reduced 
expression of the TAAs mel-4, Mart-1 and tyrosinase.  
 
The upregulation of MHC-II was in contrast to a study by Dranoff in 1993, which 
found that genetically engineering B16 to express IFN-γ did not increase MHC-II 
expression416. Loading patient DCs with the IFN-γ-treated melanoma cells resulted in 
a small but significant increase in CD83. Treating the melanoma cells with IFN-γ 
resulted in slightly reduced tumour cell viability (85% compared to 89% in untreated 
cells) and the production of apoptotic melanoma cells correlated with increased 
survival in patients. When the melanoma cells were pre-treated with IFN-γ, 
immunostimulatory heat shock proteins (hsps) remained present in the cell lysates and 
the immunostimulatory proteins calreticulin (CRT) and HMGB-1 were upregulated. 
Also significantly upregulated was ICAM-1, a lymphocyte adhesion molecule that is 
associated with sensitivity to lymphocyte-mediated cytotoxicity.  
 
Cornforth posed the interesting theory that DCs exposed to IFN-γ-treated melanoma 
cells, which have begun the DC maturation process, may be more effective in vivo 
after transfer as they may continue their maturation in a more ‘natural’, effective, 
manner, than those DCs ‘pre-matured’ with cytokine cocktails prior to transfer. It has 
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been postulated that immature DCs stimulate more TREGs but Cornforth says that may 
not necessarily be true. He suggests that the presence of hsps, CRT, HMGB-1 in 
lysate phagocytosed by the DCs may provide a more bona fide maturation signal as 
opposed to the commonly used cytokine cocktails.  
 
The well-characterised immunoregulatory cytokine interleukin 10 (IL-10) is best-
known as an anti-inflammatory mediator, inhibiting T cell responses by blocking 
MHC-II upregulation417, costimulatory molecule expression418 and inflammatory 
cytokine production in APCs419,420 (reviewed in421). IL-10 is important in maintenance 
of peripheral tolerance via its induction of TREGs422 and is also involved in directing 
CD4+ T cells toward TH2 differentiation421, though this may be situation dependent. 
Other direct IL-10 effects on T cells include suppression of activation and cytokine 
secretion423. The role of IL-10 in the anti-tumour response is not clear-cut with some 
studies demonstrating clear pro-tumoural effects, and others demonstrating anti-
tumoural benefits, such as inhibition of tumour stroma formation410. On the “IL-10 Is 
A Bad Guy” side of the argument is a study showing that IL-10 produced by MΦs 
suppresses IL-12 expression in intratumoural DCs, thereby blocking CD8+ T cell-
dependent responses to chemotherapy424. In other studies, the removal of IL-10 with 
mABs resulted in increased tumour eradication after intratumoural CpG injection425, 
while in an IL-10 knockout model enhanced Type 1 T cells responses to anti-tumour 
vaccines were observed426. 
 
Arguing for IL-10’s more nuanced role in the regulation of anti-cancer responses are 
many studies in which IL-10 mediated cancer regression. Methodologies employed 
included release of IL-10 from tumour cells427–430 and adjuvant administration of IL-10 
in mouse models431–434. Intriguingly IL-10’s anti-tumour effect was CD8+ T cell-
mediated, inducing CD8+ CTL proliferation and cytolysis and behaving as a 
chemoattractant for CD8+ T cells in vitro427–429,432,433. Recent in vivo work in several 
mouse models has demonstrated activation and intratumoural expansion of CD8+ 
CTLs that resulted in regression of large, established tumours mediated. Tumour 
elimination was dependent on high expression of the IL-10 receptor on intratumoural 
CD8+ T cells432, without involvement of IL-10R-expressing CD4+ T cells, NK cells 
or DCs . Thus the fascinating functions of IL-10 in cancer immunotherapy remain to 
be fully clarified. 
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1.9.4 CD4+ T Cell Differentiation 
During immune responses CD4+ T cells differentiate into various phenotypes, which 
are characterised by the transcription factors they express and the cytokines they 
produce390. These are primarily T-bet, IFN-γ, IL-2 and TNF-α in the case of TH1; 
GATA-3, IL-4, IL-5, IL-10 and IL-13 in the case of TH2; and RORγt and IL-17 in the 
case of TH17. Further subsets of CD4+ T lymphocytes include naturally-occurring and 
inducible TREGS, and follicular helper T cells (TFH) that provide crucial help to B cells 
in germinal centres435,436. The TH1, TH2 and TH17 subsets are the most well-
characterised, however the γδ T cells’ role in cancer is also recognised437 and we 
acknowledge that TH9438 and TH22439 cells have also been described. Figure 5 outlines 
the primary cytokines, signal paths and transcription factors that influence the 
differentiation of naïve CD4+ T cells into TREGs, TH1, TH2 and TH17 cells. 
 
CD4+ TH2 cells are generally responsible for protective responses against 
extracellular prasites such as helminths, as well as allergic responses. TH2 cells are 
also involved in the humoral immune response, which may be useful in certain cancer 
types, however these cells will not be focused on in this thesis.  
 
CD4+ TH1 cells, on the other hand, provide “help” for activation of CD8+ T cells, 
mediate protection against intracellular pathogens such as viruses, and are also key 
cells in the removal of transformed cells440–442. Recent advances in understanding of 
CD4+ T cell plasticity of function may be harnessed in future to provide a more 
robust T cell anti-tumour attack443.  
 
Factors such as the ratio of costimulatory molecules on APCs, or the balance between 
costimulation and cytokines influence T cell differentiation fate. IL-2 and the B-7 
molecules both drive TH1 and tolerising TREG responses. The balance between the two 
determines which one prevails444. The ratio of CD80 to CD86 is another factor in 
determining whether CD4+ T cells will undergo massive clonal expansion or whether 
they will differentiate into proliferation suppressing TREGs. High CD80 to CD86 ratios 
support TREG induction whereas high CD86 to CD80 levels suppress induction of 
TREGs337. In addition the cell cycle and division number determines the timing of 
release of particular cytokines by activated T cells. IFN-γ is released early and 
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Figure 5 Differentiation of helper T cell subsets is determined by cytokines. In the presence of 
interleukin-6 (IL-6), IL-21, and transforming growth factor-beta (TGF-β), naïve CD4+ T cells 
differentiate into a Th17 cell phenotype, which is characterized by the expression of transcription 
factors retinoic acid receptor-related orphan receptor-γt (RORγt) and signal transducer and activator of 
transcription 3 (STAT3). IL-1β and IL-23 cytokines can promote and stabilize this phenotype during 
cell expansion. Once programed, these cells secrete IL-17A, IL-17F, IL-21, and IL-22, which play a 
key role in enhancing autoimmunity and host defense. Cytokines IL-12, IL-4, and TGF-β and 
transcription factors T-bet, GATA3, and FoxP3 have been shown to regulate Th1, Th2, and Treg cell 
development, respectively. These distinct subsets regulate immune response to foreign, self, and 
tumour antigens. From: Th17 Cells in Cancer: The Ultimate Identity Crisis510, Bailey et al, Frontiers 
In Immunology, Copyright 2014. This is an open-access article distributed under the terms of the 
Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) or licensor are credited and that the original publication in 
this journal is cited, in accordance with accepted academic practice. 
 
1.9.5 CD4+ T Cell Effector Functions in the Anti-Tumour Immune 
Response 
Activated CD8+ cytotoxic T lymphocytes (CTLs) were once thought to be the key 
cancer eliminating cells, primarily due to their direct cytotoxic functions, however it 
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has been known for some time that CD4+ T cells are more involved in tumour 
clearance than originally realized441–443,445–447. In addition to providing “help” for CD8+ 
CTLs, specific effector functions mediated by CD4+ T cells include direct recognition 
of endogenous antigen on the surface of melanoma cells, accompanied by IFN-γ 
production448–450, and direct tumour killing451. Both CD4+ and CD8+ T cells exhibit 
IFN-γ-mediated inhibition of angiogenesis413, and Class II-restricted CD4+ T cells 
specific for NY-ESO-1 have been shown to mediate durable remission and reactivity 
against other melanoma antigens in one patient452. Expanded CD4+ TILs have 
recently been successfully utilised in ACT for melanoma449,453 and epithelial cancer454. 
IFN-γ production by CD4+ T cells also mediates the upregulation of MHC-I on some 
tumours leading to their increased recognition by CD8+ CTLs455, or their elimination 
by IFN-γ-induced M1 MΦ456. As such it was important to investigate the differences 
in CD4+ versus CD8+ T cell response to TAA presentation by APC.  
 
1.9.6 CD4+ T Cell “Help” for CTLs 
CD4+ TH cells fulfill vital functions during CD8+ CTL development and 
maintenance. Cytokines secreted by activated CD4+ T cells play a crucial role in 
activating naïve CD8+ T lymphocytes457,458 and B cells. “Help” provided by CD4+ T 
cells enhances CTL clonal expansion, assists in effector entry into peripheral tissues, 
and promotes maintenance of memory T cells454–456. These functions are only 
undertaken after CD4+ “licensing” of APCs, which facilitates the functional 
activation of the APC, enabling the APC to independently prime memory CTL. 
Ligation of CD40 with CD40L on APCs forms part of the CD4+ T cell-mediated 
APC activation that provides initial “help” for CTLs346. CD40 binding to CD40L on 
CD4+ T cells stimulates expression of CD70, the only known ligand of CD27, on DC. 
Activated DC are then able to bind CD27 on CTL, catalyzing a full-fledged CTL 
response, including secondary expansion and circumvention of TRAIL-mediated 
AICD on antigen re-exposure459. 
1.9.7 CD8+ T cell Activation  
Activated CD8+ T cells are crucial in the host defense against viral infections and 
cancer. CD8+ CTLs recognize short, 8–10-mer amino acid peptides localized in MHC 
class I molecular complexes on APCs and on cells ubiquitously distributed in the 
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body. Hydrophobicity of the TCR contact residues on both self and foreign antigens 
has recently been identified as a key element in determination of immunogenicity of 
peptides460. These cells eliminate infected or transformed cells via secretion of 
perforin and granzyme, or Fas/FasL-mediated activation of caspases, and secretion of 
IFN-γ. For this reason they are known as cytotoxic T lymphocytes (CTLs). Like naïve 
CD4+ T cells, naïve CD8+ T cells primarily reside secondary lymphoid organs and 
after activation also divide into functionally distinct subpopulations.  
 
Like CD4+ T cells CD8+ T cells recognise peptide in the context of MHC, receive 
appropriate costimulation, and integrate cytokine signals from activated APCs and 
activated CD4+ T cells to become activated. However CD8+ CTLs require 
significantly less time than CD4+ T cells to trigger their cytotoxic functions, less than 
30 minutes334,461,462. 
 
Some evidence exists demonstrating that given a strong enough signal via the TCR, or 
high enough numbers of responding T cells, costimulation is dispensable in CD8+ T 
cell activation462–464, though whether this is a physiologically plausible scenario may 
remain to be resolved. Experiments with CD28-/- mice have demonstrated that CD28 
is not absolutely required for T cell activation in vivo, suggesting that alternative 
costimulation pathways may exist465. 
1.9.8 CD8+ T cell Proliferation and Cytokine Secretion 
The combination of IL-12 and IFN-α/β are the key Signal 3 cytokines for CD8+ T 
cell activation and differentiation into cytotoxic T lymphocytes (CTLs)373. DC IL-12 
production is focused around the immunological synapse466, as is T cell IFN-γ and IL-
2 production467, promoting CTL synapse formation468 and additional STAT-4-
mediated IFN-γ production469. The adhesion molecule ICAM-1 is an important 
stabilizing factor in APC-T cell synapses and its activity is required for the formation 
of CD8+ T cell memory470.  
 
Upon activation CTLs follow chemokine gradients and migrate to peripheral sites of 
malignancy where they, ideally, eliminate cancerous cells by various mechanisms. 
These mechanisms include the secretion of cytokines (IFN-γ, TNF-α, IL-2, IL-12), 
which may be cytotoxic in and of themselves, but which also attract other cells, such 
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as MΦs, polymorphonuclear cells and NK cells, to assist in the elimination process. 
One of the common γ chain (γc) cytokines, IL-2’s anti-tumour role has been reported 
to lie in its ability to activate and expand CTLs in host tissues370, and studies are in 
progress to elucidate the regulation of IL-2 with its additional contradictory regulatory 
roles in the induction of TREGs and AICD. IL-15 induces DC production of IFN-y, 
which is part of DC-induced stimulation of CD8+ T cell proliferation471. 
1.9.9 CD8+ T Cell Differentiation 
Like CD4+ T cells, CD8+ T cell differentiation is T-bet-mediated but is supported by 
an additional transcription factor Eomesodermin (Eomes)472. Figure 6 shows a 
simplified model of the environmental cues and cell-intrinsic factors that drive T cell 
fates. However there are other markers not identified in Figure 6 that are also used to 
identify differentiated T cells.  
 
Whereas naïve T cells circulate continually through the peripheral blood and lymph, 
entering and exiting secondary lymph organs, activated effector and memory T cells 
must migrate from peripheral tissues and secondary lymph organs respectively, to the 
site of infection or malignancy to execute their effector functions473,474. Differentiation 
programmes induce the expression of homing molecules that foster the migration of 
effector cells to inflamed or malignant regions, where the cytokines released by 
effectors assist in antigen removal. The chemokine receptor CCR7 on the surface of 
naïve CD4+ T cells allows entry to lymph nodes via high endothelial venules 
(HEV)475 where they enter T cell areas before returning to circulation. Thus CCR7 
downregulation is a key differentiation feature identifying TH1 and TH2 cells whose 
chemokine receptors and cytokine profiles promote migration to sites of delayed-type 
hypersensitivity (DTH) or allergic inflammation respectively606–608.  
 
CD28 is constitutively expressed on naïve T cells and loss of CD28 expression, as 
part of a multi-marker profile, is one indicator of an antigen-experienced T cell. 
Whereas CD28 stimulation is generally thought to be required for CD4+ T cell 
activation CD28-B7 ligation is not absolutely required for activation of memory 
CD8+T cells478. Some have argued that given a strong enough signal via the TCR, or 




















CD27-CD28+ T cells are terminally differentiated T cells that fail to persist in vivo in 
adoptive cell therapy whereas CD27+CD28+ are early antigen-experienced T cells 
with strong proliferation potential that demonstrate good long-term persistence in 
adoptive cell therapy476 Persistence at one month of CD8+CD27+ infused cells 
correlates highly with anti-tumour response in clinical trials of adoptive cell therapy 
for melanoma477. 
 
CD27, expressed on resting B352 and T cells348,350, is a member of the tumour necrosis 
factor (TNF) receptor family that does not express a death domain in its cytoplasmic 
tail region. CD27 has been demonstrated to promote activated T cell survival, to be 
necessary for maintenance of memory populations and to rescue CD28-/- cell 
death351,479. CD70 on DCs binding to CD27 on CD4+ T cells provides help to CD8+ T 
cells459 and aids CD8+ memory formation459,480. In mice loss of CD27 is observed on 
CD8+ T cells after antigenic stimulation, therefore its presence and absence and can 
be used to identify memory T cells and effector T cells respectively481,482. Persistence 
 Figure 6 T cell memory. T cells may assume many phenotypes in response to stimulation. The eventual fate 
of a T cell depends on many environmental queues, including, but not limited to, cytokines, inflammatory and 
immune-modulatory products, and tissue-specific factors. These signals, in turn, influence the transcriptional 
profile of the T cell, leading to developmental choices. Generally, IL-7/15/21 and Eomes/Bcl-6 are considered to 
tip the scale toward memory. In contrast, IL-2/12, inflammatory products, and T-bet/Blimp-1 weigh toward 
terminal differentiation and effectors. Exhaustion can result when T cells experience these factors too intensely or 
for too long. A proper balancing of all these factors will lead to long-lived, protective memory. Markers 
commonly used to identify cells within a particular functional grouping are given on the right. KLRG-1, killer 
cell lectin-like receptor subfamily G member 1; PD-1, programmed cell death-1; Lag3, lymphocyte activation 
gene 3; Tim-3, T cell Ig mucin-3. From: T cell responses: naïve to memory and everything in between, Pennock 
et al, Advances In Physiological Education. Published 1 December 2013 Vol. 37 no. 4, 273-283 DOI: 
10.1152/advan.00066.2013. Permission not required for reproduction in thesis. 
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of CD27+CD8+ T cells has been highly correlated with anti-tumour responses in 
ACT for metastatic melanoma483,484. 
 
CD122 is the β chain of the trimeric IL-2 receptor on T cells. Different combinations 
of the α, β and γ protein chains form the IL-2 receptor. The three receptor chains are 
expressed separately and differently on various cell types and can assemble in 
different combinations to generate low, intermediate and high affinity IL-2 
receptors485. The combination of β and γ binds IL-2 with intermediate affinity 
primarily on memory T cells and NK cells. The combination of α, β and γ binds IL-2 
with high affinity on activated T cells486 and TREGs487. IL-2 binding to the IL-2 receptor 
also promotes the differentiation of T cells into effector T cells and memory T cells, 
as well as being required for memory cell maintenance488,489. Both IL-2 and IL-15 
mediate their effects by docking on to the common gamma chain CD122490. 
 
CD127, the IL-7 receptor α (IL-7Rα), is expressed by most resting T cells and 
downregulated following T cell activation. Long-living T cells are characterized by 
constitutive CD127 expression491,492. The combination of CD122 and CD127 are used 
to assess survival potential and responsiveness of cells to homeostatic cytokine 
signaling in vivo. Cells that are negative for CD122 display unresponsiveness to IL-2, 
which is indicative of reduced long-term persistence in vivo. In the same manner cells 
that are negative for CD127 display unresponsiveness to IL-7, which is also indicative 
of reduced long-term persistence in vivo.  
 
CD44, (homing cell adhesion molecule; HCAM) is a cell-surface glycoprotein 
involved in cell-cell interactions, cell adhesion and migration493. CD44 binds to its 
ligands hyaluronic acid and matrix metalloproteinases and participates in a wide 
variety of cellular functions including lymphocyte activation, recirculation and 
homing, hematopoiesis and tumour metastasis.  
 
CD62 ligand (CD62L), also known as L-selectin, is a homing receptor that, along 
with CCR7494, allows lymphocytes to enter secondary lymphoid tissues via high 
endothelial venules (HEV)495. Ligands on endothelial cells bind CD62L, slowing 
rolling cells for entry into lymphoid organs. CD62L is highly expressed on naïve T 
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cells, allowing these cells access to secondary lymph tissue where they can encounter 
antigen. CD62L is shed from the cell membrane after antigen encounter496,497 and this 
is accompanied by CD107 upregulation, which allows for the activated T cells lytic 
activity497.  
 
1.9.10 CD8+ T cell Effector Function in the Anti-Cancer Immune 
Response 
It is the CD8+ CTLs that ACT usually seeks to activate against the patient’s tumours. 
It has been proposed that CTLs become activated against tumours via TAA-
presentation in either the tumour environment or in the dLNs. In the periphery CTLs 
can engage MHC-I-peptide complexes on tumour cells and, if sufficient costimulation 
and cytokine signaling is also received, these peripherally activated CTLs can lyse 
tumour cells in situ. Alternatively, tumour cells that may have reached the dLNs via 
lymphatic flow may also directly present antigen to CTLs. Tumours do not express 
costimulatory molecules, therefore unless costimulation from APCs in the vicinity can 
also be engaged, this form of direct CTL priming will be ineffective.  
 
Whereas other cytokines such as TNF-α are secreted by T cells, monocytes, MΦs, 
and NK cells IL-2 is principally secreted by activated T cells498 and its presence is 
used clinically as indicative of T cell activation and killer capability. The combined 
actions of IFN-γ and TNF force cancer cells into senescence via growth arrest at 
G1/G0, and phosphorylation of molecules in the STAT1 pathway498 which ignite 
inflammatory pathways. 
 
The same group that demonstrated IL-12’s role in driving CD4+ T cells into the TH1 
phenotype showed more recently that IL-12 signaling, induced by CD40L-CD40 
interactions between DCs and CD4+ T cells, is required to induce effector cytolytic 
function in CD8+ T cells499. IL-12 also enhances CTL IFN-γ production389, which has 
direct cytotoxic action on cancer cells. Due to successful Fas/FasL and 
perforin/granzyme-mediated killing of T cells by CTL in in vitro cytotoxic assays it 
was assumed that CTLs killed tumour cells directly via these mechanisms in vivo. 
However IFN-γ deficient T cells seldom mediate tumour regression, even if their lytic 
function is intact (reviewed in 410). The efficacy of adoptively transferred TILs in 
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immunotherapy has been shown to correlate better with their cytokine production, 
particularly that of IFN-γ, and to a lesser degree TNF-α410,447,500–502.  
 
Other cell death mechanisms utilised by CTLs include activation of apoptotic, death-
inducing pathways such as the Fas/FasL and perforin/granzyme methods. Secretion of 
perforin and granzyme-containing vesicles bring about the lysis of neighbouring cells 
– including the MHC-I-expressing cells presenting the antigen to the T cells, whether 
they be APCs or tumour cells. In the perforin-granzyme-mediated method of cell 
killing, lymphocyte-secreted perforin forms a pore in target cell membranes through 
which the serine protease granzyme can enter and activate intracellular caspases and 
mitochondrial death signaling503,504. CTLs also upregulate the death ligand CD95L 
(FasL), which forms a synapse with CD95 (Fas) on the surface of target cells, 
triggering a signal cascade that ultimately activates apoptotic, caspase-mediated 
death505,506. 
 
1.9.11 Development of T Cell Memory: The Key to Preventing Cancer 
Recurrence 
Immunological memory empowers the immune response with an expedited, stonger 
response to antigen re-encounter. The majority of effector cells die during the post-
activation contraction phase507,508, but a proportion differentiate further to become 
long-lived, non-dividing memory T cells507, which are able to self-renew and maintain 
themselves in the absence of antigen. Survival in the absence of the stimulating 
antigen is a key feature of memory cells. Naïve T cells require ongoing interactions 
with self-MHC complexes509, but antigen-experienced memory T cells rely on 
cytokines510 for their continued survival – IL-7 in the case of CD4+ memory cells511,512 
and IL-15 in the case of CD8+ memory cells513.  
 
Both CD4+ and CD8+ T cells differentiate into two main classes of memory cells: 
central memory (TCM) and effector memory (TEM). Irrespective of initial phenotype the 
memory pool differs from naïve cells in three key aspects. First, the frequency of 
memory T cells specific for a given antigen is dramatically higher than that of their 
very rare naïve precursors514,515. Second, their differentiation program renders them 
competent to access both secondary lymphoid organs and peripheral tissues. This is in 
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contrast to naïve T cells and TEM whose surface molecules restrict their location to 
secondary lymphoid organs and peripheral tissues respectively (reviewed in514) where 
they await antigen encounter. Effector memory cells in peripheral tissues is one factor 
contributing to the markedly reduced response times in secondary responses. Finally, 
the activation requirements and thresholds for memory cells are less stringent than for 
naïve cells, enabling them to respond faster, to less antigen and with less 
costimulation, during antigen re-encounter, after which they secrete the full 
complement of polarised cytokine profiles. 
 
TH1 effector memory cells, commonly called T effector memory (TEM) cells derive 
from TH1 effector cells that survived the expansion contraction phase of immune 
activation516,517. Various factors have been implicated in the TEM development program 
and include strong TCR signaling; a switch toward glycolysis; IL-2-receptor 
signaling; STAT-5-mediated upregulation of the β2 chain of the IL-12 receptor; and 
expression of the Tbet and Blimp-1 transcription factors (reviewed in518). Primarily 
found in peripheral tissues519 TEM provide immediate protection upon antigen 
challenge through, for example, the rapid, high production of inflammatory effector 
cytokines. Romero et al have identified four discrete CD8+ TEM cell populations on 
the basis of their expression of CCR7 as well as CD27 and CD28520, though whether 
this describes cells throughout a differentiation spectrum is unclear. 
TCM, by contrast, preferentially reside in secondary lymphoid organs, mounting recall 
responses to antigens494. Even though TCM lack immediate effector functions, they 
rapidly proliferate and differentiate into effector T cells following antigen 
stimulation514,521. Figure 7 outlines the current understanding of human memory T cell 
subset formation. 
 
Exactly what drives the TCM development program remains unclear. The role of 
weaker TCR signaling is being elucidated522,523 with more recent work demonstrating 
a role for IFN-γ signaling in blocking memory T cell precursors that respond to weak 
TCR agonists, thus supporting the creation of high affinity TCM cells524. Other recent 
studies have highlighted the roles of mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2) in differential regulation of TEM and TCM generation. Mice with 
constitutive mTORC1 expression generated highly effective TEM cells that were 
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unable to transition into memory cells. By contrast, mTORC1-deficient mice retained 
memory characteristics but did not differentiate into effector cells. Finally, inhibition 
of mTORC2 also enhanced TCM cell generation525. Kim et al reported that while CD4+ 
help enhances CD8+ cell effectiveness and memory expansion, the CD8+ memory 






















The transcription factors Blimp-1 and Bcl-6 were known to be important drivers of B 
cell differentiation and memory, however their role in driving T cell effector function 
and memory induction has only recently been discovered527–529. Bcl-6 in particular is 
needed for CD8+ TCM cells530,531. The actions of these two transcription factors cancel 
each other out, therefore the balance of each determines effector or memory fate in 
these cells.  
 
Figure 7 Model for the generation of human memory T cell subsets. A schematic model for 
differentiation of circulating and tissue-resident memory T cell subsets. Progressive differentiation of the 
three major circulating subsets — stem cell memory T cells (TSCM cells), central memory T cells (TCM 
cells) and effector memory T cells (TEM cells) — from activated naïve T cells is shown relative to the 
extent of antigen exposure. Effector T cells (TEff cells) represent terminally differentiated cells, and death 
is one outcome of increased antigen exposure and proliferation. Naïve, TSCM and TCM cells circulate and 
and migrate to lymphoid tissue, whereas TEM and TEff cells are the subsets with the capacity to traffic to 
peripheral tissues. Tissueresident memory T cells (TRM cells) in peripheral tissue sites may derive from 
either TEM or TEff cells that migrate to these sites via tissue-specific influences. It is possible that TCM 
cells could develop into TRM cells in lymphoid sites (dotted line). TRM cells in peripheral compartments 
are likely terminally differentiated since they do not circulate or convert to other memory T cell subsets.  
From: Human memory T cells: generation, compartmentalization and homeostasis. Farber, Yudanin and 
Restifo. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Immunology 14, 24–
35, doi:10.1038/nri3567, Published online 13 December 2013. Copyright 2014. License #: 
3810001060895. 
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The surface molecule phenotype of memory cells differs from that of naïve cells and 
their functional responses also differ. Murine memory cells express high levels of 
CD44496,532 and low low levels of activation markers such as the IL-2 receptor 
(CD25)533 and CD69, whereas human memory cells can be identified on the basis of 
their CD45RA-CD45RO+ phenotype534. 
 
The CD127HIGH population has been shown in adoptive cell transfer experiments to 
represent long living T central memory (TCM) cells, especially when combined with 
CD62LHIGH status491. CD62L is also expressed on TCM that reside in secondary lymph 
tissue awaiting future antigen encounters495,497. TEM circulate in the periphery and have 
immediate effector functions upon encountering antigen, thus they do not express 
CD62L. CD44 is an indicative marker for TEM as it is expressed at a lower level on 
naïve T cells compared to memory T cells496,532. The combination of CD44 and 
CD62L is one of the bi-variate analyses used in the identification of CD8+ TCM cells 
for adoptive cell therapy in cancer496,521,535.  
 
Naïve and TCM cells express CCR7 and continually recirculate into lymph tissue 
where they can engage with inbound CCR7+ APC. Activated effector T cells, and TEM 
cells, are identified by their loss of CCR7 expression, which excludes them from 
lymph as part of their migration toward peripheral tissue.  
 
Finally, the latest member to join the T cell memory subsets in both humans and mice 
are CD95+CD122+ T memory stem cells (TSCM). In humans these cells have certain 
features of naïve T cells, being CD45RA+CD45RO-CD27HICD28HIIL7RαHICD62LHI 
and CDR7HI. They are highly proliferative, self-renewing and retain the capacity to 
differentiate into TCM and TEM, hence their ‘stem cell-like’ qualities (reviewed in514). 
Correlations between antigen-experienced T cell phenotype and anti-tumour efficacy 
have been identified with TH1 and TCM having positive prognostic indications. Thus in 
this study, it was important to determine the phenotype of T cell that resulted from 
presentation of undefined antigen by each type of APC, in terms of surface molecule 
expression, cytokine production and cytotoxic capability. 
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1.9.12 NK T cells 
Another major T cell subset is that of the natural killer (NK) T cells. Four subsets of 
Vα14-Jα18 invariant NK T (iNKT) cells have been described536. Types I and II are 
CD1d-restricted, recognizing the glycolipid alpha galactosylceramide (Type I) and an 
as yet undetermined ligand (Type II). Types III and IV are MHC Class I, and or Class 
II-restricted and may recognise self-ligands and other also undetermined ligands. 
Type I iNKT cells are the best characterised. They have the distinctive ability of being 
able to respond as an innate-like cell with minimal TCR engagement, or as a memory-
like cell via their semi-invariant TCR interacting with glycolipids presented on 
CD1d537. During viral infection they can be indirectly activated in the presence of 
large quantities of pro-inflammatory cytokines, perform functionally in a manner 
similar to innate natural killer (NK) cells and secrete predominantly TH1 cytokines538. 
They can also be activated by pathogen-presenting DCs538,539. NKT cells play a part in 
tumour surveillance, though their anti-cancer activities are less well-characterised 
than those of the CD4+ and CD8+ T cells537. Some groups are assessing the potential 
of NK T cells in immunotherapy for cancer, however the response of NK T cells to 
undefined TAAs has not been examined in this thesis.  
1.10 Immune Surveillance of Altered Cells  
Immune cells patrol tissues, continually surveying the environment, recognizing 
transformed or stressed cells and eliminating them long before they reach clinical 
detection (540, reviewed in541–543). The immune system’s response to cancer maintains a 
fine line between immune-mediated elimination of transformed cells and suppression 
of autoimmune reactions.  The majority of T cells are educated to ignore self during 
development. The goal of central tolerance mechanisms is to generate a T cell 
repertoire that is non-reactive to self antigens and reactive against ‘non-self’. While 
extremely effective, central tolerance is not fail-proof. Self-reactive T cells do enter 
the periphery where they can cause autoimmune disease under certain 
circumstances319,544. However, peripheral tolerance mechanisms act as a back-stop to 
control inappropriate immune reactivity in tissues.  
 
The concept of cancer immune surveillance has been broken into three phases: 
elimination, equilibrium and escape545 Figure 8. During the elimination phase the 
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immune system successfully identifies and eliminates altered cells and tumour 
progression is halted. The unstable nature of transformed cells means that selective 
pressure from the immune response drives neoantigen development via DNA 
mutations or alterations of gene expression. Equilibrium is an active phase during 
which cancerous factors, which avoided elimination, continue to attempt to subvert 
immune responses. Vulnerable tumour clones are eliminated where possible and the 
tumour cells continue to evolve.  Finally, escape occurs if immune mechanisms are 
unable to control the malignant changes. Escape variants emerge that have the ability 
to repel, evade or repress the anti-tumour mechanisms and tumour outgrowth is the 
result.  
1.11 Immune evasion by Tumour Cells  
Despite elimination of pre-clinical tumours and immunoediting542,546,547 tumours that 
escape continue to display antigens that the immune system can recognise. Thus, 
while some tumours downregulate antigens targeted by the immune system in an 
effort to avoid detection, others actively oppose host immune mechanisms, such as the 
induction of anergy in tumour-specific T cells548.  
 
Tumours growing in immunologically privileged locations such as the brain or eyes 
may not be subject to immune surveillance and in some cases tumour stroma has 
acted similarly, providing a barrier against immune infiltration68,549,550. Immune 
infiltration has also been hindered in cancerous tissue by the down-regulation of 
adhesion molecules551,552, furthering immunological ignorance. In an additional 
example of immunological ignorance tumour cells that have not migrated to the 
lymph nodes fail to activate lymph node T cells and are ignored68,553. 
 
The generation of immune-suppressive features by either tumour cells, tumour 
stroma, or immune or epithelial cells in the tumour microenvironment is another 
active strategy. High levels of transforming growth factor β (TGF-β) is a key feature 
in many malignancies. This molecule elicits anti-proliferative effects, as well as 
inhibiting activation and differentiation of innate and adaptive immune cells419,554–558, 
and promoting differentiation of CD4+CD25- cells into CD4+CD25+ TREGs483. The 
angiogenic vascular endothelial growth factor (VEGF) inhibits monocyte 
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differentiation into DCs559, and expression of prostaglandins560,561 by tumour cells has 
been reported to correlate with reduced tumour control in mice and humans. The pro-
tumoural role of IL-10562 in immune evasion has also been identified via its effects in 
suppressing macrophages. In concert with IL-10, TGF-β has also been reported to 
divert the immune response away from anti-tumour TH1 actions and toward less 
effective TH2 humoral responses563. 
 
Malignant cells may also avoid immune detection due to tolerance mechanisms 
designed to protect normal tissues from immune-mediated destruction. The lack of 
costimulatory molecules on MHC-I and MHC-II positive tumours may result in 
anergic tumour-specific CD4+ and CD8+ T cells548,564,565, although costimulatory 
requirements are less stringent for antigen presentation to antigen-experienced T cells 
in the periphery.  
 
Tumours may also upregulate molecules that allow them to resist immune-mediated 
killing and they can also co-opt “counter attack” strategies by killing tumour specific 
CTLs555. CD95/CD95L-mediated deletion of TAA-activated T cells via activation 
induced cell death (AICD) is a result of repeated TCR stimulation with antigen566, 
such as may be encountered in the tumour setting567,568. FasL-expressing CTLs 
ligating Fas on target cells, trigger an apoptotic, caspase-mediated death signal 
cascade505,506. In the face of programmed cell death-mediated killing by immune 
lymphocytes tumours acquire anti-apoptotic capacities such as the overexpression of 
antiaptoptic proteins FLIPL,S, Bcl-2 and survivin, or of serine protease inhibitors that 
block Granzyme B activity (reviewed in555). Conversely tumours can also 
downregulate proapoptotic molecules and produce soluble decoy receptors for death 
ligands on CTLs555. Many reports demonstrate the existence of CD95-resistant 
malignancies that express CD95L569–574 and apoptose TILs in human tumours570,575. 
However other studies have shown that CD95L-expressing tumours are targeted for 
neutrophil-mediated destruction576–579. Thus the effectiveness of this strategy in 
immune evasion is currently inconclusive.  
 
The perforin-granzyme-mediated killing pathway, described under CD8+ T cell 
differentiation, is another major mechanism for CD4+ and CD8+ CTLs and may also 
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be relevant in tumour immune evasion580–583. Perforin-deficient mice have 
demonstrated vulnerability to some tumours induced by direct injection, carcinogen-
induction or oncolytic virus generation584, as well as the spontaneous development of 
lymphomas585. Interestingly, however, one study has shown that Granzymes A and B 
may not be critical in this process586. Evidence for tumours resisting perforin-mediated 
killing has been observed in myeloid leukemia, though the mechanisms were not 
studied587. In addition, Granzyme B inhibition by serine protease inhibitors has been 
documented in prostate cancer588, while impaired perforin binding has been observed 
on leukaemia cells589.  
1.11.1 TREGs and T Cell Exhaustion 
While the concept of T cell exhaustion was originally identified in chronic murine 
infections it has also been described in cancer patients. Exhausted T cells lose critical 
functions such as the ability to make IL-2, IFN-γ and TNF-α, which affects their 
cytotoxic capacity. They show reduced proliferation and deficient memory T cell 
properties, being unable to renew themselves in the absence of antigen and failing to 
carry out a strong secondary response if the antigen is re-encountered590. Expression 
of inhibitory receptors such as PD-1, CTLA-4, TIM-3, LAG-3 and others identifies 
activated effector cells. However their continued expression is an identifying 
characteristic of exhausted T cells, which have failed to down-regulate these negative 
immune regulators as memory cells do upon resolution of a threat591,592. 
 
PD-1 is an important immune-regulatory inhibitory receptor whose expression is low 
on naïve T cells and upregulated on activated T cells, B cells and myeloid cells593,594. 
Engagement of PD-1 by its ligand programmed death ligand 1 (PD-L1), expressed on 
APCs, prevents T cell activation to promote tolerance and inhibit autoimmunity. PD-1 
promotes programmed cell death (PCD) in antigen-specific T cells in the lymph 
nodes595 while simultaneously reducing PCD in TREGs596. High levels of PD-1 is a 
major clinical indicator of exhausted T cells with impaired anti-tumour function597. 
Upregulation of other immunoregulatory molecules such as CTLA-4 also contribute 
to tumour-specific T cell exhaustion, with co-expression of PD-1 and CTLA-4 
corresponding to increased T cell exhaustion. Thus monoclonal antibodies (mABs) 
against PD-1, and or, CTLA-4, are now used to block the inhibition of tumour-
specific T cells in some cancers597,598. 
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TILs that co-express PD-1 and T-cell Ig- and mucin-domain–containing molecule–3 
(TIM-3) display the most severe exhaustion phenotype and combined targeting of 
both molecules has been more effective than blocking either one individually in pre-
clincical models599. More than 300 clinical trials are investigating immune regulators, 
the majority targeting CTLA-4 and PD-1 and, or, PD-L1, but mABs against killer 
immunoglobulin-like receptors (KIR), TIM-3, LAG-3 and BTLA are in 
progress591,600,601. 
1.11.2 Subversion of DCs in Cancer 
Understanding how DCs are modified by the tumour-host dynamics is critical for the 
design of cancer therapies in general and DC-mediated ACT approaches in particular. 
The earliest reports of DC abnormalities in cancer patients came in the mid 1980s 
with the observation of dramatically reduced numbers and morphological changes in 
malignancy-associated Langerhans cells compared to those in benign lesions602–604. 
Experimental evidence eventually accumulated that confirmed direct suppressive 
effects of tumours on DCs, including IL-10-mediated suppression, defects in 
expression of various molecules605, and inhibition of actin polymerization, which 
limits DC motility and adhesion606. The Gabriliovich group reported reduced antigen 
presentation and T cell proliferation, as well as VEG-F-mediated inhibition of DC 
maturation559,607. This was soon followed with evidence of reduced CD80 and CD86 
expression in tumour-associated DCs608, as well as a report of melanoma-derived 
factors switching DCs from anti-tumourigenic to tolerogenic609. 
 
These early reports have been followed up with numerous corroborating studies in 
which tumours have been demonstrated to inhibit maturation of DCs, which then 
block antigen-specific T cell responses610. Another DC evasion strategy is the 
impairment of antigen presentation by the downregulation of immunogenic TAAs611–
613 or the evolution of neoantigens614. These changes are observed more in metastases 
than in primary tumours. 
 
Recent work in a mouse model of ovarian cancer showed that DCs responding to 
tumour-produced molecules lost the ability to stimulate T cell activation615. Thus it is 
possible that ‘exhausted’ T cells in the tumour microenvironment may not necessarily 
 58 
be exhausted. It may be instead a failure on the part of the DCs, which are responding 
to the continual presence of transformed cells, to properly activate the T cells. 
1.11.3 The Controversial Role of Macrophages in Cancer: Tumour 
Associated Macrophages (TAMs) 
MΦs represent the majority of immune cells in the human body and are highly 
represented in the tumour microenvironment, sometimes contributing 50% or more of 
the tumour’s mass616–619. These MΦs are known as tumour-associated MΦs (TAMs) 
and are derived from recruited, circulating blood monocytes620 and locally 
proliferating MΦs134,621.  
 
Some studies show MΦs to have a clear anti-tumour benefit622–625. MΦs can exhibit 
direct cytotoxicity of tumour cells, destroy tumour extra-cellular matrix (ECM) and 
inhibit angiogenesis. They can also present antigen to CTL, thus harnessing the anti-
tumour adaptive response. It has been shown, however, that just like DCs, MΦ 
phenotypes also transition during tumour formation, from M1 during early stage in 
response to inflammatory stimuli, to M2 in later stages as tumour cells and tumour 
stroma alter the microenvironment of the MΦs626. Thus the functions of TAMs 
change during tumour growth and tumour progression and analysis of this feature 
must be taken into account when assigning pro- or anti-tumoural conclusions627. 
 
In a humanized model Pallasch et al give an example of how therapeutic antibodies 
induce tumour cell death through MΦ activation. In this study they investigated the 
difference between treatment-resistant and treatment-sensitive leukaemic B cells, 
which initially respond to treatment with alemtuzumab (anti-CD52 antibody) before 
developing resistance624. Alemtuzumab-mediated cell death was caused by the 
recruitment of MΦs that phagocytosed the tumour cells. When investigating how to 
improve the response to alemtuzumab they found a successful synergistic response to 
alemtuzumab and low dose cyclophosphamide.  Cyclophosphamide, but no other 
alkylating agent, caused the transitory release of stress-related cytokines such as IL-8, 
VEGF, TNF-α and CCL4 from the malignant cells. These factors activated MΦs, 
which were able to engulf the tumours.  
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These results are interesting in light of Asano and colleagues’ findings, discussed in 
the MΦ section, which showed that CD169+CD11c+ MΦs in the border of the 
cortical sinus and paracortical sinus were able to present dead cell antigen to T cells 
that had migrated from the T zone to the sinus border177. Pallasch and colleagues 
noted that tumour cells in the bone marrow, a low MΦ region of the body, were 
refractory to alemtuzumab treatment, while tumour cells in the blood and spleen were 
highly responsive. This response was abolished after MΦs were depleted with 
clodronate liposomes. Cyclophosphamide-induced cell death would not only cause an 
increase in local activation of MΦs in response to stress cytokines, it would also 
cause increased flow of dead cell antigens into draining LNs, which would be 
phagocytosed by CD169+CD11c+ MΦs in the sinus, which could then present dead 
cell antigens to CD8+ T cells. This could help explain Pallasch’s compartment-
specific findings. However Pallasch et al defined MΦs as 
CD11b+/GR1lo/CD11c−/F4/80+ whereas Asano found that CD169+CD11c- MΦs 
were not able to stimulate OT-I proliferation. So issues of MΦ definition remain to be 
clarified in order to rationalize these conclusions, however both studies clearly 
highlight an important role for MΦs in anti-tumour immunity and treatment.  
 
On the opposing side of the argument, many studies have found MΦs, particularly 
M2 MΦs, to be distinctly unhelpful616,628,629. Several studies have reported that the 
number of TAMs is associated with poorer outcomes in breast, ovarian and prostate 
cancers134,630. In a murine model of breast cancer, incorrectly polarized MΦs resulted 
from an EFG-CSF1 paracrine loop between MΦs and cancer cells, which augmented 
invasion and metastasis631–633. Using the murine hepatocellular carcinoma Hepa1-6 
model Wang et al showed that a change from MHC-IIHI to MHC-IILOW in TAMs was 
associated with tumour progression634. This was in concordance with the work of 
Baumgart in 1998 which had showed that MHC-IIHI MΦs were protective and 
showed a TH1 bias, while MHC-IILO MΦs promoted a TH2 response635. In other words 
the loss of antigen-presentation capacity significantly affected the TAMs’ ability to 
halt cancer growth.  
 
Aggressive tumours secrete factors such as macrophage inhibitory factor (MIF), 
which inhibits the migration of anti-tumour M1 MΦs toward the tumour636, and IL-10, 
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which is secreted by M2-type MΦs has been described as a tumour-derived factor 
involved in converting M1 MΦs to the M2, pro-tumour phenotype637. Tumours can 
attract circulating monocyte-derived MΦs by producing CCL2 and hijack them into 
pro-tumoural aides, which assist in tumour angiogenesis, ECM degradation and 
invasion616. Figure 8 overviews the multitudinous roles assigned to TAMs in the 
tumour microenvironment.  
 
Figure 8 TAMs as central regulators of the tumour microenvironment. Factors that promote the 
polarization of TAMs towards a pro-tumour phenotype (a–c) can be subdivided into those derived from the 
immune system, actively produced by tumour cells, or resulting from tissue stress. (a) From leukocytes, this 
includes cytokines and other soluble factors such as immune complexes. (b) Neoplastic cells can produce 
chemokines that recruit macrophages, including CSF1 and CCL2 depending on the tissue involved, as well 
as directly producing immunosuppressive molecules such as IL-10 and PGE2. (c) Signs of dysregulated 
tissues include leaky vasculature, hypoxia, ECM remodeling and cell death. These signals all direct the pro-
tumour functions of TAMs (d–f) including immune suppression, tumour cell dissemination, and promoting 
angiogenesis. (d) Immune suppression can occur through soluble or cell surface mediators, and may be 
indirect such as through the recruitment of regulatory T cells. (e) Neoplastic cell invasion of ectopic tissue 
can be promoted through directed release of cytokines such as EGF, or through protease-dependent ECM 
remodeling that may directly affect neoplastic migration or increase chemoattractant bioavailability. (f) In 
addition to the interplay of TAMs with endothelial cells through production of VEGFA and other 
angiogenic factors, subsets of TAMs expressing the Tie2 receptor interact with mural cells/pericytes to 
regulate vascular structure. Reprinted from Trends in Immunology, Volume 33, Issue 3, Ruffell, Affara & 
Coussens, Differential macrophage programming in the tumour microenvironment, Pages 119–126, 
Copyright March 2012 with permission from Elsevier. License #: 380622086418 (Ruffell, Affara, & 
Coussens, 2012). 
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While much pre-clinical and clinical data corroborate the hypothesis of a tumour-
promoting role for MΦs, exceptions do exist. Examples include the loss of tumour 
control when Kupffer cells were deleted in rat livers638. In a model of colon cancer 
deletion of peritoneal MΦs or Kupffer cells led to highly differentiated tumours and a 
reduced survival. Interestingly, while the tumours in mice that had a full complement 
of MΦs displayed hallmarks of malignancy, their tumour loads were lower and 
survival longer than MΦ-depleted mice639. Thus the clear anti- and pro-tumoural roles 
of MΦs were highlighted in these experiments and point to the need to modify MΦ 
activities, rather than eliminate them.  
 
A Review by Qian and Pollard stated that “Analysis of the transcriptome of TAMs 
derived from studies in mouse models of breast cancer has also provided evidence 
that an enrichment in macrophage transcripts is predictive of poor prognosis and 
reduced survival in human breast cancer”640. However, the 2009 study by DeNardo et 
al, showed that care must be taken when drawing direct predictions from mouse 
models for application to human cancers. That study showed strong differences in the 
cell populations in human versus mouse breast cancer. In humans CD4+ T cells are 
the predominant infiltrate, producing IFN-γ at levels 10-fold higher than IL-4 or IL-
13. In mice however, the predominant cells in MMTV-PyMT tumours are TAMS and 
the CD4+ T cells from these tumours show high IL-4, IL-13 and IL-10 with minimal 
IFN-γ641. These cytokines have a very strong influence on MΦ polarization and as 
such make it difficult to draw correlations between the human and mouse examples. It 
also highlights the importance of analysing the cytokine setting in which the TAMs 
are found before considering applications to other tumour types. Pollard, however, 
objects to DeNardo’s assessment of the leukocytic infiltrate in established human 
tumours as “inflammatory”, stating that “there are few of the hallmarks of 
inflammation, such as edema, swelling, and fever”640. Clearly there is still much room 
for discussion on these issues. 
 
Ruffell, Affara and Coussens sum it up nicely when they describe MΦs as having an 
‘identity crisis’627. They point out the difficulty of identifying TAMs due to their lack 
of lineage-defining markers and their varied marker expression that depends on 
activation status and the tissue in which the MΦ is found. They additionally highlight 
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the fact that murine MΦs are typically identified by the expression of F4/80, a 
molecule not expressed by all MΦ populations and also present on skin-resident 
Langerhans cells and adipocytic eosinophils. In addition, CD11c, the molecule most 
commonly used to identify DCs, is constitutively expressed by subsets of tissue-
resident MΦs and is induced on other MΦ populations under the kind of 
inflammatory conditions found in tumour microenvironments. As such F4/80 cannot 
be said to be the sole identifier of murine MΦs, nor can CD11c alone be used to 
positively identify DCs.  
 
Positive TAM identification in humans is further clouded since most 
immunohistochemistry studies rely on the single marker CD68, which is also 
expressed by fibroblasts in the tumour tissue627. This makes accurately assigning 
functional roles to TAMS very difficult. It may be that roles assigned to TAMS are in 
fact carried out by other stromal, myeloid or immune cells. Among other suspects, 
fibrocytes, mesenchymal cells that develop from monocyte precursors, have a dual 
MΦ/fibroblast phenotype and may be more involved in tumour promotion than is 
currently appreciated. Further careful dissection of the type of cell carrying out 
angiogenic, metastatic and immunosuppressive activities is still required for 
clarification of the situation. The point is not that TAMS do not carry out these 
activities, but that other cells do also and it is important to accurately identify the 
causative agent. 
 
An attempt by Galon and colleagues to improve colorectal cancer staging by using 
large cohort meta-analysis revealed that of the three main APCs, MΦs were at best 
neutral in terms of prognostic outcome: “only neutrophils and mast cells … showed a 
moderate positive impact on patient survival, whereas macrophages and iDCs were 
slightly (almost but not quite significantly) associated with a bad outcome”208.  
However it must be noted that this study does not appear to differentiate between M1 
and M2 MΦs and a paper published just 11 months earlier by Galon and colleagues 
specifically identified M1 MΦs as a positive prognostic indicator in colorectal 
cancer640.   
 
Continuing to look from the point of view of prognostic indicators, clinical trial 
results showed that penetration of tumours by CD8+ CTLs642,643, TH1 and TH17 CD4+ 
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T cells, NK cells, DCs and M1 MΦs is an independent predictor of favorable patient 
outcome. The opposite prognosis is frequently associated with intratumoural 
infiltration of CD4+CD25+FOXP3+ regulatory T cells, TH2 CD4+ T cells, myeloid-
derived suppressor cells, M2 MΦs and neutrophils. Thus the verdict on MΦs, while 
currently leaning toward the negative, may still be said to be out. 
 
1.11.4 B Cells in the Tumour Setting 
As with DCs and MΦs both pro-tumoural and anti-tumoural B cell correlations have 
been observed, as well as pertubations in B cell populations in cancer patients644. B 
cell infiltration of squamous cell carcinomas (SCC) of the vulva and head and neck 
were associated with a worse prognosis and mAB-mediated depletion of B cells 
improved the response to platinum- and Taxol-based chemotherapies622. A review by 
Gunderson highlights the pro-tumoural activities of B cells and discusses potential 
ameliorative approaches for cancer therapy645. 
 
While acknowledging the pro-tumoural role of B cells in certain cancer types, in pre-
clinical models of melanoma and breast cancer B cell elimination resulted in the loss 
of the anti-tumour response in vivo209,446. In a breast cancer model adoptive transfer of 
tumour-reactive B cells has been shown to inhibit lung metastases and ignite T cell-
mediated tumour regression213. In the clinical setting studies have also demonstrated 
increased survival correlating with B cell infiltration in high grade serous ovarian 
cancer646,647. Further, meta-analysis of immune cell infiltrates has demonstrated a 
positive correlation between TH1 cells and B cells in human colorectal tumours648. 
Individual studies have also reported improved clinical outcomes in patients with 
increased intratumoural or peritumoural CD20+ B cells (either alone, or in 
combination with other immune cells), including HCC649, melanoma650, bladder 
carcinoma651,652, prostate carcinoma653, serous epithelial ovarian carcinoma646,654, 
NSCLC655, HNC656 and multiple myeloma657. Thus, as with DCs and MΦs careful 
meta analysis of the data is required to refine our knowledge on which APC fosters a 
favourable outcome in which cancer type. 
 
Using different tumour cell lines modified to express model antigens (secreted OVA 
and PSA, intracellular GFP and membrane-boundHER-2/neu) Brown et al showed in 
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that absolute numbers of CD4+ and CD8+ T cells increased by about 2-fold in 
tumour-draining lymph nodes during the anti-tumour response, while B cell numbers 
increased seven to eight-fold658. Assays also showed high levels of anti-tumour 
antigen antibodies in the sera of mice growing OVA+, PSA+, GFP+ or HER-2/neu 
tumours. Numbers of tumour antigen-specific B cells also increased. This data 
highlights the importance of B cells in the anti-tumour response but it must be noted 
that this work also demonstrated the role of the tumour line itself in the size of the 
anti-tumour response, in other words, different tumour types will generate differing 
immune responses. Small cell lung carcinoma-OVA but not B16OVA or B16PSA 
tumours generated high antigen-specific antibodies. It must be noted that small cell 
lung carcinoma-OVA is generated in BALB/c mice, while B16OVA are generated in 
BL/6 mice and strain-specific immune responses have been noted in other studies, 
albeit MΦ-mediated153. However further dissection of these strain-specific differences 
is possibly warranted. 
 
Using a B cell knock out model Schultz et al demonstrated the essential role of B cells 
in the in vivo T cell response to retrovirally induced tumours659. Lack of B cells 
affected both the CD4+ and CD8+ T cells. The reduced CD8+ T cell response could 
reflect the lack of B cell help to TH CD4+ T cells, or it could reflect a previously 
unappreciated role for B cells in the CTL response. Further data by Schultz implied 
that B cells might be important for priming both T cell subsets. The B cell role in T 
cell priming was particularly strong in the lymph nodes and may represent an 
important focus in anti-tumour therapy given that tumours drain specifically to 
particular LNs as opposed to the spleen where more general lymph filtering occurs. 
Studies such as the one by Shultz demonstrate the collaborative, systems-biology 
nature of APCs in the anti-tumour response and emphasise the fact that no one APC 
alone is responsible for anti-tumour effects. It is for this reason, as well as the limited 
responses seen in DC ACT, that it is important to assess whether or not a synergistic 
improvement can be seen when more than one APC is used. The ideal scenario for 
some cancer types may be therapeutics that drive both a TH1 response, and an 
effective antibody response. If, as this thesis hypothesised, the combination of a DC 
and a B cell drives a superior T cell response, it is possible that this combination 
could also drive a useful anti-cancer antibody outcome.  
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When the immune system response to cancer is undermined, cancer outgrowth at the 
expense of normal tissue function is the result. CTL-resistant tumours develop escape 
mechanisms, generating an immunosuppressive tumour microenvironment in which 
CTLs can be shut down by inhibitory tumour mechanisms541. Tolerance toward cancer 
antigens can develop instead of immunogenicity and CTLs can become anergic. That 
being so cancer immunotherapy seeks to educate T cells and enhance their inherent 
ability to fight TAAs.  
1.12 Cancer Immunotherapy: Augmenting the Inherent Anti-tumour Response  
In the late 1800s the physician William Coley inadvertently initiated cancer 
immunotherapy following his observation of cancer regression in a patient with a 
concomitant erysipelas infection660. Subsequent attempts to treat cancer patients with 
bacterial infections met with limited success but provided the first hint at immune 
involvement in cancer control.  
 
The Age of Cancer Immunotherapy arrived in earnest in 2013 with Science Magazine 
heralding immunotherapy for cancer as “The Breakthrough Of The Year”661. The 
word cure is, understandably, used with caution among oncologists and the goal of 
many standard of care approaches these days is to prolong survival and augment the 
quality of remaining life where possible. However, the targeted inclusion of the 
immune system in the treatment of cancer has brought about a revolutionary approach 
to cancer care. The observation that patients with certain cancers such as renal cell 
carcinoma and melanoma sometimes experienced spontaneous remission 
demonstrated that the immune system could delay and even eradicate malignancies. In 
addition an increased rate of certain cancers has been documented among 
immunocompromised patients662,663. These observations led to studies of approaches 
that seek to augment the body’s natural immune response to cancer, such as 
identification of tumour-associated antigens, tumour-produced immune-suppressive 
factors as well as modifications to immune cells. 
 
Cancer immunotherapy has shown more objective promise in clinical trials than 
cancer vaccines664. A meta-analysis of the response to glioblastoma multiforme 
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revealed significantly longer times to recurrence in patients who had received 
immune-based therapies plus chemotherapy compared to those patients who had 
received immune-based therapy or chemotherapy alone665. However complete 
regression, partial responses, stable disease and progressive disease have been 
reported in all cohorts of cancer patients treated with immunotherapy, indicating 
response variation among patients and highlighting the need for ongoing 
characterization of all immunological aspects these treatments. 
 
In order for the immune system to destroy an established tumour, three conditions 
must be met: (1) adequate numbers of T cells with high avidity for tumour antigens 
(2) migration to and infiltration of the tumour stroma, and (3) activation of immune 
cells at the tumour location to initiate appropriate effector functions (lysis of tumour 
cells or the secretion of cytokines which can bring about tumour destruction)440,664. 
The success of immunotherapy ultimately depends on the targeted cytotolytic activity 
of innate natural killer (NK) cells and adaptive cytotoxic T lymphocyte (CTLs) via 
their production of IFN-γ and Fas/FasL-mediated killing. However there are multiple 
steps in the development of an anti-tumour response where the immune system can 
fail, as discussed previously in the section on immune evasion. Thus, there are 
multiple opportunities along this developmental path for immunotherapy to transform 
a faulty or faltering immune response. 
 
Figure 10 lists the immunotherapies that are currently available in the USA. 
Immunotherapy can be broadly divided into passive and active approaches666. Passive 
immunotherapies include tumour-targeting monoclonal antibodies (mABs) such as 
Keytruda (Pembrolizumab) that binds to PD-1 on the surface of tumours and T cells. 
Ipilimumab/Yervoy, the FDA-pproved anti-CTLA-4 mAB for advanced melanoma is 
another example. The use of oncolytic viruses to selectively lyse cancer cells is 
another passive immunotherapy approach, as is Adoptive Cell Therapy (ACT), which 
involves adoptively transferring activated lymphocytes back into the patient.  
 
Active immunotherapies include the use of immunostimulatory cytokines such as 
interleukin-2 (IL-2) or interferons. Inhibition of indoleamine 2,3-dioxigenase 1 


























metabolites. There is also the use of pattern recognition receptor (PRR) agonists for 
their role in augmenting antigen-presenting cell (APC) activation. One example is the 
use of Imiquimod in basal cell carcinoma to activate toll-like receptor (TLR) 7 on 
antigen-presenting cells (APC). Finally, agents that provoke immunogenic cell death 
(ICD), have also been used in active immunotherapy. Doxorubicin, one of the 
anthracyclines used to treat carcinomas, is just one example of an FDA-approved 
inducer of ICD. With regards to melanoma specifically, several of these approaches 
have been used in clinical trials including DC-loaded with melanoma cell lysates667, 
the cytokines IL-2668 and IFN-α669, adoptive transfer of tumour-infiltrating 
 Figure 9 Anticancer immunotherapy. Several anticancer immunotherapeutics have been developed 
during the last three decades, including tumour-targeting and immunomodulatory monoclonal antibodies 
(mAbs); dendritic cell (DC)-, peptide- and DNA-based anticancer vaccines; oncolytic viruses; pattern 
recognition receptor (PRR) agonists; immunostimulatory cytokines; immunogenic cell death inducers; 
inhibitors of immunosuppressive metabolism; and adoptive cell transfer. 1MT, 1-methyltryptophan; APC, 
antigen-presenting cell; IDO, indoleamine 2,3-dioxigenase; IFN, interferon; IL, interleukin; IMiD, 
immunomodulatory drug; NLR, NOD-like receptor; TLR, Toll-like receptor. From Classification of 
Current Anticancer Immunotherapies by Galluzzi et al105 Reprinted under the terms of the Creative 
Commons Attribution 3.0 License. Reprinted with kind permission of the author Jan 13 2016. 
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lymphocytes (TILs) accompanied by IL-2670,and the mAB anti-CTLA-4671, though 
successful treatment with α-CTLA-4 may be accompanied by immune-mediated 
vitiligo672. 
 
During homeostatic environmental sampling healthy tissues avoid phagocytic 
destruction by their surface expression of CD47, which sends a “Don’t Eat Me” signal 
by binding to SIRPα on the phagocyte surface673. Calreticulin, a pro-phagocytic 
damage-associated molecular pattern (DAMP), can block CD47, permitting removal 
of cellular remains674. The “Don’t Eat Me” signal path has been exploited by tumour 
cells to avoid immune-mediated destruction and attempts have been made to “make 
MΦs eat cancer” by the use of soluble anti-SIRP-α molecules52,625. Thus an 
understanding of how APCs specifically and non-specifically internalize undefined 
antigen can lead to improved tactics in the design of tumour immunotherapies. 
 
1.12.1 Adoptive Cell Therapy for Cancer 
Adoptive cell therapy (ACT) is a highly individual approach to cancer treatment, 
which involves removing patient T cells, and or, DCs and activating them ex vivo for 
the treatment of cancer. The patient’s immune cells are activated against the patient’s 
tumour outside the body, in some cases adapted to improve their specificity and 
response to cancer, expanded to large numbers and reinfused back into the patient 
Figure 11. Prior to reinfusion the patient normally undergoes lymphodepletion, the 
temporary removal of immune cells by chemotherapy or total body irradiation 
(TBI)36,675. Lymphodepletion eliminates immune-dampening TREGs along with other 
lymphocytes that would compete for lympho-specific cytokines necessary for survival 
of the transferred cells1,36,676,677. Lymphodepletion also provides better engraftment of 
transferred T cells, creating an environment that stimulates their proliferation, as well 
increasing the persistence of infused DCs. ACT with tumour-infiltrating lymphocytes 
(TILs) has the longest history but this type of ‘passive’ immunotherapy may not 


























The transfer of tumour-reactive T cells into patients has been applied in different 
ways: adoptively transferring TILs and high-dose interleukin-2; transducing patient T 
cells with highly reactive T cell receptors against the patient’s main tumour associated 
antigens (only available if the TAA(s) are known); or T cells genetically engineered 
to express chimeric antigen receptors (CARs) which essentially fuse a specific 
monoclonal antibody (immunoglobulin light chain variable fragment) onto the T cell 
CD3 transmembrane and endodomains yielding a hybrid TCR678. CAR T cells 
comprise an extracellular single chain variable fragment (scFv), hinge and 
transmembrane regions and intracellular domains that may contain 1, 2 or 3 signaling 
domains (reviewed in 679. The scFv is specific for a TAA, while the signaling domains 
consist of the essential CD3ζ chain and one or two costimulatory domains. Thus, in 
Figure 10 Tumours are often complex masses containing diverse cell types. These masses can be 
surgically resected and fragmented, and the cells can be placed in wells into which a T cell growth factor, 
such as interleukin-2 (IL-2), is added. T cell populations that have the desired T cell receptor (TCR) 
specificity can be selected and expanded, and then adoptively transferred into patients with cancer. Prior to 
this adoptive transfer, hosts can be immunodepleted by either chemotherapy alone or chemotherapy in 
combination with total-body irradiation. The combination of a lymphodepleting preparative regimen, 
adoptive cell transfer and a T cell growth factor (such as IL-2) can lead to prolonged tumour eradication in 
patients with metastatic melanoma. MDSC, myeloid-derived suppressor cell; NK, natural killer; TReg, 
regulatory T cell113. 
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the event of cognate antigen encounter in vivo the CAR T cell possesses all the 
necessary requirements for optimal activation. 
 
The most advanced CAR T cell clinical applications target CD19 on B cell 
malignancies and this approach has shown unprecedented response rates, of up to 
94% in acute lymphoblastic leukaemia patients, and striking response rates in Non-
Hodgkin lymphoma and chronic lymphocytic leukemia680–682. Combinations of the 
most potent CD4+ and CD8+ effector and memory subsets showed superior efficacy 
when compared to patients who received random populations of CAR T cells683. 
However, despite these revolutionary successes utility of CAR T cells is limited to 
cancers in which TAAs have been defined, and to TAAs which are, if not unique to 
tumours, at least do not provoke unacceptable autoimmunity risks in non-transformed 
tissues. 
 
Other issues that are yet to be resolved in the use of CAR T cells include improved 
homing to tumours and in some cases counter-strategies against immunosuppression 
in solid tumours, such as the induction of anergy in the CAR T cells (reviewed in679) 
and IDO-mediated anti-CD19-CAR T cell inhibition in CLL – although whether this 
may be circumvented with adjunct use of IDO-inhibitors is the subject of current 
investigation684. 
 
T cell therapies using defined tumour antigens has seen encouraging results in 
melanoma685,686 and other cancers681, although T cells specific for TAAs shared with 
non-transformed tissue have sometimes been shown to induce autoimmune side 
effects in T cell-mediated ACT681,682,687–690. And it must be noted that immunotherapy 
for melanoma with checkpoint inhibitors is often associated with immune-related 
adverse events691. Nevertheless recent meta-analysis of 5,737 patients showed that the 
overall cumulative incidence of vitiligo in Stage III-IV melanoma patients receiving 
immunotherapy was just 3.4%, and that patient group had 2-4 times less risk of 
disease progression or death692. Thus it appears that the risk of autoimmunity is low 
and may be protective, in the case of melanoma at least. Other studies have shown 
that autoimmune-mediated pathology does not always result from TIL infusion 
despite the presence of TCRs specific for identical non-mutated self antigens. These 
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data suggest exquisite regulation processes that allow the TILs to select between 
transformed and healthy cells675,686,693. One study in mice suggests that genetic 
predisposition may explain the appearance of autoimmunity in some TAA-loaded DC 
immunotherapy recipients and not others694. However GVHD comparisons between 
mice and humans receiving genetically altered tumour-specific T cells did not 
correlate695 therefore examination of patient genetics is required before genetic 
susceptibility to autoimmunity in certain human individuals can be confirmed.  
 
Obtaining cells from the patient eliminates issues arising from donor-host mis-
matches as in the case of Graft Versus Host Disease (GVHD). Although work with 
allogeneic ACT has revealed that there may not be an absolute requirement for 
autologous lymphocytes696,697. Allogeneic lymphocytes can be used with minimal 
GVHD-mediated attack of donated lymphocytes after the anti-tumour response has 
been initiated696,698 This is helpful in cases of immune-depleted or immune-exhausted 
individuals from whom the extraction of sufficiently high numbers of functional 
immune cells may not be possible.  
 
Another approach to ACT involves activating DC ex vivo and adoptively transferring 
them into the patient to induce or reanimate T cell responses in vivo666,699. The most 
common method of DC generation in the clinic is the expansion of precursor cells 
with GM-CSF and IL-4, due to the relative ease of generation of large cell numbers700. 
However some have questioned whether these DCs are the optimal DCs for use in 
DC-based ACT and are investigating the possible superiority of peripheral blood 
monocyte-derived DCs. Many varieties of DC-based approaches are in clinical trials 
or in clinical use, but broadly speaking they all involve activating patient DCs ex vivo 
against TAAs. TAAs in the form of peptides, lysates, mRNAs or vectors expressing 
TAAs have all been used.  
 
DCs exposed to biopsy-derived tumour cells, tissues or defined TAAs, are activated 
by the addition of maturation stimuli including pathogen by-products such as 
monophosphoryl lipid A (MPL-A), the less toxic, clinical version of 
lipopolysaccharide (LPS)(reviewed in701), immunogenic proteins such as Keyhole 
Limpet Hemocyanin (KLH), inflammatory cytokines702,703 or activated cells 
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expressing the T cell co-stimulatory molecule CD40L. Once activated these TAA-
loaded DCs have the capacity to generate TAA-specific effector CTLs in vivo, which 
can cause cancer regression and the generation of memory T cells thus preventing 
tumour recurrence.  
 
A variation on the DC ACT theme involves co-culturing the tumour-activated DCs 
with the patients’ own CD8+ T cells. The T cells that respond to TAAs are selected 
for further stimulation and these tumour-specific CTLs are returned to the patient. 
These CTLs are specific for TAAs that may be rare, or alternatively highly expressed 
on cancer cells, and are often not unique to cancer tissue. 
 
The combination of ACT and lymphodepletion with the T cell stimulatory cytokine 
IL-2 has brought about persistent tumour removal in several cancer types, including 
metastatic melanoma686,704,705. However, the use of IL-2 has also been shown to result 
in T cell exhaustion and poor memory T cell induction in patients (reviewed in706) and 
despite the patient’s T cell population being highly enriched for TAA-specific T cells 
tumours often persist, or recur (reviewed in26).  
 
DC ACT has been gradually established over the past twenty-something years with 
much in vitro work showing activation of T cells707 and several clinical studies 
showing that DC-based interventions can increase overall survival for some 
patients7,697,704,708–714. A highlight of this work came in 2010 with FDA approval of 
Provenge® (sipuleucel-T), the first DC-based cancer vaccine for prostate cancer715. 
While DC are undoubtedly the single most effective APC, they do not work alone in 
vivo and the field would benefit from an assessment of the how other APC enhance 
the DC-T cell activation process.  
1.12.2 DCs in Cancer Immunotherapy 
It has been demonstrated, both in vitro and in ACT in mice, that DCs pulsed with 
tumour lysates, synthetic tumour-derived MHC-I-restricted peptides or tumour-cell-
derived RNA all generate CTL-mediated anti-tumour responses713,716–721. Similarly 
clinical trials of DCs treated with peptides, tumour lysates or viral vectors that encode 
specific antigens have demonstrated objective anti-tumour responses714,722. Ex vivo DC 
pulsed with autologous tumour antigens have been reported to induce tumour-specific 
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responses in cancer patients723,724 and numerous clinical trials have been undertaken to 
investigate the ability of DC exposed to whole tumour lysate to provoke curative T 
cell responses against cancer397,697,709,712,713,725–730. However, while an immunological 
response, as measured by anti-tumour T cell activation, can be detected in DC 
vaccination strategy evaluations, a divergence remains between the immune response 
and ultimate clinical outcomes664. 
 
Recent work by Engelhardt et al indicates that CD11c+ DCs present in the tumour 
margin, can be seen to couple with CD45.1+ cells of haematopoietic origin in the 
tumour micro-zone and are the cells that best present tumour antigen to these cells731. 
This study points toward DCs being the primary APC in the tumour 
microenvironment, however much remains to be fully clarified about the cells 
observed. Fairly ‘broadly applicable’ cell surface markers were used for cell 
identification and it remains to be confirmed whether or not the prime cells were M1-
type tumour associated macrophages or DCs.  
 
In two tumour models, TS/A mammary carcinoma and MC-105 sarcoma, BALB/c or 
C57BL/6 mice immunized with tumour lysate-pulsed DCs developed significantly 
fewer pulmonary metastases than mice immunized with irradiated tumour cells732. 
Compared to unimmunized mice, subcutaneous immunization with lysate-loaded DC, 
DC pulsed with apoptotic tumour cells or DC co-cultured with live tumour cells all 
yielded significantly fewer lung metastases. These data indicated that DCs loaded 
with undefined tumour antigens are able to generate effective anti-tumour T cell 
responses. Two further studies have also demonstrated the effectiveness of DCs 
loaded with undefined TAAs. In one, co-administration of the TLR-9 agonist CpG 
with tumour lysate in a murine model of glioma brought about increased total T cells 
and activated DCs in draining lymph nodes; two times greater survival; up to 55% 
tumour-free mice; and significantly greater IFN-γ production and tumour cell lysis by 
splenocytes733. The other study also utilized the immune-enhancing effects of CpG but 
used a different approach. Pulsing lymphoma cells with CpG for 24 hours prior to co-




Pulsing ex vivo DCs with autologous tumour lysate has also been used in various 
clinical trials. In double-negative breast cancer this approach saw increased 
circulating NK and CD8+ IFN-γ+ T cells along with delayed-type hypersensitivity 
and TH1 cytokine production, however there was no overall survival benefit compared 
to patients not receiving the vaccine735. 
 
Human studies with tumour lysate have all used CD14+ monocyte-derived 
DCs172,397,398,707,711–713,726,728–730,735–754 and work is ongoing to perfect the parameters for 
GMP-grade production of autologous, tumour-lysate-pulsed dendritic cells755. To our 
knowledge only DCs have been used as APCs in clinical trials of ACT for cancer, 
with or without tumour lysate as the antigen source, and DC-mediated ACT has had 
some very encouraging, but limited successes713,756,757. The benefits of the use of 
tumour lysate as a source of TAA will be discussed further in a later section. 
 
Due to their potent antigen presenting capability DCs are by far the most commonly 
used in clinical trials, however they are not immune to modulation by growing 
tumours615. There is evidence for DC cancer vaccines inducing good immune 
responses and clinical benefit has been gained in some individuals711,725,758, however 
widespread, consistent results remain elusive. This highlights the importance of this 
study in ascertaining whether or not benefit can be gained by including other APCs in 
the presentation of undefined tumour antigens to T cells. It was thought until quite 
recently that DCs were the only APC capable of priming a naïve T cell. However it is 
now well established that appropriately activated B cells238,243,250,759–761 and 
MΦs42,145,167,177,178,180,181,312,762 can also act as effective APC to both CD4+ and CD8+ T 
cells. There is precedent for the use of both MΦs and B cells293,763 as lysate-loaded 
APCs in the anti-cancer setting. 
1.12.3 Macrophages in Cancer Immunotherapy 
Under resting conditions BMMΦs produce high levels of suppressive cytokines (IL-
10 and TGF-β)764 in line with their homeostatic anti-inflammatory role in tissues, 
therefore polarisation toward M1 is desirable clinically for use in anti-tumour ACT. 
They are highly responsive to their milieu and modify their functions accordingly. 
Coussens et al suggest that re-polarization, rather than elimination, of MΦs is 
probably the way forward for using MΦs in anti-tumour therapies627. 
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While most immunotherapies have been directed at adaptive immune responses, MΦ-
mediated innate-directed treatments are also entering the immunotherapeutic arena765–
767. Clinical use of MΦs has focused on their tumouricidal activity with the use of 
IFN-γ-activated “killer MΦs”, not their APC capacity180. However, MΦ phagocytosis 
has also been implicated as an important mechanism of action in mAB-mediated 
immunotherapies, leading to exploration of approaches for enhancing MΦ responses 
to mABs767.  
 
In 2011 Beatty and colleagues reported on a clinical trial in which anti-CD40 mABs 
plus gemcitabine chemotherapy were tested in a small cohort of pancreatic ductal 
adenocarcinoma (PDA) patients768. The CD40 mABs were used for their T cell-
stimulating properties and tumour regressions were observed in some patients. In 
testing the mechanism of action in a mouse model they unexpectedly discovered that 
tumour regression required MΦs, but not T cells or gemcitabine. CD40-activated 
MΦs rapidly infiltrated tumours, lysed tumour cells and mediated tumour stroma 
destruction, demonstrating MΦ-mediated, T cell-independent elimination of these 
tumours.  
 
In another example of immunotherapy harnessing the direct cancer-fighting ability of 
MΦs in conjunction with mABs, Weiskopf and colleagues used MΦ recognition of 
CD47 to ameliorate tumour escape mechanisms625. CD47 on healthy cells is 
recognised by MΦs via the SIRPα receptor. Tumours escape MΦ-mediated immune 
destruction by expression of CD47. Weiskopf et al created SIRPα variants, high-
affinity CD47 antagonists and used them in combination with the anti-tumour mABs 
rituximab in lymphoma, or trastuzumab in breast cancer, to effectively treat several 
mouse tumour models. These studies highlight, amongst other things, the direct roles 
of MΦs in the anti-tumour response, and the possibilities of harnessing those 
capabilities in cancer immunotherapy.  
 
In a review Kershaw and Smyth note that the work by Weiskopf et al suggests that 
MΦs anticancer potential may have been underestimated769. They reason that mABs 
against the T cell-regulatory molecules cytotoxic T lymphocyte-associated antigen 4 
(CTLA4) and programed death 1 (PD-1) combined with the likes of variant SIRPα 
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monomers to block the ‘Don’t Eat Me’ signal to MΦs could potentially revive both T 
cell and MΦ anti-cancer responses. In light of these many potential cancer-fighting 
properties of MΦs we wished to compare their ability to activate T cells against lysate 
antigens. 
1.12.4 B Cells in Cancer Immunotherapy 
Because the use of DCs as the sole APC in cancer immunotherapy has yielded 
disappointingly low and inconsistent results some investigators are now pursuing the 
therapeutic potential of B cells as an alternative autologous APC213,293,770–772. 
Advantages over DC include larger cell numbers from smaller volumes of peripheral 
blood, a significant consideration for sick patients. Autologous B cells are available in 
vastly higher numbers than DCs and easily further expanded in vitro with soluble 
CD40 ligand to generate oligoclonal populations294,772. 
In the pre-trial phase ex vivo expansion of CD40-stimulated B cells loaded with 
melanoma cells, cell lysates or peptides resulted in activation and expansion of 
antigen-specific naïve and memory CD4+ and CD8+ T cells293,294. Interestingly 
antigen acquisition was via non-specific uptake mechanisms and was not BCR-
mediated. Nonetheless the high levels of antigen combined with CD40 signaling 
yielded sufficient costimulatory action for T cell priming.  
 
Two further pre-clinical studies have also demonstrated that antigen uptake via the 
BCR was dispensable in the induction of T cell immunity both in vitro and in vivo 
avoiding the requirement for antigen specific B cell expansion. In one study B cells 
were used to deliver viral antigen to T cells via mRNA electroporation773. In the other 
anti-CD19 mABs were used to specifically target B cells as APCs259. This feature of B 
cell antigen presentation raises the interesting possibility of B cells being extremely 
useful in the presentation of undefined TAAs to T cells. 
 
In an example of B cell-mediated immunotherapy, the Herrera group have reported 
data from ongoing clinical trials of antibody-inducing vaccines that high tumour-
specific IgG and IgM titres were generated in 80% of patients and that survival was 
significantly improved with these vaccines. The induced ABs were specific for the 
patient’s tumour cells and were responsible for the direct killing of the tumour cells. 
Notably it was the cytotoxic ability of the patient sera, not the AB titre per se, that 
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corresponded with increased survival. (Herrera, unpublished data from ongoing 
clinical trial, Cancer Immunotherapy Consortium conference, Aug 2012; 311). 
 
In the literature we found that two other groups have looked at B cell presentation of 
tumour lysate 293,763 and demonstrated successful CD4+ T cell activation by lysate-
pulsed B cells. We are not aware, of any studies examining B cell activation of CD8+ 
T cells with tumour lysate.  
1.13 Tumour lysate As a Source of Tumour Antigen 
In early phase cancer clinical trials researchers and clinicians face an uphill battle. 
Patients in early phase clinical trials are often those for whom gold-standard levels of 
care options have been exhausted. They have received the best treatments that current 
medical knowledge allows and those treatments have failed. Consequently these 
patients are ill, possibly immune-suppressed, and have established tumours, which 
have immune avoidance mechanisms in place to switch off immunotherapy-supplied 
T cells that enter the tumour microenvironment. In this scenario it is a wonder that 
any patient has benefited from immunotherapy – and yet some do. And it may be that 
immunotherapy with tumour lysate, with its broad repertoire of TAAs, that offers 
hope for preventing future tumour escape.  
 
Many TAAs recognised by T cells have been characterised. Some TAAs are unique to 
tumour tissue and are the result of mutations of critical genes in cell proliferation, 
differentiation and death pathways. Mutations in β catenin774, cdk4775, mutated p53776 
and RAS–RAF–MEK–ERK–MAP kinase signaling777 are some examples. Other 
TAAs are shared with healthy tissues and include cancer testes antigens (MAGE, 
BAGE, GAGE778), differentiation antigens (MART-1/Melan-A, tyrosinase, gp100779) 
and overexpressed, non-mutated antigens (wild type p53776, Her2/neu780). Antigens 
derived from carcinogenic viruses, such as the human papilloma virus responsible for 
cervical cancer in women, are also able to be recognised by T cells781. APCs located 
in the blood, spleen, LNs and tissues can be exposed to disseminated TAAs in the 
form of soluble proteins, RNA, DNA, immune complexes, apoptotic debris and 
necrosis, from tumour tissue that has broken down under cell death or stress 
processes782.  
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However, despite melanoma and numerous other cancers having various known 
TAAs that can be recognised by T cells783–785, limited success has been seen with the 
use of molecular vaccines based on individual cancer proteins, peptides or nucleic 
sequences. A 2008 meta-analysis of hundreds of clinical trials of many different 
cancer types showed that greater clinical success has been obtained using whole 
tumour cells or their extracts than defined antigen approaches786. For these reasons the 
use of tumour lysate (TL) has been investigated in pre-clinical models and used in 
clinical trials as a source of the full repertoire of TAAs. 
 
However, live tumour cells are poorly immunogenic and actively produce 
immunosuppressive factors such as vascular endothelial growth factor (VEGF) that 
suppresses DC differentiation and maturation787, Fas-ligand that induces T cell 
programmed cell death788 and MIC ligands that block NKG2D-facilitated destruction 
by immune cells789. Galectin-1113 and indoleamine 2,3-dioxygenase790 prevent  T cell 
activation while IL-10791 and TGF-β792 have additional immunopathology-repressing 
effects on DC and T cell functions that impede an anti-tumour response. 
 
Thus TL contains all possible immunogenic antigens in the patient’s tumour, while at 
the same time containing tolerising and immunosuppressive, properties due to it being 
prepared from self-tissue. These properties make it exquisitely suited to activating a 
patient’s immune system against their TAAs, however the self-antigens among the 
transformed targets render it a problematic immune stimulator. Overcoming the 
immune-inhibition mechanisms, which serve to protect against anti-self responses, 
that are utilized by tumours to evade destruction by the immune system is one of the 
major hurdles of immunotherapy in general, and of the use of TL in particular.  
 
Many examples exist in the literature of the successful use of TL both in pre-clinical 
models and in clinical trials709,711,728,733,739,745,793–795. From a clinical perspective there are 
several clear benefits to using autologous whole tumour lysates. In the first instance 
no patients are ineligible for antigen-presenting cell-whole tumour lysate therapy as 
there is no requirement to select patients on the basis of their HLA-A2 status. 
Furthermore, TL potentially offers the full spectrum of TAAs to both CD4+ and 
CD8+ T cell types, generating a more robust primary immune response, as well as 
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lessening the possibility of tumour escape. ‘Help’ from CD4+ T cells fosters long-
term CD8+ T cell memory, giving them the ability to expand should they ever re-
encounter that antigen, essential preventing recurrence of the cancer796–798.  
 
However, perhaps the most compelling evidence for the continued investigation of 
TL’s clinical utility comes from the clinical outcomes of peptide-pulsed versus whole 
tumour cell-pulsed vaccinations, which show that more patients experienced objective 
clinical responses to whole tumour or tumour extracts used as antigens (including DC 
loaded with tumour extracts, modified tumour cells or tumour RNA) than to specific 
tumour antigens (synthetic peptides or proteins and viral or plasmid vectors encoding 
peptides or proteins)786. 
 
In this thesis MHC class I and II-restricted presentation and cross-presentation of 
whole OVA protein, OVA peptides and OVA-secreting B16.OVA melanocyte lysate 
was assessed using transgenic mice bearing T cell clones with TCR specific for H-
2K(b)/OVA323-339  and H-2K(b)/OVA257-264 (SIINFEKL) epitopes. The TCR of OT-I 
CD8+ mice respond exclusively to the SIINFEKL peptide, while the TCR of OT-II 
CD4+ mice respond only to OVA323-339, thus allowing the generation of high numbers 
of responding T cells and tracking of CD4+- and CD8+-mediated responses. The B16 
murine melanoma model is widely used and established as invaluable in the 
development of effectual ACT approaches for melanoma patients799. As a non- or 
low-immunogenic tumour799 B16 melanoma provides one of the more rigorous litmus 
tests for evaluating an immunotherapy procedure. Murine DCs loaded with apoptotic 
B16 melanoma cells have been shown to induce anti-tumour immunity173. In those 
studies both CD4+ and CD8+ T cells were activated and the anti-tumour response 
required both cells.  
 
Targeting a genetic mutation in a tumour, such as the ALK mutation in some 
neuroblastomas, is another approach to individualized treatment. But the only a small 
percentage of tumours are caused by a single, or few, genetic mutations, and most 
show genetic evolution and plasticity during their development. Melanoma’s 
inflammation-induced reversible dedifferentiation is just one example800. The results 
of a large genomic study of the childhood cancer neuroblastoma indicated that the 
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likelihood of finding common genetic anomalies appears to be quite low801. While 
confirming ALK mutations in approximately 10% of patients, and finding single digit 
percentages in a few other gene mutations, they found few of the expected recurrent 
gene mutations that would identify potential neuroblastoma targets801,802. The 
challenge with defining immunogenic targets by gene sequencing alone is that you are 
pursuing a moving target. They concluded that tumour targets must be thought of as 
dynamic, not static targets due to their DNA instability. Each tumour will be at a 
different stage of development in each patient and the knowledge of when to target 
each genetic change as they arrive would take decades of study, if it could ever be 
attained.  
 
By contrast, cell therapy targeted against known and unknown TAAs with TL ignores 
genetic changes that have occurred, or may yet occur, and treats the current state of 
the tumour. Enhancing the patients’ own APC and T cell responses to that current 
state, should, in theory, generate an anti-tumour response. Speed is critical when 
trying to eliminate rapidly changing tumour cells. The cells must be prepared within 
as short a time frame as possible – hours to days where possible, not weeks or months. 
 
Finally, Cornforth makes the point that lysates from patient tumours may contain 
cancer stem cells, which could account for their effectiveness at preventing 
recurrence, since the ‘source’ cell antigens are also identified and destroyed415. 
1.13.1 Which Form of Cell Death is More Immunogenic? 
Polly Matzinger introduced the “Danger Model”, a paradigm shift suggesting that 
immunity is not just activated against foreign, non-self entities but also distressed, 
damaged, destroyed and dead cells of the organism78,803. Under this paradigm the 
encounter by immune cells of intracellular components in the extracellular milieu is 
what alerts the immune system to “danger”. Items such as nucleic acids, lipids, 
HMGB1 protein, ATP, uric acid and other intracellular components are only released 
under conditions of anomalous cell death804. These trauma-induced intracellular 
components can, in addition to bacterial and viral moieties, bind to TLRs and activate 
inflammatory responses95. Identification of which components of endangered cells 
engage with the immune system has been the focus of many studies of discrimination 
between forms of cell death804–806. A large study showed that TLRs are not only used 
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for PAMPs but also for stress-signals such as HMBG1 released from apoptotic 
tumour cells dying after chemotherapy or radiotherapy. The mutational loss of TLR4 
in breast cancer patients abrogated the anti-tumour response12.  
 
Tumour cells can be treated by non-lethal UVB irradiation, gamma irradiation, 
oxidation, heat treatment and freeze-thaw lysis to achieve apoptotic or necrotic cell 
death or senescence (permanent arrest of the cell cycle in G1 phase) as required. 
There has been debate in the literature over which form of cell death is more 
immunostimulatory. Apoptotic cells can release TLR4-binding HMGB1807. 
Additionally intracellular calreticulin appears on the apoptotic cell’s surface and binds 
to the CRT receptor on the surface of MΦs and DC leading to receptor-mediated 
phagocytosis14, DC activation and a CTL response.  Phosphatidylserine (PS) is 
another normally intracellular molecule that ‘flips’ to the external cell surface of 
apoptotic cells and encounters the PS receptor on DC leading to the initiation of cross-
presentation of TAAs by the DC808–810. Work by Asano showed that apoptotic, x-ray 
irradiated OVA-transfected EG7 T cell thymoma cells presented by CD169+CD11c+ 
MΦs in the boundary between the sinus and the T cell zone were able to stimulate 
OT-I T cell proliferation and cytokine production177.  
 
However the majority consensus appeared to be that necrotic cell death is the more 
immunogenic form of cell death, primarily owing to the release of inflammation-
inducing DAMPs811. Necrotic cells release heat shock proteins (HSP) such as HSP70 
and 90 and HMGB1, all of which interact with toll-like receptor 4 (TLR4) on DC 
triggering antigen processing and presentation12,812. Inhibition of fusion between the 
phagosome and the lysosome means these potential TAA are not degraded but traffic 
to the antigen presentation compartment794. Glucose-regulated protein 170 (GRP170), 
an endoplasmic reticulum (ER) chaperone related to HSPs, is able to interact with 
scavenger receptor A on DC and increase tumour cell immunogenicity813. Uric acid, a 
by-product of purine metabolism, is also released by necrotic cells and induces DC 
maturation814,815. Necrotic cells are able to induce incomplete DC maturation in the 
absence of maturation stimuli816 most likely as a response to the profusion of HSPs 
released by dead cells172,753. Necrotic cell lysate can be generated by repeated freeze-
thaw cycles and produces a substance comprising all cell components from the 
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demolished plasma membrane, cell RNA and DNA and organelles such as the 
mitochondria.  
 
Obeid et al made a shift in this thought paradigm with the discovery that calreticulin 
relocation from the cytosol to the cell surface dictated the immunoreactivity of the 
cell as opposed to the necrotic or apoptotic status of the cell14, pointing to the fact that 
the style of death is probably of less importance than which immunosuppressive or 
immunoreactive molecules are upregulated or released in response to the death 
process. Yatim et al may have concluded the argument with their recent report that 
cross-priming of CD8+ T cells depends on receptor-interacting protein kinase-1 
(RIPK1) dimerization and nuclear factor κB (NF-κB)–induced transcription within 
dying cells, which can be upregulated by both apoptotic and necrotic cells817. 
Nonetheless, while neither CRT, nor RIPK1 expression was analysed, Chiang’s work 
with TL has shown that necrosis of tumour cells can be most efficiently achieved by 
oxidation of the tumour cells with hypochlorous acid (HOCl) prior to lysis739,741 and 
that oxidized lysate stimulates an enhanced immune response compared to freeze-
thaw lysis.  
 
Debate continues over whether necrotic or apoptotic lysate is more immunogenic, but 
both have been shown to have comparable ability to mature DCs and to generate an 
anti-tumour immune response when presented by DCs in vivo. We had observed T 
cell responses to soluble freeze-thaw lysate in previous work but we were interested 
to compare the response with a potentially more immunogenic lysate. 
1.13.2 Improving the Immunogenicity of Tumour Lysate 
Various approaches to TL have been used in pre-clinical models and in the clinic, 
including necrotic TL, apoptotic tumour cells, oxidised whole tumour cell lysates, 
DC-tumour fusion vaccines, DCs pulsed with whole tumour RNA (reviewed in 794).  
 
Supernatants (SN) of freeze-thawed TL, such as was used in this study, have also 
been used in clinical trials as a source of tumour-derived antigens. These supernatants 
mainly consist of soluble tumour proteins, which are taken up by DC via non-specific 
macro-pinocytosis818, processed and presented on MHC class II molecules to CD4+ T 
cells. However this non-receptor-mediated uptake of antigen does result in 
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significantly less cross-presentation of soluble ovalbumin than cell-associated OVA 
protein819. In addition, SNs are also likely to contain tumour-produced 
immunosuppressive factors alongside the cross-presentation-enhancing HSPs, 
HMGB1, uric acid and pro-inflammatory cytokines. 
 
Debate also continues over whether or not TL is immunogenic at all, with some 
researchers reporting freeze-thaw-derived lysates as being inhibitory to DCs175,820 and 
others observing the opposite397,821. Of critical importance in this debate is the method 
of TL preparation, which determines the way in which the tumour cells die. It is 
believed that cells releasing ‘stress’ factors, or ‘danger’ signals upon death are able to 
generate a strong immune response whereas cells quietly and neatly undergoing 
apoptosis do not tend to elicit this same response. Hatfield has demonstrated the 
partial reversal of lysate-induced DC suppression in vitro by inducing tumour cell 
stress prior to lysis. Only DCs pulsed with stressed cell lysates provided protection 
against tumour challenge175. 
 
HOCl oxidation of cells prior to lysis has also been demonstrated to enhance TL 
immunogenicity740,741,822. After comparing different cell death methods Chiang found 
that induction of oxidative death prior to lysis was a superior method for increasing 
the immunogenicity of ovarian cancer lysate398,739–741,823. Chiang cites three possible 
mechanisms why oxidized lysate is more immunogenic than non-oxidised. The 
deamination of serines converts side chains to aldehydes, which are more 
immunogenic824; the unraveling of protein structure to reveal hidden epitopes; and 
scavenger receptor recognition of oxidized lipids. However Prokopowicz and 
colleagues reported that modification of the N-linked carbohydrate side chain, not the 
formation of aldehydes or chloramines, was responsible for enhanced presentation of 
HOCl-modified OVA825. Increased efficiency of uptake of HOCl-OVA was receptor-
mediated and they are investigating whether the scavenger receptor lectin-like 
oxidized low-density lipoprotein receptor (LOX-1) is the target. Targeting 
glycoprotein antigens to scavenger receptors on the APCs surface helps explain the 
improved immunogenicity of HOCl-lysate. 
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Given that TL is often suppressive, using APCs with TL enables researchers to 
improve TL immunogenicity by influencing DC behavior in the course of ex vivo 
pulsing. Interferons, Toll-like receptor agonists and p38 mitogen-activated protein 
kinase (MAPK) inhibitors can all be used to influence the milieu of the DCs, leading 
to DC differentiation that steers the polarization of T cells into CTL and TH17 cells as 
opposed to TREG826 . Indeed initial mouse vaccine research indicated that murine bone-
marrow-derived DC pulsed with whole TL could provoke a strong anti-tumour 
response and cytolytic activity in vitro and in vivo827. Inducing DC maturation with 
maturation stimuli such as TNF-α, IL-1β, IFN-γ, prostaglandin E2 and R848 (a TLR8 
agonist) can improve DC capacity to present TAA703 and the effectiveness of clinical-
grade DC-based vaccines should be greatly enhanced once the ideal combination of 
maturation compounds is outlined828. 
 
Lysates have shown varying immunogenic responses in vitro, however both apoptotic 
and necrotically prepared cells have demonstrated anti-tumour responses when 
presented by DCs in vivo. The first clinical trial for ovarian cancer using oxidized 
whole tumour lysate and DCs was begun in 2012745. A combinatorial approach was 
used that included intravenous bevacizumab to inhibit tumour-induced angiogenesis, 
and oral cyclophosphamide to inhibit TREGs, lymphodepletion and vaccine-primed T 
cells. Initial results published in 2013 showed that of the initial six patients four had 
achieved clinical responses, including one complete response728. The trial is ongoing 
with further modifications to optimise outcomes.  
1.14 Significance: Defined Tumour Antigens and DCs Are Not Enough 
Mature DCs have been demonstrated to provide protective anti-tumour immunity, and 
the majority of the immunological community believes that a protective T-cell-based 
anti-tumour response is contingent upon fully-functioning DCs. However, despite 
some dramatic successes, clinical results in DC ACT remain disappointing for reasons 
that are not yet completely understood. In spite of the DC’s impressive antigen 
presentation credentials various factors do limit their clinical use, namely their 
scarcity in peripheral blood (<1% of total leukocytes)829, inefficient migration to 
secondary lymph tissue after administration, their destruction by antigen-specific TEM 
cells en route to lymph tissue, lack of proliferation, and their relatively short T cell 
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presentation time in vivo. Hence, the promising pre-clinical studies have not resulted 
in further FDA-approved DC-based immunotherapies beyond the 2010 approval of 
Provenge for prostate cancer830,831. 
 
Thus the best APC, or combination of APCs, for tumour immunotherapy is yet to be 
defined. Published work describes DCs as the foremost APCs but clearly shows that B 
cells and MΦs also have important antigen-presentation abilities, which differ 
according to the particular immune setting. MΦ behaviour can be manipulated toward 
the desired effector functions while B cells can be easily expanded and migrate to 
LNs avoiding destruction by antigen-specific T cells283,294,832,833. Both MΦs and B cells 
have been explored as alternatives to DCs for cell-based therapies176,181. 
 
Importantly, while many studies have looked at non-naturally occurring virally 
transduced or genetically engineered antigens few studies have assessed cross-
presentation of naturally occurring antigens processed from apoptotic/necrotic tumour 
cells. Given that the promise of DC ACT has failed to deliver robust clinical results 
this work seeks to identify whether we have overlooked something in the choice of 
DC as the singular APC for ACT.  
 
Ralph Steinman, in commenting on limitations in the use of defined tumour peptides 
for DC-based immunotherapy states: “Cancer cells are much too formidable to 
combat with limited weaponry”699. This sentiment seems appropriate not just for the 
use of a broad range of TAAs, as are found in tumour lysate, but also for the 
examination of a wider range of APCs. The success of ACT depends, in part, on being 
able to generate sufficient numbers of patient cells to carry out the procedure. 
Deriving adequate numbers of DCs from cancer patients for generating DCs for ACT 
is difficult, even more so in the case of peripheral blood DCs to which the ACT 
community may be turning700,834, therefore being able to combine patient DCs and B 
cells and, or, MΦs would help reduce this rate-limiting step in the procedure. To help 
delineate a more efficient APC therapeutic strategy this study considered the 
efficiency of T cell responses to lysate TAAs presented by DCs compared with MΦs,  
B cells and combinations thereof. In the same way that combination immunotherapies 
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are the treatment du jour for cancer, we believe that combinations of APC should be 
given more attention in ACT.  
1.15 Hypothesis and Aims: 
The over arching goal of this research project was the improvement of adoptive T cell 
therapy for cancer, which was addressed by asking these questions:  
1. Does oxidised lysate result in an enhanced T cell response compared to 
soluble freeze-thaw lysate? 
2. Does a combination of APCs enhance T cell responses to lysate when 
compared against using DCs alone? 
3. Are both CD4+ and CD8+ T cells activated into effector cells when primed 
with tumour lysate(s) by GMDC or a combination of APCs? 
4. What is the cytolytic capacity of lysate-primed CD4+ and CD8+ T cells in 
vitro and in vivo? 
 
We hypothesised that priming T cells against tumours using tumour lysate-derived 
antigens would be enhanced by the combination of a DC and a MΦ, or a DC and a B 
cell, or a B cell and a MΦ, or all three APCs combined. 
 
This hypothesis was tested through the following objectives: 
1. Preparation of soluble fraction freeze-thaw lysate and oxidised whole freeze-
thaw lysate. 
2. Analysis and comparison of the three APCs’ response to loading with soluble 
and HOCl-oxidised lysates. 
3. Examination of the proliferation response and cytokine profile of T cells 
primed with the various lysate-loaded APC(s). 
4. Identification of which APC(s) stimulated the greatest cytotoxic T cell 
response. 
 
Figure 12 outlines the basic experimental approach to these hypotheses. Chapter 3 
comprises the results of soluble and oxidised lysate preparation, optimising APC 
culture conditions and the response of APCs to loading with lysates. Chapter 4 
presents the results of the T cell phenotype response to being primed with lysate-
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loaded APCs. Chapter 5 encompasses the T cell functional response of in vivo 
cytotoxicity post priming with oxidised lysate-loaded APCs. 
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Materials & Methods 
“Cancer cells are much too formidable to combat with limited weaponry” 
Steinman & Dhodapkar 20011 
 
2.1 Culture of B16.OVA Tumour Cells 
B16-F0 is a murine melanoma cell line of C57BL/6 origin and H-2b haplotype. 
B16.OVA cells are derived from B16.F0 but have been stably transfected with 
chicken ovalbumin (OVA) cDNA and secrete the OVA protein, which was used as a 
model tumour antigen in this study. These cells originated from cells that were 
transferred from the Malaghan Institute of Medical Research, Wellington, New 
Zealand on March 5, 2008. The cells were tested to confirm they were free of 
Mycoplasma (Appendix 1, Supplementary Figure 1).  
 
Vials of B16.OVA melanoma cells were removed from liquid nitrogen storage and 
thawed quickly in a 37°C water bath until a small piece of ice remained in the vial. In 
a laminar flow hood Dulbecco’s Phosphate Buffered Saline (DPBS) (Appendix 2) 
with 5% Foetal Bovine Serum (FBS) (DPBS5) was immediately added to the thawed 
cells and the cells centrifuged at 300 x g for 5 minutes at 4°C. This wash step removes 
the freezing mix that contains the cryoprotectant dimethyl sulfoxide (DMSO) added 
to prevent cell death during freezing. The supernatant was discarded and the cells 
resuspended in 5 mL Roswell Park Memorial Institute Medium1640 supplemented 
with 10% FBS (RPMI10; Appendix 2) and 1% Geneticin® (Geneticin® Selective 
Antibiotic (G418 Sulfate) (50 mg/mL); Life Technologies; Cat: 10131035) for 
plasmid antibiotic selection. The addition of Geneticin® creates a selective medium 
that selects for cells expressing the plasmid responsible for production of ovalbumin 
(OVA) protein. The cells were added into an additional 5 mL RPMI10 in a BD Falcon 
tissue culture flask (BD Biosciences) and the resuspended cells pipetted into the flask. 
Cells were incubated at 37°C with 5% CO2. Cells were grown to approximately 80% 
confluence prior to being split into two (or more) tissue culture flasks for further 
expansion of cell numbers. B16.OVA cell growth was tested in complete Dulbecco’s 
Modified Eagle Medium (cDMEM) and complete Iscove’s Modified Dulbecco’s 
Medium (cIMDM) but enhanced cell growth was achieved in RPMI10.  
2 
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Cells were passaged by pouring off non-adherent cells into a 50 mL Falcon tube, 
rinsing the flask with DPBS and adding enough warm DPBS with 0.02% EDTA to 
cover the surface of the flask. EDTA is used for the dissociation of attachment-
dependent cell lines from plastic ware. EDTA is an ion-chelating agent that deprives 
cells of calcium, which is critical for cell adhesion. The use of EDTA avoids the non-
specific proteolysis of proteins, including the critical protein OVA, inherent in the use 
of trypsinisation methods of cell release. Previous work in our laboratory and others2 
has shown that this method yields more consistent lysates than trypsinisation. Cell 
death is consistently minimal with this method. The flask was incubated at room 
temperature for 5-10 minutes until adherent cells lifted off into suspension when the 
flask was banged twice, gently but firmly, against a hand. Using a 10 mL pipette on 
the fastest setting the flask surface was flushed approximately 10 times and the 
adherent cell suspension added to the non-adherent cells. The flask was rinsed once 
with DPBS and the cell suspension centrifuged at 250 x g for 7 minutes at 20°C. The 
supernatant was discarded and the cells resuspended in RPMI10+Geneticin (1%). The 
cells were divided equally between two, or more, fresh flasks and media added up to 
the appropriate volume. The cells were incubated at 37°C with 5% CO2 until they 
reached approximately 80% confluence.  
 
Once the desired volume of cells was reached (up to 10 x 175cm2 flasks) cells in 
active growth (log) phase, approximately 80% confluent, were treated with 5 μg/mL 
Brefeldin-A (BrefA)(Sigma) for 5 hours to allow OVA protein to accumulate inside 
the cells prior to harvest. 
 
Flow Cytometry confirmed negligible MHC-I-SIINFEKL expression by the 
B16.OVA cells prior to incubation in Brefeldin A. Brefeldin A redistributes 
intracellularly produced proteins from the cis/medial Golgi complex to the 
endoplasmic reticulum, trapping proteins that are normally secreted inside the cells. 
Thus the cell lysates were also assayed by Western Blot (WB), which confirmed the 
presence of OVA (Chapter 3, Figures 2 and 3s).  
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2.2 Polymerase Chain Reaction (PCR) Testing of Mycoplasma  
B16.OVA cells were washed twice in DPBS and resuspended in DPBS for DNA 
extraction. Cells were stored at -20°C prior to DNA extraction. DNA was extracted 
using Purelink DNA minikit from Invitrogen (Cat: K1820-01) according to 
manufacturer’s instructions. DNA concentration was measured by Nanodrop and 
diluted to 10 ng/mL in miliQ (MQ) water. Ten µL was added to PCR reaction for a 
total of 100 ng. One ng of Mycoplasma DNA was used as a positive control. The 
primers used amplified DNA from highly conserved regions of the 16SrRNA gene, 
which do not detect eukaryotic DNA or bacteria closely related to Mycoplasmas. 
 
PCR PROTOCOL 
Reaction Mix   Volume (µL) 
MQ water    6.26 
10X PCR buffer   2 
50 mM MgCl2 (1.85 mM final) 0.74 
10 mM dNTPs (0.2 mM final) 0.4 
10 µM fwd primer (0.1 mM final) 0.2 
10 µM rev primer (0.1 mM final) 0.2 
Platinum Taq    0.2 
Sample    10 
Total     20 
 
PCR Cycle Conditions 
94°C  90s 
94°C  30s 
70-60°C 30s (touch down, 1°C per 2 cycles for first 20 cycles, last 20 remain at 
60°C) 
72°C  45s 
Repeat 40 cycles 
72°C  4 mins 
 
The following day the PCR DNA was run on a 2% agarose gel for 30 mins at 97 
volts. No Mycoplasma DNA was observed in B16.OVA cell samples (Appendix 1, 
Supplementary Data Figure 1). 
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2.3 Preparation of Soluble Fraction Tumour Lysate (s-L) 
We tested the soluble fraction of freeze-thaw-generated B16.OVA and the whole 
portion of HOCl-oxidised B16.OVA. Tumour lysate (TL) preparation was carried out 
under sterile conditions, in a laminar flow hood, 5 hours after the addition of 5 μg/mL 
BrefA to the B16.OVA tumour cells. We used Brefeldin A at 5 µg/mL as we reasoned 
based on previous data that this concentration should be sufficient to yield the desired 
effect, while minimising unwanted side effects such as changes to the cell structure 
(Golgi, ER, actin filaments and others) and reduction in protein synthesis3. Cells were 
harvested using a 0.02% solution of EDTA in Dulbecco’s Phosphate-Buffered Saline 
(DPBS).  
 
Complete EDTA-free protease inhibitor (PI) tablets (Roche Diagnostics Ltd, Mt 
Wellington, Auckland, NZ) were dissolved in DPBS (no Ca++, no Mg++). (1 tablet in 
50 mL DPBS as per manufacturer’s instructions). Bref-A-treated B16.OVA cells were 
resuspended in the protease inhibitor cocktail at 2.4 x 107 cells/mL before being 
subjected to six repeat cycles of freeze-thaw lysis (dry-ice and methanol or 
isopropanol bath for 15 minutes followed by 37°C water bath for 5 minutes).  The 
protease inhibitor solution was important for minimizing protein degradation by 
proteases released during lysis and subsequent storage. The resultant lysate was 
centrifuged at 1700 x g for 10 minutes to generate a soluble fraction and an insoluble 
pellet. The bulk of the soluble fraction was removed and the tube re-spun for a further 
10 minutes to extract as much soluble fraction as possible. The soluble fraction was 
dispensed into aliquots and stored at -80°C.  
 
Total protein concentration was ascertained by either BCA Assay or 
spectrophotometer (Nanodrop, Thermo Fisher) where 1 A280 = 1 mg/mL. The 
standard curve of a BCA assay generated a total protein concentration of 13.72 
mg/mL (10.48 – 16.97). Nanodrop protein concentration averaged 11.34 (9.38 – 
13.29) (Appendix 1, Supplementary Data Table 1). Western Blots revealed two bands 
in the 40 and 45 kDa range as expected for OVA proteins (Chapter 5, Figure 63). 
2.4 Preparation of Oxidised lysate (ox-L) 
Cells destined for oxidized lysate (ox-L) were treated prior to lysis with hypochlorous 
acid (HOCl) according to the method of SK-OV-3 cell oxidation described by Chiang 
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et al3.  A 90 μM HOCl solution was prepared by diluting the stock sodium 
hypochlorite solution (NaOCl, reagent grade, available chlorine 10-15%; Sigma 
Aldrich Corp.) with DPBS and adding immediately to B16.OVA cells (final cell 
density 1 x 106/mL). The oxidizing cell suspension was incubated for 1 hour at 37°C, 
5% CO2, with gentle agitation every 15 - 30 minutes to induce oxidation-dependent 
tumor cell death. Tumor cells were washed twice in DPBS to remove all NaOCl and 
resuspended in protease inhibitor cocktail prior to 6 cycles of freeze-thaw lysis (dry-
ice and methanol or isopropanol bath for 30 minutes followed by 37°C water bath for 
5 minutes).  Cells were lysed to complete fragmentation, determined by Trypan Blue 
staining, prior to aliquotting and storage at -80°C. 
2.5 Measurement of stock HOCl concentration  
Chiang et al oxidised ovarian cancer at 60 μM hypochlorous acid (HOCl), therefore it 
was necessary to determine the concentration of HOCl in the stock sodium 
hypochlorite reagent (NaClO; 12-15% solution; ECP Lab Chem ltd, Birkenhead, 
Auckland, NZ). HOCl concentration was calculated using the following protocol. A 
calibrated pH meter was used to test the pH of the stock NaClO solution, which was 
found to be 11.6. Sodium hydroxide (NaOH) was added to the NaClO to pH12 and 
absorbance measured at 292 nm on a Spectronic Genesys2 spectrophotometer 
(Thermo Fisher Scientific, USA).  
 
The absorbance of the undiluted stock NaClO averaged 3.16 (range: 3.007 - 3.275) 
and that of the pH12 NaClO averaged = 3.25 (Range: 3.209 – 3.247). Similar 
absorbance results were obtained by Nanodrop (ND1000, Thermo Fisher, USA). 
Undiluted stock NaClO absorbance measured 0.315 (at 1 mm therefore x 10 = 3.15). 
NaClO at pH12 measured 0.37 (at 1 mm therefore x 10 = 3.7). 
 
The following formula was used to measure the concentration: 
• [concentration] = Abs252nm /ε 
ε = extinction coefficient = 350 M-1cm-1  
• A = ε c l   
Absorbance = extinction coefficient x concentration of the substance being measured 
x path length (cuvette) Therefore c = A/(ε x l) 
C = 3.16/(350 M-1 x 10 cm-1) = 9.03 x 10-4 M (0.903 mM or 903 µM) 
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Therefore the following calculation was used to determine the volume of stock NaClO 
to add to the cell suspensions: 
 (90 µM/903 µM) x 2000 µL = 199 µL 





2 Molar NaClO solution 
(903 μM HOCl) (μL) 
DPBS (μL) TOTAL 
VOLUME 
140 200 310 1490 2000 
130 200 288 1512 2000 
120 200 266 1534 2000 
110 200 244 1556 2000 
100 200 221 1578.5 2000 
90 200 199 1601 2000 
80 200 177 1623 2000 
70 200 155 1645 2000 
60 200 133 1667 2000 
50 200 111 1689 2000 
40 200 89 1711 2000 
30 200 66 1734 2000 
20 200 44 1756 2000 
10 200 22 1778 2000 
0 200 0 1800 2000 
 
2.6 Western Blot 
B16.OVA tumour cells (+/- oxidation treatment) were washed twice with DPBS, 
lysed on ice in RIPA Lysis Buffer (1 Unit of Complete Protease Inhibitor (CPI), 1 µM 
of Sodium Orthovanodate (NaO), and 1mM of Phenyl Methane Sulfonyl Fluoride 
(PMSF) in Radio-Immuno-Precipitation Assay (RIPA) buffer. RIPA buffer consists 
of 50 mM of Tris Cl (pH = 8), 150 mM NaCl, 1% Nonyl Phenoxypolyethoxylethanol 
40 (NP-40), 0.5% Sodium Deoxycholate, 0.1% SDS in milliQ water). The protein 
lysate was centrifuged at 1,300g for 20 minutes at 4°C, the pellet discarded and lysate 
aliquotted and stored at -80°C.  
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Laemmli buffer (240 mM Tris, 6.9% SDS, 40% Glycerol, 20% β – mercaptoethanol, 
and 0.02% bromophenol blue) was added to each protein sample to make a final 
volume of 20 µL with MilliQ water. Protein samples were denatured in a heating 
block at 99 °C for 10 minutes, and immediately transferred to ice to maintain 
denaturation. A total of 1x 106 tumour cells per sample was resolved on Bolt 4-12% 
Bis-Tris Plus pre-cast electrophoresis gels (Novex by Life Technologies, Carlsbad, 
CA, USA) and transferred to iBlot nitrocellulose Gel Transfer Stack membranes 
(Novex by Life Technologies, Carlsbad, CA, USA). The membrane was blocked with 
5% skim milk powder in TBST solution (1 hr at room temperature or overnight at 
4°C). The membrane was probed with optimally titrated anti-OVA (gift from 
Professor Vernon Ward, Department of Microbiology and Immunology, Otago 
University, Dunedin). Whole OVA protein was used as a positive control. Optimally 
titrated anti-Mouse IgG (Fab Specific)-Peroxidase (Sigma Aldrich, St Louis, MO, 
USA) was used as the 2° antibody and the Amersham Biosciences Enhanced Chemi-
Luminescent (ECL; Thermo Scientific) substrate used to detect the presence of OVA 
protein. 
2.7 APC Preparation and Activation 
2.7.1 Mice 
Specific pathogen-free male and female C57BL/6 and OT transgenic mice were 
housed in and obtained from the Hercus Taieri Resource Unit, Hercus Building, 
University of Otago, Dunedin, New Zealand. Experiments were carried out under the 
approval of the Animal Ethics Committee, University of Otago, Dunedin, New 
Zealand. Tissue retrieval was carried out under AEC# 37/13 and 09/14. In vivo studies 
were conducted under AEC #59/15. 
 
2.7.2 Dendritic Cells 
The tibiae and femurs of six to twelve week old C57BL/6 mice were isolated 
asceptically and placed in DPBS (Gibco, Paisley, Scotland). The prepared bones were 
washed in cold 70% ethanol for two minutes and rinsed twice in cold DPBS. The ends 
of the bones were removed and the bone marrow flushed into a sieve with a 25-gauge 
needle and 10 mL syringe filled with cold DPBS. The cell suspension was collected in 
a 50 mL Falcon tube (BD BioSciences) and centrifuged for 7 minutes at 300x g at 
4°C. The supernatant was poured off, the cells resuspended by gentle pipetting and 2 
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mL of warm ACK RBC lysis buffer (Appendix 2, Recipes) added for 3 minutes to 
lyse red blood cells (RBCs). Residual cells were washed in DPBS and resuspended in 
5 mL IMDM (Gibco) supplemented with 5% FBS and 20 ng/mL Granulocyte 
Macrophage Colony Stimulating Factor (GM-CSF; R&D Systems, Minneapolis, MN, 
USA) (IMDM5+GM) for counting. IMDM5+GM was added to six well plates and 2.5 
x 106 cells plated, to a total volume of 4 mL per well. The cells were incubated at 
37°C plus 5% CO2 for four days. On day four approximately 50% of the culture 
medium was removed and replaced with a corresponding volume of fresh, warm 
medium. On day six cells were harvested, washed with DPBS, resuspended at 1 x 106 
c/mL and the appropriate number of cells plated in 12, 24 or 96 well plates for pulsing 
with antigen. In 72 hour proliferation assays a total of 5.0 x 104 APCs were plated 
with 5.0 x 105 T cells. In double combination wells 2.5 x 104 of each APC was plated. 
In triple combination wells 1.25 x 104 APCs was plated. In this way the number of 
APCs remained the same i.e. 10:1 ratio to T cells, with the proportion of APCs in 
each well being equally divided. In 10-day expansion studies 1.0 x 105 APCs were 
plated with 1 x 106 T cells. 
 
Immature DCs (iDC) were pulsed with lysate or whole OVA protein antigen 
overnight prior to the addition of splenocytes. Peptide antigens were added at least 4 
hours prior to the addition of splenocytes. 
Antigens used were: 
• Whole OVA protein (Sigma): 50 µg/mL 
• Soluble TL: the soluble fraction of 2.4 x 107 lysed cells per mL used at a ratio 
of 6:1, 3:1 or 1:1 lysed tumor cells per APC  
• Oxidised TL: the whole portion of 2.4 x 107 lysed oxidized cells per mL used 
at a ratio of 6:1 or 1:1 lysed tumor cells per APC  
• The OT-I-specific peptide OVA257-264, (SIINFEKL; Mimotopes, Clayton, VIC, 
Australia) (2 µg/mL) 
• The OT-II-specific peptide OVA323-339 (ISQAVHAAHAEINEAGR; 
Mimotopes, Clayton, VIC, Australia) (2 µg/mL) 
•  The irrelevant melanoma peptide gp100: melanocyte-associated gp100; amino 
acid sequence: NH2-ALNFPGSQK-COOH; reconstituted in miliQ water. A 
melanoma-associated melanocyte differentiation antigen used as a negative 
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control against non-specific responses (2 µg/mL); Mimotopes, Clayton, VIC, 
Australia; cat: 100509 
Lipopolysaccharide (LPS; 1 μg/mL) and the unmethylated oligodeoxynucleotide CpG 
(1896) (Geneworks) (0.3 μg/mL) were used to activate the APCs. These immune 
stimulators were variously added either at the same time as the lysates (overnight 
loading and activation) or after overnight lysate loading, 6 hours prior to the addition 
of T cells. 
 
Phenotype analysis was conducted by Flow Cytometry and the cell preparation 
protocol is detailed under Flow Cytometry: T cell Phenotype and Proliferation 
Response. 
 
Table 1 lists the surface markers that were used to investigate phenotypic differences 
between the cells grown in M-CSF and GM-CSF +/- IL-3. The markers Ly6C, Ly6G 
and CD11b were eliminated early on as being unhelpful for distinguishing between 
DC and MΦ as these markers were expressed to a high degree on both cell 
populations. The markers commonly used to identify DCs and MΦs are usually 
expressed by both cells and also on other cell types. Often the level of expression, 
high versus intermediate or low, is the only distinguishing feature of a given 
molecule. Thus careful phenotyping is required to analyse the particular capabilities 
of each cell population.  
 
The antibody panels shown in Table 2 were chosen for on going comparison. These 
panels provided a range of molecules that are common to both DC and MΦ. 
Variations in expression levels of the molecules allowed differences between GMDC, 




Table 1 Surface markers investigated for phenotyping DCs and MΦs 
Molecule Brief description & reason for inclusion in panel 
MHC-II Molecule for presentation of exogenous antigen. To identify ability to 
present peptides to T cells 
CD11c Transmembrane integrin for adherence to endothelium & phagocytosis. 
Highly expressed on DC subtypes and also on MΦs. 
F4/80 One of a family of tissue adhesion GPCRs. Extensively used MΦ 
marker. Expressed on many, but not all, murine MΦs 
CD169 Sialoadhesin, a cell adhesion molecule. Binds sialic acids. CD169+ 
MΦs noted to be responsible for cross-presentation of dead cell antigen 
to CD8+ T cells in vivo4 
CD40 APC costimulatory molecule. Binds CD154 (CD40L) on T cells. 
Necessary for APC activation & subsequent T cell activation. Identifies 
APC costimulatory capacity. 
CD80 Costimulation molecule for T cell activation and survival. Binds to 
CD28 and CTLA4 on T cells. Identifies APC costimulatory capacity. 
CD86 Costimulation molecule for T cell activation and survival. Binds to 
CD28 and CTLA4 on T cells. Works in tandem with CD80. Identifies 
APC costimulatory capacity. 
CD115 
(CSF1R) 
Colony stimulating Factor 1 receptor. CSF1R controls MΦ production, 
differentiation and function. Present at high levels on MΦs and at low 
to intermediate levels on DCs 
Ly6C Enriched on monocytes. Useful when used with LY6G to determine 
relative amounts of granulocytes and monocytes or MΦs. 
Ly6G (Gr-1) Enriched on granulocytes. Useful when used with LY6C to determine 
relative amounts of granulocytes and monocytes or MΦs. 
CD135 (Flt3) Flt3L receptor. Important in haematopoietic stem cell and progenitor 
cell development. Present on common lymphoid progenitors and 
multipotent progenitors but not haematopoietic stem cells. Has been 
reported to be required for DC development and to be a differentiating 
marker between DCs and MΦs at the gene level. 
CD206 Mannose receptor. Primarily present on MΦs and immature DCs. Role 
in antigen uptake and presentation. 
CD45R 
(B220) 
Subset of CD45 isoforms. Predominantly expressed on B cells but also 
to a lower degree on plasmacytoid DC. 
CD8 Co-receptor for the TCR. Binds MHC-I. Also expressed on subsets of 




Macrophage-1 antigen. Involved in phagocytosis, cell-mediated 
cytotoxicity, chemotaxis and activation. Expressed on monocytes, 





Table 2 Panels of Antibodies to Surface Markers Used To Phenotype DCs and MΦs  
 Pane l  1  Pane l  2  Pane l  3  Pane l  4  










1/200 (0.125 µL) 
FL2  CD135 (Flt3)-PE  
1/200  







CD115-PE (BL)  
1/200  
(0.5 µL)  
FL4 B220 (CD45R)  
PerCP-Cy5.5 
1/400 (0.25 µL)  
pDC marker 





(0.25 µL)  
CD8-PE-Cy7 
1/400  
(0.25 µL)  
CD8-PE-Cy7 
1/400  
(0.25 µL)  
CD8-PE-Cy7 
1/400  
(0.25 µL)  




FL8 L/D NIR*  L/D NIR*  L/D NIR*  L/D NIR* 
FL9 CD11c-BV421  
1/160 (0.625 µL) 
CD206-BV421 
1/333 (0.3 µL) 
CD80-BV421 
1/200 (0.5 µL)  
CD11c-BV421  
1/160 (0.625 µL) 
 
*L/D NIR: Dead Cell Discrimination Dye Live/Dead Near InfraRed, Life Technologies 
2.7.3 Macrophages 
Bone marrow progenitor cells were prepared in the identical manner to bone marrow 
derived DCs as described above. In M1 MΦ experiments residual cells were washed 
in DPBS5 and resuspended in IMDM (Gibco) supplemented with 10% FBS and 5 
ng/mL Granulocyte Macrophage Colony Stimulating Factor (GM-CSF; R&D 
Systems, Minneapolis, MN, USA) (IMDM10+GM).  In M2 MΦ experiments the cells 
were resuspended in IMDM+10% FBS+1-100 ng/mL macrophage colony-stimulating 
factor (M-CSF).  
 
Cells were re-suspended at 1 x 106 cells/mL in IMDM10+GM-CSF or M-CSF, placed 
in a T75 tissue culture flask and incubated overnight at 37°C plus 5% CO2. The 
following day interleukin-3 (IL-3) (5 ng/mL) was added to the cells in the flask, and, 
to minimize contaminating fibroblasts5, nonadherent bone marrow cells were 
transferred to sterile, non-tissue culture-coated 94 mm bacteriological petri dishes (5 
mL per dish) and returned to the incubator (37°C plus 5% CO2). Cells were observed 
each day. On days 4 and day 8 the petri dishes were tilted and the dish gently rinsed 
once in the aspirated medium to remove non-adherent cells. Five mL of fresh warm 
medium was replaced into the dishes. On D10 non-adherent cells were aspirated by 10 
mL pipette and discarded and the adherent cells used for experiments.  
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The M1 MΦs used in this study were never loosely adherent, in fact adherence was 
one feature that was used to distinguish between MΦs and DCs. Significant time was 
spent ascertaining the best method for gently removing them from non-tissue culture-
treated plastic ware. Studies by La Flamme et al indicated that cold PBS was used for 
BMMΦ harvest6,7 therefore in early experiments ice-cold DPBS (5 mL) was added to 
each dish and the dishes refrigerated for 5 minutes. The cell solution was then flushed 
vigorously with a 10 mL pipette on the highest speed and the released cells in solution 
aspirated into a 50 mL Falcon tube. This refrigeration-flushing procedure was 
repeated two or three more times until few cells were left on the plates. In our hands 
the cold PBS method took inordinate amounts of time and was less effective than a 
0.02% solution of EDTA in DPBS.  
 
Optimization of MΦ culture methodology revealed that culture on non-tissue culture-
coated bacteriological petri dishes and incubation in 0.02% EDTA for 5 minutes prior 
to harvest allowed much easier release of the MΦs. EDTA is an ion chelator that 
causes the cells to downregulate their adherence molecules by calcium deprivation8.  
For this harvest method to work optimally the medium must be discarded and the 
dishes rinsed once in the EDTA solution to minimise remaining medium prior to 
starting the 5-minute incubation period. Following incubation the M1 MΦs released 
easily from the dishes with gentle flushing by 10 mL pipette. 
 
Released cells were centrifuged (7 minutes, 300 g, 4°C), resuspended in 
IMDM10+GM-CSF/M-CSF at 1 x 106 c/mL and plated in 12, 24 or 96 well plates for 
pulsing with antigen. Cell numbers were the same as those described for DCs. The 
MΦs were activated with LPS&CpG and pulsed with identical antigens at the 
concentrations described for DCs. 
2.7.4 B cells 
The spleens of six to twelve week old C57BL/6 mice were isolated asceptically and 
placed in Dulbecco’s Phosphate Buffered Saline (DPBS; Gibco, Paisley, Scotland). In 
a laminar flow hood on an ice tray the spleen was placed inside a 70 μM cell filter 
sitting in a petri dish of DPBS. The ice tray was used to keep cell temperatures as low 
as possible to maximise murine cell viability. BD Biosciences recommend that murine 
cells be kept between 4-8°C during preparations while human cell viability is better 
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preserved at room temperature. The plunger from a sterile syringe was used to gently 
press the spleen through the sieve. Cell aggregates were dissociated by flushing the 
cell suspension through the sieve with a 10 mL pipette. The cell suspension was 
collected in a 50 mL Falcon tube (BD BioSciences) and centrifuged for 7 minutes at 
300 x g at 4°C. The supernatant was poured off, the cells resuspended by gentle 
pipetting and 5 mL of warm ACK RBC lysis buffer (Appendix 2, Recipes) was added 
for 3 minutes to lyse red blood cells (RBCs). Residual cells were washed in DPBS 
and resuspended in 90 μL of AutoMACS® buffer (Appendix 2, Recipes) per 107 cells. 
Anti-CD43 (Ly-48) MicroBeads (Miltenyi Biotec GmbH, Germany), which are 
present on nearly all leukocytes except immature and resting mature B cells, were 
vortexed and 10 μL of beads were added per 90 μL of cell suspension. The bead/cell 
suspension was briefly vortexed and incubated at 4°C for 15 minutes. Cells were 
washed with AutoMACS buffer (1-2 mL per 107 cells), centrifuged (300 g, 5 minutes, 
4°C) and resuspended in 500 μL of buffer per 108 cells. At this point cells were 
passed through a large cell column on an AutoMACS Pro Separator (Miltenyi Biotec 
GmbH, Germany) ‘DepleteS’ programme. The negative fraction was collected, 
resuspended in B cell medium (Iscove’s Modified Dulbecco’s Medium plus 10% 
FBS; IMDM10) and counted. Aliquots of pre-sorted cells along with the positive and 
negative fractions were stained for the B cell markers B220 (CD45R), CD19, the pan-
T cell marker CD3 and the DC marker CD11c to check for purity and DC or T cell 
contamination. Spleen-derived B cells were pulsed with whole protein overnight and 
peptide antigen for four hours prior to the addition of splenocytes. The antigens used 
and their dosages were identical to those described for DCs. 
 
Table 3 Antibody Panel Used for Staining AutoMACS-Isolated B cells 
	 Panel		
FL1	  
FL2		 CD19 PE 1/200 0.5 µL 
FL3	 CD3 PE-CF594 1/200 0.5 µL 
FL4	 CD45R (B220) PerCPCy5.5 1/400 0.25 µL  
FL5	  
FL6		 CD11c APC 1/400 0.25 μL 
FL8	  
FL9	 FVS450* 
*FVS450: Dead Cell Exclusion Dye Fixable Viability Stain 450, BD Biosciences 
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2.8 T cells 
2.8.1 Isolation of T cells 
The spleens of six to twelve week old OT-I and OT-II mice were isolated asceptically 
and placed in Dulbecco’s Phosphate Buffered Saline (DPBS; Gibco, Paisley, 
Scotland). In a laminar flow hood, on an ice tray, spleens were placed inside a 70 μM 
cell filter sitting in a petri dish of DPBS. The plunger from a sterile syringe was used 
to gently mince the spleens through the sieve. Cell aggregates were dissociated by 
flushing the cell suspension through the sieve with a 10 mL pipette. The cell 
suspension was collected in a 50 mL Falcon tube (BD BioSciences) and centrifuged 
for 7 minutes at 300 x g at 4°C. The supernatant was poured off, the cells resuspended 
by gentle pipetting and 5 mL of warm ACK RBC lysis buffer (Appendix 2, Recipes) 
added for 3 minutes to lyse red blood cells (RBCs). Residual cells were washed in 
DPBS and resuspended in 40 μL of AutoMACS® buffer (Appendix 2, Recipes) per 
107 cells.  
 
The anti-CD4 and anti-CD8 negative selection kits (Miltenyi Biotec GmbH, 
Germany), consist of a cocktail of biotin-conjugated monoclonal antibodies against 
CD8a (for isolating CD4 T cells) or CD4 (for selecting CD8 T cells), CD11b, CD11c, 
CD19, CD25, CD45R (B220), CD49b (DX5), CD105, anti-MHC Class II, Ter-119, 
and TCRγ/δ.  The antibody cocktail was vortexed and 10 μL of antibodies were added 
per 107 cells. The antibody-labeled cell suspension was briefly vortexed and incubated 
at 4°C for 5 minutes. AutoMACS buffer was added (30 μL per 107 cells), and anti-
biotin beads (20 μL per 107 cells). The bead/cell suspension was incubated at 4°C for 
10 minutes, topped up with AutoMACS buffer to 500 μL per 108 cells (if necessary). 
At this point cells were passed through a large cell column on an AutoMACS Pro 
Separator (Miltenyi Biotec GmbH, Germany) ‘DepleteS’ programme. The negative 
fraction was collected, resuspended in T cell medium (Advanced DMEM/F12+5% 
FBS, penicillin and streptomycin (P/S; 2 U/mL), β-Mercaptoethanol (2Me; 1%), 
GlutaMax (1%), HEPES Buffer(1%), and IL-7 (5 ng/mL) and counted. 
  
In 10 day Prime-Boost experiments additional cytokines and growth factors were 
added as needed for T cell growth, differentiation and survival. These included IL-2 
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(for the first 24-48 hours only; 2 ng/mL); IL-7, IL-15 and IL-21 all at 100 ng/mL; and 
5 ng/mL GM-CSF.  
 
GM-CSF was included in the T cell medium for several reasons. GM-CSF-
differentiated DCs become reliant on GM-CSF and die when GM-CSF is removed 
from the medium therefore we reasoned that retaining low levels of GM-CSF would 
provide critical DC support to ensure good presentation to T cells. In addition 
increased Type 1-skewing DC content and activity has been observed following local 
and systemic GM-CSF administration, which supports a role for GM-CSF as an 
immune stimulant and vaccine adjuvant in cancer patients. GM-CSF has shown 
clinical activity as an immune stimulant in tumor cell and dendritic cell vaccines and 
other clinical cancer treatments9–15, and may increase antibody-dependent cellular 
cytotoxicity. It has been noted that the successful use of myeloid-acting cytokines to 
enhance anti-tumor responses may require the use of GM-CSF in combination with 
cytotoxic or other targeted therapies16. 
 
The negative fractions were stained for the surface molecules CD3, CD8 or CD4, 
CD28, CD27, PD-1, CD44, CD122, CD127, CD62L, CD157 (CTLA-4) and CCR7 to 
assess the naïve T cell status. Table 4 shows the antibody panels used to identify T 
cell phenotypes. 
Table 4 Antibody Panels Used To Assess T Cell Phenotype 
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FL8 CD8 APC-H71/400 
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CD4 APC-H7 1/800 0.125 
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FL9 FVS450 FVS450 FVS450 
FL10    
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2.8.2 VPD450 Labeling 
In initial proliferation assays Violet Proliferation Dye 450 (VPD450; BD Biosciences, 
San Jose, CA, USA) was used to identify proliferating T cells in lieu of the more 
widely used Carboxyfluorescein succinimidyl ester (CFSE). The emission wavelength 
of VPD450 is located at the left end of the emission spectrum (450 nm), enabling 
more flexibility when choosing remaining fluorophores for the antibody panel. CFSE 
with its broad emission spectrum peaking around 517 nm is more restrictive, sitting 
entirely within the FITC channel and overlapping significantly with many mid-range 
fluorophores. 
 
Freshly isolated CD4+ and CD8+ T cells were resuspended for proliferation dye 
labelling in DPBS with no FBS. Fluorescent proliferation dye labelling took place in a 
laminar flow hood with the lights off. We confirmed that the optimal dose of Violet 
Proliferation Dye 450 (VPD450, BD Biosciences, NJ, USA) was 1 µM VPD450 
added undiluted to cells in suspension at between 1 x 107 to 2 x 107 cells/mL. The dye 
binds to plastic therefore dilution in DPBS prior to adding to cells is not 
recommended unless used at a higher concentration such as 10 μM (BD BioSciences 
Technical Bulletin Jan 2012). One μL of undiluted 1 mM VPD450 stock solution was 
added per 1 mL of cell suspension for a final VPD450 concentration of 1 μM. The 
cells were immediately vortexed briefly, wrapped in tin foil and incubated at room 
temperature on a ground rotator for 5 - 10 minutes. The reaction was quenched by 
diluting the cells in DPBS (9 x the volume of the cell suspension). Cells were 
centrifuged (300g, 7 mins, 4°C), resuspended in 10 mL medium+10% FBS and 
centrifuged again (300g, 7 mins, 4°C). Cells were resuspended in T cell medium and 
counted. Cell concentrations were adjusted as appropriate in T cell medium and added 
to lysate-loaded APCs. 
 
We noted that VPD450-labeled cells had a ‘shoulder’ of apparent proliferation on 
untreated cells (Figure 12), which did not correlate with what was observed under the 
microscope. Elia et al17 showed that under optimal conditions processing cells by 
Flow Cytometry on Day 0 of VPD labelling generates two peaks in both human 
peripheral blood mononuclear cells (PBMCs) and mouse splenocytes (Figure 13). At 
this time point no proliferation has occurred and thus the double peaks are an artefact 
of VPD labelling.  In a similar manner, our VPD-labelled splenocytes did not return a 
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sharp single peak in untreated cells, as is observed in CFSE labelled cells, making 
identification of true proliferation difficult. However, by taking a Day 0 sample we 
could verify that the splenocytes also showed two peaks at this time point and thus 
true proliferation could be determined. Examples of gating strategies are found in 
Chapter 4, Figure 38 and Appendix 1, Supplementary Figure 16. 
 
















Figure 13 VPD450-labelled mouse splenocytes have double peak on Day 0. Mouse splenocytes were 
enriched for CD4+ cells using a positive panning selection technique. The enriched CD4+ cells were 
loaded with 1 µM of VPD450, then stimulated with antiCD3ε + CD28 (2 µg/mL) antibodies for three 
days. Cells were harvested at each day of culture including an aliquot for a day 0 time point to 
determine how the cell population loaded with the VPD450 dye. A = day 0 load, B = day 1 time point, 
C = day 2 time point, and D = day 3 time point. The cell population did not load as a single peak at day 
0 (A). If this control was not present, it would be assumed that the cells had completed one round of 
division at day 1 (B). At day 2 (C), the cell population started to divide, which is evident by the three 
additional peaks, and at day 3 (D), the cell population had completed five rounds of division. The day 0 
load is very important for recording the baseline VPD450 load. Reproduced with permission from BD 
Biosciences Technical Bulletin, Jan 2012. 
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Figure 12 VPD450-labelled splenocytes display false proliferation peak. Freshly isolated OT-I and 
OT-II splenocytes were sorted for CD4+ and CD8+ T cells by antibody and magnetic bead labelling as 
described above. Cells were labelled with 1 μM VPD450 and analysed within hours on a Gallios Flow 
Cytometer. Data was analysed and graphed in Flow Jo Version 9. Representative data from twenty 
independent experiments. 
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2.8.3 CFSE Labeling of T cells 
Owing to the Day 0 double peak issue with VPD450 we elected to use 
carboxyfluorescein succinimidyl ester (CFSE; Life Technologies, Vybrant CFDA SE 
Cell Tracer Kit, V12883, Thermo Fisher, MA, USA) in later proliferation 
experiments. Working in a hood with the light off we resuspended cells at 5 x 107 
cells/mL. A 10 μM (2X) CFSE solution was prepared by adding 1 μL of 10 mM stock 
to 1 mL DPBS. This solution was added to an equal volume of cell suspension 
resulting in a final concentration of 5 μM CFSE. The tube was immediately vortexed 
briefly, wrapped in foil and incubated for 5 minutes at room temperature on a ground 
rotator to ensure even staining. The cells were washed twice by diluting in ten 
volumes of room temperature DPBS+5% FBS followed by sedimentation by 
centrifugation (300g, 5 min, 20°C). Labelled cells were resuspended in T cell medium 
(Advanced DMEM+5% FBS+HEPES (1%)+GlutaMax (1%) +/- IL-2 (5 ng/mL) +/- 
α-CD28 (2 μg/mL) +/- IL-7, IL-15, IL-21 (all 100 ng/mL) at 10 – 20 x 106 cells/mL 
for plating with APCs. 
2.8.4 T Cell-APC Co-Cultures 
At least four hours after the addition of peptide antigen OT-I and OT-II splenocytes 
dyed with violet proliferation dye 450 (VPD450) or CFSE were added to the lysate-, 
OVA- or peptide-loaded APCs at a ratio of 10 T cells to 1 APC. In 72-hour 
proliferation assays 5.0 x 104 single APCs were cultured with 0.5 x 106 T cells. In 
double APC combinations 2.5 x 104 of each APC were added to each well for antigen 
loading. In triple APC combination wells, 1.67 x 104 of each APC were added to each 
well for antigen loading. This was achieved by adding 100 μL of an individual APC, 
50 μL per two APCs or 34 μL per three APC cell suspensions to each well.  
 
The APCs and T cells were co-cultured for 72 hours and the CD3+CD8+ or 
CD3+CD4+ T cell proliferation response measured by Flow Cytometry. Co-culture 
supernatants were also harvested at the 24, 48 and 72-hour time points for cytokine 
analysis by Enzyme Linked Immunosorbent Assay (ELISA) (IFN-γ, TNF-α, IL-2 and 
IL-12). Some co-culture supernatants were also assayed by Legendplex Flow 
Cytometric Bead array (BioLegend, San Diego, CA, USA). 
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In 10-day Prime-Boost Assays 5.0 x 104 APCs and 0.5 x 106 T cells or 1.0 x 105 APCs 
and 1 x 106 T cells were added to each starting co-culture. Cells were fed with fresh 
media and cytokines no less than every 2 days, as described in Section 2.8.1. 
 
2.9 Flow Cytometry: Cell Phenotype and Proliferation Analysis 
Early experiments of T cell proliferation and membrane or intracellular expression of 
molecules were analysed on an LSR Fortessa (BD Immunocytometry Systems, San 
Jose, CA, USA), equipped with 405 nm, 488 nm, 561 nm and 640 nm excitation 
lasers located in the Flow Facility of the Department of Microbiology and 
Immunology, Otago University, Dunedin New Zealand.  
 
However the vast majority of experiments were processed on a Gallios instrument 
(Beckman Coulter) containing 405 nm, 488 nm and 640 nm excitation lasers located 
in the Pathology Department of the Dunedin School of Medicine, Otago University, 
Dunedin New Zealand. Data were analysed using FlowJo software versions 9 and 10 
(TreeStar, Ashland, OR, USA).  
 
Antibodies were purchased from Becton Dickinson (BD) Biosciences (Franklin 
Lakes, NJ, USA) and BioLegend (San Diego, CA, USA). Unstained, single-
fluorophore-stained cells and Fluorescence Minus One (FMO) controls were used to 
determine negative and positive populations.  
 
Cells were washed once in room temperature PBS prior to viability staining in live 
cell exclusion dye (room temperature, 15 mins). Cells were then washed with ice cold 
FACS Staining Buffer (DPBS, 2% fetal bovine serum and 0.1% sodium azide), 
pelleted, vortexed prior to the addition of optimally titrated antibodies to the residual 
liquid (80-100 µL). The antibodies used for surface staining of DCs and MΦs are 
listed in Table 2. The antibodies used for surface staining of B cells are listed in Table 
3. The antibodies used for surface staining of T cells are listed in Table 4. 
 
After 15 minutes incubation at 4°C in the dark, cells were washed twice in FACS 
Buffer, fixed with 4% paraformaldehyde, stored at 4°C and usually analyzed the 
following day, or within a week at the most. Alternatively, for intracellular staining, 
following surface staining cells were fixed and permeabilised (FoxP3 Fix/Perm Buffer 
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set, BioLegend, San Diego, CA, USA) and incubated with intracellular mABs for 20-
30 minutes at 4°C in the dark.  Cells were stored at 4°C and analysed the next day. 
The number of events acquired was 3 × 104 to 1 × 105 . 
 
Identification of responding T cells was achieved by labelling APC-splenocyte co-
cultures with antibodies to the pan-T cell marker CD3, CD4 (in OT-II splenocytes) 
and CD8 (in OT-I splenocytes). T cell responses were assessed by analysing 
proliferation as determined using Flow Cytometry of VPD450- (BD) or CFSE- (Life 
Technologies) stained T cells. 
 
Cells were stained with the antibodies shown in Table 5 as appropriate. Dilutions 
were used to ascertain the optimal AB titration, as is common practice in many labs. 
Thus, while AB concentrations are not stated, the company that supplied the AB, 
along with the catalogue number and clone have been supplied, therefore the 
concentration may be calculated by future investigators.  
 
Table 5 Titrations of fluorophore-conjugated antibodies used in Flow Cytometric 
analysis of antigen-specific T-cell proliferation, phenotype functionality and memory. 
 
ANTIBODY FLUOROPHORE TITRATION CHANNEL VOLTAGE GAIN 
CD3 FITC 1/400 FL1 395 1.0 
CD8α PE-CY7 1/400 FL5 625 2.0 
CD8α APC 1/200 FL6 475 2.0 
CD8α APC-H7 1/400 FL8 450 2.0 
CD4  PE-Cy7 1/800 FL5 625 2.0 
CD4  APC 1/800 FL6 475 2.0 
CD4 APC-H7 1/800 FL8 450 2.0 
CD28  FITC 1/100 FL1 395 1.0 
CD44  FITC 1/100 FL1 395 1.0 
CD27  PE 1/200 FL2 375 2.0 
CD122 PE 1/200 FL2 375 2.0 
CCR7 PE 1/400 PE 375 2.0 
PD-1  PerCPCy5.5 1/400 FL4 550 2.0 
CD127 PerCPCy5.5 1/400 FL4 550 2.0 
CD69 APC 1/200 FL6 475 2.0 
CD62L APC 1/200  FL6 475 2.0 
CD152 APC 1/200 FL6 475 2.0 




















Figure 15 shows the gating strategies used in MΦ-T cell proliferation experiments. 
Doublets were first gated out off the forward scatter height (FSC-H) versus side 
scatter area (SSC-A) plot. Dump channels were used to gate out dead cells (viability 
dye positive cells) as well as any APCs (CD11c and CD19 in DC and B cell co-
cultures respectively) that may have been harvested along with the T cells. Due to the 
highly adherent nature of MΦs gating out CD11c+ cells was unnecessary in MΦ-T 
cell co-cultures. Finally the cells in the CD3+CD8+, or CD3+CD4+ double positive 
quadrants were selected and analysed for VPD+ or CFSE+ proliferation. CD19+ B 
cell and DC gating strategies are shown in Appendix 1, Supplementary Figure 16 and 
Chapter 3, Figure 25. 
 
  
Figure 14 Gating strategy used in DC-T cell proliferation co-cultures. Day 6 bone marrow-derived 
GMDCs were prepared as previously described. GMDCs were loaded overnight with lysates (1:1 tumour 
cell:APC) or whole OVA protein (50 μg/mL). The following morning the irrelevant melanoma peptide 
gp100, SIINFEKL peptide or OVA323-339 peptide (all 2 μg/mL) were added at least 4 hours prior to the 
addition of VPD450-labelled OT-I or OT-II splenocytes. 72 hours later cells were harvested, stained with 
dead cell exclusion dye, and labelled with mABs against CD11c (Dump channel), CD3, CD8α and 
collected by LSR Fortessa or Gallios Flow Cytometer. Data was analysed on FlowJo Version 9 or X. 
Proliferation was expressed as percentage of cells that had reduced fluorescence compared with untreated 




















Table 5 lists information on fluorophore-conjugated antibodies used in various 
experiments in this thesis. Details of individual staining panels are provided in figure 
legends or in associated supplementary figures. Fluorescence Minus One (FMO) 
controls were used for gating analyses to identify issues of spectral overlap. 
Compensation was calculated using unstained and single colour stained cells or 
CompBeads. Post-acquisition compensation matrices were calculated and applied and 
data analysis performed using FlowJo version 9.4.10 and version X (Tree Star, 
Ashland, OR, USA). Gates were set by comparing unstained cells, single colour 
stained cells and fully-stained cell populations. 
  
Figure 15 Gating strategy used in macrophage-T cell proliferation co-cultures. Day10 bone 
marrow derived MΦs were prepared as previously described. MΦs were loaded overnight with lysates 
(1:1 tumour cell:APC) or whole OVA protein (50 μg/mL). The following morning the irrelevant 
melanoma peptide gp100, SIINFEKL peptide or OVA323-339 peptide (all 2 μg/mL) were added at least 
4 hours prior to the addition of VPD450-labeled OT-I or OT-II splenocytes. 72 hours later cells were 
harvested, stained with dead cell exclusion dye, and labelled with mABs against CD3, CD8α/CD4 
and collected by LSR Fortessa or Gallios Flow Cytometer. Data was analysed on FlowJo Version 9 or 
X. Proliferation was expressed as percentage of cells that had reduced fluorescence compared with 
untreated cells. Sample data of numerous independent experiments.  
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Table 6 Fluorophore-Conjugated Antibody Information 




Dendritic Cells & Macrophages  
Anti-mouse I-A/I-E (MHC-II) 
Clone: M5/114.15.2 
FITC Activation BioLegend 107606 0.5 
Hamster anti-mouse CD11c 
Clone: HL3 





PE Phenotype BioLegend 135306 0.2 
Anti-mouse CD169 (Siglec-1) 
Clone: 3D6.112 
PE Phenotype BioLegend 142403 0.2 
Anti-mouse F4/80  
Clone: BM8 
PE Phenotype BioLegend 1123110 0.2 
Anti-mouse CD115 
Clone: 53-6.7  
PE Phenotype BioLegend 135505 0.2 
Rat Anti-Mouse CD8α 
Clone: 53-6.7 




Clone: GL-1  
PE-Cy7 Activation BioLegend 105014 0.2 
Anti-mouse CD11c 
Clone: N418  
APC Phenotype BioLegend 117310 0.2 
Anti-mouse CD40 
Clone: 3/23 
APC Activation BioLegend 124612 0.2 
Anti-mouse F4/80  
Clone: BM8 
APC Phenotype BioLegend 123115 0.2 
Anti-mouse CD11c  
Clone: N418 
BV421 Phenotype BioLegend 117343 0.2 
Anti-mouse CD80  
Clone: 16-10A1 
BV421 Activation BioLegend 104725 0.1 
Anti-mouse CD206 
Clone: 068C2 
BV421 Phenotype BioLegend 141717 0.1 
 
T cells  
Anti-mouse CD3 
Clone: 17A2 
FITC Phenotype BioLegend 100204 0.5 
Anti-mouse CD28 
Clone: E18 
FITC Naive BioLegend 122008 0.5 
Anti-mouse CD44 
Clone: IM7 
FITC Memory BioLegend 1003006 0.5 
Rat anti-mouse CD44 
Clone: IM7 
FITC Memory BD Biosciences, 
Pharmingen 
553133 0.5 
Rat anti-mouse CD27  
Clone: LG.3A10 
PE Memory BD Biosciences, 
Pharmingen 
558754 0.2 
Rat anti-mouse CD122 
Clone: TM-β1 
PE Memory BD Biosciences, 
Pharmingen 
55362 0.2 
Rat anti-mouse CCR7 
Clone: 4B12 
PE Memory BD Biosciences, 
Pharmingen 
560682 0.2 
Hamster Anti-Mouse CD3e;  
Clone: 145-2C11 
PE-CF594 Phenotype BD Biosciences, 
Pharmingen 
562286 0.2 
Anti-mouse CD127  
Clone: SB/199 
PerCPCy5.5 Memory BioLegend 121113 0.2 
Anti-mouse PD-1 
Clone: 29F.1A12 
PerCPCy5.5 Exhaustion BioLegend 135208 0.2 
Rat Anti-Mouse CD8α 
Clone: 53-6.7 
PE-CY7 Phenotype BD Biosciences, 
Pharmingen 
552877 0.2 
Rat Anti-Mouse CD4 
Clone: RM4-5 
PE-Cy7 Phenotype BD Biosciences, 
Pharmingen 
552775 0.2 





APC Naïve/Memory BioLegend 104411 0.2 
Anti-mouse CD152 (CTLA-4) 
Clone: 
APC Activation BioLegend 106310 0.2 
Anti-mouse CD4 
Clone: 6K1.5 
APC-H7 Phenotype BD Biosciences 560181 0.2 
Anti-mouse CD8 
Clone: 53-6.7 
APC-H7 Phenotype BD Biosciences 560182 0.2 
Anti-mouse IL-10 
Clone: JES5-16E3 
BV-421 TH2 BioLegend  505021 0.2 
Rat anti-mouse IFN-γ 
Clone: XMG1.2 
AF700 TH1 BD Biosciences 557998 0.2 
Cell Division Violet Cell 
proliferation Dye 
(VPD450) 
Proliferation BD Horizon™ 562158 
 
n/a 
Cell Division Vybrant® CFDA 
SE Cell Tracer Kit 
(CFSE) 
Proliferation Life Technologies V12883 n/a 
 









PE Phenotype BioLegend 115507 0.2 
Anti-mouse/human CD45R/B220 
Clone: RA3-6B2 
PerCP/Cy5.5 Phenotype BioLegend 103236 0.2 
Anti-mouse/human CD11c 
Clone: N418 
APC Isolation Purity BioLegend 117310 0.2 
Hamster Anti-Mouse CD3e;  
Clone: 145-2C11 




LIVE/DEAD® Fixable Yellow 








LIVE/DEAD® Fixable Red Dead 









LIVE/DEAD® Fixable Violet Dead 


























BD Horizon™ 562247 
 
 
Figure 16 shows a Fluorescence Minus One (FMO) layout for the panel used for T 
cell phenotyping. Three panels were used with the same fluorophores attached to 
mABs specific for different molecules. This FMO was used to identify any issues of 
spectral overlap within the panel. This FMO identified that PE was contributing 
significantly into the FITC channel and that the PerCPCy5.5 signal was not strong 
enough. After voltages were adjusted these issues were eliminated (see Figure 17). 
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Figure  shows the compensation matrix for the corrected panel along with the 
unstained and singly-stained cells used to generate the compensation matrix. Table 6 
shows the voltages used in these experiments. 
 
Finally, intracellular staining for IDO was carried out on lysate-loaded APCs. APCs 
were prepared as previously described and loaded with lysates+LPS&CpG overnight. 
Twenty-four hours later cells Brefeldin A was added to the cells for 3 hours prior to 
harvest. Cells were centrifuged in plates (3 mins, 300 x g, 4°C), the media aspirated 
and cells incubated in Accutase Cell Detachment Solution for 10 minutes (Sigma 
Aldrich). Cells were centrifuged in plates (3 mins, 300 x g, 4°C), the Accutase 
discarded and the cells resuspended in DPBS for transfer to FACS tubes. Cells were 
centrifuged (3 mins, 300 x g, 4°C), the excess DPBS discarded and the cells stained 
with FVS450 dead cell exclusion dye (BD; 1 μL/mL, 15 mins, 4°C). Cells were 
washed in FACS buffer and stained for surface CD11c-FITC (15 mins, 4°C). Cells 
were washed twice in FACS buffer and fixed with FoxP3 Fix/Perm buffer 
(BioLegend) (500 μL 1X Fix Buffer per tube, 20 mins, 4°C). Cells were washed once 
with FACS buffer and permeabilised with 1 X FoxP3 Perm Buffer (BioLegend) (500 
μL per tube; 15 mins, 4°C). Permeabilisation of cells renders cells more buoyant so 
post-permeabilisation wash step centrifugations were at 700 x g (3 mins, 4°C). 
Following a single centrifugation cells were resuspended in 1 X FoxP3 Perm Buffer 
and the intracellular mAB (anti-IDO1 Antibody conjugated to Alexa Fluor® 647; 
BioLegend; 654003) was added to the residual cell suspension in the tube i.e. 80-100 
μL (30 mins, 4°C). Following incubation 500 μL of FACS buffer was added to each 
tube and the cells washed twice (700 x g, 3 mins, 4°C). Stained cells were 






Figure 16 Fluorescence Minus One (FMO) for T cell phenotype panel. T cells were isolated from OT mice 
by magnetic bead separation as previously described. 0.5 x 106 T cells were labeled with Fixable Viability Stain 
450 (FVS450) followed by surface staining for FITC, PE, PerCPCy5.5, APC, APC-H7, minus one mAB-
conjugated fluorophore per sample. Cells were fixed in 4% paraformaldehyde, stored overnight at 8°C and 
acquired the following day on a Gallios Flow Cytometer. 100,000 events were collected per sample. Data was 













Table 7 Voltages used in T cell phenotyping panel 
CHANNEL FLUOROPHORE VOLTAGE GAIN 
FSC  250 5.0 
SSC  300 10.0 
FL1 FITC 395 1.0 
FL2 PE 375 2.0 
FL4 PerCPCy5.5 550 2.0 
FL6 APC 475 2.0 
FL8 APC-H7 450 2.0 
FL9 FVS450 300 1.0 
 
2.10 Cytokine Measurement: ELISA 
Enzyme-linked immunosorbent assay (ELISA) was utilised to assess T cell 
functionality. Levels of the cytokines interferon gamma (IFN-γ), tumor necrosing 
factor alpha (TNF-α), interleukin-10 (IL-10) and interleukin-12 (IL-12) were 
measured in lysate-loaded APC or T cell-APC co-culture supernatants (cell-
conditioned media) after 24 – 72 hours, as appropriate. 
 
The amount of IL-12, IL-10, IFN-γ or TNF-α was assayed by ELISA using Nunc-
Immuno Maxisorp 96 well plates (Thermo Fisher Scientific, Denmark), purified anti-
mouse IL-12, IFN-γ, TNF-α and IL-10 (all from BioLegend); recombinant mouse IL-
12, IFN-γ, TNF-α and IL-10; and biotinylated anti-mouse IL-12, IFN-γ, TNF-α and 
IL-10 (all from BioLegend). The ELISA antibody pairs are listed in Table 8. 
 
  
Figure 17 Compensation matrix and unstained and single stained controls used to set 
compensation in T cell phenotyping panels. T cells were isolated from OT mice by magnetic bead 
separation as previously described. 0.5 x 106 T cells were labeled with Fixable Viability Stain 450 
(FVS450) followed by surface staining for FITC, PE, PerCPCy5.5, APC and APC-H7. Cells were 
fixed in 4% paraformaldehyde, stored overnight at 8°C and acquired the following day on a Gallios 
Flow Cytometer. 100,000 events were collected per sample. Data was analysed and graphed in FlowJo 
Version X.  
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Primary Antibody Secondary Antibody Supplier Catalogue 
Number 
IFN-γ Purified anti-mouse IFN-γ  BD Biosciences 551216 
  Biotin anti-mouse BD Biosciences 55410 
TNF-α Purified anti-mouse TNF-α;  
clone: MP6-XT22 
 BioLegend 506302 




IL-10 Purified anti-mouse IL-10;  
clone: JES5-16E3 
 BioLegend 505002 




IL-12 Purified anti-mouse IL-12 p70  BD Biosciences 554658 
  Biotin anti-mouse IL-
12 p70/p40 
BD Biosciences 554476 
Streptavidin-
HRP 
  BioLegend 405210 
 
Plates were coated with 50 μL of purified cytokine diluted in the appropriate coating 
buffer (Appendix 2, Recipes). Plates were incubated for 2 hrs at 37°C or overnight at 
4°C. Plates were washed six times in freshly made wash buffer (Appendix 2, 
Recipes), excess liquid removed by tapping upside down on paper towels, and 
blocked with 200 μL blocking buffer (Appendix 2, Recipes), for 1 hour at 37°C.  
Plates were washed six times and blotted. Standard curves were generated on each 
plate by doubling dilutions of 100 μL of purified cytokine standards. Standards and 
samples were plated in duplicate and incubated for 2 hrs at 37°C or overnight at 4°C. 
Plates were washed six times and blotted. The appropriate biotinylated rat anti-mouse 
antibody was diluted in blocking buffer, 100 μL added to the plates, and incubated at 
37°C for no longer than 30 minutes. Plates were washed six times and blotted. 
Streptavidin-HRP (BioLegend) was diluted 1/3000 in blocking buffer. 100 μL was 
added to each well and the plates incubated at 37°C for 20 minutes. Plates were 
washed six times and blotted. 3,3',5,5'-tetramethylbenzidine (TMB) soluble substrate 
(Novex, Life Technologies, Cat # 00-2023) was added to each well. TMB yields a 
blue color when enzymatically digesting HRP. With the addition of sulfuric acid the 
reaction is stopped and the color changes to yellow with maximum absorbance at 450 
nm. 10N H2SO4 (FIXANAL, Fluka Analytical, Sigma-Aldrich, Chemie GmbH, 
Steinheim, Germany; cat: 38294; sulfuric acid 0.5 mol) was diluted 1/10 with dH2O 
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and 100 μL of 1N H2SO4 added to each well. Absorbance at 450 nm was read within 
30 minutes on a BioTek Synergy 2 Microplate Reader (Thermo Fisher Scientific). 
2.11 T cell In Vitro Cytotoxicity: VITAL Assay 
The VITAL assay was developed by Hermans et al18 as a fluorometric alternative to 
the use of radioactive isotopes for the measurement of cytotoxic capability against 
target cells. Survival of fluorescent targets can be measured as a readout of an effector 
cells’ killing ability. 
 
Effector cells were generated as described above by co-culturing T cells with lysate-
loaded APCs for 72 hours. B16.OVA melanoma target cells were labelled with CFSE 
as described above under CFSE labelling of T cells.  CFSE-labelled melanoma cells 
were added to 96 well flat-bottom plates (2 e 5 cells/well) and incubated for 2 hours at 
37°C+5% CO2 to allow a monolayer to form.  
Effector T cells were added in different effector to target ratios, in triplicate. Cells 
were incubated for 6 – 8 hours at 37°C+5% CO2. Following incubation cells were 
harvested and propidium iodide (PI; 5 μg/mL) added to each tube. Cells were 
collected by Flow Cytometry, analysed by gating on CFSE+PI+ cells and calculating 
the survival of target cells relative to antigen-negative controls. The percentage of 
specific lysis was calculated as follows: 
 
1. Adjusted % survival = 100 x % survival/Mean % survival in absence of 
effectors 
2. % specific lysis = (100 – adjusted % survival) 
 
We were concerned that due to the large number of samples the use of PI may yield a 
falsely high level of cytotoxicity due to the length of time cells remained in PI prior to 
processing. We therefore modified this protocol by staining cells with a live/dead 
discrimination dye followed by fixing the cells in 2-4% paraformaldehyde prior to 
harvesting into tubes for FACS analysis. This allowed us to harvest cells and store 
them overnight at 4°C for processing the next day rather than analysing them 
immediately as is required for PI staining (as per R&D Systems “Flow Cytometry 
Protocol for Analysis of Cell Viability using Propidium Iodide”). 
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2.12 In Vivo Cytotoxicity 
These experiments were approved by the Animal Ethics Committee, University of 
Otago and conducted under Animal Ethics approval number AEC59/15. Figure 18 
outlines the timeline of these assays. APCs and T cells were generated as previously 
described in this chapter. GMDCs +/- B cells were loaded with lysate and activated 
with LPS and CpG. The following day CD4+ OT-II and CD8+ OT-I T cells were 
isolated and equal numbers of CD4+ and CD8+ T cells added to the lysate-loaded 
APCs at a ratio of 10 T cells to 1 APC. At Day 3 or 4, effector T cells were harvested, 
washed twice in sterile DPBS, counted and resuspended at 1 x 107 cells/mL. Effector 
cells were adoptively transferred into C57BL/6 female mice via i.v. injection into the 















The following morning target cells were prepared. Splenocytes isolated from 
C57BL/6 mice were divided into three tubes and pulsed with 1 µg/ml OVA257-264 
(SIINFEKL) peptide or 5 µg/ml OVA323-339 peptide, or left unpulsed as a control 
against non-specific killing. Peptide loaded cells were incubated at 37°C for 3 hours, 
washed three times in DPBS and the concentrations adjusted to 5 x 107 c/mL for 
CFSE and VPD450 labeling. SIINFEKL pulsed cells were stained with 25 µM CFSE 
(CFSEHI) and OVA323-339 peptide-pulsed cells were stained with 2.5 μM CFSE 


















Figure 18 Schematic of in vivo cytotoxicity assay timeline. GMDC and B cells were prepared as 
previously described loaded with lysates+LPS&CpG and co-cultured with T cells to generate effector 
cells. 2 x 106 effectors per mouse were i.v. injected in 200 μL of PBS. The following morning peptide 
loaded and unpulsed target cells and were prepared and injected into the effector-bearing mice (3.3 x 106 
per target type per mouse). 24-hours later mice were sacrificed and splenocytes prepared into single cell 
suspensions. Cells were stained with dead cell exclusion dye, fixed in 4% PFA  and stored overnight at 
4°C. 1 x 106 cells per mouse were acquired the following day on a Gallios Flow Cytometer and the data 
analysed to assess target cell killing. 
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stained with 10 μM VPD450. CFSE and VPD450 labeling was carried out as 
described previously in this chapter.  
 
Dye-stained cell concentrations were adjusted to 50 x 106 c/mL in DPBS. Equal 
volumes of the 50 x 106 c/mL target cell types (unpulsed, SIIN-pulsed & OVA323-339-
pulsed) were mixed together and 200 µL (10 e 6 target cells; 3.33 x 106 per target type 
per mouse) was drawn into sterile syringes and injected into the tail vein of recipient 
mice.  
 
Mice were sacrificed 17-24 hrs after adoptive transfer of target cells. Spleens were 
isolated and splenocyte single cell suspensions prepared as described previously in 
this chapter for OT splenocytes. Splenocytes were labelled with the dead cell 
exclusion dye Live/Dead Near InfraRed (Life Technologies), fixed with 4% 
paraformaldehyde, stored overnight at 4°C and analysed the following day on a 
Gallios Flow Cytometer (Beckman Coulter). Table 9 lists the dyes and mABs used to 
label cells in these assays. Figure 62 in Chapter 5 shows the gating strategy and 
sample data from these experiments. 
 
The percentage lysis of target cells was calculated using the formula:  
% Lysis = 100 - (number of peptide-pulsed ÷ number of unpulsed)) 
Table 9 Dyes and monoclonal antibodies used in in vivo cytotoxicity assays 
 In Vivo Cytotoxicity Panel 
FL1 CFSEHI and CFSELO 
FL2 PE CD19, CD11c (Dump Channel) 1/400 0.25 uL 
FL3  
FL4 PerCPCy5.5 CD3 1/400 0.25 uL 
FL5  
FL6 APC CD8 1/400 0.25 uL or 
APC CD4 1/800 0.125 uL 
FL7  
FL8 Live/Dead Near Infrared 
FL9 VPD450unpulsed cell 
FL10  
 
2.13 Ex Vivo Proliferation and Cytokine Analysis 
Wild type C57BL/6 mice were injected with 50,000 B16.OVA cells and sacrificed 
when tumours reached 150 mm2. Tumour draining lymph nodes were excised and, in 
a laminar flow hood, gently pressed through a 70 μM cell sieve to create a single cell 
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suspension. Cells were washed twice in DPBS (300 x g, 5 mins, 4°C) and 
resuspended in freezing mix (50% medium, 40% FBS, 10% DMSO). Single cell 
suspensions were place in pre-cooled “Frosty Boys” and cryopreserved in liquid 
nitrogen for future use. Cells were retrieved from liquid nitrogen, quickly thawed in a 
37°C water bath until a small lump of ice remained in the vial. Cells were washed 
twice in room temperature fresh media, plated in flasks and allowed to rest overnight. 
The following day tumour dLN cells were added to lysate-loaded APCs at a ratio of 
10:1, +/- α-PD-1 and α-CTLA-4 as indicated in the appropriate figure legends. Cells 
were cultured for 10 days and fed no less than every other day. The media included 
IL-2 (2 ng/mL); 24-48 hours only); IL-7, IL-15 and IL-21 (all 100 ng/mL). Anti-
CD28 was also included in the medium in an attempt to augment the tumour-specific 
T cells’ fold expansion. Cell conditioned media were harvested, stored at -20° and 
analysed by anti-IFN-γ and anti-IL-12 ELISA.  
 
2.14 Statistical Analyses 
Analyses were performed and graphs created in Graph Pad Prism (GraphPad Software 
Inc, San Diego, CA). A significance level of 0.05 or less was considered statistically 
significant. 
 
The Mann-Whitney U test was used for comparisons of two groups. The Kruskal-
Wallis non-parametric comparison of location was applied for comparisons of three or 
more groups. This test was chosen based on the assumption that data was not likely to 
be normally distributed considering the group sizes. The measures were calculated as 
independent not paired since some samples had different numbers of data points. 
Dunn’s test for multiple comparisons, with Bonferroni correction, was applied post-
hoc to the rank sums to calculate differences between the groups. The Bonferoni 
adjustment is conservative so statistically significant results noted ought to be robust. 
 
Differences between treatments for in vitro and in vivo cytotoxicity assays were 
analysed by a biostatistician using negative binomial regression, which accounts for 
an over-dispersed Poisson distribution. The model included terms for the groups and 
adjusted for the number of cells collected. No adjustment was made for multiple 
comparisons, however all p values were <0.0001 indicating that the results are highly 
unlikely to be due to chance. 
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Generation of Tumour Lysate  
& the APC Response 
3.1 Delivering Antigen to the Immune System: DC, MΦ and B cell 
Style 
3.1.2.1 Dendritic Cells 
The DC used in most, if not all, murine studies using tumour lysate have been GM-
CSF-differentiated myeloid-type DCs1–3. However, another method for generating 
DCs in vitro involves culturing the bone marrow-derived precursor cells with FMS-
like tyrosine kinase 3 ligand (Flt3L) to generate a lymphoid-like DC4,5. Flt3L binds to 
its receptor Flt3 on monocytes and DCs and has been shown to preferentially expand 
the CD8α+ DC population and enhance the T cell response in the Plasmodium 
infection setting6. While CD8α+ DCs have been shown to preferentially cross-present 
antigen, Flt3L-generated DCs were not used in this study as previous work has 
demonstrated their tolerogenic nature7 as well as their inferior nature in the in vivo 
anti-tumour setting4,5,8,9. Moreover, it has been noted that more Flt3L-derived cells 
were required to elicit the same anti-tumour results in vivo as were observed with 
fewer GM-CSF-derived cells4,5. More evidence for the choice of GM-CSF-generated 
DCs for this current study comes from work showing that in vitro differentiation of 
DCs in Flt3L resulted in cells resembling the comparatively tolerogenic lymphoid-
resident DCs obtained under non-inflammatory, homeostatic conditions. This 
contrasted with the more immunogenic phenotype and function of GM-CSF–
differentiated cells9. Examination of the signaling pathways of GM-CSF and Flt3L 
reveals that the tolerogenic nature of Flt3L is explained by its activation of STAT3, 
which inhibits NFκB and MHC-II and upregulates production of the inhibitory 
molecule IDO7. GM-CSF, by contrast, activates canonical NF-κB signalling, and 
STAT5 as well as STAT3. This signalling combination overrides STAT3-mdiated 
inhibition resulting in an immunogenic DC7. The elaboration of distinct murine 
dendritic cells by GM-CSF versus Flt3 ligand has ramifications for inflammation and 
trafficking with GM-CSF–driven DC development in vivo driving the production of 
strongly immunogenic DCs that promote TH1 immune responses. In a murine model 
3 
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of cancer, both Flt3L and GM-CSF administration gave rise to DCs, but GM-CSF 
resulted in an enhanced anti-tumour response8.  
 
The majority of pre-clinical and clinical studies use GM-CSF-differentiated bone-
marrow precursor cells or monocyte-derived DCs respectively. IL-4 is required when 
culturing human DCs to prevent their return to a CD14+ monocyte10. Some evidence 
exists showing that adding IL-4 to murine DC cultures increases their 
immunostimulatory properties11. It has been shown that under serum-free growth 
conditions murine BMDCs differentiated with GM-CSF +/- IL-4 have similar 
macropinocytosis and mannose receptor-mediated uptake of FITC-albumin and FITC-
dextran particles respectively11. In that work IL-4+ and IL-4- GMDCs showed similar 
IL-12 production in response to LPS stimulation. However the GMDCs differentiated 
in the absence of IL-4 showed suboptimal levels of the presentation molecule MHC-II 
and costimulatory molecules CD40 and CD80. In contrast the GMDCs cultured in the 
presence of IL-4 showed stronger stimulation of allogeneic splenocytes in a mixed 
lymphocyte reaction (MLR) and of naïve, antigen-specific OT-II transgenic T cells 
when loaded with the Class II ovalbumin peptide (OVA323-339) or with whole OVA 
protein.  
 
We are not aware of any studies using Flt3L-differentiated DCs and tumour lysate, 
however for the reasons described we used the GM-CSF-stimulated DCs whose 
characteristics resemble in vivo inflammatory, monocyte-derived, myeloid DCs. We 
required an immunogenic DC that could efficiently take up lysate, present lysate-
derived peptides on MHC-II, cross-present peptides on MHC-I, secrete IL-12, 
upregulate costimulatory molecules and effectively stimulate antigen-specific T cells. 
Therefore we chose to use the GM-CSF-derived DCs and evaluated the importance of 
IL-4 by comparing the response of GMDC and IL4DCs to soluble lysate and oxidised 
lysate.  
3.1.2.2 Macrophages 
Many studies demonstrate the potential utility of MΦs in the response to undefined 
tumour antigens and we hypothesized that MΦs may cooperate with DCs and B cells 
in priming anti-tumour T cells, whether directly, or indirectly via their DC or B cell 
interactions. 
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Subcapsular sinus (SCS) MΦs access lymphatic antigens by extending processes into 
the sinuses. Elegant multiphoton intravital microscopy of murine LNs identified 
intricate MΦ-B cell-DC interactions in antigen presentation activities12–15. SCS MΦs 
acquired antigen in sinus-extending processes and translocated it to their follicularly-
located tail regions where specific antigen was passed to B cells via their BCRs and 
non-specific antigen immune complexes were recognised via the B cells’ complement 
receptors. In these studies antigen retention by MΦs, as opposed to antigen 
degradation, greatly enhanced B cell activation. B cells internalized these antigens 
and migrated into the follicle where antigen was transferred to fDCs, or migrated to 
the B cell-T cell border to present antigen to T cells. This in vivo evidence 
demonstrates extensive antigen acquisition/presentation interactions between these 
cells, with SCS MΦs playing a vital role in the entry of native antigen to B cell 
follicles. Work from a different group has also demonstrated transfer of BCR-
captured antigen from B cells to MΦs16. 
 
We are only aware of one pre-clinical study that has utilized TL-loaded MΦs as the 
APC17. MΦs transduced to produce M-CSF and IFN-γ displayed increased MHC-II, 
CD80 and ICAM-1; increased antigen presentation and cytotoxicity; and increased 
production of tumour necrosis factor (TNF), nitric oxide (NO) and IL-1. Taking these 
MΦs in vivo yielded increased splenic CTL IFN-γ and TNF production after ACT of 
the transduced MΦs and elicited anti-tumour effects in murine pulmonary metastatic 
melanoma. This study argued that improperly activated MΦs may give misleading 
results and demonstrated that MΦs engineered to secrete M-CSF and IFN-γ, which 
had been pulsed with freeze-thaw generated TL were able to generate a strong anti-
tumour response17, namely secretion of IL-2 by T cells, specific cytotoxicity and 
reduced metastases in tumour-bearing mice. Given that MΦs work alongside DC 
during both T cell activation and maintenance we wished to investigate their role in 
presenting undefined antigens either alone or in combination with DCs and/or B cells. 
3.1.2.3 B Cells 
Lanzavecchia was the first to report that B cells are able to act as effective APCs, 
efficiently taking up and presenting MHC-restricted antigen18. Many subsequent 
studies have shown that activated B cells act as efficient APCs16,19–41 and have 
demonstrated their role in the priming and restimulation of CTL21,42–46. B cells have 
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been demonstrated to play a vital role in anti-tumour responses. Therefore spleen-
derived B cells were also assessed as individual APCs and in combination with 
GMDCs and M1 MΦs.  
 
While unactivated B cells are poor antigen presenters, or tolerogenic, the B cell role 
as cross-presenters to CD8+ CTLs is a fact that is not widely appreciated47. The use of 
EBV-transformed B cells to present human melanoma-derived antigen was reported 
by Topalian et al in 199448 and suggested the idea of using B cells in anti-tumour 
therapy. The focus in the ensuing two decades was on the exciting possibilities raised 
by using DCs in ACT. However subsequent limitations in the use of DCs as APCs for 
ACT, combined with further understanding of B cell antigen presentation capacities 
have sparked renewed investigations of the use of B cells as APCs pre-clinically and 
in the clinic. B cells loaded with melanoma lysate have been successfully used to 
examine murine and human T cell responses. Murine studies demonstrated effective 
generation of IFN-γ-producing CD4+ T cells by lysate-loaded B cells, and these B 
cell-primed T cells conferred protection after melanoma rechallenge32. In humans 
activated melanoma-lysate-loaded B cells also generated tyrosinase-specific CD4+ T 
cells36. Therefore precedent exists for the use of B cells as presenters of undefined 
antigens to T cells in both mice and humans and we wished to investigate whether 
lysate-loaded B cells in combination with DCs, MΦs, or both, could stimulate an 
improved T cell response. 
3.1.3 Phenotype Analysis of DC and Macrophage Populations 
During this study no definitive panels of markers existed that were in common 
practice for defining different DC and MΦ populations – or if these panels did exist 
they were not widely advertised. It is our observation that different groups use 
different combinations of surface markers and this can make judgments about cell 
type imprecise at best - as in the case of defining cells as MΦs or DCs solely on the 
basis of F4/80 or CD11c expression respectively - and inaccurate at worst.  
 
This study aimed to compare two distinct GMDC and MΦ cell populations, therefore 
in order to determine phenotypic differences a robust panel of markers needed to be 
designed. Based on the literature we designed and tested a range of markers to 
identify differences between the populations. The surface markers that were used to 
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investigate phenotypic differences between the cells grown in M-CSF and GM-CSF 
+/- IL-3 are listed in Table 2 of Materials and Methods.  
 
MHC-II along with the canonical costimulation markers CD40 and CD80 were used 
to assess the immature status of the DC and MΦ prior to lysate loading and the 
activation response post lysate loading. These markers gave us an indication of the 
antigen presentation potential of the APCs. 
 
The transmembrane integrin CD11c has historically been used as a single identifying 
marker for DCs. However, this molecule is only found on certain DC subsets and is 
also expressed to a significant degree on MΦs. In this study it was used to identify 
which type of DC and MΦ were being generated. CD135 is a lymphoid DC marker 
and was also used to help identify the type of DC generated. 
 
The tissue adhesion G-protein coupled receptor (GPCR) F4/80 is expressed on many, 
but not all murine MΦs, and thus also gives insight into which type of MΦ is being 
generated. F4/80 has been used as a classical MΦ marker, however it is also 
expressed on subsets of DCs. The combination of both F4/80 and CD11c as a bare 
minimum is more helpful in assigning a more DC- or MΦ-like status to GM-CSF-
stimulated cells.  
 
The colony stimulating factor 1 receptor (CSF1R), also called CD115, is expressed at 
high levels on bone marrow MΦs49 and at low to intermediate levels on DCs, making 
it another useful distinguishing marker.  
 
The mannose receptor CD206 is known to be expressed on MΦ and immature DCs 
and we were interested to see if our cells expressed this marker as it could be useful 
for analysis of lysate uptake mechanisms. We were also interested in the CD169 
status of these cells since studies have identified them as important in presenting dead 
cell antigen to T cells in vivo50,51.  
 
Table 1 (Materials and Methods) lists all the molecules that were investigated during 
the optimization phase. All GMDCs and MΦ cultures were compared to identify key 
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differences between the two cell populations and ensure consistency of cell 
phenotypes. The antibody panels shown in Table 2 (Materials and Methods) were 
chosen for on going comparison. These panels provided a range of molecules that are 
common to both DC and MΦ. Variations in expression levels of the molecules 
allowed us to distinguish differences between the three cell types (GMDC, IL4DC 
and MΦ), indicative of differing functions and capabilities. 
 
We generated two types of DC and two types of MΦs and compared their phenotypes 
and their responses to the two lysates in terms of their ability to upregulate 
presentation and costimulation machinery, and to secrete IL-12. We are not aware of 
any other studies combining APCs in anti-cancer treatments. However one study has 
used DCs, MΦs and B cells in the analysis of adjuvant-stimulated intracellular signal 
pathways52 for improving vaccine development and other groups have looked at 
antigen transfer between MΦs and DCs and B cells16,40,53. 
 
3.1.4 Tumour Lysate: A Source of Undefined Tumour Antigens 
ACT for cancer can be generated against defined or undefined antigens in the forms 
of known tumour associated proteins, peptides or lysates. In the ideal scenario a 
patient’s tumour antigens are defined. However, for the majority of cancers, this is not 
the case, therefore particular antigens cannot be targeted with therapy. Thus 
oncologists initially utilize more generalized systemic treatment approaches such as 
chemotherapy and radiotherapy. This fact, as well as the issues with the use of single 
or multiple peptides, was the key reason for the use of TL in this study. Since lysate 
comprises the total contents of the neoplastic cell, it potentially represents an ideal 
source of TAA, including immunodominant antigens. APC processing of TL leads to 
presentation of CD4+ and CD8+ peptide sequences, thus covering both T helper and 
CTL activation.  In addition, since the lysate is sourced from the patient’s own 
tumour, HLA haplotyping is irrelevant.  
 
A further reason for the choice of TL as the source of antigen is the highly 
heterogeneous nature of tumour tissue.54–58. This is a critical issue, as vaccinating 
against a single immunodominant antigen will only target one area of the tumour, 
potentially allowing other areas of the tumour to continue to grow unchecked. TL has 
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been used in pre-clinical and clinical studies and has been demonstrated to be a safe, 
well-tolerated and effective source of tumour antigens59–66.  
 
The obvious drawback to using TL is that TAA can also be self-antigens and tumours 
can hijack immune tolerance mechanisms to escape immune control. While some 
TAAs may be mutated, most of the antigens in TL are normal tissue antigens and so 
tolerance must be overcome in order to mediate cancer regression. This is particularly 
so in the case of non-mutated self-antigens that are simply overexpressed on tumours 
as compared to healthy tissue.  
 
The corollary to breaking tolerance is the risk of autoimmune disease. Numerous 
studies with TAA-specific T cell transfer have shown autoimmune side effects in both 
mice and humans (reviewed in67). By contrast fewer studies in mice have reported 
severe, fatal autoimmune responses when using DCs loaded with tumour antigens that 
are shared with normal tissue68,69. One recent mouse study showed that TL-loaded 
DCs, which induced tumour control after ACT, stimulated increased levels of 
autoantibodies but that this was transient and did not lead to overt symptoms70. The 
autoimmune response was required for the anti-tumour response, but did not lead to 
outright autoimmune pathology. This phenomenon of biochemical autoimmunity in 
the absence of clinical symptoms has also been observed in melanoma patients 
(reviewed in71). In clinical trials to date many autoimmune reactions to self-antigens 
in cancer immunotherapy have been minor, self-limiting and without chronic 
sequelae, for example vitiligo and uveitis caused by deletion of healthy melanocytes 
along with the cancerous cells in melanoma after treatment with TILs72–75. In the case 
of melanoma at least, these autoimmune reactions appear to be necessary for 
induction of a robust anti-cancer response73,76,77. However there are exceptions and 
serious side-effects of severe uveitis with visual impairment and enterocolitis with 
bowel perforation requiring colectomy have also been reported (reviewed in78). 
Cancer immunotherapy clinicians are aware of autoimmune risks inherent in 
treatment with TAAs and are continually refining their approaches to ameliorate 
undesirable adverse events, while maximizing anti-tumour efficacy. 
 
 177 
While acknowledging the issue of autoimmune reactions, we wished to increase the 
immunogenicity of the tumour lysate because in spite of specific TAAs being 
recognizable by the immune system, TLs can be immunosuppressive. Thus there was 
a need to make the lysate TAAs more immunogenic. It has been noted that cells that 
are stressed prior to lysis yield a more immunostimulatory lysate2,79,80. We therefore 
experimented with making TL more immunogenic in order to overcome normal 
tolerance-associated immune suppression since other studies have demonstrated poor 
DC response to freeze-thaw lysate2. Comparative studies by Chiang et al 
demonstrated that ovarian cancer cells damaged by oxidation created a lysate that was 
superior at activating DCs and T cells than lysates prepared from heat-treated, freeze-
thawed or UVB-irradiated cells61,81,82.  Based on these studies the APCs’ responses to 
the soluble fraction of freeze-thaw-generated lysate and the whole portion of oxidised 
cell lysate were compared. 
 
We wished to determine whether lysate antigens presented by various APCs could 
activate CD4+, or CD8+ T cells, or both to induce an anti-tumour response. For this 
reason we used B16.OVA melanoma cells as the source of our tumour lysate. While 
OVA is a foreign, and therefore imitation, cancer antigen, this model allows the 
generation of high numbers of CD4+ and CD8+ T cells making it a good model to use 
as a starting point for further studies using actual tumour antigens. 
 
3.1.6 Functional Analysis of Lysate-Loaded APCs 
In addition to analysis of upregulation of MHC and costimulatory molecules we 
assessed the production of IL-12 by the APCs in response to lysate. IL-12, produced 
by NK cells83, B cells84, DCs85 and MΦs86 is the major factor in the induction of IFN-γ 
production by T cells85,87 and is a key driver in the differentiation of CD4+ T cells into 
TH1 cells85. Therefore, the APCs’ output of IL-12 in response to TL was assessed as 





The aim of the studies summarised in this chapter was to assess the response of the 
three APCs to two types of tumour lysate. We aimed to create a form of tumour lysate 
that would yield an enhanced APC presentation profile. We also aimed to identify 
which culture conditions would generate the best APC(s) for presenting TL to CD4+ 
and CD8+ T cells. 
 
We hypothesized that of the three APCs GMDC and M1 MΦ would be the most 
efficient at taking up TL and would respond best to tumour lysate through their 
upregulation of MHC Class II and costimulatory molecules CD40 and CD80 as well 
as their production of IL-12. 
 
To address the hypothesis the following objectives were undertaken: 
1. Preparation of OVA-positive soluble fraction freeze-thaw lysate (soluble lysate) 
and HOCl-oxidised whole freeze-thaw lysate (oxidised lysate) 
2. Optimisation of culture conditions for generation of bone marrow-derived DC and 
MΦ  
3. Assessment of activation and cytokine responses of GMDC, MΦ and B cells to 
soluble and oxidised lysates as an indicator of the potential for each lysate-APC 





3.3.1 Generation of B16.OVA Tumour Lysate 
We aimed to produce a lysate that would overcome suppression via increased danger 
or stress signals, and, ultimately, induce maximal T cell responses. Following on from 
previous work Mycoplasma-free (Appendix 1, Supplementary Figure 1), OVA-
secreting B16.OVA cells were used as the lysate source. Since OVA is a secreted 
protein cells were pre-incubated in the protein transport inhibitor Brefeldin A prior to 
freeze-thaw lysis to ensure adequate levels of OVA in the lysate.  
 
Soluble OVA protein is located in the soluble fraction of the lysate making this 
fraction the immunostimulatory portion of the lysate. Brefeldin A, impedes the 
dissemination of newly synthesized MHC class I molecules from the endoplasmic 
reticulum (ER) to the trans-Golgi network88. Based on previous data88 it was assumed 
that no loss of Brefeldin A’s effects should occur during the 1 hour oxidation 
treatment. Comparison of the T cell proliferation response to B16.OVA cells that 
were incubated in Brefeldin A for 1 hour and 5 hours prior to lysis is discussed in 
Appendix 1, Supplementary Data 8.17. 
 
B16 cells have very low levels of MHC-I expression89 and OVA is a secreted protein, 
therefore we did not expect high expression of the OVA257-264 peptide (hereafter 
referred to as SIINFEKL) bound to MHC class I on the cell surface (MHC-I-SIIN). 
As expected, after incubation with the protein transport inhibitor Brefeldin A the cells 
expressed very low levels of MHC-I-SIIN (Figure 19) (average 7%; range 2 – 13 in 
four independent experiments). For comparison B16F10 cells, which do not express 
OVA, were also assayed for MHC-I-SIIN expression, which was absent (Appendix 1, 
Supplementary Figure 2). 
 
The presence of MHC-I-SIIN on the cell surface prior to lysis was negligible and 
therefore not useful as an indicator of the presence of OVA. Therefore the resulting 
lysates were assayed by Western Blot (WB) to confirm that the OVA protein had been 
retained through the oxidation and freeze-thaw procedures. Lysates containing 20, 40 
and 60 μg of protein were assayed. Western Blots revealed two bands in the 40 and 45 
kDa range as expected for OVA protein (Figure 20), with the size of the bands 
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Figure 20 Protein blot showing expression of model tumour antigen OVA in soluble lysate of 
B16.OVA cells after death by freeze-thaw lysis. 1 x 106 B16.OVA cells were lysed in sample buffer. 
20, 40 and 60 μg of protein were resolved on BOLT 4-12% Bis-Tris Plus Pre-Cast gradient gels and 
transferred to nitrocellulose membranes with the iBlot Transfer system. OVA expression was detected 
with anti-OVA monoclonal antibody. The membrane was probed with secondary HRP-conjugated anti-
mouse IgG followed by SuperSignal WestPico Chemiluminescent Substrate. The film was developed 
after a 5 minute exposure and scanned using Canon Scan software. 45 kDa bands are indicative of OVA 
protein. 1/1000 and 1/750 refers to the dilution of the primary antibody. Data shown are representative 
of three independent experiments. 
 Figure 19 Very little SIINFEKL peptide in the context of MHC-I is expressed on the surface of 
B16.OVA cells. B16.OVA cells were cultured as described in Materials & Methods. Following 5 
hours incubation with Brefeldin A 5 x 105 cells were stained with antibodies to H-2Kb bound to 
SIINFEKL conjugated to PE. Cells were fixed with 2% paraformaldehyde, stored overnight at 4°C 
and acquired the following day on a Gallios Flow Cytometer. Representative dot plots of. B16.OVA 
cells after Brefeldin A treatment. Representative data from three independent experiments in which 
results were very similar. 
Unstained 
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Previous studies have demonstrated superior immunogenicity of HOCl-oxidised 
freeze-thaw lysate61,79,82. Therefore we compared the APC response to both the soluble 
fraction of freeze-thaw lysate (hereafter referred to as soluble lysate and abbreviated 
as s-L) and to HOCl-oxidised whole freeze-thaw lysate (hereafter referred to as 
oxidised lysate and abbreviated as ox-L). Oxidation of the B16.OVA cells was 
achieved using sodium hypochlorite prior to six rounds of freeze thaw lysis. We 
assayed the oxidised lysate by Western Blot for the presence of OVA protein in order 
to verify that oxidation of the cells had not altered the OVA protein. Once again 
concentration-dependent levels of OVA protein were detected in the oxidised lysate 
(Figure 21). However in contrast to the clean result seen with the soluble lysate in the 






















Figure 21 Protein blot showing expression of model tumour antigen OVA in lysate of B16.OVA 
cells is retained after death by oxidation followed by freeze-thaw lysis. 1 x 106 oxidised B16.OVA 
cells were lysed in sample buffer. 20 and 40 μg of protein were resolved on BOLT 4-12% Bis-Tris Plus 
Pre-Cast gradient gels and transferred to nitrocellulose membranes with the iBlot Transfer system. OVA 
expression was detected with anti-OVA monoclonal antibody. The membrane was probed with 
secondary HRP-conjugated anti-mouse IgG followed by SuperSignal WestPico Chemiluminescent 
Substrate. The film was developed after a 1 minute exposure and scanned using Canon Scan software. 45 
kDa bands are indicative of OVA protein. The numbers on the left denote the migration of the molecular 
weight markers. Data shown are representative of three independent experiments. 
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3.3.2 Cell Types Differ in Their Resistance to Oxidation-Induced Cell Death 
Chiang et al showed that incubating cells in 60 μM HOCl achieved 95% cell death of 
SK-OV-3 human ovarian cancer cells79,82; therefore we used the same HOCl 
concentration. However, incubating B16.OVA cells in 60 μM HOCl resulted in only 
57% cell death (46 – 73) (Figure 22). This variation in HOCl doses prompted 
evaluation of other cell lines to validate our B16.OVA result. For a direct comparison 
with B16.OVA, three more melanoma cell lines were chosen: B16gp33, B16F10 and 
Mel888 (Figure 23). In addition, we compared three non-melanoma cell lines to 
ascertain if differences in oxidation were cell type-specific. Thus we also compared 
the colon carcinoma cell line MC38, the human monocytic leukaemia cell line THP-1 
and the murine lung epithelial tumour cell line TC1. The different cell lines each 
required a different amount of HOCl to achieve 95% cell death (Figure 22 and 
Appendix 1 Supplementary Fig. 4). The melanoma and THP-1 cell lines were more 
sensitive to death by oxidation than TC-1 or MC38 cells. With 90 μM HOCl we saw a 
range of 80 to 96% death of melanoma and THP-1cells. By contrast TC-1 and MC38 
cell lines required greater than 90 μM to achieve 95% cell death. These data showed 
that the cell types differed in their sensitivity to death by oxidation and therefore the 































 Figure 22 Concentration-dependent oxidation-induced death of B16.OVA cells. B16.OVA melanoma cells 
were cultured as described in Materials and Methods. Cells were incubated with different concentrations of 
HOCl as shown on the x axis for 1 h at 37°C. Cells were washed, stained with Propidium Iodide (5 μg/mL) and 
acquired by a Gallios Flow Cytometer within an hour. Data was analysed by FlowJo V9 or V10. The percentage 
of highly PI positive cells corresponded to the percentage of dead cells.. A) Representative data from three 
independent experiments. B) The percentage of highly PI positive cells corresponded to the percentage of dead 
cells and was plotted against HOCl concentration. Summary data of 3 independent experiments. Statistically 
significant differences were calculated by Kruskal-Wallis test followed by Dunn’s post test with Bonferroni 
correction. compared to untreated * p<0.05; ** p<0.01. Error bars = mean ± s.e.m. of 3 independent 
experiments. 
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Summary data of 3 experiments. Stats: error bars = mean+sd of Student's 


















3.3.3 Optimising Dendritic Cell and Macrophage Culture Conditions  
To compare the immune response to the lysates, two types of dendritic cells  and two 
types of macrophages were generated from bone marrow-derived precursors. 
Different culture conditions for APC generation were assessed (Figure 24). Bone-
marrow precursor cells differentiated with GM-CSF were designated GMDC. Those 
differentiated with GM-CSF+IL-4 were designated IL4DC. Cells differentiated with 
GM-CSF+IL-3 were designated M1 MΦs. For comparison we cultured bone marrow 
cells in macrophage colony-stimulating factor (M-CSF), and these were designated 
M2 MΦs. Given that this study aimed to compare the ability of different cell types to 
act as APCs for tumour cell lysate it was important to verify that three different cell 
types were being generated. Therefore the morphology and molecular phenotype of 
these cells was carefully and continuously monitored. 
 
GM-CSF and M-CSF respectively are known M1 and M2 MΦ-inducing stimulants90, 
with GM-CSF driving an M1 inflammatory MΦ phenotype and M-CSF promoting an 
anti-inflammatory or homeostatic M2 MΦ response91. For simplicity MHC-II, 
CD11c, F4/80, CD40 and CD80 are shown in Figure 24. CD169 and CD206 were 
also assessed but no differences between culture conditions were observed for these 
molecules (data not shown). As expected, differentiating bone marrow precursor cells 
in M-CSF yielded a distinct M2 MΦ phenotype (Figure 24) with low expression of 
 Figure 23 Concentration-dependent induction of death in four melanoma cell lines by HOCl oxidation. 
B16.OVA, B16.gp33, B16.F10 and Mel888 melanoma cells were cultured as described for B16OVA tumour cells 
in Materials and Methods. Geneticin was only added to B16.OVA cells. Harvested cells were incubated in 
different concentrations of HOCl as shown on the x axis for 1 hr at 37°C. Cells were washed, stained with 
Propidium Iodide (5 μg/mL) and acquired by a Gallios Flow Cytometer within an hour. Data was analysed by 
FlowJo V9 or V10. The percentage of highly PI positive cells corresponded to the percentage of dead cells. 
Statistically significant differences were calculated by Kruskal-Wallis test followed by Dunn’s post test with 
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MHC-II (6%; 4 – 7), CD11c (17%; 12 – 26) and F4/80 (7%; 3 – 14) (Figure 24). The 
full Flow Cytometric gating strategy is shown in Figure 25, using sample GMDC 


















Cells cultured in M-CSF yielded markedly lower levels of MHC-II than those grown 
in GM-CSF+/-IL-3 or IL-4 (M2 MΦs: 6%; M1 MΦs: 42% ns; GMDC: 52% ns; IL-
4DC: 62% p<0.05) (Figure 24).  
 
A similar result was observed with the CD11c molecule with 17% of M2 MΦs 
positive for this marker compared with 78% of M1 MΦs (p<0.001), 62% of GMDC 
(p<0.05), and 53% of IL4DC (ns).  
 
CD40 expression was unexpectedly high on M2 MΦs (62%) and unexpectedly low on 
M1 MΦs (1%), GMDC (2%) and IL4DC (2.5%).  
In line with expected results M2 MΦs displayed significantly lower percentages of 
CD80+ cells compared to M1 MΦs (78%, p<0.01), GMDC 65% (ns) and IL4DC 
(53% p<0.05). 
Figure 24 M2 MΦs, M1 MΦs, GMDCs and IL4DC display different phenotypes. Bone marrow-derived 
precursor cells were cultured in IMDM+10 ng/mL M-CSF and 10% FCS (M2 MΦ), IMDM + 5 ng/mL GM-
CSF+5 ng/mL IL-3 and 10% FCS (M1 MΦ), IMDM + 20 ng/mL GM-CSF and 5% FCS (GMDC) or IMDM + 
20 ng/mL GM-CSF+10 ng/mL IL-4 and 5% FCS (IL4DC). Day 10 MΦs and Day 6 DC were harvested as 
described in Materials & Methods, stained with Live/Dead NIR dead cell exclusion dye and labeled with mABs 
against DC and MΦ surface markers: MHC-II, CD11c, CD169, F4/80, CD40 and CD80, as per Table 2 in 
Materials & Methods. Cells were fixed in 4% paraformaldehyde, stored overnight at 4°C and acquired the 
following day on a Gallios Flow Cytometer. Data was analysed on FlowJo V9 or VX and graphed in Prism. 
Summary data of 3 (M2 MΦ) and 11 (M1 MΦ, GMDC, IL4DC) separate experiments is shown. Statistically 
significant differences were calculated by Kruskal-Wallis test followed by Dunn’s post test with Bonferroni 











































Finally, F4/80 expression was also very low on M-CSF-differentiated M2 MΦs: 7% 
compared with 88% on GM-CSF+IL-3-differentiated M1 MΦs, 43% of GMDCs and 
41% of IL4DCs (p<0.05).  
 
Having identified that GM-CSF+IL-3 yielded the required MΦs we went on to 
identify the optimal media for these DCs and MΦs. Various media had been noted in 
the literature, with one study reporting that IMDM and RPMI had differential impacts 
on the levels of MHC Class II molecules, TLRs and scavenger receptors on DCs 
owing to differing amounts of aryl hydrocarbon receptors in these two media92. We 
therefore cultured these cells in two different media and on three different types of 
plastic ware and compared the resulting phenotypes.  
 
GMDC grown in RPMI and IMDM showed no difference between any surface 
markers tested (Figure 26). Culturing M1 MΦs on bacteriological or tissue culture 
plates did not alter expression of any of the markers tested, however harvesting these 
cells was significantly easier when grown on bacteriological plates. The M1 MΦ 
showed no differences in expression of MHC-II, CD11c, Ly6C, CD169, CD40, 
CD11b or CD135 when grown in RPMI or IMDM. M1 MΦs grown in RPMI on 
tissue culture plates, however, showed a strong, though not statistically significant, 
down-regulation of F4/80: 75% in IMDM versus 41% in RPMI; (p<0.3) (Appendix 1, 
Supplementary Data, Figure 25). A strong, though not statistically significant, down-
regulation of F4/80 in RPMI was also observed on the bacteriological dishes: 82% in 
IMDM versus 4% in RPMI (p=0.3). (Figure 27) Because of the down-regulation of 
this canonical MΦ marker that was observed in M1 MΦs cultured in RPMI we used 





   
Figure 25 Gating strategy used in DC MΦ  phenotype analysis. D6 GMDC, D6 IL4DC and D10 MΦ were 
stained with Live/Dead exclusion dye (Live Dead Near Infrared)) and Fc receptor block followed by surface 
molecule staining with the following monoclonal antibodies: MHC-II-FITC, CD11c-BV421, CD135-PE, 
CD169-PE, CD115-PE (BL), F4/80-PE, CD206-BV421 (BL), CD40-APC, CD80-BV421 (BL). Antibody-
stained cells were washed twice and fixed in 4% paraformaldehyde. Cells were stored overnight at 4°C and 
analysed the next day on a Gallios Flow Cytometer. 5 x 104 - 1 x 105 cells were collected in each sample 
wherever possible.  The gating strategy consisted of doublet exclusion followed by dead cell exclusion and then 
gating on the cells of interest using unstained cells and single stained cells as negative gating controls. 























Figure 26 GMDC display the same phenotype irrespective of RPMI or IMDM culture media. Bone 
marrow-derived precursor cells were prepared as described in Materials & Methods and cultured in RPMI 
or IMDM (+ 20 ng/mL GM-CSF and 5% FCS). On Day 6 cells were harvested, stained with Live/Dead 
NIR dead cell exclusion dye and labeled with mABs against the surface markers MHC-II, CD11c, Ly6C, 
F4/80, CD169, CD40, CD11b and Flt3 (CD135) as per Table 2 in Materials & Methods. Cells were fixed 
with 4% paraformaldehyde, stored overnight at 4°C and acquired the following day on a Gallios Flow 
Cytometer. Data was analysed on FlowJo Version 9 or X and graphed in Prism. Statistically significant 
differences were calculated using a Mann-Whitney U test. Error bars = mean +/- s.e.m of two independent 
experiments. 
Figure 27 Comparison of M1 macrophages cultured in IMDM versus RPMI. Bone marrow precursor 
cells were prepared as described in Materials & Methods were cultured in RPMI or IMDM (+ 5 ng/mL GM-
CSF, 5 ng/mL IL-3 and 10% FCS) on bacteriological (non-tissue culture-treated) dishes (BP). On Day 10 M1 
MΦs were harvested as described in Materials & Methods, stained with Live/Dead NIR dead cell exclusion 
dye and labeled with mABs against MHC-II, CD11c, Ly6C, F4/80, CD169, CD40, CD11b and Flt3 (CD135) 
as per Table 2 in Materials & Methods. Cells were fixed with 4% paraformaldehyde, stored overnight at 4°C 
and acquired the following day on a Gallios Flow Cytometer. Data was analysed on FlowJo Version X and 
graphed in Prism. Statistically significant differences were calculated using a Mann-Whitney U test. 
Summary data of two independent experiments. CD40 and Flt3 were only measured in the second 






















































































Results of 2 separate experiments;
Stats = paired Student's t-test; *p<0.05; **p<0.01; ***p<0.001 
Error bars = mean with s.e.m.
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3.3.4 Comparison of Unactivated GMDC, IL4DC and MΦ Morphology & 
Phenotypes 
Having identified the optimal medium for GMDCs and M1 MΦs, we compared 
GMDCs cultured with and without the cytokine interleukin-4 (IL-4). The three cell 
culture conditions generated three distinct cell populations, hereafter referred to as 
GMDC, IL4DC and MΦ. These three cell populations differed in morphology 
(Appendix 1, Supplementary Figure 5), phenotypic characteristics (Figure 28) and in 
their surface molecule (Figure 30) and IL-12 (Figure 35) response to tumour lysate 
antigens.  
3.3.4.1 GMDC, IL4DC and MΦ Morphologies 
The GMDC and IL4DC cultures appeared the most similar under the microscope, 
however a noticeable difference between them was the appearance in the IL4DC 
cultures of a much higher proportion of large (≈ 36 μM), round, clear cells that dotted 
the dishes (Appendix 1, Supplementary Figure 5). In the GMDC cultures these cells 
were present in much lower percentages (experimenter observation; data not 
quantified). We included anti-B220 in the DC and MΦ panels to ascertain whether or 
not these cells could be plasmacytoid DCs but the percentage of B220+ cells was 
extremely low indicating very low pDC percentages in the cultures (Data lost – 
sample images of GMDC and IL4DC can be seen in Appendix 1, Supplementary 
Figure 5). GMDC and IL4DC cultures had high numbers of semi-adherent and 
floating cells above a background of adherent and semi-adherent cells.  
 
On Day 0 the cells in the MΦ cultures are round and non-adherent or minimally 
adherent. By Day 3 adherent cells emerge in clusters that are much smaller than DC 
clusters, and begin to show MΦ morphology. By Day 10 there was a confluent, or 
near-confluent, layer of MΦs on the bacteriological dishes. The cells in the MΦ 
cultures were much larger than those in the DC cultures (diameters of 10 μM and 
above and elongations of up to 86 μM compared with diameters of 4-10 μM in the 
GMDC and IL4DC cultures). The MΦs were fewer in number and resolutely adherent 
with very few non-adherent cells. In contrast to the two DC cultures MΦs could not 
be harvested by pipetting but required growth in non-tissue culture-treated dishes and 
incubation in EDTA solution before they could be harvested by repeated flushing with 
a 10 mL pipette.  
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3.3.4.2 GMDC, IL4DC and MΦ Surface Phenotypes 
In addition to observing morphological variation the three cell populations were 
analysed by Flow Cytometry for the presence of DC and MΦ surface markers. Figure 
25 shows the gating strategy used in GMDC surface marker phenotype analysis. An 
example of MΦ gating is found in Appendix 1, Supplementary Figure 6. 
 
Staining a mixed population of DCs and MΦs for use as single stain controls proved 
unsatisfactory for use in compensation, as did using one set of voltages for both cell 
types. This is due to DCs and MΦs differing in size and granularity and thus 
autofluorescence.  Accordingly a set of single stain control cells was prepared for 
each cell type and the voltages adjusted for each cell type to ensure accurate 
compensation and optimal voltages. This method allows for direct comparison of the 
percentage of cells positive for a given fluorophore within a population, and for 
comparison of mean or median fluorescence intensity (MFI) between untreated and 
treatment groups of the same cell type. However MFI between the DCs and MΦs 
could not be directly compared due to the lack of an internal standard control. 
 
Figure 28 shows the summary data of phenotyping analysis of GMDCs, IL4DCs and 
M1 MΦs. Contrary to expectations CD11c expression was higher on MΦs than 
GMDC or IL4DC. In subsequent experiments the percentage of GMDC positive for 
CD11c remained consistently around 60%. No difference in CD11c expression was 
observed between GMDC and IL4DC. By contrast CD11c expression on M1 MΦs 
remained consistently higher than either GMDC or IL4DC (84%; 62 – 96; p< 0.01).  
 
No difference was identified in the percentage of GMDC and M1 MΦ positive for 
MHC-II (49% and 43% respectively). The percentage of IL4DC positive for MHC-II 
was significantly higher on 69%. Analysis of the median fluorescence intensity of 
MHC-II was not informative due to bimodal distribution in the GMDC population   
 
CD169 was not expressed on any of these APCs (Appendix 1, Supplementary Figure 
5). CD40 expression was also consistently negligible across the three unstimulated 
APCs. 
 191 
In contrast to the low levels of CD40 CD80 was constitutively expressed at 
intermediate to high levels across the three cell types. No difference was seen in 
CD80 expression between GMDC and IL4DC (66% and 53% respectively) but CD80 
was consistently significantly higher on M1  MΦs (82%; 60 – 95; p<0.01).  
 
As was the case with MHC-II, CD11c and CD80 F4/80 also distinguished the two 
populations by the level of expression. The two DC populations expressed F4/80 at 
intermediate levels (51% on GMDC and 42% on IL4DC) while the MΦs expressed it 
to a significantly higher degree (91%(p<0.001). 
 
None of the three cell types showed expression of the Flt-3 ligand receptor, CD135 
(Appendix 1, Supplementary Figure 5). GMDCs, IL4DCs and MΦs all showed low 
levels of CD8α (5%, 7% and 10% respectively) with no significant difference 
detected.  
 
MΦs and GMDCs showed intermediate positivity for CD115 (CSFR1) (62% and 
49% respectively). IL4DCs expressed CD115 at significantly lower levels (14%) 
however this difference was only statistically significant between IL4DCs and MΦs 
(p<0.01). The mannose receptor CD206 appeared at low levels on the GMDC and 
IL4DC (< 5%) (Appendix 1, Supplementary Figure 5). On MΦs the expression of 
CD206 varied widely between 22.5 and 62.3%, but expression was significantly 
higher than either GMDC or IL4DC (p<0.05). 
 
Finally, CD11b, the so-called macrophage-1 antigen (Mac-1) proved unhelpful as a 
distinguishing marker as it was expressed to very high levels on both GMDC and 
MΦs (data not shown). CD11b expression on IL4DC was not assessed as we had 
discounted it as a potential distinguishing marker prior to comparing GMDC and 
IL4DC. 
 
Thus these data showed by morphology and molecular phenotype that the three 
culture conditions generated three distinct populations of cells whose response to 







Figure 28 Variations in GMDC, IL4DC and MΦ  surface marker phenotypes. Bone marrow-derived precursor cells 
were cultured for 10 days in GM-CSF (5 ng/mL)+IL-3 (5 ng/mL)+FCS10% (MΦ); 6 days in GM-CSF (20 ng/mL)+FCS 
(5%) (GMDC); or 6 days in GM-CSF (20 ng/mL)+IL-4 (10 ng/mL)+FCS (5%) (IL4DC). Cells were harvested and 0.5-1 
x 106 cells were stained with dead cell exclusion dye and labeled with fluorophore-conjugated antibodies against a range 
of common DC and MΦ identifying markers: CD11c, MHC-II, F4/80, CD115, CD135, CD8α; as well as the 
costimulatory markers CD40, and CD80). Cells were fixed with 4% paraformaldehyde, stored overnight at 4°C and 
collected the following day on a Gallios Flow Cytometer. Data were analysed on FlowJo Version X and graphed in 
Prism. Summary data showing the mean (± s.e.m) of ten independent experiments. Each dot represents one experimental 
replicate. These molecules were measured on IL4DCs in 4 experiments. CD86, CD115 and CD8α were measured on all 
cells in 4 experiments. Statistically significant differences were calculated by Kruskal-Wallis test followed by Dunn’s 





















MHC-II on Bone Marrow-Derived Dendritic Cells +/- IL4 versus 
Bone Marrow-Derived Macrophages
Results of 10 separate experiments (DC) & 8 separate experiments (Mφ);
Stats = unpaired Student's t-test; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 























CD40 on Bone Marrow-Derived Dendritic Cells versus 
Bone Marrow-Derived Macrophages
Results of 10 separate experiments (DC) & 8 separate experiments (Mφ);
Stats = unpaired Student's t-test; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 





















CD86 on Bone Marrow-Derived Dendritic Cells versus 
Bone Marrow-Derived Macrophages
Results of 4separate experiments;
Stats = unpaired Student's t-test; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 





















F4/80 on Bone Marrow-Derived Dendritic Cells versus 
Bone Marrow-Derived Macrophages
Results of 10 separate experiments (DC) & 8 separate experiments (Mφ);
Stats = unpaired Student's t-test; *p<0.05; **p<0.01; ***p<0.001; ****p<0. 01 

























CD8 on GM-CSF-stimulated Bone Marrow-Derived Cells (GM-DCs) versus 
GM-CSF+IL-4-stimulated Bone Marrow-Derived Cells (IL-4 DCs)
Results of 4 separate experiments;
Stats = unpaired Student's t-test; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
Error bars = mean with s.e.m.






















CD11c on Bone Marrow-Derived Dendritic Cells +/- IL4 versus 
Bone Marrow-Derived Macrophages
Results of 10 separate experiments (DC) & 8 separate experiments (Mφ);
Stats = unpaired Student's t-test; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 

























Results of 10 separate experiments (DC) & 8 separate experiments (Mφ);
Stats = unpaired Student's t-test; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0 1 























CD115 on Bone Marrow-Derived Dendritic Cells +/- IL4
versus Bone Marrow-Derived Macrophages
Results of 10 separate experiments;
Stats = unpaired Student's t-test; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 




3.3.5 B cell Isolation  
B cells were isolated from the spleens of C57BL/6 mice by magnetic bead selection as 
discussed in Materials & Methods. Isolated cells were stained for the common B cell 
markers anti-CD19 and anti-B220, as well as the DC/MΦ and T cell markers CD11c 
and CD3 to verify the effectiveness of the sorting procedure. CD19CD45 double 
positive cell purity consistently averaged 95.4% (93.2 – 98%). Figure 29 shows the 
gating strategy and representative data from one B cell isolation procedure. Previous 
work in our lab had ascertained the optimal B cell culture conditions therefore further 
optimization was not required.  
3.3.6 APC Responses to Lysates & Activation Stimuli 
Once the growth conditions had been optimised and having demonstrated, based on 
morphology and phenotype, that different cell populations could be cultured and 
isolated, we then compared the APC response to loading with tumour lysate and 
immune stimulants. Previous work in our lab had shown that soluble lysate was able 
to induce upregulation of MHC-II and costimulatory markers on DC93. However, 
antigen presented by immature APCs often induces immunological tolerance94–96, 
therefore we wished to add appropriate immune stimuli to enhance APC activation. 
Certain antigen uptake capacities in immature DC are greater than those of activated 
DC, therefore we tested the response of immature APC loaded with lysate alone 
(Figure 30). We also compared the APC response to a range of immune activators 
(LPS&CpG, LPS&IFN-γ and CpG&IFN-γ; Appendix 1, Supplementary Figure 8) 
and the response to loading the APCs with lysate and activators (Figure 32). 
3.3.6.1. GMDC But Not M1 MΦ Upregulate CD40 In Response to Oxidised 
Lysate 
No statistically significant differences in the percentage of GMDC, IL4DC or M1 
MΦs positive for MHC-II, were observed in response to soluble or oxidised lysate 
(Figure 30). Likewise, neither lysate had any impact on the median fluorescence 




   
Figure 29 C57BL/6 splenocytes labeled with anti-CD43 magnetic beads yield up to 98% pure B cell 
populations. Splenocytes from WT C57BL/6 mice were lysed with RBC lysis buffer and incubated with 
anti-CD43 magnetic beads as per the manufacturer’s instructions (described in Materials and Methods). 
Cells were subjected to a negative selection protocol on an AutoMACS Pro and the resulting populations 
stained with Lived/dead exclusion Dye (FVS450). Cells were incubated with Fc receptor block prior to 
incubation with monoclonal antibodies against CD11c (APC), CD3 (PE-CF594), CD19 (PE) and B220 
(PerCPCy5.5). Cells were fixed with 4% PFA and stored overnight at 4°C. Cells were processed the 
following day on a Gallios Flow Cytometer and the data analysed on FlowJo Version 10 or Flow Jo 2. 
Representative Flow Cytometric dot plots from multiple experiments. 
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The percentage of GMDC that was positive for CD40 was significantly upregulated 
only in response to oxidised lysate (53%; p<0.05 compared to UT). No statistically 
significant increases in CD40 were observed in either IL4DCs or M1 MΦs in 
response to either lysate when measured by either Mann Whitney U or Kruskal-Wallis 
followed by Dunn’s post test.  
 
With regards to CD80, this molecule was highly expressed on all three APCs, and no 
increases were seen in response to lysates. However, the median fluorescence 
intensity of CD80 increased significantly on both IL4DCs (p<0.01) and M1 MΦs 
(P<0.05) compared to UT cells (Appendix 1, Supplementary Figure 11).  
 
Finally, CD86 was also highly expressed on UT cells and no increases were seen in 
response to the lysates. 
 
Taken together these data demonstrated few, slight variations in the individual APCs’ 
response to the lysates in terms of their stimulation of peptide presentation and co-









Figure 30 Unactivated GMDC, IL4DC and MΦ  vary in their responses to soluble and oxidised lysates. Bone 
marrow-derived precursor cells were cultured for 10 days in GM-CSF (5 ng/mL)+IL-3 (5 ng/mL)+FCS10% (MΦ); 6 
days in GM-CSF (20 ng/mL)+FCS (5%) (GMDC); or 6 days in GM-CSF (20 ng/mL)+IL-4 (10 ng/mL)+FCS (5%) 
(IL4DC). APCs were resuspended at 0.5 x 106 cells/mL and 1 x 105 cells pulsed overnight with s-L and Ox-L (1:1 ratio 
tumour cell:APC) or LPS&CpG as a biological control. The following day cells were harvested and stained for dead 
cell exclusion dye. Cells were labeled with mABs against A) MHC-II, B) CD40, C) CD8 D) CD86, fixed in 4% 
paraformaldehyde and stored overnight at 4°C. Cells were acquired the following day on a Gallios Flow Cytometerthe 
data analysed on FlowJo Version 10 and graphed in Prism. Summary data of 3 independent experiments in which the 
means of the 3 experiments were compared. Statistically significant differences were calculated by Kruskal-Wallis test 
followed by Dunn’s post test with Bonferroni correction. * p<0.05. Error bars = mean ± s.e.m. UT: untreated; sL: 



































































MHC-II Expression on Lysate-Pulsed
GM-CSF-stimulated Bone Marrow-Derived Cells (GM-DCs), 
GM-CSF+IL-4-stimulated Bone Marrow-Derived Cells (IL-4 DCs) 
& GM-CSF+IL-3-stimulated Bone Marrow-Derived Cells (BMMφ)
Results of 4 separate experiments;
Stats = unpaired Student's t-test compared with UT; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 







































































CD40 Expression on Lysate-Pulsed
GM-CSF-stimulated Bone Marrow-Derived Cells (GM-DCs), 
GM-CSF+IL-4-stimulated Bone Marrow-Derived Cells (IL-4 DCs) 
& GM-CSF+IL-3-stimulated Bone Marrow-Derived Cells (BMMφ)
Results of 4 separate experiments;
Stats = unpaired Student's t-test compared with UT; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 









































































CD80 Expression on Lysate-Pulsed
GM-CSF-stimulated Bone Marrow-Derived Cells (GM-DCs), 
GM-CSF+IL-4-stimulated Bone Marrow-Derived Cells (IL-4 DCs) 
& GM-CSF+IL-3-stimulated Bone Marrow-Derived Cells (BMMφ)
Results of 4 separate experiments;
Stats = unpaired Student's t-test compared with UT; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 







































































CD86 Expression on Lysate-Pulsed
GM-CSF-stimulated Bone Marrow-Derived Cells (GM-DCs), 
GM-CSF+IL-4-stimulated Bone Marrow-Derived Cells (IL-4 DCs) 
& GM-CSF+IL-3-stimulated Bone Marrow-Derived Cells (BMMφ)
Results of 2 separate experiments;
Stats = unpaired Student's t-test compared with UT; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
Err r bars = mean with s.e.m.
 197 
3.3.6.2 B cells Upregulate CD86 In Response to Oxidised Lysate  
The percentage of B cells positive for MHC-II did not increase in response to 
overnight loading with soluble or oxidised lysate (Figure 31). However the percentage 
of B cells positive for CD86 increased from 76% (UT) 95% in response to oxidised 
lysate (p<0.05) (Figure 31). By contrast neither CD40 nor CD80 percent positivity, 
nor MFI, increased in response to either lysate (Appendix 1, Supplementary Fig 12). 
  
Figure 31 The percentage of B Cells positive for MHC-II increases in response to LPS&CpG but not 
soluble or oxidised lysate, and CD86 expression increases on B cells exposed to oxidised lysate. Freshly 
isolated splenocytes were sorted for CD43 negative cells by magnetic cell sorting (AutoMACS Pro). 1 x 105 B 
cells were pulsed overnight with s-L and Ox-L (1:1 ratio tumour cell:APC) or LPS&CpG as a biological 
control. The following day cells were harvested and stained for dead cell exclusion dye. Cells were labeled with 
mABs against MHC-II, CD40, CD80 and CD86, fixed in 4% paraformaldehyde and stored overnight at 4°C. 
Cells were acquired the following day on a Gallios Flow Cytometer, the data analysed on FlowJo 2 and graphed 
in Prism  Summary data of 3 independent experiments in which the means were compared. Statistically 
significant differences were calculated by Kruskal-Wallis test followed by Dunn’s post test with Bonferroni 













































MHC-II % +ve B Cell Response to lysates only Dec 2015





































CD86 % +ve B Cell Response to lysates only Dec 2015




3.3.6.3 APC Responses to Lysates Plus Activation Stimuli 
Freeze-thaw tumour lysate-loaded human DC, matured with IFN-γ and LPS, have 
been shown to express high levels of costimulatory molecules and to produce high 
levels of IL-1281. Therefore the APC responses to loading with tumour lysate and our 
chosen activation stimuli were also compared. Tumour lysate has been variously used 
by different groups at ratios of between 1:1 and up to 10:1 (tumour cell:DC). Earlier 
experiments were carried out using 10 μL of lysate, which equated to a 3:1 ratio. For 
reasons of attempting to reproduce their results as well as clinical applicability in later 
experiments we later elected to use the 1:1 ratio used by Chiang et al in their clinical 
trials of ovarian tumour lysate61.  
 
In the experiments described in this section GMDC, IL4DC and MΦ were pulsed 
overnight with soluble lysate and oxidised lysate at a ratio of 1 lysed tumour cell to 1 
APC plus LPS+CpG. Differences in the exogenous presentation molecule MHC-II 
and the co-stimulation markers CD40, CD80 and CD86 were analysed by Flow 
Cytometry (Figure 32). Appendix 1, Supplementary Table 2 shows the antibody 
panels used in these experiments.  
 
3.3.6.4 No Further Increase in GMDC Upregulation of CD40 Is Observed In 
Response to the Addition of LPS&CpG  
The percentage of GMDC and IL4DC positive for MHC-II showed no statistically 
significant increase over untreated cells when pulsed with soluble lysate+LPS&CpG 
or oxidised lysate+LPS&CpG (Figure 33A). While the percentage of M1 MΦs 
positive for MHC-II was approximately halved compared to UT (70%) on exposure to 
soluble lysate+LPS+CpG (35%), oxidised lysate+LPS&CpG (37%) and LPS&CpG 
alone (37%), these differences were not statistically significant.  
 
If normal Gaussian distributions are assumed then significant increases in the 
percentage of GMDC and IL4DC positive for CD40 were observed in response to 
oxidised lysate+LPS&CpG (Figure 33B). However, normal distribution was 
considered unlikely due to group sizes. For this reason a Kruskal-Wallis non-
parametric comparison of location was used, followed by Dunn’s post test with 
Bonferroni correction, was applied for statistical significance. Under these 
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assumptions of abnormal distribution CD40 only increased on GMDC in response to 
oxidised lysate+LPS&CpG (53%; p<0.05).  
 
CD80 and CD86 were both highly expressed on all three APCs and no increases were 
observed in either percent positivity or median fluorescence intensity in response to 
lysates and activators (Figure 33C, D).   
 
3.3.6.5 B Cells Upregulate MHC-II In Response to LPS&CpG But Not Lysates 
Previous work had demonstrated that unactivated B cells were not able to stimulate a 
T cell response (Chapter 4, Figure 45) and that the B cell response to soluble lysate 
plus CpG alone did not greatly enhance the T cell response (Appendix 1, 
Supplementary Figure 22). Therefore three different B cell activation scenarios were 
compared to assess the B cell response to lysate and LPS&CpG. The aim of this 
experiment was to assess whether loading B cells with lysates after activating with 
LPS&CpG yielded a more favourable B cell phenotype for T cell presentation and 
activation. B cells were either loaded overnight with lysate and LPS&CpG, or loaded 
overnight with LPS&CpG followed by 6 hours of lysate loading, or loaded overnight 
with lysate followed by 6 hours of LPS& CpG stimulation (Figure 33). 
 
While marked increases in the percentage of cells positive for MHC-II were recorded, 
once again, under the assumptions of Kruskal-Wallis test (that does not require the 
data to follow a normal distribution), post hoc Dunn’s test revealed that these 
increases were not statistically significant. Nonetheless, loading B cells with 
LPS&CpG overnight prior to loading with s-L resulted in a significant increase in 
MHC-II over cells that were loaded with s-L overnight and stimulated with 
LPS&CpG the following day (86% and 24% respectively; p<0.05). An identical, 
though not statistically significant, trend was observed for oxidised lysate. There was 
no difference between B cells loaded with lysate only. 
 
In a similar manner the percentage of B cells positive for CD86 increased from 76% 
(UT) to 97% in response to overnight pulsing with LPS&CpG followed by loading 
with soluble lysate (p<0.05). These results demonstrated that LPS&CpG were not 




   
Figure 32 GMDC, IL4DC and MΦ  vary in their activation response to s-L and ox-L plus LPS+CpG. Bone 
marrow-derived precursor cells were cultured as described previously. APCs were resuspended at 0.5 x 106 cells/mL 
and 1 x 105 cells pulsed overnight with s-L and Ox-L (1:1 ratio tumour cell:APC) +/- LPS&CpG as per the x axes. 
The following day cells were harvested and stained for dead cell exclusion dye. Cells were labeled with mABs 
against A) MHC-II, B) CD40, C) CD8 D) CD86, fixed in 4% paraformaldehyde and stored overnight at 4°C. Cells 
were acquired the following day on a Gallios Flow Cytometer, the data analysed on FlowJo Version 10 and graphed 
in Prism. Summary data of 3 independent experiments in which the means of the 3 experiments were compared. 
Statistically significant differences were calculated by Kruskal-Wallis test followed by Dunn’s post test with 































































































MHC-II Expression on Lysate-Pulsed
GM-CSF-stimulated Bone Marrow-Derived Cells (GM-DCs), 
GM-CSF+IL-4-stimulated Bone Marrow-Derived Cells (IL-4 DCs) 
& GM-CSF+IL-3-stimulated Bone Marrow-Derived Cells (BMMφ)
Results of 4 separate experiments;
Stats = unpaired Student's t-test compared with UT; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 






























































































CD80 Expression on Lysate-Pulsed
GM-CSF-stimulated Bone Marrow-Derived Cells (GM-DCs), 
GM-CSF+IL-4-stimulated Bone Marrow-Derived Cells (IL-4 DCs) 
& GM-CSF+IL-3-stimulated Bone Marrow-Derived Cells (BMMφ)
Results of 4 separate experiments;
Stats = unpaired Student's t-test compared with UT; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 






























































































D86 Expression on Lysate-Pulsed
GM-CSF-stimulated Bone Marrow-Derived Cells (GM-DCs), 
GM-CSF+IL-4-stimulated Bone Marrow-Derived Cells (IL-4 DCs) 
& GM-CSF+IL-3-stimulated Bone Marrow-Derived Cells (BMMφ)
Results of 2 separate experiments;
Stats = unpaired Student's t-test compared with UT; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 































































































CD40 Expression on Lysate-Pulsed
GM-CSF-stimulated Bone Marrow-Derived Cells (GM-DCs), 
GM-CSF+IL-4-stimulated Bone Marrow-Derived Cells (IL-4 DCs) 
& M-CSF+IL-3-stimulated Bone Marrow-Derived Cells (BMMφ)
Results of 4 separate experiments;
Stats = unpaired Student's t-test compared with UT; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
Error bars = mean with s.e.m.
*
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identical, but not statistically significant for oxidised lysate. Though this is likely due 
to the conservative Bonferroni adjustment. 
 
In contrast to MHC-II and CD86 neither CD40 nor CD80 percent positivity, nor MFI, 
increased in response to any lysate plus activation stimuli scenario (Appendix 1, 
Supplementary Figure 12). 
 
These data showed that for GMDC, IL4DC and B cells the addition of LPS&CpG 
stimulated a trend toward upregulated MHC-II in response to both lysates. However 
the LPS&CpG was not required to stimulate upregulation of CD40 in response to 
oxidised lysate on GMDC or IL4DC. Likewise, for B cells oxidised lysate alone 
stimulated upregulation of CD86 without the addition of LPS&CpG. Similarly for M1 
MΦs the addition of LPS&CpG stimulated no change in phenotype in response to the 
lysates. Taken together these data demonstrated differences in the individual APCs’ 
responses to the lysates. Soluble lysate and oxidised lysate differed in their ability to 
stimulate the APCs’ antigen presentation and co-stimulation machinery and oxidised 
lysate alone was able to differentially induce upregulation of two key costimulatory 




























Figure 33 The B Cell MHC-II and CD86 response to various s-L and ox-L +/- LPS&CpG loading 
approaches. Freshly isolated splenocytes were sorted for CD43 negative cells by magnetic cell sorting 
(AutoMACS Pro,). B cells were pulsed overnight with s-L and ox-L (1:1 ratio tumour cell:APC) +/- the 
immune stimuli LPS (1 μg/mL) & CpG (0.3 μg/mL) as indicated on the x axes. The following day cells were 
harvested, stained with live/dead exclusion dye and mABs against the surface markers MHC-II, CD40 and 
CD80. Cells were fixed with 4% paraformaldehyde, stored overnight at 4°C and acquired by a Gallios Flow 
Cytometer the next day. Data were analysed on FlowJo 2 and graphed in Prism. Summary data showing 
results of 3 independent experiments. Statistically significant differences were calculated by Kruskal-Wallis 
test followed by Dunn’s post test with Bonferroni correction. * p<0.05. Error bars = mean ± s.e.m. UT: 
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3.3.7 APC Viability Varies in Response to Lysates 
Previous reports have noted that tumour lysate was not toxic to DCs2, however we 
noted differences in the ability of soluble lysate to induce APC death (Figure 34). 
GMDC activated with LPS+CpG and loaded with oxidised lysate were highly 
susceptible (39% viability compared with 8% in UT; p<0.05).  
 
Overall there was a general trend toward reduced viability in all conditions in the 
IL4DC with oxidised lysate-loaded cells showing only 22% viability after 24 hours 
compared with 74% in the untreated cells (p<0.01).  
 
M1 MΦs retained excellent viability irrespective of lysate loading or LPS&CpG 
stimulation. We examined whether a soluble MΦ-secreted factor may have an effect 
on DC viability. GMDC, IL4DC MΦ were incubated overnight with lysate at a 1:1 
ratio. The next day MΦ conditioned medium (MCM) was added to the wells of the 
GMDC and IL4DC and these cells were incubated for a further 24 hours and analysed 
by Flow Cytometry. No significant increases in viability were observed in the GMDC 
and IL4DC groups in the presence of MCM (data not shown). 
 
Reduced viability is not unexpected in UT B cells since approximately 50% of 
unstimulated B cells in culture will die every 24 hours. Low B cell viability was 
unchanged with the addition of lysate, unless activation occurred prior to lysate 
loading. Significantly improved viability was observed in B cells activated with 
LPS&CpG overnight followed by lysate loading. LPS&CpG-activated B cell viability 
was 61% after loading with soluble lysate compared to 15% for B cells loaded 
overnight with lysate followed by the addition of LPS&CpG (p<0.05). The trend was 




Figure 34 GMDC, IL4DC, MΦ  and B cell viability varies in response to soluble and oxidised 
lysates +LPS&CpG. Bone marrow-derived precursor cells and B cells were prepared as previously 
described. 1 x 105 DCs and MΦs were pulsed overnight with s-L and ox-L (1:1 ratio tumour cell:APC) 
and LPS+CpG. 1 x 105 B cells were activated with LPS&CpG and loaded with lysate(s) as per the x 
axis in B. After 24 hours cells were harvested, stained with live/dead exclusion dye  and mABs against 
surface markers. Cells were fixed with 4% paraformaldehyde, stored overnight at 4°C and acquired by 
Gallios Flow Cytometer the next day. Data were analysed on FlowJo 2 and graphed in Prism. 
Summary data showing results of 3 (B cells) and 4 (DCs & MΦs) independent experiments. 
Statistically significant differences were calculated by Kruskal-Wallis test followed by Dunn’s post 
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GM-CSF-stimulated Bone Marrow-Derived Cells (GM-DCs), 
GM-CSF+IL-4-stimulated Bone Marrow-Derived Cells (IL-4 DCs) 
& GM-CSF+IL-3-stimulated Bone Marrow-Derived Cells (BMMφ) 




3.3.8 The Addition of LPS&CpG Yields Increased IL-12 Over Lysates Alone  
The APC populations were compared for their ability to produce IL-12 in response to 
the two tumour lysates (Figure 35). After 24 hours exposure to soluble and oxidised 
lysate in the presence or absence of LPS&CpG cell conditioned media were collected 
and stored at -20°C for analysis by anti-IL-12 ELISA.  
 
GMDC, M1 MΦs (Figure 35) and IL4DC (Appendix 1, Supplementary Figure 13) all 
produced small amounts of IL-12 in response to soluble lysate (6 ng/mL, 10 ng/mL 
and 2 ng/mL respectively). All three APCs also produced IL-12 in response to HOCl-
wFTL, however GMDC and M1 MΦs produced more IL-12 (11 ng/mL and 8 ng/mL 
respectively) than IL4DC (4 ng/mL; p<0.05).  
 
Taken individually there was no difference in IL-12 production between soluble and 
oxidised lysate-loaded APCs, irrespective of whether the APCs were stimulated with 
LPS&CpG. However, stimulating the cells with LPS&CpG during lysate loading 
resulted in strong trends toward increased IL-12 for GMDC, and a statistically 
significant increase for M1 MΦs when analysed by Mann Whitney U test between the 
two groups (for example GMDC+s-L and GMDC+s-L+LPS&CpG). No improvement 
in IL-12 response over GMDCs was observed in IL4DCs and these results can be seen 
in Appendix 1, Supplementary Figure 13. The difference in IL-12 response between 
GMDC and M1 MΦs was notable (s-L+LPS&CpG 24 ng/mL and 46 ng/mL 
respectively; ox-L+LPS&CpG: 26 ng/mL and 45 ng/mL respectively) but not 




























Figure 35 Stimulation of GMDCs and M1 MΦs with LPS&CpG during lysate loading yields enhanced IL-12 
production over lysates alone and the M1 MΦ  IL-12 response to lysate is greater than that of GMDC. Bone 
marrow-derived precursor cells  were prepared as described previously. 50,000 APCs were pulsed overnight with s-
L and ox-L (1:1 ratio tumour cell:APC) +/- LPS+CpG as indicated on the x axis. After 24 hours cell conditioned 
media (supernatants) were collected and stored at -20°C. Supernatants were analysed by anti-IL-12 ELISA. 
Summary data of at three or four independent experiments showing IL-12 production after 24- hours exposure to s-L 
and ox-L +/- LPS+CpG. Statistically significant differences were calculated by Mann Whitney U test. * p<0.05. . 


















































IL-12 Production By GMDC, Mφ & IL4DC or DC+Bc at 24 & 48 hrs (CFSE+)
Results of at least 3 separate experiments; stats= Student's unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;
error bars = mean with s.e.m;
IL-12 production is greatest in GMDC, Mac & IL4DC stimulated with HOClwFTL, not sFTL;
The addition of LPS+CpG greatly increases IL-12 production by GMDC, M1 Mac & IL4DC cf lysate alone; 
in GMDCs, IL4DCs and M1 Macs there is no difference between LPS&CpG-treated & LPS&CpG+lysate-treated therefore this effect is due to LPS&CpG alone. However 
the addition of B cells lifts the IL-12 response beyond that of LPS&CpG alone. This does not occur in IL4DCs.
The addition of B cells appears to increase IL-12 production in GMDC+sFTL & GMDC+HOClwFTL cf GMDC alone;
The addition of B cells= no advantage with sFTL-loaded IL4DC;
HOClwFTL stimulates more IL-12 from GMDCs than sFTL, but not from Macs or IL4DC;
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3.4 Discussion  
3.4.1 Oxidation Can Increase the Immunogenicity of Tumour Lysate 
The use of TL represents a clinical method for accessing undefined TAAs in solid 
tumours, which may be inaccessible to patient immune cells, whether due to lack of 
infiltration or active tumour inhibition mechanisms. Different methods of tumour 
lysate preparation have been described in the literature, including heat treatment97–100, 
gamma irradiation2,101, ultraviolet irradiation (UVC)102, in situ ablation103,104 and 
oxidation61,79,80,82,105–108. Oxidation was chosen over irradiation, as access to an 
irradiator was difficult. Heat treatment was rejected since Chiang et al have shown 
that T cells primed with DC loaded with heat killed SK-OV-3 ovarian cancer cells did 
not mount an immune response against the antigens they were testing82.  In addition 
data from another study also argued that heat shock proteins (HSP) per se were not 
responsible for an improved APC response to lysate prepared from heat-stressed 
cells2. We prepared the soluble fraction of freeze-thaw lysate (soluble lysate) and the 
entire contents of HOCl-oxidised lysate (oxidised lysate) and compared the response 
of APCs to both of these lysates.  
 
Lysate contains all possible immunogenic antigens in the patient’s tumour, while at 
the same time containing highly immunosuppressive and immune-tolerising 
properties, primarily due to being self-tissue-derived.  The outcome of antigen 
presentation is directly controlled by pathogen-related and cell death-related signals, 
and indirectly controlled by molecules and cytokines generated during tissue infection 
or damage that direct the immune response.  At the start of this study there was still 
uncertainty over which cell death conditions were immunogenic and which are 
immunologically ignored109 and a 2014 review noted that cell-death-associated 
immunomodulators of DC function were still in urgent need of further 
characterisation110. However a recent publication has reported that inflammatory 
substances such as DAMPs are insufficient to elicit cross-priming of CD8+ T cells. 
The key requirement for robust cross-priming by DCs is for receptor interacting 
protein kinase-1 (RIPK-1) signalling and NFκB transduction in the dying cells, 
irrespective whether the cells are dying by apoptosis or necrosis111. This information 
on how the nature of the cell death impacts on the function of the lysate-pulsed APCs 
would have been useful for manipulating the cells used for generating tumour lysate 
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in this study, however at the time of creating oxidised lysate this information was not 
known.  
 
OVA protein, the model tumour antigen in this system, is not a natural TAA and is 
immunogenic therefore there are pros and cons to using this system. The use of OVA 
with transgenic T cells specific for OVA peptides allows the generation of large 
numbers of T cells as well as the identification of whether CD4+ or CD8+ T cells, or 
both, are contributing to the anti-tumour response to undefined TAAs. OVA was 
detected in Western blots of both soluble lysate and oxidised lysate however bands 
below the OVA molecular weight of 45 kDa were detected in the oxidised lysate.  
These lower molecular weight products may be a result of proteolytic degradation. 
Despite resuspending the oxidised cells in protease inhibitors after oxidation and 
immediately prior to freeze thaw lysis, it is possible that degradation of proteins 
occured prior to extraction. Other researchers have noted that even with protease 
inhibitors, using ice cold solutions and working on ice smaller bands are still 
sometimes observed. Proteins can degrade before, during, and after extraction. Some 
peptide bonds can be more prone to hydrolysis than others giving rise to specific 
lower molecular weight proteolytic degradation products during boiling with reducing 
or denaturing agents. Amino acids are neutralized by sodium hypochlorite to form 
water and salt and this loss of hydroxyl ions is accompanied by a drop in pH. 
Hypochlorous acid, which is present in sodium hypochlorite solution, acts as a solvent 
when it comes into contact with organic tissue, releasing chlorine that, when 
combined with protein amino groups, forms chloramines. The combination of 
hypochlorous acid (HOCl-) and hypochlorite ions (OCl-) lead to amino acid 
degradation and hydrolysis112. Thus it is likely that pre-treatment of the B16.OVA 
cells with NaClO rendered the proteins more susceptible to hydrolysis during 
subsequent Western Blot preparation, resulting in the lower weight molecular bands 
observed in the Western Blots.  
 
3.4.2 Cell Lines’ Response To Oxidation-Induced Death 
It was noted during B16.OVA oxidation experiments that 100% cell death could not 
be achieved. The killing ability of hypochlorous acid always plateaued leaving a small 
proportion of cells (≈ 2-5%) alive (Figure 22). We remain curious to know whether 
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these cells would be more immunostimulatory than cells that were sensitive to death 
by oxidation. However culturing these oxidation-resistant cells and generating lysate 
from them to compare the T cell response against soluble lysate and oxidised lysates 
remains to be done. 
 
We were concerned that oxidation may require changing to a cell line that expressed 
membrane-bound OVA to avoid loss of soluble OVA during oxidation as NaOCl 
treatment may generate necrotic cells with porous membranes. We assumed that the 
holes in the membranes could allow OVA that accumulated by treatment with the 
transport inhibitor Brefeldin A to leak out and be lost during subsequent wash steps to 
remove the NaOCl. However this did not appear to be the case as anti-OVA Western 
Blots demonstrated the presence of OVA in the oxidised lysates as well as the soluble 
fraction lysates (Figure 20, Figure 21).  
 
Small but significant differences were noted in the cytotoxic capacity of HOCl among 
the seven cell lines tested. These differences may reflect where these cells are located 
in vivo. For example the murine lung epithelial tumour cell line TC1 showed the 
greatest resistance to death by oxidation, with only 50% of cells dead in 90 μM HOCl 
(Appendix 1, Supplementary Figure 4). This result is biologically plausible since the 
lungs are exposed to the highest concentration of oxygen in the body and thus these 
cells may have evolved mechanisms of dealing with oxidative stress, such as a high 
capacity to neutralise reactive oxygen species (ROS). In contrast 90 μM HOCl killed 
95% of THP-1, a human monocytic leukaemia cell line, and 90% of MC-38, a colon 
carcinoma cell line MC38. In the blood, the site of monocytic leukaemic cells, and in 
the glandular, mucus-secreting structures of the gut where adenocarcinomas such as 
MC-38 form, oxygen levels are tightly controlled within narrow ranges113. The cells of 
the gastrointestinal tract are well endowed with superoxide disumutase activity to 
neutralise free-radicals generated by food and pathogen-mediated inflammation114,115. 
Thus it would appear that, for the MC-38 cells at least, the increased sensitivity of 
these cells to death by oxidation might not result from a reduced capacity to adapt to 
high levels of ROS.  
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3.4.3 Generation of GMDCs & Macrophages 
 DCs and MΦs were generated using the technique of isolating murine bone marrow 
precursor cells and culturing them with GM-CSF that has been common practice in 
labs worldwide for decades since Inaba and Steinman first published this protocol116. 
There are two main methods commonly employed to generate what are currently 
known as bone marrow-derived DCs (BMDC) and two methods for generating either 
M1 or M2 bone marrow-derived MΦs (BMDM). In the longest used method so-called 
BMDC are generated with high-dose GM-CSF+/-IL-4, which gives rise to a 
heterogeneous cell population of adherent, semi-adherent and non-adherent myeloid-
like cells. BMDM are cultured in GM-CSF+IL-3 or M-CSF to give rise to M1 or M2 
MΦs respectively. Both the BMDC and M1 BMDM cell populations display all the 
typical monocyte-derived MΦ markers F4/80, CD11b, Ly6C, Ly6G, MHC-II, 
CD11c, CD80 and CD40, albeit to varying degrees.  
 
MΦs are found in virtually every tissue type where they can limit infections early in 
the disease process and can initiate specific immune responses. The heterogenic 
nature of MΦs may be the reason for their remarkably plastic and wide-ranging 
involvement in innate and adaptive immune responses. However it also makes 
studying them difficult, and makes phenotyping BM-derived MΦs important so that 
we know which MΦ type we are studying. Any given myeloid cell population shares 
overlapping features of both DCs and macrophages making it difficult to assign them 
to one or other cell type. If one takes the argument that all GM-CSF-derived cells are 
MΦs117, then this thesis lends weight to the idea that MΦs are in fact more effective 
in the anti-tumour response than previously thought. 
 
M1-type bone marrow-derived MΦ are typically generated with low-dose GM-CSF 
and a high percentage of FCS (at least 10%) that induces a more MΦ-like phenotype 
to the cells due to as yet unidentified factors in the FCS118. IL-3 may or may not be 
included. According to Hume IL-3 and GM-CSF are not additive in culture, however 
we were unable to find any reference to murine studies that have analysed this. The 
phenotype of MΦs cultured +/- IL-3 was not compared in this study.  
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Several reports have highlighted that the GM-CSF BMDC-differentiation method 
generates a heterogeneous population of granulocytes, dendritic cells and MΦs11,119,120. 
As such, instead of comparing DCs, MΦs and B cells, or a combination thereof, it 
could be argued that this thesis has in fact compared two different populations of BM-
derived APCs, each generated by different methods and displaying different 
phenotypes, both under the microscope and on the Flow Cytometer. However, 
irrespective of the name given to each population of cells, this thesis has demonstrated 
that BM-derived cells grown in GM-CSF+5% FCS or GM-CSF+IL-4+5% FCS or 
GM-CSF+IL-3+10% FCS show differential antigen presentation capacity and 
costimulation responses to lysate loading.   
 
A statement from a recent review highlights that there are strong opinions on both 
sides of the DC MΦ divide but makes the important point, which this thesis and the 
bulk of current literature supports, that GM-CSF-differentiated cells are important 
tools that can be harnessed in the anti-cancer response: “Csf-2 (GM-CSF) is a 
cytokine that is critical for promoting the differentiation of mouse and human 
hematopoietic progenitors and monocytes into cells that resemble mouse splenic 
cDCs … and remains to date a key cytokine for generating DC-based vaccines for 
clinical use”121. 
 
Whether they are called DCs or MΦs or APCs, the bone marrow-derived APCs 
generated by GM-CSF are an immunogenic APC. It is for this reason that GM-CSF is 
in current clinical use in a number of treatment approaches, such as increasing the DC 
yield and reconstitution during haematopoietic stem cell (HSC) transplant122; most, if 
not all, ex vivo DC generation and tumour antigen loading protocols123; GM-CSF-
secreting viral vectors for cancer that increase GM-CSF levels at the tumour site124; 
and finally as a vaccine adjuvant in immune-compromised Hepatitis B patients as well 
as Hepatitis C, HIV, fungal and mycobacterial treatments125. GM-CSF activates the 
MEK/ERK, PI3K/PKB,NFκB and STAT5 pathways that increase DC proliferation, 
survival, differentiation and immunogenicity. Flt3L, on the other hand, induces 
STAT3 signalling leading to downregulation of NFκB, MHC class II and 
upregulation of IDO, all of which produce tolerogenic DC functions7. 
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Hume makes that point that “Whether or not tissue macrophages derive from 
definitive progenitors in the marrow, and must transit through a blood monocyte 
precursor, it is possible to isolate committed progenitor cells from bone marrow that 
express receptors for hematopoietic growth factors, and to use those growth factors to 
generate relatively pure populations of macrophages (in CSF1), classical DC (in 
FLT3L), or macrophages with APC activity (in GM-CSF; otherwise called bone-
marrow-derived DC)”126. In other words Hume would argue that this study compared 
two variations on the MΦ theme as opposed to a DC and a MΦ. Hume would also 
argue that what this thesis refers to as GMDCs should more accurately be called 
antigen-presenting MΦs (APMΦ). Irrespective of the name given to these cells, this 
study aimed to define which of the three APCs would yield a phenotype that was most 
favourable for T cell presentation and activation. 
 
3.4.4 Unactivated GMDC, IL4DC & Macrophage Morphology & Phenotypes 
This is not the first study to compare cells generated from bone marrow with different 
cytokine combinations. Masurier et al compared human cells grown in GM-CSF, 
GM-CSF+Flt3L and GM-CSF+IL-4 and found that the MHC-IIHI cells with typical 
myeloid DC morphology and immunophenotype (CD11c+ 33D1+ DEC-205+ F4/80+), 
were the most effective in tumour trials120. Campisano also examined heterogenous 
GM-CSF-stimulated murine cultures. They found that the addition of IL-4 induced 
DC maturation while impairing granulocyte and monocyte development119. The 
CD11c+ and CD11c- fractions had similar MHC-II and CD80 levels, and similar 
phagocytic and endocytic capacities, however only the CD11c+ fraction when loaded 
with apoptotic/necrotic lysate induced protection in mice. Finally, another recent 
study has also highlighted the heterogeneic nature of GM-CSF-differentiated bone 
marrow populations. They compared the loosely adherent and non-adherent 
populations and found differences in MHC-II and CD11c expression indicative of 
DCs and MΦs127. Their bi-variate analysis of MHC-II versus CD11c expression 
revealed similar MHC-II CD11c profiles in their non-adherent cells to our GMDCs 




The differences in the levels of MHC-II on M1 MΦs in Figures 25, 28 and 29 may be 
attributed to different MΦ culture methodologies employed between these two 
experiments. In the former the key difference between GMDC and M1 MΦ culture 
conditions were the variation in GM-CSF and FCS concentrations and the addition of 
IL-3 to the MΦ cultures. In the latter experiment, in the interests of methodological 
refinement to ensure the generation of two different cell populations, differentiating 
MΦ cultures were fed differently to those in Figure 27. On days four and seven non-
adherent cells were removed by very gentle flushing of the plate, discarding of culture 
medium and replacement of fresh medium. This resulted in a greater proportion of 
large, adherent MΦ-like cells, whereas not removing the non-adherent cells resulted 
in a population that contained a greater proportion of cells that were more similar to 
those in the GMDC cultures. While CD11c expression in the MΦ populations was 
unaltered, MHC-II expression was greatly reduced to levels that would be expected 
on unactivated MΦs. 
 
Direct comparison of MΦ versus DC median fluorescence could not be drawn due to 
the difference in MΦ auto fluorescence compared to DCs and the requirement for 
different voltages during acquisition by Flow Cytometry. Comparison of MHC-II 
density on the surface of these cells could be used as a mechanistic explanation for 
differences in T cell response initiated by MΦs and DCs. This may require the use of 
an internal standard measure, such as fluorescent beads, against which changes in 
median fluorescence intensity could be normalized. Since cells and not fluorescent 
beads were used for single stain controls in the majority of experiments, this standard 
measure is not available but could be included in future investigations. 
 
The GMDCs generated in this study were CD8α- and therefore myeloid-like DCs. It 
has been reported that cross-presenting CD8α+ lymphoid DCs are responsible for 
potent anti-tumour responses128 however CD8α- myeloid DCs engineered to secrete 
GM-CSF have also been shown to have potent anti-tumour activity8. Thus CD8α 
positivity or negativity per se may be irrelevant in the anti-tumour response.  
 
The phenotypes generated in this study highlight the misnomer of CD11c+ cells being 
called DCs. We saw higher CD11c on our MΦs than our DCs and an abundance of 
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expression of CD11c on many MΦs as well as activated NK cells has been previously 
noted.  
 
Our M1 MΦ displayed all the same markers as the GM-CSF-derived GMDC, with 
only variations in expression levels of some markers to distinguish the two cell 
populations (Figure 28). By contrast M2-like MΦ, generated with M-CSF, showed 
distinct marker expression levels from those of M1 MΦ and GMDC (Figure 24). The 
differences between the M-CSF- and GM-CSF-stimulated MΦs pointed to functional 
differences between the two MΦ types. These functional differences have been 
shown, for example, in a study that found that protective or immunostimulatory MΦs 
expressed high levels of MHC class II and drove a TH1 bias, unlike MHC-IILO MΦs, 
which predisposed to a TH2 outcome129. 
 
Monocytes and eosinophils express low to intermediate levels of F4/80. F4/80 is 
commonly used as the canonical MΦ marker but levels of this marker vary by tissue 
and it is expressed on other cells. We saw F4/80 downregulation in RPMI medium. 
This alteration in cell phenotype would suggest a change of function, and highlights 
the importance of optimizing the growth conditions to generate the particular MΦ of 
interest. The fact that F4/80 is not present on various MΦ populations in different 
tissues, and expressed, albeit to a lower level on certain DC subpopulations, as well as 
on eosinophils, highlights the need for caution when using it as a sole MΦ-identifying 
marker204. 
 
Merad et al state in their 2013 review that Flt3L/CD135 expression is an “excellent 
marker” for discriminating cDCs from MΦs121 but point out that collagenase digestion 
affects Flt3L expression. When raising cDCs from BM precursors collagenase is not 
used, thus this issue is only relevant when analysing non-lymphoid cDCs in tissue. 
However, if the GM-CSF-derived cells are Flt3L negative, then by Merad’s argument 
they must be called MΦs and not DCs.  
 
The gene transcription analysis used in Merad’s review121 also puts subcapsular MΦs 

























Figure 36 Heat map representation of transcripts differentially expressed in progenitor and 
differentiated DCs. (a) Heat map representation of pathogen-recognition receptors (PRRs) and antigen 
receptors, cytokine and cytokine receptors, and chemokines and chemokine receptors in common 
myeloid progenitors (CMPs), granulocyte macrophage progenitors (GMPs), macrophage DC 
progenitors (MDPs), common DC progenitors (CDPs), and CD8+ spleen pDCs, CD8+ spleen cDCs, 
CD103+CD11b− lamina propria cDCs, CD4+ spleen cDCs, CD103+CD11b+ lamina propria DCs, 
CD103− CD11b+ lamina propria cDCs, epidermal Langerhans cells (LCs), red pulp macrophages 
(MFs), and blood monocytes. Red represents high and blue represents low relative expression. (b) 
Principal components analysis (PCA) of 15% of the most variable transcripts expressed by lymphoid 
tissue CD8+ cDCs, lymphoid tissue CD8− cDCs, nonlymphoid tissue CD103+ cDCs, nonlymphoid 
tissue CD11b+ cDCs, epidermal LCs, monocytes, and MF populations provides a visual representation 
of the heterogeneity of the mononuclear phagocytic lineage. cDC and MF populations cluster distinctly 
on opposite sides of the PCA, whereas the CD11b+ cDC distribution throughout the PCA suggests that 
these cells are more heterogeneous. Intriguingly, the CD11c subcapsular MF population clusters near 
DCs, suggesting that this population is more closely related to DCs than to macrophages (which is 
further suggested by the expression of zbtb46). (Additional abbreviations used in figure: MLN, 
mesenteric lymph node; SI, small intestine; SLN, skin-draining lymph node.) Figure published in The 
Dendritic Cell Lineage: Ontogeny and Function of Dendritic Cells and their Subsets in the Steady State 
and the Inflamed Setting193. Used with permission of the author, Miriam Merad. 
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presentation ability. “The CD11b+ cDC subset consists of a mixture of tissue cDCs 
and macrophages, which contributed to the confusion that still exists on the exact 
contribution of DCs and macrophages to tissue immunity”121. This sentence from the 
Merad review implies that this current study worked with a mix of cDCs and MΦs 
and as such can not assign causality to either. However, once again, the purpose of 
this thesis was not to assign names to cell populations but to compare the functional 
abilities of the three populations. 
 
We were particularly interested in CD169 after reading that CD169+ MΦs were 
responsible for cross-presentation of dead-cell associated antigens in vivo50. However 
none of our in vitro-generated cell populations were positive for this molecule (Figure 
28). Therefore there is no evidence that CD169 played a role in cross-presentation by 
these cells. 
 
By contrast the Colony stimulating Factor 1 receptor (CD115) was another marker, in 
conjunction with MHC-II, which proved somewhat useful as a DC-MΦ 
distinguishing marker (Figure 28). MΦs and GMDCs showed varying levels of 
intermediate expression. IL4DCs expressed this marker at levels significantly lower 
than MΦs. However, a Csf1r-EGFP transgene has been used as a marker for all tissue 
macrophages130, and Helft et al recently described CD115 as being present on MΦs 
and absent on DCs127. Therefore this data would also argue for describing both of 
these cell populations as variations on the MΦ theme, rather than distinct DC and 
MΦ populations. The phenotype profiles of the two populations suggest that our 
GMDCs contain a greater proportion of DCs and our M1 MΦs contain a lesser 
proportion of DCs. 
 
The mannose receptor CD206 appeared at surprisingly low levels on the GMDC and 
IL4DC (< 5%) (Figure10). On MΦs the expression of CD206 varied between 22.5 
and 62.3%, significantly higher than either DC. However higher levels of the 
mannose receptor have been observed to be associated with M2 MΦs131 therefore it is 
possible that high levels of CD206 were not necessarily desirable. 
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CD40 was also unexpectedly absent on GMDC. This key co-stimulatory molecule is 
usually expressed to some degree on immature GMDC, though not on M1 MΦs127 and 
suggests a reduced T cell stimulatory capacity in these cells. 
 
3.4.5 GMDC, IL4DC and M1 MΦ Activation Response to Soluble and Oxidised 
Lysates  
Previous work has demonstrated activation of DCs in response to human tumour 
lysate132,133. Gallucci et al showed that signals from stressed or necrotically dying but 
not healthy or apoptotically dying cells activated DCs in the absence of foreign 
signals134. However it has also been shown that high numbers of apoptotic cells can 
stimulate DC maturation and presentation of endogenous antigen from apoptotic cells, 
even without accompanying “danger” signals211. Others have also reported DC cross-
priming and activation of CTLs with apoptotic human cells135,136 Thus controversy 
exists over the ability of apoptotic cells and cell lysates to activate APCs with some 
groups reporting DC inhibition in the presence of lysates2. Although as mentioned in 
the opening chapter of this discussion, RIPK-1 signalling and NFκB transduction 
have recently been identified as the key components in immunogenic cell death111. 
 
GMDCs, IL4DCs and MΦ were compared for upregulation of MHC Class II and the 
co-stimulatory markers CD40,CD80 and CD86 (Figure 30) in response to oxidised 
and soluble lysates. In line with Hatfield et al2 who found that the soluble fraction of 
B16.OVA freeze-thaw lysates inhibited the DC response we found no upregulation of 
MHC-II, CD80 or CD86 on DCs or M1 MΦs in response to soluble or oxidised 
lysates (Figure 30). By contrast an increase in CD40 was observed on oxidised lysate-
loaded GMDCs. There were some differences in methodology with Hatfield et al 
using a ratio of 3 tumour cells to 1 DC whereas our ratio was 1:1 (although Hatfield et 
al tested a range of ratios, 1:1 – 10:1 and found the same response). In addition 
Hatfield et al incubated their DCs with lysate for 8 hrs prior to the addition of the 
TLR agonists LPS 100 ng/mL; OK-432 10 μg/mL; poly I:C 100 μg/mL and CpG 2 
μg/mL to mature the DCs. We added the LPS&CpG at the same time as the lysate.  
 
Hatfield et al found that stressing cells with radiation or heat shock prior to freeze-
thaw lysis significantly reduced lysate-induced inhibition of MHC-II as well as IL-12 
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production in LPS-treated DCs2. Their data showed that that induction of heat shock 
proteins (HSP), particularly HSP70, in the cells prior to lysate preparation resulted in 
less suppression of DC function. While we found no increase in MHC-II, CD80 or 
CD86 in DCs loaded with oxidised lysate, we did find that that pre-incubation of 
tumour cells in sodium hypochlorite increased the percentage of APCs positive for 
CD40 (p<0.05). HSP levels in the lysate were not assessed and therefore it is 
unknown whether HSPs played a role in upregulation of CD40 on the DCs by the 
oxidised lysate. 
 
IL4DC showed no statistically significant upregulation of MHC-II, CD40, CD80 or 
CD86 in response to either lysate, with or without immune stimulants. Furthermore 
IL4DCs viability was lower than that of GMDC or MΦs when pulsed with soluble 
lysate and significantly so when pulsed with oxidised lysate (Figure 34). As such 
these surface molecule data may be biased due to the low viability of samples, but 
biased or not, IL4DC do not appear useful as lysate-presenting cells because of their 
low viability in the presence of the lysates. 
 
Filaci and colleagues found that the DNA of apoptotic cells bound to HLA Class II 
molecules on human MΦs and this resulted in inhibited antigen presentation and 
down-regulation of costimulatory molecules, as well as increased production of anti-
inflammatory TGF-β by the MΦs137. When DCs and MΦ were co-cultured the DCs 
showed reduced antigen presentation capacity, reduced costimulatory capacity and 
reduced TNF-α. Their summation of the situation was that the MΦs were behaving in 
a self-tolerising manner, in other words skewing toward an M2 response typical of 
homeostasis.  
 
Thus, in our hands the superiority of oxidised tumour lysate over soluble freeze-thaw 
lysate depended on which APC was processing the lysate. Taken together these data 
showed that GMDC were more likely than MΦs to promote a T cell response against 
undefined lysate antigens. 
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3.4.6 B Cell Activation Response to Soluble and Oxidised Lysates  
Activated B cells pulsed with freeze-thaw lysates have been successfully used to 
present undefined antigen to murine and human CD4+ T cells32,36. In our hands B cells 
only upregulated MHC-II in response to LPS&CpG whereas CD86 was upregulated 
in response to oxidised lysate (Figure 31).  
 
A statistically significant increase in MHC-II was recorded when B cells were 
activated overnight with LPS&CpG and lysate loading occurred the following 
morning (Figure 33). No difference was observed between B cells loaded with lysates 
in this manner and B cells loaded overnight with LPS&CpG. When compared to the 
lysate-loaded B cells these data suggest that the LPS&CpG was important in the 
observed B cell MHC-II responses.  
 
By contrast, the statistically significant increase in CD86 observed in oxidised lysate-
loaded B cells, did not increase in the presence of LPS&CpG suggesting that factors 
in the lysate stimulated this costimulatory molecule whereas the LPS&CpG activated 
the MHC-II presentation machinery. 
 
3.4.7 APC IL-12 Response to Soluble & Oxidised Lysates  
IL-12 secreted by activated DCs after CD40 ligation provides crucial cytokine 
information that drives TH1 differentiation138, CTL effector function139 and the 
development of T cell memory140. Therefore we were interested in the production of 
IL-12 by lysate-loaded APCs as an indicator of their capacity to stimulate IFN-γ 
production and promote TH1 skewing of the immune response to undefined antigens. 
 
GMDCs, M1 MΦs and IL4DCs all produced IL-12 in response to both soluble lysate 
and oxidised lysate (Figure 35) and the IL-12 production was significantly higher 
when the immune stimulants LPS&CpG were added to the APCs at the time of lysate 
loading. LPS&CpG were added in an attempt to improve the ability of the APCs to 
present lysate antigens to T cells. However comparison of the response to lysates 
alone versus lysates+LPS&CpG demonstrated that LPS&CpG was not required for 
the observed upregulation of CD40 on DCs, or for the upregulation of CD86 on B 
cells. The addition of LPS&CpG only enhanced MHC-II expression on GMDC. 
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However, despite the lack of consistent MHC-II and costimulatory molecule 
upregulation across the APCs in response to the addition of LPS&CpG to the lysates, 
a strong trend toward increases IL-12 production (p=0.06) was observed when 
LPS&CpG was added to both soluble and oxidised lysate. This increase was 
statistically significant in the M1 MΦ+s-L+LPS&CpG group compared to soluble 
lysate alone. 
 
We were surprised to see strong IL-12 production by the M1 MΦs in response to 
activation and lysate loading, given their lacklustre MHC-II, CD40, CD80 and CD86 
responses compared to the DCs. However, as with the GMDCs and IL4-DCs the M1 
MΦ-produced IL-12 was not greater than that induced by LPS&CpG alone. Therefore 
the increase was due to the effect of the activation stimulants and not the lysate. 
 
The B cell conditioned media was inadvertently discarded therefore no IL-12 
response by B cells was evaluated. These experiments were carried out after the 
MΦ+B cell combination had been excluded as a viable option therefore no MΦ+B 
cell data exists for IL-12 production.  
 
The combinations of GMDC+B cell and IL4DC+B cell were analysed and GMDC+B 
cell, but not IL4DC+B cell, stimulated greater IL-12 production than GMDC alone. In 
contrast to all other APCs loaded with lysate+LPS&CpG, in which there was no 
increase in IL-12 over that induced by LPS&CpG, the GMDC+B cell combination 
elevated IL-12 to levels higher than LPS&CpG alone. This suggested a synergistic 
effect generated by the interactions of these two APCs. 
 
3.4.8 APC Viability Response to Lysates 
In concordance with previous work that found that lysate was not toxic to DCs2 we 
noticed only small reductions in viability in GMDC loaded with soluble lysate +/- 
stimulants and in GMDC loaded with oxidised lysate. However we did observe a 
significant drop in viability of GMDC loaded with oxidised lysate+LPS&CpG.  
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IL4DC viability was not as robust in the presence of either lysate. Only 60% of 
IL4DC remained alive after overnight pulse with soluble lysate and 56% were viable 
after overnight pulse with soluble lysate+LPS&CpG. IL4DC fared even worse when 
loaded with oxidised lysate and oxidised lysate+LPS&CpG. For this reason we 
terminated the comparative experiments on these DCs. 
 
Tumour cells treated with HOCl prior to lysis were washed three times in DPBS 
therefore the likelihood of enough HOCl remaining in the lysates to cause APC cell 
death seems low. Also M1 MΦs retained excellent viability irrespective of lysate 
loading or LPS&CpG stimulation, and thus HOCl as a contributing factor in APC 
death seems further unlikely.  
 
Incubation of GMDC and IL4DC for a further 24 hours after the addition of MΦ 
conditioned cell medium (MCM) resulted in no statistically significant improvement 
in viability (data not shown). However this experiment would have been improved if 
the MCM had been added at the start of the lysate pulsing period, rather than after 24 
hours of lysate pulsing. 
3.4.9 Concluding Remarks  
In this study we investigated the capacity of three APC cell types to present tumour 
antigens  using a model system in which tumour cells have been engineered to express 
ovalbumin. OVA is not a tumour antigen, however it is frequently used as a model 
system for for assessing MHC Class II-mediated CD4+ and MHC Class I-mediated 
CD8+ T cell responses. We assessed the potential for antigen presentation and 
costimulation of T cells by mouse GMDC, IL-4DC, M1 MΦ and B cells after loading 
with B16.OVA tumour lysates.  
 
We hypothesized that, on exposure to lysates, GMDCs and M1 MΦs would display 
superior upregulation of MHC-II, costimulatory molecules and IL-12 compared to B 
cells. However, following oxidised lysate exposure GMDC, but not IL4DC or M1 
MΦs, upregulated CD40, while B cells upregulated CD86. On exposure to 
LPS&CpG, though not lysates, GMDC and B cells upregulated MHC-II. These data 
indicated that GMDC and B cells, in concert with LPS&CpG, could potentially 
present undefined lysate-derived tumour antigen to CD4+ T cells, and provide 
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costimulatory signals for T cell activation. M1 MΦ, by contrast, appear unable to 
present lysate-derived tumour antigen to CD4+ T cells or to provide appropriate 
costimulation. IL4DC, by virtue of their low viability when pulsed with lysates, also 
appeared less useful as APCs in the lysate setting. 
 
These data demonstrated by morphology, surface molecule phenotype and IL-12 
response that the three culture conditions generated three distinct populations of cells 
whose response to lysate differed in key aspects of presentation and APC and T cell 
activation capacity. In vivo, cells of the mononuclear phagocyte system (MPS) 
encounter a diversity of growth factors, including CSF-1/IL34, GM-CSF, IL-4, IFN-γ, 
and Flt3L amongst others. Each factor influences the resultant MPS cell phenotype. 
Progenitor cells cultured in one of these individual growth factors most likely have no 
corresponding cell in vivo, and there are no data that distinguishes a growth factor that 
explicitly promotes distinct DCs nor excludes them from the MPS117. The name 
assigned to the cells in this study may be technically erroneous, however the data 
supports the conclusion that bone marrow-derived precursors stimulated with GM-
CSF alone, which may be more accurately called MΦs, perform better when 
presenting undefined lysate antigens than those differentiated with GM-CSF and IL-4.  
 
Finally GMDC and M1 MΦs both demonstrated enhanced IL-12 responses to both 
forms of lysate when LPS&CpG was included during antigen loading. Taken together 
these data suggest variances in processing of the undefined TAAs in TL by the APCs 
and point to varying T cell stimulatory capacities. We next compared their ability, 
individually and in combination, to stimulate CD4+ and CD8+ T cell responses to 
tumour-associated and self antigens found in the two lysates.  
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The T Cell Response To Priming 
by Tumour Lysate-Loaded Dendritic 
Cells, B Cells, Macrophages & 
Combinations Thereof 
4.1 Introduction 
4.1.1 Activating T Cells With Lysate-Loaded APCs in Cancer 
Therapy 
In studies using tumour lysate as the source of tumour antigen to activate T cells the 
APC used has primarily been a DC1–43, with few studies utilizing MΦs44 or B cells45,46. 
Tumour lysate-loaded DCs have been used in clinical trials for treatment of 
melanoma6,20,21,29,30,47, breast cancer5,32,48, glioblastoma multiforme49,50, renal cell 
carcinoma48, fibrosarcoma39, cutaneous T cell lymphoma18, prostate cancer34, 
gynaecological51, bone and soft tissue malignancies41, and multiple myeloma52, 
demonstrating the broad applicability of this approach to cancer in general. All of 
these lysate-loaded DC studies, both human and murine, showed an induction of 
immunogenic T cell responses. These variously included T cell proliferation; 
production of IFN-γ and other TH1 cytokines; circulating antigen-specific T cells; in 
vitro and in vivo cytotoxicity; control of primary tumours and metastases; tumour-
specific T cell responses; desirable T cell phenotypes; delayed type hypersensitivity 
(DTH) reaction against cancer cell lysates; and CD8+ cytotoxic T lymphocyte (CTL) 
influx at the tumour site. These responses demonstrate the immunogenic potential of 
lysate-primed T cells. 
 
Lysates consist of large clusters of undefined proteins and MΦs or B cells may be 
able to acquire these proteins more effectively than DCs via their scavenging, BCR-
mediated or BCR-independent uptake mechanisms. They may also serve as transfer 
agents passing lysate antigens to DCs for presentation to T cells53–56. We hypothesized 
that combining DCs with MΦs, and or B cells, may yield a more robust T cell 
response against tumours via a systems biology approach of cooperating APCs. In this 
chapter we evaluated the T cell response evoked by priming with the lysate-pulsed 
APCs over a range of time points.  
4 
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4.1.2 The T cell Differentiation & Effector Phenotype Response To 
Lysate-Loaded APCs 
T cell stimulation can be triggered by antigen-dependent and antigen-independent57–59 
means, the latter being triggered by cytokines. Analysis of cytokines produced by the 
cells also assists with identification of the type of T cell produced by the treatment. 
Cytokines secreted by T helper cells that stimulate APCs include IL-2 and IFN-γ by 
TH1 cells and IL-4, IL-5, IL-6, IL-10, IL-13 by TH2 cells (Reviewed in60). The 
cytokine profile (IFN-γ, TNF-α and IL-10) of T cells primed with DCs, MΦs, B 
cells and combinations of these three APCs was assessed as an indication of their 
skewing toward TH1 and CTL effector functions. 
 
Analysis of the T cell phenotype response to treatment is critical for determining why 
a treatment was succesful or why the treatment failed.We examined the naïve, T 
effector (TEFF), T effector memory (TEM), and T central memory (TCM) status of the 
naïve and lysate-experienced CD4+ and CD8+ T cells. We assessed the surface 
markers CD27, CD28, PD-1, CD44, CD122, CD127, CD62L and CCR7 to compare 
the phenotypes of T cells primed by each of the lysate-loaded APCs or APC 
combinations.  
 
Many groups look at the production of IL-2 as an indicator of T cell activation. IL-2 
binds to activated T cells and the complex is rapidly internalised, resulting in a short 
signal time. Therefore there is little point staining for this cytokine unless cells are 
harvested at very early time points. More importantly, T cell proliferation by 
definition would suggest IL-2 production therefore assessing IL-2 production seemed 
tautologous in these experiments. 
4.1.2.1 IL-12 
IL-12 forms part of the Signal 3 cytokine information secreted by DC61, IFN-γ-primed 
MΦs62 and B cells63–65 after CD40 ligation. IL-12 drives TH1 differentiation66, CTL 
effector function67 and the development of T cell memory68. IL-12 potently induces 
IFN-γ production in T cells63 and inhibits IL-4, thereby skewing the immune response 
away from a Type 2 response and promoting the TH1 profile61.  
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In situations of high antigen T cell activation can occur in the absence of Signal 3, but 
in situations of low antigen the contribution of adjuvant or IL-12 assistance is more 
critical. It has been noted that the “… presence or absence of the third signal appears 
to be a critical variable in determining whether stimulation by antigen results in 
tolerance versus development of effector function and establishment of a responsive 
memory population”67c.  
 
Optimal secretion of IL-12 is another commonly used indicator of successful T cell 
activation conditions4 therefore we evaluated whether co-cultures of lysate-loaded 
APCs and T cells contained high levels of IL-12. 
4.1.2.2 IFN-γ 
The ability of T cells to secrete IFN-γ and demonstrate tumour cytotoxicity in vitro 
are two measures applied to the selection of cells for ACT for patients with solid 
tumours69–71. However retrospective analysis of ACT in melanoma patients has 
identified a negative correlation with in vivo effectiveness and in vitro TA-specific 
IFN-γ production and cytolysis69,71–73(Figure 37). Cells expressing high levels of 
CD62L correlated with enhanced patient responses after adoptive transfer. Thus it is 
the combination of phenotype and effector cytokine function, which must be carefully 
analysed when assessing the T cell response to priming with undefined antigen. 
 
The ratio of TH1 to TH2 cytokines induced by treatment, and induction of IFN-γ+ T 
cells in particular, is currently one of the most commonly used clinical indicators of a 
patient’s tumour-specific immune response to cancer immunotherapy5,6,24,31,74,75, 
therefore we wished to verify that IFN-γ was being produced in the undefined TAA-
primed T cell co-cultures.  
4.1.2.3 TNF-α 
TNF-α is produced by monocytic lineage cells, primarily MΦs, which are also 
sensitive to TNF-α’s effects (reviewed in76 and77). Trauma or exposure to LPS 
stimulates production of high levels of TNF-α and it has been shown to be strongly 
pro-inflammatory with a central role in several inflammatory disease processes 
























TNF-α functions via activation of pathways that lead to three distinct cellular 
outcomes: survival and proliferation, pro-inflammatory gene transcription and cell 
death (reviewed in78). TNF-α has been shown to cooperate with IFN-γ to mediate 
tumour rejection79,80. Cellular growth is suppressed in tumour cells engineered to 
secrete high levels of TNF-α, even in the absence of T, B and NK cells (reviewed in 
81). The pleiotropic nature of TNF-α is highlighted by the anti-tumoural82–84 and pro-
tumoural85–92 effects that have been extensively described, and by the fact that anti-
TNF-α therapy has been implicated in the development of skin cancer93 and 
lymphoma94 . 
 
Some recent insight into TNF-α’s seemingly opposing roles has been gained with a 
study that suggests the membrane-bound TNF-α may have a protective role in cancer 
Figure 37 A schematic illustration summarizing results indicating the inverse relationship of in vitro 
and in vivo effector functions of adoptively transferred naive and effector T cell subsets. After 
primary antigen stimulation, naive CD8+ T cells proliferate and progressively differentiate into terminally 
differentiated effector T cells. Phenotypic and functional changes characterize the differentiation process. 
The gradual acquisition of complete effector functions (dashed red line) is associated with the progressive 
inability of T cells to cause tumour regression upon adoptive transfer (black line). Such mechanisms 
initially involve the downregulation of lymphoid-homing and costimulatory molecules, which results in a 
poor in vivo activation of T cells. Other mechanisms occur later and include the inability to produce IL-2 
and access homeostatic cytokines, the imbalance of proapoptotic and anti-apoptotic signals, and the 
acquisition of a state of replicative senescence. +, low expression; ++, intermediate expression; +++, high 
expression. Figure taken from Acquisition of full effector function in vitro paradoxically impairs the in 
vivo antitumour efficacy of adoptively transferred CD8+ T cells. Gattinoni et al.  J Clin Invest. 2005 Jun 1; 
115(6): 1616–1626. doi:  10.1172/JCI24480. Used with kind permission of N. Restifo email 
correspondance 28.5.15. 
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while the soluble form may be responsible for pro-tumoural effects95. Therefore we 
wished to assess the level of soluble TNF-α in the conditioned cell media of our 
lysate-primed T cells. 
 
4.1.2.4 IL-10 
IL-10 is a well-characterised immunoregulatory cytokine that is important in 
maintenance of peripheral tolerance via its induction of TREGs96 and its skewing of the 
immune response toward a TH2 outcome97. Tumour-derived IL-10, amongst other 
factors, can inhibit effective maturation of DC by suppressing their upregulation of 
MHC and co-stimulatory molecules, as well as IL-12 production98. MΦ-produced IL-
10 has been shown to block CD8+ T cell-dependent responses to chemotherapy by 
suppressing IL-12 expression in intratumoural dendritic cells99.  
 
However, the role of IL-10 in the anti-tumour response is not clear-cut. Some studies 
demonstrated clear pro-tumoural associations in melanoma and other cancers100–105. 
Other studies have reported IL-10’s anti-tumoural benefits, such as inhibition of 
tumour stroma formation81 and tumour-toxic NO production106, and identified IL-10 as 
a potentially positive prognostic factor107,108. For these reasons it was important to 
characterize the IL-10 response in lysate-primed T cells to verify if lysate skewed 
CD4+ T cells toward a TH1 or TH2 response, or may be responsible for any inhibition 
of T cell response observed. 
4.1.3 Development of Memory Phenotype After Priming By Lysate-
Loaded APCs 
TEM cells are found primarily in peripheral tissues where they deliver immediate 
protection upon antigen exposure through, for example, the prompt production of 
effector and inflammatory cytokines. TCM, on the other hand, reside primarily in 
secondary lymphoid organs, and elicit recall reactions to previously encountered 
antigens. Even though TCM lack immediate effector functions, they proliferate and 
differentiate quickly into effector T cells following antigen re-exposure. The 





 Table 10 Summary of expression and function of T cell molecules examined 
Surface Molecule Expression and Function 
CD27 Expressed on all naïve CD4+ T cells & approximately 80% of memory T cells. 
Downregulated on murine CD8+ T cells after antigenic stimulation – presence & 
absence used to identify memory T cells and effector T cells respectively 110,111. 
CD27+CD8+ T cell persistence highly correlated with anti-tumour responses in 
ACT for metastatic melanoma112,113  
CD28 
Usually constitutively expressed on naïve, non-antigen-experienced T cells114–117 
Binds costimulatory markers CD80 (B7.1) and CD86 (B7.2)118 on APCs. Ligation 
of CD28 and TCR delivers potent signals for naïve T cell activation and 
survival119–122, proliferation and cytokine production - especially IL-2121 and IL-
6123 Antigen presentation without CD28-mediated costimulation leads to T cell 
anergy124,125  
CD44 
Indicative marker for effector memory T cells (TEM). Expressed at lower level on 
naïve T cells compared to memory T cells126,127 
CD62L 
Highly expressed on naïve T cells, allowing these cells access to secondary lymph 
tissue where they can encounter antigen. Shed from the cell membrane after 
antigen encounter127,128 allowing exit from lymph tissue. Also expressed TCM 
residing in secondary lymph tissue awaiting future antigen encounters128,129. TEM 
circulating in the periphery have immediate effector functions upon encountering 
antigen, thus they do not express CD62L. The combination of CD62L, which is 
discarded after antigen encounter, and CD44, which is expressed at high levels 
after T cell activation, is used to identify TCM cells127 
CD122 
β chain of the trimeric IL-2 receptor (IL-2R). IL-2 binding IL-2R promotes 
differentiation of T cells into effector T cells and memory T cells, as well as being 
required for memory cell maintenance130,131. CD122-negative cells display 
unresponsiveness to IL-2, indicative of reduced long-term persistence in vivo 
CD127 
Also known as IL-7 receptor α (IL-7Rα). Expressed by most resting T cells, 
downregulated following T cell activation. Long-living T cells characterized by 
constitutive CD127 expression132. CD127-negative cells display unresponsiveness 
to IL-7 indicative of reduced long-term persistence in vivo. Combination of 
CD122 and CD127 are used to assess survival potential and responsiveness of 
cells to homeostatic cytokine signalling in vivo. CD127HIGH population shown in 
ACT experiments to represent long living T central memory (TCM) cells, 
especially when combined with CD62LHIGH status133 
PD-1 
Important immune-regulatory inhibitory receptor expressed on activated T cells, 
B cells and myeloid cells134,135. Low expression on naïve T cells. Expression 
upregulated on activated T cells135,136. Promotes programmed cell death (PCD) in 
antigen-specific T cells in LNs136 while simultaneously reducing PCD in TREGs137. 
High expression indicative of exhausted T cells with impaired anti-tumour 
function138  
 
Taken together the combination of surface molecules expressed, and cytokines 
produced, by T cells allows us to assess their functional response to priming with 
lysate-derived undefined antigen and their potential utility in ACT.  
 
We examined the memory phenotype transition in naïve CD4+ and CD8+ T cells and 
lysate-primed T cells. We wished to identify whether lysate-primed T cells would 
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adopt the TCM phenotype that has been shown to be more effective on a per cell basis 
than TEM in ACT for cancer109.  
 
4.2 Objectives  
The aim of the studies summarised in this chapter was to assess the T cell response to 
being primed and/or restimulated by a lysate-loaded GMDC, M1 MΦ, B cell, or 
combination of these APCs. We hypothesized that the combination of two or more 
APCs would enhance the T cell response leading to stronger T cell proliferation, 
cytokine production and cytotoxic capacity.  
 
To address this hypothesis the following objectives were undertaken: 
1. Determine the strongest in vitro T cell responses to B16.OVA lysate antigens 
when presented to ovalbumin transgenic (OT)-II (CD4+) and OT-I (CD8+) T 
cells by lysate-loaded GMDC, M1 MΦ, B cells and combinations of these 
three APCs.  
This was accomplished via: 
1. Proliferation assays 
2. Cytokine analysis of IFN-γ, TNF-α, IL-12 and IL-10 
3. Phenotype analysis 
 
2. Analysis of fold expansion and T cell phenotype yielded by priming naïve T 
cells with one antigen presenting cell and restimulating those antigen-
experienced T cells with the same antigen presenting cell or with a different 





4.3.1 Tumour Lysate Dose Titrations 
Our first aim was to determine the ability of the different lysate-loaded APC to 
stimulate CD4+ or CD8+ T cell proliferation. Isolated T cells were stained with the 
proliferation dyes Violet Proliferation Dye 450 (VPD450) or carboxyfluorescein 
succinimidyl ester (CFSE) and cultured with lysate-loaded APCs. We first confirmed 
that 72 hours was the optimal time point for assessing proliferation (See Appendix 1, 
Supplementary Figure 17) and thereafter conducted proliferation assays to analyse 
differences in T cell proliferation generated by each of the lysate-loaded APCs.  
 
Previous work in our lab had shown by thymidine uptake assay that DCs pulsed with 
soluble lysate were able to induce CD8+ T cell proliferation139. Initially we wished to 
ascertain an optimal T cell stimulatory dose of tumour lysate therefore T cells were 
primed with DCs loaded with different volumes of lysate equating to different ratios 
of tumour cells to APC. We compared the T cell response to different concentrations 
of soluble fraction of freeze-thaw lysate (Figure 38) and to the whole portion of 
freeze-thaw lysate (data not shown). Figure 39 shows the Gating Strategy used to 
assess the proliferation response to OVA by Violet Proliferation Dye 450 (VPD450) 
stained CD8+ T cells. 
 
CD8+ T cells responded differently to DCs loaded with different volumes of soluble 
lysate. Five microlitre volumes were insufficient to stimulate CD8+ T cell 
proliferation whereas 20 and 50 μL appeared to have an inhibitory effect on T cell 
proliferation. Ten microlitres of soluble lysate produced from B16.OVA cells that had 
been incubated in Brefeldin A for 5 hours prior to freeze-thaw lysis generated an 
average of 16% proliferation in five experiments and was chosen as the T cell-
stimulatory volume for initial ongoing experiments. Ten microlitres equated to the 
contents of 240,000 lysed tumour cells, or a ratio of 6 tumour cells per DC. The whole 
portion freeze-thaw lysate yielded no proliferation response. These experiments were 
conducted prior to the oxidised lysate experiments. Later experiments that compared 
soluble and oxidised lysate used the oxidised lysate at the same volumes 





 Figure 38 Gating strategy for flow cytometric analysis of APC stimulated T cell proliferation 
assays. 5 x 104 Day 6 GMDC were prepared as previously described. 5 x 104 DCs were pulsed 
overnight with soluble lysate (1 tumour cell:1APC) or OVA protein (50 μg/mL). The following 
morning gp100 and SIINFEKL peptides (2 μg/mL) were added to the relevant wells 4 hours prior to 
the addition of Violet Proliferation Dye 450-labelled, magnetic bead-isolated CD4+ or CD8+ T cells 
(10 T cells:1 APC). 72 hours later cells were stained with dead cell discrimination dye and labeled with 
mABs against CD11c, CD3 and CD8. Cells were fixed in 4% paraformaldehyde, stored overnight at 
4°C and collected the following day on an LSR Fortessa or a Gallios Flow Cytometer. Flow data was 
analysed and graphed on FlowJo software V9 or VX. Representative data of the DC-stimulated CD8+ 
T cell response to OVA from approximately 30 experiments. 
Figure 39 GMDCs loaded with 10 μL of soluble fraction freeze-thaw lysate stimulate CD8+ T 
cell proliferation. Bone marrow-derived precursor cells were incubated for 6 days in GM-CSF (20 
ng/mL)+FCS (5%) (GMDC) 4.0 x 104 unactivated APCs were pulsed overnight with the soluble 
fraction of freeze-thaw lysate (s-L) (6:1 ratio tumour cell:APC) or whole OVA protein (50 μg/mL). 
The following morning 2 μg/mL SIIN peptide was added for at least 4 hours prior to the addition of 
VPD450-stained OT-I splenocytes (10 T cell:1 APC). After 72 hours cells were stained with dead cell 
exclusion dye, labeled with mABs to surface markers and fixed in 2% paraformaldehyde. Cells were 
stored overnight at 4°C and acquired the following day on an LSR Fortessa Flow Cytometer. Data was 
analysed on FlowJo Version 9 and graphed in Prism. Summary data of T cell proliferation after 72 
hours exposure to s-L-loaded DC. Error bars = mean ± s.e.m. of 3 independent experiments plated in 
triplicate.  






















































































4.3.2 Activating Stimuli Concentration Titrations  
An experiment was conducted to identify whether any improvements could be 
observed in the T cell response to APCs loaded with OVA protein and activated with 
various APC-activating stimuli. No difference was observed between doses or 
between the groups (LPS+IFN-γ, LPS+CpG, IFN-γ+CpG) (data not shown) therefore 
we continued with the LPS+CpG combination due to its MHC-II-enhancing effect on 
the B cells and its IL-12-inducing effect on GMDC and M1 MΦs. 
4.3.3 T Cell Proliferation Response To Priming by Lysate-Loaded 
APCs 
The clonal expansion of antigen-specific T cells is the outcome of effective peptide 
presentation and costimulation by APC. Thus proliferation is one key indicator of T 
cell responsiveness to antigen. Class I and Class II-restricted presentation of peptides 
from B16.OVA melanoma cell lysate was assessed via in vitro T cell proliferation 
assays of CD8+ and CD4+ T cells respectively. We assessed the proliferation 
response to the soluble fraction of freeze-thaw lysate and the entire portion of 
oxidized whole freeze thaw lysate . 
 
Initial experiments utilised GMDC loaded with soluble lysate to prime CD4+ and 
CD8+ T cells. Immature Day 6 GMDCs were pulsed overnight with lysate at a ratio 
of 6 lysed tumour cells to 1 DC. The following day unsorted OT-I or OT-II 
splenocytes, or magnetic bead isolated CD4+ or CD8+ T cells were stained with 
proliferation dye and added at a ratio of 10 T cells to 1 DC.  The cells were harvested 
after 72 hours of culture as this was the time point in which we saw the greatest 
proliferation when compared with 24 or 48 hours (Appendix 1, Supplementary Figure 
19).  
In preliminary experiments we used unsorted splenocytes in an attempt to get closer 
to the systems biology nature of the in vivo situation, and we compared these 
responses to those of sorted T cells. No differences were observed in the T cell 
responses between unsorted OT-I and OT-II splenocytes and isolated CD4+ and 
CD8+ T cells, therefore we continued with isolated CD4+ and CD8+ T cells for 




4.3.3.1 DC Priming of T lymphocytes 
We began by examining the T cell response to undefined tumour antigens in soluble 
lysate presented by unactivated GMDC. Figure 3 shows the gating strategy used to 
identify lysate-responsive T cells and Figure 40 shows summary data of these results.  
 
In T cells primed with GMDC no response was observed to the irrelevant melanoma 
peptide gp100 in either OT-I or OT-II splenocytes (Figure 40). The functional control 
samples stimulated 62% CD4+ and 49% CD8+ T cell proliferation in response to 
whole OVA protein. The proliferation response to SIINFEKL peptide by CD8+ T 
cells was lower on 27%, while CD4+ T cell proliferation was 61% in response to the 
OVA323-337 peptide. No difference was observed between the responses to OVA and 
OVA323-337 peptide by CD4+ T cells. GMDC loaded with soluble lysate stimulated 
19% CD8+ proliferation. This proliferation was not statistically significant when 
analysed by Kruskal-Wallis non-parametric comparison of location followed by a 
Dunn’s post hoc test with Bonferroni correction for multiple comparisons. However a 
Mann Whitney U test comparing the UT and lysate-treated groups was statistically 
significant (p<0.01) CD4+ T cells did not proliferate in response to soluble lysate-
loaded GMDCs. 
 
Having noticed the low response to SIINFEKL peptide we compared the GMDC-
primed T cell response to the SIINFEKL in our laboratory and the SIINFEKL of three 
other independent laboratories. There was no concentration-response to different 
doses of SIINFEKL (2, 4, 8, 10 μg/mL; data not shown) and no differences in the 
response to SIINFEKL from the four different sources indicating that the source of 
the low response did not lie in our batch of SIINFEKL (Appendix 1, Supplementary 
Figure 20). 
 
Later experiments with LPS&CpG-activated APCs appeared to stimulate less CD8+ T 
cell proliferation than unactivated APCs (Appendix 1, Supplementary Figure 23). 
However the two conditions (+/-LPS&CpG) were not compared side by side in the 
same experiment so the reduced proliferation was not attributed to the use of the 



















4.3.3.2 M1 MΦ Priming of T Lymphocytes 
MΦs are known to have excellent scavenging capacity, which we hypothesised may 
be useful in acquiring lysate antigens for presentation to T cells. Unactivated M1 MΦs 
pulsed overnight with whole OVA protein generated an increase in proliferation, 
however this was not statistically significant by Kruskal-Wallis or Mann-Whitney U 
tests. Likewise the proliferation observed in response to the OVA323-339 peptide was 
also not statistically significant when analysed by the same tests. Finally, neither 
unactivated M1 MΦs pulsed overnight with soluble lysate (Figure 41), nor M1 MΦs 
pulsed overnight with soluble lysate+LPS+CpG (data not shown) were able to 













Figure 40 GMDCs do not induce CD8+ or CD4+ T cell proliferation in response to soluble freeze-
thaw lysate. Day 6 GMDC were prepared as described previously. 5 x 104 GMDCs were pulsed 
overnight with lysate (6:1 tumour cell:APC) or OVA protein (50 μg/mL). The following morning the 
irrelevant melanoma peptide gp100 and OVA257-264 peptide (SIINFEKL) or OVA329-337 peptide (2 
μg/mL).\ were added 4 hours prior to the addition of 0.5 x 106 Violet Proliferation Dye 450-labelled 
CD4+ or CD8+ T cells. 72 hours later cells were stained with dead cell discrimination dye and labeled 
with mABs against CD11c, CD3 and CD8. Cells were fixed in 2% paraformaldehyde, stored overnight at 
4°C and analysed the following day on an LSR Fortessa Flow Cytometer. Flow data was analysed on 
FlowJo software V9 and graphed in Prism. Summary data of the means of 3 independent experiments 
plated in triplicate. Statistically significant differences were assessed by Kruskal-Wallis test followed by 
Dunn’s post test with Bonferroni correction. * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. Error 
bars = mean ± s.e.m.  








































Student's paired T-test. * P < 0.05. ** P < 0.005, *** P < 0.0001. Error bars = s.e.m 
of triplicates of 8 separate experiments
****
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4.3.3.3 B cell Priming of T lymphocytes 
Activated B cells have been shown to be effective antigen presenting cells. Lysate-
loaded activated B cells have been used in at least two studies45,46, therefore we 
compared the ability of lysate-loaded B cells to stimulate T cell proliferation with that 
of GMDCs and MΦs. B cells were isolated from C57BL/6 mice by magnetic assisted 
cell sorting, pulsed with lysates overnight and co-cultured with proliferation dye-
labeled OT-I or OT-II splenocytes for 72 hours.  We compared unstimulated and 
CpG-activated lysate-loaded B cell stimulation of T cells. No significant 
improvements in T cell proliferation were observed in CpG-activated B cells 
(Appendix 1, Supplementary Figure 22) therefore unactivated B cells were used in 
these initial experiments.  
 
Figure 42 shows summary data of the T cell proliferation response to unactivated 
soluble lysate-loaded B cell antigen presentation. B cells stimulated 80% CD8+ 
(p<0.05) and 66% CD4+ (ns) T cell proliferation in response to whole OVA protein. 
Likewise SIINFEKL and OVA323-339 peptides yielded strong T cell responses - 94% 
and 93% respectively. However soluble lysate presented by unactivated B cells was 
unable to stimulate CD4+ or CD8+ T cells to proliferate. The ability of B cells to 
prime T cells with oxidised lysate was also assessed in two priming experiments. B 
cells activated overnight with oxidised lysate+LPS&CpG were unable to stimulate T 
Figure 41 M1 MΦs pulsed overnight with soluble lysate do not induce CD4+ or CD8+ T cell 
proliferation. Day 10 M1 MΦs were prepared as previously described. 5 x 104 M1 MΦs were pulsed 
overnight with lysate (6:1 tumour cell:APC) or OVA protein (50 μg/mL). The following morning the 
irrelevant melanoma peptide gp100 and OVA257-264 peptide (SIINFEKL) or OVA329-337 peptide were added 4 
hours prior to the addition of 0.5 x 106 Violet Proliferation Dye 450-labelled OT-I or OT-II splenocytes. 72 
hours later cells were stained with dead cell discrimination dye and labeled with mABs against CD11c, CD3 
and CD8. Cells were fixed in 2% paraformaldehyde and stored overnight at 4°C and analysed the following 
day on an LSR Fortessa Flow Cytometer. Flow data was analysed on FlowJo software V9 and graphed in 
Prism. Summary data of the means of 3 independent experiments plated in triplicate. Statistically differences 
were assessed by Kruskal-Wallis test followed by Dunn’s post test with Bonferroni correction. Error bars = 
mean ± s.e.m. 
Expt 1a.1-11 MΦs as Antigen Presenting Cells 
For Proliferation of CD3+ OT-I & OT-II T Splenocytes 











































Expt 1a.1-11 MΦs as Antigen Presenting Cells 
For Proliferation of CD3+ OT-I & OT-II T Splenocytes 












































NOTE: No stats as 3 wells of cells combined into 1 FACS tube in this first experiment
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4.3.3.4 T Cell Priming by Combined Unactivated APCs Loaded With Tumour 
Lysate Antigens 
Having assessed the ability of lysate-loaded GMDC, M1 MΦs and B cells to prime 
CD4+ and CD8+ T cells we now compared combinations of these three APCs. Figure 
44 shows the gating strategy and sample raw data of the T cell response to soluble and 
oxidised lysate. Figure 43 shows summary data of the proliferation response by CD4+ 
T cells. Consistent with earlier results (Figure 40) CD4+ T cells did not proliferate in 
response to priming with lysate by any individual APC, nor did they proliferate when 
primed with any combination of APCs. 
 
Figure 46 shows summary data of the proliferation response by CD8+ T cells in 
response to soluble lysate when presented by unactivated APCs. Each of the APC 
combinations yielded an increased number of CD8+ T cells over priming by an 
individual APC, however there was wide variability in the responses. The only 
Figure 42 Unactivated B cells do not induce CD4+ or CD8+ T cell proliferation in response to 
soluble freeze-thaw lysate. B cells were isolated from spleens of C57/BL6 mice by anti-CD43 
magnetic bead negative selection on an AutoMACS Pro. . Cells in the negative fraction were pulsed 
overnight with lysate (6:1 tumour cell:APC) or OVA protein (50 μg/mL). The following morning the 
irrelevant melanoma peptide gp100 and OVA257-264 peptide (SIINFEKL) or OVA329-337 peptide were 
added 4 hours prior to the addition of 0.5 x 106 Violet Proliferation Dye 450-labelled OT-I or OT-II 
splenocytes.  72 hours later cells were stained with dead cell discrimination dye and labeled with 
mABs against CD19, CD3 and CD8. Cells were fixed in 2% paraformaldehyde, stored overnight at 
4°C and analysed the following day on an LSR Fortessa (BD Biosciences) or a Gallios (Beckman 
Coulter) Flow Cytometer. Flow data was analysed on FlowJo software V9 and graphed in Prism. 
Summary data of 2 (CD4) and 3 (CD8) independent experiments carried out in triplicate. Statistically 
differences were assessed by Kruskal-Wallis test followed by Dunn’s post test with Bonferroni 
correction. CD8+: the difference between OVA and UT was only significant without the adjustment 
for multiple comparisons. CD4+:  the difference between OVA and UT was not significant with or 
without the adjustment for multiple comparisons * p<0.05; ** p<0.01. Error bars = mean ± s.e.m. 
Expt 1a.2: B Cells as Antigen Presenting Cells 
For Proliferation of OT-I T Cells 




























Student's paired T-test. * P < 0.05. ** P < 0.005, *** P < 0.0001. 




































































statistically significant increases were achieved in the B cell+M1 MΦ and triple 
combination groups when analysed by Kruskal-Wallis followed by a Dunn’s post test 
without Bonferroni adjustment for multiple comparisons. Thus the results of these 
experiments were inconclusive. 
 
In an effort to increase the low percentage of proliferation in response to lysate the 
selected immune stimulants LPS&CpG were added to the APCs at the time of lysate 
loading and the T cell proliferation response to both soluble and oxidized lysate was 
compared.  No difference was recorded in the CD4+ T cell proliferation response to 
oxidised lysate compared to soluble lysate (figure 46) after two experiments and so, in 
light of previous similar CD4+ results this was not repeated a third time.  
 
When the combination of LPS&CpG-activated GMDC+B cells was used to present 
oxidised lysate antigens CD8+ T cell proliferation averaged 29% compared to 11% in 
three independent experiments (Figure 46). However this proliferation was only 
statistically significant compared to UT groups (p<0.05).  In addition the viability of 
T cells primed with oxidised lysate was markedly improved in nearly all priming 
conditions compared to T cells primed with soluble lysate. For these two reasons we 















   
Figure 43 Combining GMDC, M1 MΦs and B cells has no effect on the response of CD4+ T cells to 
priming with soluble lysate. 5 x 104 Day 6 GMDC, Day10 M1 MΦs and freshly isolated splenic B cells, or 
combinations thereof, were pulsed overnight with whole OVA protein (50 μg/mL) and B16.OVA TL (1:1 ratio 
tumor cell to APC). The total number of APCs plated was the same in each well. In double APC combination 
wells the ratios were 50:50. In triple combination wells the ratio was 1/3 of each APC. The following morning, 
the irrelevant melanoma peptide gp100 (2 μg/mL) and SIIN (2 μg/mL) were added 4 hours prior to the 
addition of 0.5 x 106 VPD450-labeled CD4+ T cells (10:1 ratio, T cell to APC). APCs and T cells were co-
cultured for 72 hours, stained with dead cell exclusion dye, labeled with surface antibodies against CD11c, 
CD19 (dump), CD3 and CD4 or CD8. Cells were fixed in 4% paraformaldehyde, stored overnight at 4°C and 
collected the following day on a Gallios Flow Cytometer. Data was analysed on FlowJo version X and graphed 
in Prism. Summary data of 3 experiments plated in duplicate or triplicate. Statistically significant differences 











































































































Combined Ex 1: Combinations of APCs 
































Figure 44 Sample raw data of CD4+, CD8+ and CD4+CD8 T cell response to priming by GMDC, GMDC+MΦ  and GMD+B 
cell loaded with soluble or oxidised lysate. Day 6 C57/BL6 BMDC, Day10 M1 MΦs and freshly isolated splenic B cells, or 
combinations thereof, were prepared as described previously. 5.0 x 104 APCs in varying ratios (double combination: 50:50; triple 
combination: 1/3 each) pulsed overnight with whole OVA protein (50 μg/mL) and B16.OVA TL (1:1 ratio tumor cell to APC) +/-
LPS (1 μg/mL) and CpG (0.3 μg/mL). The following morning, VPD450- or CFSE-labeled 0.5 x 106 CD4+ or CD8+ T cells, or 0.25 
x 106 of each, were added (10:1 ratio, T cell to APC). APCs and T cells were co-cultured for 72 hours, stained with dead cell 
exclusion dye, labeled with surface antibodies against CD11c, CD19 (dump), CD3 and CD4 or CD8. Cells were fixed in 4% 
paraformaldehyde, and stored overnight at 4°C. 5.0 x 104 cells per sample were acquired the following day on a Gallios Flow 
Cytometer. Data was analysed on FlowJo Version X. A dump channel for CD19 + and CD11c+ cells was included to preclude the 
possibility of B cell proliferation. The B cell+MΦ and Triple combinations were eliminated and so are not shown. Representative 
data from one experiment is shown. The GMDC+M1 MΦ and GMDC+B cell response to oxidised lysate only is shown. 
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Figure 45 The combination of GMDC+B cell, GMDC+M1 MΦ  or GMDC+B cell+M1 MΦ  stimulates a 
non-statistically significant trend toward increased proliferation of CD8+ T cells over that stimulated by 
GMDC, M1 MΦ  or B cells alone. 5. 5 x 104 Day 6 GMDC, Day10 M1 MΦs and freshly isolated splenic B 
cells, or combinations thereof, were pulsed overnight with whole OVA protein (50 μg/mL) and B16.OVA TL 
(1:1 ratio tumor cell to APC). The total number of APCs plated was the same in each well. In double APC 
combination wells the ratios were 50:50. In triple combination wells the ratio was 1/3 of each APC. The 
following morning, the irrelevant melanoma peptide gp100 (2 μg/mL) and SIIN (2 μg/mL) were added 4 
hours prior to the addition of 0.5 x 106 VPD450-labeled CD8+ T cells (10:1 ratio, T cell to APC). APCs and T 
cells were co-cultured for 72 hours, stained with dead cell exclusion dye, labeled with surface antibodies against 
CD11c, CD19 (dump), CD3 and CD4 or CD8. Cells were fixed in 4% paraformaldehyde, stored overnight at 
4°C and collected the following day on a Gallios Flow Cytometer. Data was analysed on FlowJo version X and 
graphed in Prism. Summary data of 3 experiments plated in duplicate or triplicate. Statistically significant 
differences were assessed by Kruskal-Wallis test followed by unadjusted Dunn’s test* p < 0.05; ** p <0.01. Error 
bars = mean +/- s.e.m.  
Figure 46 Irrespective of whether it is presented by GMDC, M1 MΦ , B cell or combinations thereof, 
oxidised lysate does not stimulate more CD4+ T cell proliferation than soluble freeze-thaw lysate. 5 x 104 
Day 6 GMDC, Day10 M1 MΦs and freshly isolated splenic B cells, or combinations thereof, were pulsed 
overnight with whole OVA protein (50 μg/mL) and B16.OVA TL (1:1 ratio tumor cell to APC). The total 
number of APCs plated was the same in each well. In double APC combination wells the ratios were 50:50. In 
triple combination wells the ratio was 1/3 of each APC. LPS (1 μg/mL) and CpG (0.3 μg/mL) were added at the 
same time as the lysates. The following morning, the irrelevant melanoma peptide gp100 (2 μg/mL) and SIIN 
(2 μg/mL) were added 4 hours prior to the addition of 0.5 x 106 VPD450-labeled CD4+ T cells (10:1 ratio, T 
cell to APC). APCs and T cells were co-cultured for 72 hours, stained with dead cell exclusion dye, labeled with 
surface antibodies against CD11c, CD19 (dump), CD3 and CD4 or CD8. Cells were fixed in 4% 
paraformaldehyde, stored overnight at 4°C and collected the following day on a Gallios Flow Cytometer. Data 
was analysed on FlowJo version X and graphed in Prism. Summary data of 2 experiments plated in duplicate. 













































































































Combined Ex 1: Combinations of APCs 
for Stimulation of OT-I T cells In Response to Tumor Lysate


























































































OT-I T Cell Proliferation After Presentation of 
Soluble Freeze-Thaw Lysate or
Oxidised Whole Freeze-Thaw Lysate 
by Different APCs  
Results of 3-4 separate experiments; Stats: Sudents unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;
error bars = mean with s.e.m;




4.3.4 T Cell Cytokine Production in Response To Priming by Lysate-
Loaded APCs 
T cell proliferation assays assess only T cell clonal expansion and give no indication 
of effector functional capacity. Since T cell proliferation is not always accompanied 
by effector functions140 functional assays such as cytokine production and cytotoxic 
capability are normally conducted alongside proliferation assays.  
4.3.4.1 IFN-γ Response to Soluble and Oxidised Lysates 
Lysate-loaded GMDCs, M1 MΦs and B cells, and combinations thereof, were 
compared for their ability to stimulate IFN-γ production in APC-CD4+ and APC-
CD8+ T cell co-cultures. We tested cytokine production in both unactivated and 
LPS&CpG-stimulated samples. In CD4+ co-cultures unactivated lysate-loaded APCs, 
or APC combinations, stimulated essentially no IFN-γ (Figure 48).  
 
Figure 47 Oxidised lysate only stimulates more CD8+ T Cell Proliferation than soluble freeze-
thaw lysate when presented by GMDC+B cell. 5 x 104 Day 6 GMDC, Day10 M1 MΦs and freshly 
isolated splenic B cells, or combinations thereof, were pulsed overnight with whole OVA protein (50 
μg/mL) and B16.OVA TL (1:1 ratio tumor cell to APC). The total number of APCs plated was the 
same in each well. In double APC combination wells the ratios were 50:50. In triple combination wells 
the ratio was 1/3 of each APC. LPS (1 μg/mL) and CpG (0.3 μg/mL) were added at the same time as 
the lysates. The following morning, the irrelevant melanoma peptide gp100 (2 μg/mL) and SIIN (2 μ
g/mL) were added 4 hours prior to the addition of 0.5 x 106 VPD450-labeled CD4+ T cells (10:1 ratio, 
T cell to APC). APCs and T cells were co-cultured for 72 hours, stained with dead cell exclusion dye, 
labeled with surface antibodies against CD11c, CD19 (dump channel), CD3 and CD8. Cells were fixed 
in 4% paraformaldehyde, stored overnight at 4°C and collected the following day on a Gallios Flow 
Cytometer. Data was analysed on FlowJo version X and graphed in Prism. Summary data of 3 
independent experiments. Statistically significant results were calculated by Kruskal-Wallis test 
















































































OT-I T Cell Proliferation After Presentation of 
Soluble Freeze-Thaw Lysate or
Oxidised Whole Freeze-Thaw Lysate 
by Different APCs  
Results of 2 separate experiments; Stats: Sudents unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;
error bars = mean with s.e.m;
APC & Antigen Used To Stimulate T cells
*
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In CD4+ T cell-APC co-cultures where the APCs had been activated with LPS&CpG 
the amount of IFN-γ produced was much higher than in unactivated samples (Figure 
49). GMDC loaded with soluble lysate+LPS&CpG stimulated production of 35 
ng/mL IFN-γ, and GMDC loaded with oxidised lysate +LPS&CpG stimulated 29 
ng/mL. The DC+B cell combination yielded equivalent levels of IFN-γ (34 ng/mL in 
response to soluble lysate +LPS&CpG and 32 ng/mL in response to oxidised lysate 
+LPS&CpG). M1 MΦs, and the DC+MΦ and triple combinations stimulated 
essentially no IFN-γ when loaded with either soluble or oxidised lyate +LPS&CpG..  
Thus in CD4+ T cell samples the GMDC+B cell combination yielded no advantage in 
IFN-γ production over GMDC alone.  
 
In APC-CD8+ T cell co-cultures none of the unactivated individual APCs, or APC 
combinations stimulated production of statistically significant levels of IFN-γ 
(Figure 50).  
 
As with the CD4+ T cells, the use of LPS&CpG along with the lysates stimulated 
greatly increased production of IFN-γ in CD8+ T cell-APC co-cultures (Figure 51), 
though these levels were not greater than those observed in CD4+ cultures. CD8+ T 
cells primed with GMDC loaded with soluble lysate+LPS&CpG or oxidised 
lysate+LPS&CpG induced production of 34 ng/mL and 39 ng/mL IFN-γ respectively, 
compared with 0.34 ng/mL in untreated samples. As with CD4+ T cells IFN-γ 
production in cultures of CD8+ T cells primed by M1 MΦs or the DC+MΦ or triple 
combinations loaded with either soluble or oxidised lysate +LPS&CpG was markedly 
lower than that stimulated by the GMDC or GMDC+B cell combinations. The DC+B 
cell combination again yielded the most IFN-γ in response to both soluble 
lysate+LPS&CpG (40 ng/mL) and oxidised lysate +LPS&CpG (44 ng/mL. However 
these increases were not statistically significant compared to GMDC when analysed 
by Kruskal-Wallis followed by unadjusted Dunn’s test. The only significant 








Figure 49 CD4+ T cells primed with soluble or oxidised lysate-loaded GMDC or GMDC+B cell 
+LPS&CpG produce equivalent amounts of IFN-γ . 5 x 104 Day 6 GMDC, Day10 M1 MΦs and 
freshly isolated splenic B cells, or combinations thereof, were pulsed overnight with whole OVA 
protein (50 μg/mL) and B16.OVA TL (1:1 ratio tumor cell to APC). The total number of APCs plated 
was the same in each well. In double APC combination wells the ratios were 50:50. In triple 
combination wells the ratio was 1/3 of each APC. LPS (1 μg/mL) and CpG (0.3 μg/mL) were added at 
the same time as the lysates. The following morning 0.5 x 106 VPD450-labeled CD4+ T cells (10:1 
ratio, T cell to APC) were added. APCs and T cells were co-cultured for 72 hours, supernatants 
collected prior to harvest and stored at -80°C prior to analysis by anti-IFN-γ ELISA as described in 
Materials and Methods. Data was analysed in Exel and graphed in Prism. Summary data of 3 
independent experiments. Statistically significant results were calculated by Kruskal-Wallis test 
followed by unadjusted Dunn’s test. * p < 0.05. Error bars = mean +/- s.e.m. 
Figure 48 A No increase in IFN-γ  production is observed when CD4+ T cells are primed with 
combinations of unadjuvanted soluble lysate-loaded GMDC, M1 MΦ  and B cells. 5 x 104 Day 6 
GMDC, Day10 M1 MΦs and freshly isolated splenic B cells, or combinations thereof, were pulsed 
overnight with whole OVA protein (50 μg/mL) and B16.OVA TL (1:1 ratio tumor cell to APC). The total 
number of APCs plated was the same in each well. In double APC combination wells the ratios were 50:50. 
In triple combination wells the ratio was 1/3 of each APC. LPS (1 μg/mL) and CpG (0.3 μg/mL) were 
added at the same time as the lysates. The following morning, OVA323-339 peptide (2 μg/mL) was added 4 
hours prior to the addition of 0.5 x 106 VPD450-labeled CD4+ T cells (10:1 ratio, T cell to APC). APCs 
and T cells were co-cultured for 72 hours, supernatants collected prior to harvest and stored at -80°C prior 
to analysis by anti-IFN-γ ELISA as described in Materials and Methods. Data was analysed in Exel and 
graphed in Prism. Summary data of 3 independent experiments. Statistically significant results were 
calculated by Kruskal-Wallis test followed by unadjusted Dunn’s test. * p < 0.05; ** p < 0.01. Error bars = 



















































































IFN-y Production in OT-II T-Cell Co-Culture Supernatants After Antigen 
Presentation By DC, Mφ, B cell or Combinations Thereof
Results of 4  separate experiments; 























































































IFN-y Production in CD4+ T-Cell Co-Cultur  Supernat nts at 72 hrs (CFSE+)
After Antigen Presentation
By DC, Mφ, B cell or Combinations Thereof
Results of 1-3 separate experiments; stats= Stud nt's unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;






   
Figure 51 When soluble or oxidised lysates are presented to CD8+ T cells by GMDC+B cell+LPS&CpG 
no increase in IFN-γ  production is observed compared to presentation by GMDC alone. 5 x 104 Day 6 
GMDC, Day10 M1 MΦs and freshly isolated splenic B cells, or combinations thereof, were pulsed overnight 
with whole OVA protein (50 μg/mL) and B16.OVA TL (1:1 ratio tumor cell to APC). The total number of 
APCs plated was the same in each well. In double APC combination wells the ratios were 50:50. In triple 
combination wells the ratio was 1/3 of each APC. LPS (1 μg/mL) and CpG (0.3 μg/mL) were added at the same 
time as the lysates. The following morning 0.5 x 106 VPD450-labeled CD8+ T cells (10:1 ratio, T cell to APC) 
were added. APCs and T cells were co-cultured for 72 hours, supernatants collected prior to harvest and stored 
at -80°C prior to analysis by anti-IFN-γ ELISA as described in Materials and Methods. Data was analysed in 
Exel and graphed in Prism. Summary data of 3 independent experiments. In DC+OVA, MΦ UT, MΦ+OVA 
and Triple+s-L only two observations were recorded. Statistically significant results were calculated by 






















































































IFN-y Production in CD8+ T-Cell Co-Culture Supernatants at 72 hrs (CFSE+)
After Antigen Presentation
By DC, Mφ, B cell or Combinations Thereof
Results of 1-3 separate experiments; stats= Student's unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;





Figure 50 No statistically significant increases in IFN-γ  production are observed when CD8+ T cells are 
primed with unadjuvanted lysate-loaded GMDC, M1 MΦ , B cell or combinations thereof. 5 x 104 Day 6 
GMDC, Day10 M1 MΦs and freshly isolated splenic B cells, or combinations thereof, were pulsed overnight 
with whole OVA protein (50 μg/mL) and B16.OVA TL (1:1 ratio tumor cell to APC). The total number of 
APCs plated was the same in each well. In double APC combination wells the ratios were 50:50. In triple 
combination wells the ratio was 1/3 of each APC. LPS (1 μg/mL) and CpG (0.3 μg/mL) were added at the same 
time as the lysates. The following morning, SIINFEKL  peptide (2 μg/mL) was added 4 hours prior to the 
addition of 0.5 x 106 VPD450-labeled CD8+ T cells (10:1 ratio, T cell to APC). APCs and T cells were co-
cultured for 72 hours, supernatants collected prior to harvest and stored at -80°C prior to analysis by anti-IFN-
γ ELISA as described in Materials and Methods. Data was analysed in Exel and graphed in Prism. Summary 
data of 3 independent experiments. Statistically significant results were calculated by Kruskal-Wallis test 
















































































IFN-y Production in OT-I T-Cell Co-Culture Supernatants After Antigen Presentation
By DC, Mφ, B cell or Combinations Thereof
Results of 5 separate experiments; stats= Student's unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;




4.3.4.2 IL-12 Response to Soluble and Oxidised Lysates 
IL-12 secreted by activated DCs after CD40 ligation is a crucial cytokine for driving 
TH1 differentiation66, CTL effector function67 and the development of T cell 
memory68. We therefore examined the IL-12 in co-cultures of T cells primed by 
lysate-loaded APCs. After 48 hours exposure to soluble and oxidised lysate-loaded 
APCs cell conditioned media were collected for analysis by anti-IL-12 ELISA. All 
untreated samples produced less than 15 ng/mL IL-12, and all OVA-primed samples 
produced a minimum of 29 ng/mL (range 29 – 105 ng/mL) (Figure 52, Figure 53). 
 
 shows summary data for CD4+ T cell-APC co-cultures. GMDC loaded with soluble 
or oxidised lysate stimulated 38 ng/mL and 44 ng/mL IL-12 respectively, significantly 
more than the untreated samples (1.6 ng/mL; p<0.05). The combination of GMDC+B 
cell loaded with soluble lysate generated 28 ng/mL IL-12 while oxidised lysate 
yielded 30 ng/mL, The difference in IL-12 between GMDC and GMDC+B cell was 
not statistically significant for either soluble or oxidised lysate. 
 
We did not see any proliferation in CD4+ T cells primed with GMDC+OVA, 
GMDC+MΦ+lysates or the triple combination+lysates. We did not expect to see IL-
12 production in these groups, however one group was checked and there was no 
increased IL-12 in groups containing MΦs.  
 
Figure 52 shows summary data for CD8+ T cell-APC co-cultures. These results 
showed a similar pattern to that of CD4+ T cells with no statistically differences in 
IL-12 production between groups. 
 
However there appeared to be less IL-12 in GMDC+B cell groups so we compared 
IL-12 production in GMDC+B cell cultures prior to the addition of T cells (Figure 
54). The combination of B cell+GMDC nearly tripled the average production of IL-12 
in the soluble lysate-treated samples (64 ng/mL compared with 21 ng/mL in 
GMDC+soluble lysate; p<0.05). A similar response was seen in the oxidised lysate-
treated samples with 26 ng/mL IL-12 in GMDC+oxidised lysate and 55 ng/mL in the 














Figure 53 The production of IL-12 is not increased when two or three APCs are used to prime CD8+ T 
cells with B16.OVA soluble or oxidized tumour lysate. 5 x 104 Day 6 GMDC, Day10 M1 MΦs and freshly 
isolated splenic B cells, or combinations thereof, were pulsed overnight with whole OVA protein (50 µg/mL) 
and B16.OVA TL (1:1 ratio tumor cell to APC). The total number of APCs plated was the same in each well. 
In double APC combination wells the ratios were 50:50. In triple combination wells the ratio was 1/3 of each 
APC. LPS (1 μg/mL) and CpG (0.3 μg/mL) were added at the same time as the lysates. The following 
morning 0.5 x 106 VPD450-labeled CD8+ T cells (10:1 ratio, T cell to APC) were added. APCs and T cells 
were co-cultured for 72 hours, supernatants collected prior to harvest and stored at -80°C prior to analysis 
by anti-IL-12 ELISA as described in Materials and Methods. Data was analysed in Exel and graphed in 
Prism. Summary data of 3 independent experiments. In DC+OVA, MΦ UT, MΦ+OVA and Triple+s-L only 
two observations were recorded. Statistically significant results were calculated by Kruskal-Wallis test 
followed by unadjusted Dunn’s test. Error bars = mean +/- s.e.m.  
Figure 52 The production of IL-12 is not increased when two or three APCs are used to prime CD4+ T 
cells with B16.OVA soluble or oxidized tumour lysate. 5 x 104 Day 6 GMDC, Day10 M1 MΦs and freshly 
isolated splenic B cells, or combinations thereof, were pulsed overnight with whole OVA protein (50 µg/mL) 
and B16.OVA TL (1:1 ratio tumor cell to APC). The total number of APCs plated was the same in each well. 
In double APC combination wells the ratios were 50:50. In triple combination wells the ratio was 1/3 of each 
APC. LPS (1 μg/mL) and CpG (0.3 μg/mL) were added at the same time as the lysates. The following 
morning 0.5 x 106 VPD450-labeled CD4+ T cells (10:1 ratio, T cell to APC) were added. APCs and T cells 
were co-cultured for 72 hours, supernatants collected prior to harvest and stored at -80°C prior to analysis 
by anti-IFN-γ ELISA as described in Materials and Methods. Data was analysed in Exel and graphed in 
Prism. Summary data of 3 independent experiments. Statistically significant results were calculated by 











































































IL-12 Production By DC, Mφ, B cell or Combinations Thereof
 in CD8+ T-Cell Co-Culture Supernatants at 24 & 48 hrs (CFSE+)
Results of 1 (IL-4DC)-4 separate experiments; stats= Student's unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;































































































IL-12 Production By DC, Mφ, B cell or Combinations Thereof
 in CD4+ T-Cell Co-Culture Supernatants at 24, 48 and & 72 hrs (CFSE+)
Results of 1 experiment; stats= Student's unpaired t-test; *p<0.05; **p<0.01; *** <0.001;




















4.3.4.3 TNF-α Response to Soluble and Oxidised Lysates 
TNF-α is produced by monocytic lineage cells, primarily MΦs (reviewed in 75 and 77) 
and has been shown to cooperate with IFN-γ to mediate tumour rejection79,80. 
Interestingly, membrane-bound but not soluble TNF-α was shown to be responsible 
for anti-tumour response in one study95. Therefore we wished to evaluate the presence 
of soluble TNF-α in the cell-condition media of lysate-primed APC-T cell co-
cultures. 
 
Very low levels of TNF-α were detected in CD4+ or CD8+ T cell co-cultures after 72 
hours of culture with the various protein, peptide or lysate-loaded APCs (Figure 55). 
























































IL-12 Production By GMDC, Mφ & IL4DC or DC+Bc at 24 & 48 hrs (CFSE+)
Results of at least 3 separate experiments; stats= Student's unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;
error bars = mean with s.e.m;
IL-12 production is greatest in GMDC, Mac & IL4DC stimulated with HOClwFTL, not sFTL;
The addition of LPS+CpG greatly increases IL-12 production by GMDC, M1 Mac & IL4DC cf lysate alone; 
in GMDCs, IL4DCs and M1 Macs there is no difference between LPS&CpG-treated & LPS&CpG+lysate-treated therefore this effect is due to LPS&CpG alone. However 
the addition of B cells lifts the IL-12 response beyond that of LPS&CpG alone. This does not occur in IL4DCs.
The addition of B cells appears to increase IL-12 production in GMDC+sFTL & GMDC+HOClwFTL cf GMDC alone;
The addition of B cells= no advantage with sFTL-loaded IL4DC;
HOClwFTL stimulates more IL-12 from GMDCs than sFTL, but not from Macs or IL4DC;
Mac+Bc was unfortunately not tested..
*
Figure 54 The combination of LPS&CpG-activated, lysate-loaded GMDC+B cell induces a synergistic 
increase in IL-12 production over LPS&CpG alone. 5 x 104 Day 6 GMDC, Day10 M1 MΦs and freshly 
isolated splenic B cells, or combinations thereof, were pulsed overnight with whole OVA protein (50 μ
g/mL) and B16.OVA TL (1:1 ratio tumor cell to APC). The total number of APCs plated was the same in 
each well. In double APC combination wells the ratios were 50:50. LPS (1 μg/mL) and CpG (0.3 μg/mL) 
were added at the same time as the lysates. Supernatants collected after 48 hours and stored at -80°C prior 
to analysis by anti-IL-12 ELISA as described in Materials and Methods. Data was analysed in Excel and 
graphed in Prism. Summary data of 3 independent experiments. Statistically significant results were 
calculated by Kruskal-Wallis test followed by unadjusted Dunn’s test.* p < 0.05. Error bars = mean +/- s.e.m. 
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Figure 55 Soluble TNF-α  is not present in lysate-primed CD4+ or CD8+ T cell co-cultures. 5 x 104 
Day 6 GMDC, Day10 M1 MΦs and freshly isolated splenic B cells, or combinations thereof, were pulsed 
overnight with whole OVA protein (50 µg/mL) and B16.OVA TL (1:1 ratio tumor cell to APC). The total 
number of APCs plated was the same in each well. In double APC combination wells the ratios were 50:50. 
In triple combination wells the ratio was 1/3 of each APC. LPS (1 μg/mL) and CpG (0.3 μg/mL) were 
added at the same time as the lysates. The following morning OVA323-339 or SIIN peptide (2 μg/mL ) were 
added to the CD4+ or CD8+ wells respectively prior to the addition of 0.5 x 106 VPD450-labeled CD4+ or 
CD8+ T cells (10:1 ratio, T cell to APC). APCs and T cells were co-cultured for 72 hours, supernatants 
collected prior to harvest and stored at -80°C prior to analysis by anti-IFN-γ ELISA as described in 
Materials and Methods. Data was analysed in Exel and graphed in Prism. Summary data of 3 independent 
experiments. In DC+OVA, MΦ UT, MΦ+OVA and Triple+s-L only two observations were recorded. 
Statistically significant results were calculated by Kruskal-Wallis test followed by unadjusted Dunn’s test. 






































































































TNF-a Production By DC, Mφ, B cell or Combinations Thereof
 in CD4+ T-Cell Co-Culture Supernatants at 24, 48 and & 72 hrs (CFSE+)
Results of 1 experiment; stats= Student's unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;


























































































TNF-a Production By DC, Mφ, B cell or Combinations Thereof
 in CD4+ T-Cell Co-Culture Supernatants at 24, 48 and & 72 hrs (CFSE+)
Results of 1 experiment; stats= Student's unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;
error bars = mean with s.e.m;
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4.3.4.4 IL-10 Response to Soluble and Oxidised Lysates 
IL-10 is associated with TREGs and immune suppression96. However IL-10 has also 
been shown to promote tumor regression (reviewed in 81,108), therefore we wished to 
assess whether lysate-loaded APCs stimulated high or low levels of IL-10. 
 
Little IL-10 was detected in CD4+ or CD8+ T cell-APC co-cultures (Figure 56). No 
differences were observed between APCs priming the T cells or between oxidised and 
soluble lysates. 
  
Figure 56 No difference in IL-10 production is observed between oxidized lysate-primed T cell co-cultures 
and soluble lysate-primed co-cultures. 5 x 104 Day 6 GMDC, Day10 M1 MΦs and freshly isolated splenic B 
cells, or combinations thereof, were pulsed overnight with whole OVA protein (50 µg/mL) and B16.OVA 
soluble or oxidised lysate (1:1 ratio tumor cell to APC). The total number of APCs plated was the same in each 
well. In double APC combination wells the ratios were 50:50. In triple combination wells the ratio was 1/3 of 
each APC. The following day CD4+ or CD8+ wells respectively prior to the addition of 0.5 x 106 VPD450-
labeled CD4+ or CD8+ T cells (10:1 ratio, T cell to APC). APCs and T cells were co-cultured for 72 hours, 
supernatants collected prior to harvest and stored at -80°C prior to analysis by anti-IFN-γ ELISA as 
described in Materials and Methods. Data was analysed in Excel and graphed in Prism. Summary data of 3 
independent experiments. For CD8+ DC UT, MΦ UT & triple+ox-L only two observations were recorded and 
in MΦ+OVA and Triple+s-L only one observation was recorded. Statistics were not applied due to the wide 











































































IL-10 Production By DC, Mφ, B cell or Combinations Thereof
 in CD4+ T-Cell Co-Culture Supernatants at 72 hrs (CFSE+)
Results of 1-3 experiments; stats= Student's unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;


















































































IL-10 Production By DC, Mφ, B cell or Combinations Thereof
 in CD8+ T-Cell Co-Culture Supernatants at  72 hrs (CFSE+)
Results of 1-3 experiment; stats= Student's unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;
error bars = mean with s.e.m;
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4.3.5 Proliferation Response to Priming and Re-stimulation with 
Lysate-loaded APCs 
The overarching aim of this thesis was the improvement of ACT for cancer. As such 
one of the key goals is the expansion of sufficient lysate-primed T cells for adoptive 
transfer into patients. We therefore investigated the fold expansion of CD4+ and 
CD8+ T cells when primed with the lysate-loaded APCs and APC combinations over 
a 10 day period. We also aimed to restimulate the primed T cells with the same APCs 
and APC combinations to ascertain what impact priming with one APC and boosting 
with the same or a different APC might have on T cell priming and restimulation.  
 
We were unable to stimulate CD4+ T cells to expand in response to priming with 
soluble or oxidised lysate (Data not shown). Small numbers of live CD4+ T cells were 
observed in the oxidized lysate-primed samples and the GMDC+B cell and Triple 
combinations after 10 days. All CD8+ T cells primed with soluble lysate were dead 
by Day 10. 
 
CD8+ T cells could be stimulated to expand approximately 2 fold when primed by 
GMDC presenting oxidized lysate antigen (Figure 57). When data from all the 
experiments are collated no combination of APC gives any advantage over the use of 
GMDC alone. However in two of the three experiments CD8+ T cells primed with 
oxidised lysate-loaded GMDC+B cell proliferated approximately two fold higher than 
T cells primed by GMDC alone (Figure 57).  
 
Since soluble lysate-primed CD4+ and CD8+ T cells and oxidised lysate-primed 
CD4+ T cells were all dead by D10 we were unable to re-stimulate those lysate-
primed T cells. In one experiment with oxidised lysate-primed CD8+ T cells, enough 
cells remained alive at D10 to attempt re-stimulation. The T cells were restimulated 
with the same APC, or APC combination, with which they had been primed. 
Alternatively the T cells were restimulated with a different APC or APC combination 
from that which was used for priming. By Day 20 the greatest fold expansion was 
observed in the “Primed with DC, Boosted with DC” and “Primed with MΦ, Boosted 
with MΦ” groups, however the fold expansion was only 1.13 and 1.01 respectively 
(data not shown). Attempts were also made to re-stimulate OVA-primed CD8+ T 
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cells with the same or different APC(s). Insufficient data was obtained for statistical 
analysis therefore this result is discussed in Appendix 1, Supplementary Figure 28.  
 
  
Figure 57 No differences are observed between CD8+ T cells primed for 10 days with 1, 2 or 3 
oxidised lysate-loaded APCs. 1 x 105 Day 6 GMDC, Day10 M1 MΦs and freshly isolated splenic B 
cells, or combinations thereof, were pulsed overnight with whole OVA protein (50 µg/mL) and 
B16.OVA soluble or oxidised lysate (1:1 ratio tumor cell to APC). The total number of APCs plated was 
the same in each well. In double APC combination wells the ratios were 50:50. In triple combination 
wells the ratio was 1/3 of each APC. The following day CD4+ or CD8+ wells respectively prior to the 
addition of 1 x 106 CD8+ T cells (10:1 ratio, T cell to APC). APCs and T cells were co-cultured for 10 
days with fresh media and cytokines being replaced every 2 days. Fold expansion was assessed by 
counting live cells under Trypan Blue dead cell exclusion staining. Summary data of 3 independent 
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4.3.6 Naïve T cell Phenotype 
We wished to observe the effect that priming with different lysate-loaded antigen 
presenting cells had on the resulting T cell phenotype. We therefore examined the 
phenotype of the naïve CD4+ and CD8+ T cells used in APC co-cultures and 
compared it to that of the primed T cells. Freshly isolated CD4+ and CD8+ T cells 
were analysed by Flow Cytometry for the presence of a range of molecules that 
collectively classify T cells as naïve. CD27, CD28, PD-1, CD44, CD122, CD127, 
CD62L and CCR7 were evaluated. Antibody panels used in T cell phenotyping are 
found in Materials and Methods Table 4.  
 
Figure 58 shows the gating strategy used to phenotype both naïve and lysate-primed T 
cells. For the sake of simplicity only the GMDC+OVA, GMDC+oxidised lysate and 
GMDC+B cell+oxidised lysate plots are shown. For comparison a full set of plots are 
found in Appendix 1, Supplementary Figure 32. Figure 59 shows summary data for 
seven CD8+ and four CD4+ independent experiments assessing naïve T cell 
phenotypes. 
 
The molecules CD27 and CD62L were both highly expressed on all freshly-isolated 
CD4 and CD8 T cells (Figure 59). CD8 and CD4 T cell expression of CD27 was 
indistinguishable at 86% and 89% respectively. CD62L expression on CD4+ T cells 
was slightly lower (74%) than that of CD8+ T cells (83%). 
 
CD28 was consistently expressed at very low levels on both CD4+ and CD8+ T cells 
(5% and 1% respectively). Three different antibodies, two conjugated to FITC, one 
conjugated to PE, were compared and all returned the same result. We also observed 
very low expression of the early T cell activation marker CD69 on both CD4+ and 
CD8+ T cells as well as the T cell exhaustion marker PD-1. 
 
There were slight differences in the expression of CD122 and CD127 on CD4+ and 
CD8+ T cells. CD122 expression was not expressed on either cell type. CD127 
expression varied more between the two cell types with CD8+ cells having an average 
of 8% expression and CD4+ cells an average of 2%. 
 
 261 
CD44 expression was identical with 15% of CD8+ T cells positive for this marker and 




















   
Figure 59 Naïve CD4+ and CD8+ T cell phenotypes show similar profiles. Freshly isolated OT-II and 
OT-I splenocytes were labeled with CD4 and CD8 negative selection bead cocktails respectively and 
sorted by AutoMACS Pro. The resultant CD4+ and CD8+ T cells were stained with dead cell exclusion 
dye and labeled with mABs against the surface molecules CD3, CD8, CD27, CD28, CD44, CD122, 
CD127, PD-1, CD62L and CD69. Labeled cells were fixed in 4% PFA, stored overnight at 4°C and 
collected the following day on a Gallios Flow Cytometer. Data was analysed on FlowJo VX Software. 
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Results of 10 separate experiments
Restifo (2005) reported MFI for CD27, CD62L, CD69, CD44, not % +ve
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Results of 4 separate experiments
Restifo (2005) reported MFI for CD27, CD62L, CD69, CD44, not % +ve
Make graph of MFI as well
Figure 58 Gating strategy for Day 0 T cells. Freshly isolated OT-II and OT-I splenocytes were labelled with 
CD4 and CD 8 negative selection bead cocktails respectively and sorted by AutoMACS Pro as described in 
Materials & Methods. The resultant CD4+ and CD8+ T cells were stained with dead cell exclusion dye (FVS450) 
and labeled with mABs against the surface molecules CD3, CD8, CD27, CD28, CD44, CD122, CD127, PD-1, 
CD62L and CD69. Labeled cells were fixed in 4% PFA, stored overnight at 4°C and collected the following day 
on a Gallios Flow Cytometer. Data was analysed on FlowJo VX Software and graphed in Prism Representative 
data of 7 (CD8+) and 3 (CD4+) independent experiments. 
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4.3.7 Phenotype of T Cells Primed with Lysate-loaded APCs 
We wished to identify whether T cells primed with undefined tumour antigen would 
adopt the TCM phenotype that has been shown to be more effective on a per cell basis 
than TEM in ACT for cancer109,141. Therefore the 10-day lysate-experienced T cells 
were assayed using mABs against the same surface markers as were used to assess the 
naïve T cells and the the phenotypes compared. Figure 60 shows the gating strategy 
and representative naïve and Day 10 CD8+ T cell data from ten independent 
experiments. Figure 61 shows summary data of Day 10 CD8+ T cells primed by 
GMDC and GMDC+B cells. Only the results of GMDC and GMDC+B cell-primed T 
cells are reported in this chapter as they were the only groups for which the most 
complete data was obtained. Appendix 1, Supplementary Figure 32 shows a 
representative dot plot data set for comparison of bi-variate analysis between all 
groups. Appendix 1, Supplementary Figure 33 shows the full summary data available 
for all groups. Statistically significant differences were calcualated using the Kruskal-
Wallis test, since a normal distribution can not be assumed with such low numbers. 
This test can be applied to groups containing different numbers of samples. The 
Kruskal-Wallis was followed by Dunn’s post test Unadjusted p values were used to 
compensate for the loss of power in the Dunn’s post test.  
 
CD8+ T cells primed by GMDC+OVA, GMDC+Bc+OVA, GMDC+ox-L or 
GMDC+Bc+ox-L all had reduced CD27 percent positivity compared to naïve T cells 
(). (GMDC+OVA: 69%; GMDC+ox-L: 39%; GMDC+Bc+OVA: 57%; 
GMDC+Bc+ox-L: 47% (p<0.05); naïve: 82%). One outlier had a marked impact on 
the mean of the GMDC+ox-L group, therefore while this result is technically 
statistically significant a further repeat is required to clarify the situation. No 
differences were observed between the GMDC and GMDC+B cell-primed groups. 
 
The CD44 percent positivity response was the opposite to that of CD27 with 
GMDC+OVA and GMDC+B cell+OVA groups having higher percent positivity 
compared with naïve T cells (74% (p<0.05), 46% (ns) and 15% respectively). 
GMDC+ox-L and GMDC+Bc+ox-L-primed T cells also showed increased CD44 over 
naïve (73% (ns) and 66% (p<0.05), respectively. However once again outliers in these 
groups mean that a further repeat is required. 
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CD62L decreased significantly across all groups compared to naïve T cells. 
GMDC+OVA (14%), GMDC+B cell+OVA (23%), GMDC+ox-L (15%) and 
GMDC+Bc+ox-L (20%).  
 
At Day 10 CD28 and CD127 was detected at less than 1% across all treatment groups 
and fewer than 3% CD8+ T cells were positive for PD-1 and CD122 across all 
groups. CD69 percent positivity was low (<3%) across all groups (Appendix 1, 
Supplementary Figure 33). 
 
Appendix 1, Supplementary Figure 32 shows representative Flow Cytometric data 
highlighting the difference in percentages of CD8+ TEM, TCM and TN/TSCM cells 
between groups primed with the various APCs. Figure 28 shows the same data for 
GMDC and GMDC+B cell groups alone. The GMDC and GMDC+B cell groups 
cluster together with similar percentages of CD44+CD62L- TEM and CD44+CD62L 
TCM cells. CD8+ T cells primed with oxidized lysate-loaded GMDC and GMDC+B 
cell exhibited 73% and 76% TEM, and 21% and 19% TCM respectively. Approximately 
5% and 4% of these cells displayed a CD44-CD62L+ TN/TSCM phenotype. By contrast 
CD8+ T cells primed with oxidized lysate-loaded M1 MΦs, DC+MΦ, Bc+MΦ or the 
Triple combination displayed lower percentages of TEM (36%, 44%, 40% and 43% 
respectively) and higher proportions of TCM (53%, 42%, 44% and 44% respectively). 
Thus, while these data remain preliminary, the phenotypes generated in response to 
priming suggest that CD8+ T cells have the capacity be activated into TEM and TCM by 





Figure 60 Gating strategy and raw data for Day 10 CD8+ T cells primed with GMDC or 
GMDC+B cell loaded with oxidised lysate. Day 6 GMDC and freshly isolated B cells were prepared 
as previously described. 1 x 105 GMDC or 0.5 x 105 GMDC and 0.5 x 105 B cells were pulsed 
overnight with whole OVA protein (50 μg/mL) and B16.OVA oxidised lysate (1:1 ratio tumor cell to 
APC) plus LPS&CpG. The following day freshly isolated OT-II and OT-I splenocytes were labeled 
with CD4 and CD 8 negative selection bead cocktails respectively and sorted by AutoMACS Pro and 
plated with lysate-loaded APCs (10:1 ratio, T cell to APC). APCs and T cells were co-cultured for 10 
days with fresh media and cytokines being replaced every 2 days. The resultant CD8+ T cells were 
stained with dead cell exclusion dye and labeled with mABs against the surface molecules CD3, CD8, 
CD27, CD28, CD44, CD122, CD127, PD-1, CD62L and CD69. Labeled cells were fixed in 4% PFA, 
stored overnight at 4°C and collected the following day on a Gallios Flow Cytometer. Data was 
analysed on FlowJo VX Software and graphed in Prism. Representative data of 9 independent naïve T 







Figure 61 Surface phenotype of Day 10 CD8+ T cells primed by oxidized lysate-loaded GMDC or 
GMDC+B cells. Day 6 GMDC and freshly isolated B cells were prepared as previously described. 1 x 105 
GMDC or 0.5 x 105 GMDC and 0.5 x 105 B cells were pulsed overnight with whole OVA protein (50 µg/mL) 
and B16.OVA oxidised lysate (1:1 ratio tumor cell to APC) plus LPS&CpG. The following day freshly 
isolated OT-II and OT-I splenocytes were labeled with CD4 and CD 8 negative selection bead cocktails 
respectively and sorted by AutoMACS Pro and plated with lysate-loaded APCs (10:1 ratio, T cell to APC). 
APCs and T cells were co-cultured for 10 days with fresh media and cytokines being replaced every 2 days. 
The resultant CD8+ T cells were stained with dead cell exclusion dye and labeled with mABs against the 
surface molecules CD3, CD8, CD27, CD28, CD44, CD122, CD127, PD-1, CD62L and CD69. Labeled cells 
were fixed in 4% PFA, stored overnight at 4°C and collected the following day on a Gallios Flow Cytometer. 
Data was analysed on FlowJo VX Software and graphed in Prism. Summary data of 3 - 9 independent 
experiments. Statistically significant results were calculated by Kruskal-Wallis test followed by unadjusted 












































KOP4 D10 Primed T cell Phenotype CD62L 
Restifo (2005) reported MFI for CD27, CD62L, CD69, CD44, not % +ve
Make graph of MFI as well
Restifo, 2005: CD62LHI subset have superior anti-tumor properties. Interestingly, the T cells in this graph with the 














































KOP4 D10 Primed T cell Phenotype CD44 
Restifo (2005) reported MFI for CD27, CD62L, CD69, CD44, not % +ve













































KOP4 D10 Primed T cell Phenotype CD27 
Restifo (2005) reported MFI for CD27, CD62L, CD69, CD44, not % +ve
Make graph of MFI as well
Make graph comparing naive MFI with D10 (& D20) MFI to show change from
naive to "early effector" to "effector" phenotype 
Early effectors do better in ACT than fully differentated effectors
Loss of CD27 in fully differentiated effector T cells may be responsible for/
contribute to CD8+ T cell impaired expansion & survival after ACT (Restifo, 2005)
Note reduced CD27 on DC & DC+Bc-primed T cells. CD27 is higher on Mφ, DC




4.4 Discussion  
We are aware of one other study directly comparing DCs, MΦs and B cells and their 
role in the immune response to the model antigen OVA using four different 
adjuvants142. The setting for that study was infectious disease rather than cancer. In 
addition the Mamula laboratory has looked at the interplay of DC, B cells and MΦs 
antigen presentation in the setting of autoimmune disease and cancer143,144. To our 
knowledge, this is the first study to compare the T cell response to being primed with 
combinations of lysate-loaded APCs. 
4.4.1 Tumour Lysate Dose Titrations 
It has been shown that the number of tumour cells plays a major role in whether or not 
CTLs can effectively eliminate tumours, with tumour cell numbers over a certain 
threshold impairing CTL function145. The amount146–148, and the affinity149,150, of 
antigen being presented to T cells, as well as the number of responding T cells146, all 
play critical roles in determining the magnitude of the T cell response. Tumour lysate 
has been variously used by different groups at ratios of between 1:1 up to 
100:16,11,151,152 (tumour cell:DC).  We carried out concentration titrations to compare 
the T cell response to priming by APCs loaded with different volumes of lysate 
equating to ratios of 3:1, 6:1, 12:1 and 30:1 tumour cells to DCs. The greatest 
proliferation response by CD8+ T cells was observed at the 6:1 ratio and initial 
experiments were carried out with this ratio. Higher concentrations appeared to induce 
an inhibitory effect, which was not unexpected given that lysates are known to be 
immunosuppressive. However it has been suggested that this suppression may have 
been due to the protease inhibitors in which the lysed tumour cells were resuspended. 
While the use of protease inhibitors was specifically recommended for this project we 
did note that Chiang et al did not resuspend their lysed tumour cells in protease 
inhibitors3. It would be interesting to compare the T cell response to lysate created 
without these inhibitors. 
 
4.4.2 The T cell Proliferation Response is Reduced When Lysate-
Loaded APCs are Activated with LPS&CpG  
Antigen presented by immature APC can induce immunological tolerance153–155 
therefore immune-activating stimuli must be a part of any anti-cancer therapy. The 
combination of the immunostimulatory adjuvants IFN-γ and monophosphoryl lipid A 
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(MPL) (a clinical grade, low-toxicity form of bacterial lipopolysaccharide)4 has been 
used clinically with tumour lysate. Other groups have experimented with whole 
tumour lysate and TLR agonists such as LPS, CpG and alpha-galactylceramide156,157.  
However all of these experiments were carried out using DCs as the only APC. Thus 
it was necessary to consider which TL preparation in conjunction with which immune 
activating stimuli would lead to improved T cell activation in the OVA-transgenic 
mice model when DC or MΦ or B cells or a combination thereof were used as the 
APC(s).  
 
A common understanding at the time of beginning these experiments was that 
phagocytic capacity is reduced in activated DCs compared to immature DCs158. We 
therefore reasoned that we might see a greater T cell response if APC were loaded 
with lysate prior to adjuvant stimulation. Two experiments suggested this might be 
the case, however, incorrect data analysis led to the decision to continue loading the 
APCs with lysate plus activation stimuli overnight. More comprehensive reading of 
the literature revealed that while macropinocytic uptake activities of activated DCs 
may be reduced146, FC-γ-R-mediated, DEC205-mediated, clathrin-mediated and 
phagocytic acquisition mechanisms remain intact in activated DCs146,159–161. Therefore 
the decision to load with lysates plus activation stimuli overnight serendipitously 
proved to be the better decision since it fostered enhanced B cell activation, which 
allowed the cooperative effects of the GMDC+B cell combination to be observed. 
However an improved approach might be to load the GMDC and B cells 
differentially. It would be interesting to compare B cells loaded with LPS&CpG 
overnight followed by lysate loading for 6 hours the following day, and GMDC 
loaded with lysates overnight followed by LPS&CpG activation for 4-6 hours the 
following day. By optimally activating both cell types individually prior to combining 
them, rather than treating them identically as was done in this project, the T cell 
response may be enhanced.  
 
In vitro T cells may be activated via antigen-specific APC-mediated means or non-
specific mechanisms such as cyokines. It is common to study T cell activation 
responses via the use of non-specific T cell activators. Such activators include 
mitogenic lectins such as phytohemagglutinin (PHA) or Concanavalin A, or the 
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protein kinase C (PKC) signal transduction activator phorbol 12-myristate 13-
acetate (PMA) together with IL-2-inducing ionomycin240. The use of beads coated 
with anti-CD3 and anti-CD28 mABs replicates stimulation by APCs to a degree, 
yielding a slightly more physiologically relevant result162.  
 
None of these artificial stimulants reproduce in vivo priming by an APC presenting 
peptide on MHC, but can provide a useful functional control to verify that a given cell 
can produce cytokines. Assessing the T cell response in vitro to APC+peptide 
stimulation provides a more relevant model of what may happen in vivo. Thus, rather 
than inducing an artificially high result by stimulating our lysate-primed T cells with 
mitogens or mABs we evaluated the T cell response to the defined antigen OVA, 
along with undefined TAA, presented by APCs. In this case presentation of whole 
OVA provides a more meaningful functional control than anti-CD3/anti-CD28.  
 
We hypothesized that treating lysate-loaded APCs with LPS&CpG would increase the 
T cell proliferation response allowing us to observe more clearly the effect of the 
different APC combinations on the T cell response. Unexpectedly, instead of 
increasing CD8+ T cell proliferation the proliferation response fell from an average of 
approximately 20% when primed by unactivated GMDCs to an average of around 
10% when primed by GMDCs that had been pulsed overnight with lysate plus 
LPS&CpG. In two experiments APCs were pulsed overnight with lysate and 
activation stimuli added the following morning. In that scenario CD8+ T cell 
proliferation was not greater than in T cells primed with APCs loaded overnight with 
lysate plus LPS&CpG, and for CD4+ T cells the proliferation was less (data not 
shown), so we continued pulsing overnight with lysates plus activation stimuli. As 
mentioned previously, this ultimately proved to be a better decision. 
4.4.3 The APC Presenting Lysate Antigens, Not the Lysate Type, 
Determines T Cell Proliferation Response  
In vitro T cell fluorescence diluting assays are widely used to study naïve and antigen-
specific T cell proliferation. We assessed the 72 hour T cell proliferation response to 
soluble and oxidized lysate and we expected that the oxidised lysate would yield 
greater T cell proliferation. However, interestingly, these results demonstrated that the 
greatest T cell proliferation occurred only when GMDC+B cells presented oxidized 
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lysate antigens to CD8+ T cells. Thus the APC presenting the lysate was important, 
not simply the oxidised lysate antigens.  
 
Previous work in our laboratory demonstrated that small numbers of proliferating 
antigen-specific murine T cells were generated in response to priming with soluble 
lysate139. This has also been demonstrated in human studies of parathyroid carcinoma 
lysate-loaded DC-primed T cells, in which in vitro T cell proliferation assays returned 
stimulation indices of 1.8-5.7163. However other studies using tumour lysate-loaded 
DCs have demonstrated the ability to generate large numbers of T cells23. Because the 
soluble lysate generated a low T cell response when presented by GMDCs we 
experimented with increasing the immunogenicity of the tumour cells. Recent work 
by Chiang et al had identified sodium hypochlorite oxidation of ovarian cancer cells 
(SK-OV-3) as a more effective method of generating highly immunostimulatory 
tumour lysate (TL) than heat-treated or irradiated cells. This was assessed by the 
ability of DC to take up TL, produce TH1-priming cytokines, stimulate an MLR and 
produce T cells that could control tumour growth in vivo3,4,36,164. Others have also 
reported on the immune enhancing properties of hypochlorous acid165. This approach 
appeared promising therefore we compared the T cell response to soluble and 
oxidised lysates. 
 
Contrary to Chiang’s results we saw no increase in T cell proliferation in the oxidized 
lysate samples when presented by GMDC. OVA protein was detected in the oxidized 
lysate, therefore the absence of OVA was not the reason for the lack of improved 
proliferation. We posited that the antibody used in the Western Blot was able to 
recognise oxidized OVA epitope whereas the OT-I T cells could not. However this 
theory was disproved in later experiments in which GMDC+B cell were combined 
(Figure 46) and in in vivo experiments.  
 
Rather than differing between the two lysates per se, in our hands the CD8+ T cell 
proliferation response differed according to which APC was presenting the lysate 
antigens. For CD4+ T cells, no improvement over GMDC-stimulated proliferation 
was observed in any soluble or oxidised lysate-primed group (Figure 46). No 
difference in proliferation was observed between soluble and oxidized lysate-primed 
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CD8+ T cells when the lysates were presented by any APC or APC combination 
except GMDC+B cell. The exception was when M1 MΦs presented oxidised antigens 
the CD8+ T cell proliferation was less than that induced by presentation of soluble 
lysate.  
 
HOCl is a physiologically relevant adjuvant found in sites of inflammation where it is 
produced by activated granulocytes, which flood into these areas along with antigen-
presenting DCs166. Rather than just bactericidal activity inside the phagolysosome 
these volatile, strong oxidizing agents also act in the intracellular milieu to cause 
oxidative changes to lipids167, enzymes168 and extracellular matrix proteins169. The 
adjuvant effects of HOCl are independent of TLR signaling170 with HOCl-oxidised 
OVA taken up more efficiently by APCs and degraded more efficiently by 
proteinases. The enhanced uptake is mediated via a specific receptor, which binds 
preferentially to chlorinated OVA. HOCl may improve the targeting of these 
glycoprotein antigens to scavenger receptors on the surface of APCs, suggesting a 
novel mechanism that links innate and adaptive immunity. Thus plausible evidence 
exists for the concept of enhanced tumour antigen presentation and T cell activation 
by HOCl-oxidised material in vivo. 
 
In tumour lysate non-immunostimulatory elements, such as tolerising self-antigens, 
may vastly outnumber the immunostimulatory components, which in this setting is 
primarily the model antigen OVA. We reasoned that high amounts of self antigen in 
the lysate would have an inhibitory effect on T cell activation via normal tolerance 
mechanisms, however, the object of this study was to activate T cells against 
undefined antigens therefore determining which factors were inhibitory to T cells was 
outside the remit of this thesis. Nevertheless, an interesting report has identified the 
intracellular accumulation of lipids in DCs as inhibitory to T cell stimulation in 
tumour-associated DCs (TADC)171. Tumour-produced reactive oxygen species (ROS) 
caused endoplasmic reticulum (ER) stress in TADC. ER stress led to the IRE1α-
mediated activation of the transcription factor XBP1, which switches on lipid-
synthesis genes. This increase in intracellular lipids interfered with DC antigen 
presentation and hindered their anti-tumour role. DC-initiated T cell immunity was 
restored when XBP1 was silenced. It is possible that this mechanism played a role in 
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down regulating the T cell response to oxidized lysate presented by GMDC and that 
this was overcome or ameliorated by the combination of GMDC+B cell, but 
examination of this theory was beyond the scope of this project. 
 
We noticed the low response to SIINFEKL and so compared our SIINFEKL to that of 
three other laboratories and found identical responses across the batches. The ability 
of CD8+ and CD4+ T cells to respond to whole OVA was more in line with expected 
proliferation rates and was a more relevant control since the whole protein, like the 
lysates, must be processed for presentation on MHC molecules whereas peptides are 
able to enter the MHC-peptide groove without processing via MHC-I recycling 
through early endosomes172. Thus while the SIINFEKL response was lower than we 
would have liked, we retained a relevant control that demonstrated the functionality of 
the APCs and the T cells.  
4.4.3.1 Lysate-loaded GMDC Stimulate Low Levels of CD8+ T Cell Proliferation 
The stimulation of T cell proliferation by freeze-thaw lysate-loaded DCs has been 
attempted unsuccessfully by other groups11,14,24,173. However it must be noted that 
significant differences exist between the preparation methods of the freeze-thaw 
lysates and methods of DC loading used in this current study and the four studies 
cited (soluble fraction versus whole portion lysate; sonication prior to freeze-thaw 
lysis; and timing of lysate loading on to DCs to name just three). Hatfield, who used 
the soluble fraction of freeze-thaw lysate11, suggested that the unsuccessful 
proliferation response to B16.OVA freeze-thaw lysate-pulsed GMDCs may be due to 
soluble OVA stimulating less cross-presentation than cell-bound OVA, which was 
reported by Li et al163. 
 
In our early lysate-loaded GMDC-T co-cultures lysate was loaded on to the GMDCs 
at a ratio of 6:1 and resulted in an average of 20% CD8+ proliferation (figure 40, left). 
In the interests of attempting to reproduce the oxidised lysate experiments of Chiang 
et al later experiments used the 1:1 ratio employed by Chiang et al in their oxidation 
assays. We continued to observe a T cell proliferation response however it was lower 
than that observed in the 6:1 ratio assays (Figure 46). This reduced proliferation 
response may reflect the reduced amount of OVA available to the APCs for 
presentation to the T cells.  
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The increased expression of CD40 on GMDC loaded with oxidized lysate does not 
appear to be a key factor in why GMDC+ox-L stimulated greater T cell proliferation 
than s-L. CD40 expression increased to 53% on ox-L-pulsed GMDC (p<0.05), which 
was greater than s-L (19%). However CD40 expression was also upregulated on M1 
MΦs in response to s-L and ox-L, though this increase was not statistically 
significant, and neither s-L nor ox-L-loaded M1 MΦs were able to stimulate T cell 
proliferation (Figure 46). CD40 ligation is required to link the innate and cognate 
immune responses (reviewed in165,174), but in this case does not explain the enhanced T 
cell activation by ox-L-loaded GMDC-primed T cells.  
 
Finally, we noted that while GMDC were able to present OVA peptides to both CD4+ 
and CD8+ T cells, demonstrating cross-priming ability, the IL4DC could only present 
OVA to CD4+ T cells. Proliferation clusters were observed in GMDC+OVA-primed 
CD4+ and CD8+ wells whereas proliferation clusters were only observed in 
IL4DC+OVA-primed CD4+ wells and not in the CD8+ wells. Thus in addition to the 
lower viability of lysate-loaded IL4DC compared with lysate-loaded GMDC this gave 
us further justification for continuing with GMDC instead of IL4DC. 
 
While both CD8- and CD8+ DC are able to efficiently capture antigen and present it 
on MHC-Class II, CD8+ DCs are superior to CD8- DC at cross-presenting captured 
antigen175,176. This helps to explain why these CD8-CD11bHI DCs were unable to 
stimulate strong CD8+ T cell proliferation, though it fails to explain why they did not 
stimulate CD4+ T cell proliferation. Merad suggests that, in addition to cross-
presentation, the increased CD8+ T cell priming potential of CD8+ DCs may also lie 
outside their cross-presentation abilities as they express more MHC-I-related genes 
than CD11b+ cDCs172,177. They also produce more of the TH1, CTL-promoting 
cytokines IL-12178–180 and IL-15181, as well as expressing the chemokine receptor 
XCR1. The chemoattractant XCL1 is expressed by CD8+ T cells after antigen 
presentation and promotes CD8+ DC expansion and IFN-γ production. The 
interaction of binding to its ligand XCR1 on CD8+ DC further promotes CD8+ CTL 
differentation182. Thus these CD8- GMDCs may represent a less than ideal population 
of cells for presentation of undefined tumour antigens to T cells. It has been reported 
 274 
that generation of CD8α+ DCs can be achieved using Flt3L183,184 and it would be 
interesting to compare the ability of these DCs to elicit a CD8+ T cell reponse to 
undefined tumour antigens. Though it has been reported that GM-CSF-differentiated 
DCs are superior to Flt3L DCs in the in vivo anti-tumour response185,186.  
4.4.3.2 Lysate-loaded MΦs Do Not Stimulate T Cell Proliferation 
We hypothesised that lysate-loaded MΦs may be superior to GMDCs at stimulating T 
cell proliferation as they excel at clearing apoptotic and necrotic cells and debris187,188. 
Despite showing increased CD40, lysate-loaded M1 MΦs were unable to stimulate a 
CD4+ or CD8+ T cell response (Figure 45, Figure 47).  The reason appears to lie in a 
loss of presentation ability as MHC-II percent positivity was markedly reduced in 
MΦs loaded with s-L+LPS&CpG and ox-L+LPS&CpG. 
 
IFN-γ is a strong stimulator of MΦ cytotoxic capacity and MHC-II expression and is 
secreted by activated T cells, along with GM-CSF (reviewed in189). IFN-γ alone 
blocks the actions of M-CSF in bone marrow progenitor cells but the combination of 
GM-CSF, M-CSF and IFN-γ fosters mononuclear phagocyte proliferation190. MΦs 
may have performed better had we included IFN-γ in the adjuvants. However there 
were high levels of IFN-γ in the supernatants, 5% GM-CSF was added to the media, 
and activated T cells in the co-cultures should be secreting GM-CSF also, so there 
should have been some MΦ stimulation. However this was obviously insufficient to 
overcome the lack of T cell activation by lysate-loaded MΦs. 
4.4.3.3 Lysate-Loaded B cell Do Not Stimulate T Cell Proliferation 
Researchers have begun to explore the possible use of B cells as alternative APCs in 
anti-cancer cell-based therapies 46,191–195. Two early studies utilized murine and human 
B cells loaded with melanoma lysates to activate CD4+ T cells45,46. We furthered this 
by assessing CD8+ responses such as have been observed by others46,196,197.  
 
Whole OVA protein and OVA peptides both generated strong T cell responses, 
demonstrating that the splenic B cells were able to present antigen and stimulate T 
cells, but that they weren’t able to do so when presenting soluble or oxidised lysate 
antigens.  
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4.4.3.4 Lysate-Loaded GMDC+B Cells Stimulate Greater CD8+ T Cell 
Proliferation Than GMDC Alone 
Steinman and Dhodapkar stated in 2001 that the immature DC is best for loading 
antigens for immunotherapy, whereas the mature DC represents the optimal cell for 
presentation of MHC-peptide complexes to T cells154. We began our experiments 
loading lysate on to APCs overnight and adding adjuvants the following morning, and 
in hindsight, should have continued with this method. However, despite the reduced 
overall proliferation of CD8+ T cells primed by GMDC loaded overnight with lysate 
plus adjuvant, a serendipitous outcome to continuing with loading the APCs overnight 
with lysate plus adjuvants was the appearance of increased proliferation in the 
GMDC+B cell group. Whereas we had previously consistently observed increased 
CD8+ T cell proliferation in each of the double and triple APC combination groups, 
compared to GMDC alone, we had been unable to discern differences between these 
combination groups. The addition of LPS and CpG “broke the tie” and allowed the 
GMDC+B cell combination to emerge as a stronger contender for inducing superior 
CD8+ T cell activation. The GMDC+B cell combination was superior to GMDC 
alone at stimulating C8+ T cell proliferation when presenting both both soluble and 
oxidised lysates (Figure 46). However in the presence of oxidized lysate the increase 
in CD8+ T cell proliferation was more than double compared with soluble lysate. 
  
Shirota and colleagues demonstrated that CpG-conjugated antigen stimulated B cells 
to cross-present antigen to CD8+ T cells and drive a TH1 response via strong IL-12 
production8365. This was the first time B cells had been reported to share the DC 
characteristics of non-specific antigen capture and TH1 differentiation from unprimed 
T cells. A later study also described how CD8- Flt3L-generated BMDCs, as well as 
splenic CD8- DCs, could be induced to cross-present dead cell-associated antigens, 
only after treatment with CpG198. 
 
Unconjugated CpG was loaded onto the APCs at the same time as the lysates, and was 
thus available to be picked up by the GMDC and B cells at the same time as the 
lysate. While IL-12 production by lysate-loaded B cells alone was not measured, a 
synergistic increase in IL-12 production over that produced by lysate-loaded GMDC 
was observed in overnight co-cultures of lysate-loaded GMDC+B cells (Figure 54). 
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These data, combined with the improvement in CD8+ T cell proliferation, suggest 
that the unconjugated CpG has had a similar effect to those described by Shirota and 
de Brito. This observation may be useful in the clinic the use of unconjugated CpG 
regularly takes place. 
 
4.4.4 Lysate-Loaded GMDC+B Cells Stimulate Enhanced IFN-γ But 
Not TNF-α or IL-10 Production 
The requirement in anti-tumour immunity for not just IFN-γ alone but polyfunctional 
T cells secreting multiple effector cytokines, is being increasingly recognised80,199 . 
IFN-γ, IL-12, TNF-α and IL-10 were selected as a minimum indication of T cell 
polyfunctionality in this study. IL-10 was included to observe whether lysate induces 
a regulatory T cell response. Finally, IL-2 production in response to oxidized tumour 
lysate has been used as a measure of improved T cell response200.  
 
IFN-γ secretion by CD8+ and CD4+ T cells follows recognition of p-MHC-I or p-
MHC-II respectively and IL-12 signaling. Loss of tumour control by both CD4+ and 
CD8+ T cells is observed in mice deficient in IFN-γ201,202 or the IFN-γ-R203–205. 
Tumour mediated CTL-destruction is mediated by not only direct killing mechanisms 
such as the perforin-granzyme system206, but also by the anti-angiogenic effects of 
IFN-γ203–205,207. Qin et al demonstrated in a variety of tumours (fibrosarcoma, ras-
transformed fibroblasts, colon carcinoma, and plasmacytoma) that IFN-γ-mediated 
inhibition of tumour-induced angiogenesis always preceded rejection of tumours by 
CD8+ T cells.  
 
CD8+ T effector cells can eliminate tumours in the absence of perforin but not IFN-γ, 
although CD8+ memory cells cannot eliminate tumours in the absence of perforin202.  
Further anti-tumour effects of IFN-γ include the upregulation of MHC expression on 
tumours so that peptide presentation is enhanced154,208. It has also been shown that 
tumour-specific CD4+ T cells can eliminate MHC Class II negative cancers in mice, 
in the absence of CD8+ T cells, via the indirect effects of IFN-γ on host cells209. Mice 
that were immunocompetent, apart from their capacity to produce IFN-γ, were shown 
to be more susceptible to spontaneous tumour development210, and to carcinogen-
induced tumours211.  
 277 
DCs loaded with freeze-thaw lysate of medullary thyroid carcinoma have been shown 
to induce high intracellular IFN-γ  in patient CD8+ T cells2. Thus the importance of 
this cytokine in the anti-tumour immune response is well established, as well as 
precedence for lysate-loaded DC induced IFN-γ productions. 
 
In line with other studies that found no IFN-γresponse to freeze-thaw lysate-loaded 
DCs11 our unactivated lysate-loaded GMDCs stimulated very limited amounts of IFN-
γ release by CD8+ T cells When oxidised lysate was used as the antigen source the 
combination of GMDC+B cell caused an approximately 50% increase in IFN-γ levels 
compared to GMDC alone in CD8+ T cell cultures, however this difference was not 
statistically significant.  
 
For CD4+ T cells only the GMDC+LPS&CpG and GMDC+B cell+LPS&CpG groups 
showed strikingly higher levels of IFN-γ. However the increased IFN-γ in the 
GMDC+B cell+ox-L-primed CD4+ T cells was only significant when compared to 
the GMDC+MΦ group. 
 
Thus these IFN-γ data supported the CD8+ T cell proliferation data, which showed 
increased proliferation in response to priming by oxidised lysate-loaded GMDC+B 
cell, indicative of enhanced T cell function. 
 
In contrast to Wölfl and Greenberg who found that IL-12 production was the only 
factor that correlated with fully functional TH1-primed T cell populations212 we 
observed reduced IL-12 levels in soluble and oxidised lysate-primed CD4+ and CD8+ 
T cell co-cultures compared with OVA-stimulated cells. This was in contrast to 
elevated IL-12 recorded in lysate-loaded GMDC+B cell cultures. IL-12 levels in 
GMDC+B cell-primed T cell cultures were lower than in GMDC-primed CD4+ and 
CD8+ T cells cultures, irrespective of whether they were presenting soluble or 
oxidised lysate antigens. Given that IL-12 drives the differentiation of Type 1 cells 
during specific antigenic activation, and given the increased proliferation of CD8+ T 
cells in response to priming by oxidised lysate-loaded GMDC+B cell it is possible 
that the reduced level of IL-12 is indicative of this cytokine being used up by the 
proliferating T cells.  
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No TNF-α was observed in lysate-primed CD4+ and CD8+ T cell cultures (Figure 
55). One explanation for the absence of TNF-α observed may lie in the fact that TNF-
α is transiently upregulated within 1-3 hours after CpG exposure213. This may also 
help explain why unactivated M1 MΦs were more effective than CpG+LPS-activated 
MΦs - they may have been exposed to CpG for an excessive amount of time213.  
Crabtree’s data argues that 1-3 hours of CpG exposure results in enhanced TNF-α 
production, whereas longer time periods (6-9 hours) results in TNF-α inhibition and 
increased IL-10, possibly as a result of autocrine negative feedback regulation. 
However we found no TNF-α or IL-10 in the cell culture media of T cells primed 
with any of our APCs, whether they had been activated with CpG&LPS or not. Thus 
we have no evidence for this mechanism of TNF-α, or IL-10, inhibition. 
 
A more recent study reported that membrane-bound TNF-α may have a protective 
role in cancer while the soluble form may be responsible for TNF-α’s confusing pro-
tumoural effects95. On the basis of those results the low levels of soluble TNF-α in 
this study may represent a positive rather than a negative finding. However 
membrane-bound TNF-α was not adequately assessed in this study so that 
observation that remains to be further explored. 
 
The presence of high levels of IL-10 is indicative of a skew toward immunoregulatory 
functions, via induction of tolerogenic DC function98 and TREG formation96, or 
response resolution. Therefore we were concerned to ascertain that our lysate-loaded 
APCs did not stimulate a regulatory T cell response.  
 
Hatfield et al reported that while overall levels of IL-10 were low, small but 
statistically significant increases were observed in lysate-treated DCs11. In a similar 
manner, for both CD4+ and CD8+ T cells, we also consistently observed low levels of 
IL-10 that were slightly increased in the presence of soluble- and oxidised lysate-
loaded APCs. A consistent pattern of less IL-10 in oxidized lysate-primed cultures 
was observed across all APCs for both CD4+ and CD8+ T cells, though no 
differences were statistically significant. In GMDC+B cell-primed CD8+ T cells IL-
10 was slightly lower in the soluble lysate group compared to GMDC-primed cells, 
though again, not to a statistically significant degree. 
 279 
 
In light of the consistently low levels of IL-10 we were not concerned about the 
generation of TREGs and so the expression of CD25 or FoxP3 was not analysed on our 
lysate-primed cells. Further, with the induction of costimulatory molecules and IL-12 
production in response to the lysates we reasoned that a tolerogenic state was likely 
not being induced. 
 
4.4.5 Long Term In Vitro Culture of Lysate-Primed T Cells Was Not 
Achieved 
Since significant reductions in viability were observed in lysate-primed T cells after 
72 hours the commencement of ten-day priming experiments highlighted the need for 
cell culture conditions that would support T cells survival throughout this longer time 
period. The inclusion of IL-2, IL-7, IL-15, IL-21 and GM-CSF in the cell culture 
medium yielded no improvements in fold expansion. Limited improvement in 
viability was observed at the higher cytokine doses in both GMDC- and IL4DC-
primed T cells (Appendix 1, Supplementary Figures 24 and 25). Efforts at supporting 
the long-term culture of lysate-primed T cells were unsuccessful and require further 
optimization. 
4.4.6 Lysate-loaded APCs Are Unable to Stimulate T Cell Expansion 
We attempted to examine the differences in fold expansion of T cells primed with one 
APC or APC combination and re-stimulated with the same APC(s) or another APC(s). 
These experiments established that lysate-loaded APCs have a negative effect on T 
cell viability. By Day 10 all CD4+ T cells were dead in both the soluble and oxidised 
lysate-primed groups. CD8+ T cells died in the soluble lysate-primed groups also 
therefore we were only able to analyse the fold expansion of oxidised lysate-primed 
CD8+ T cells (Figure 57).  The most obvious advantage of using oxidised lysate over 
soluble lysate was that some CD8+ T cells remained alive at Day 10 whereas in the 
soluble lysate-treated wells all T cells were dead by Day 10. Although our aim was to 
measure Fold Expansion, in reality by the end of 10 days we were simply measuring 
viability.  
 
The two conditions that stood out in these cells were the GMDC-primed and 
GMDC+B cell-primed (1.84 and 1.98 FE respectively). In two experiments an 
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approximate doubling of fold expansion was observed in the GMDC+B cell group 
compared with GMDC alone. However, while the GDMC-primed cells cluster around 
an approximate 2-fold expansion, the range of results in the GMDC+B cell condition 
makes this data on its own less convincing. Nevertheless the GMDC+B cell group 
was the only group in which T cells were split during 10-day priming. In no other 
groups were sufficient cells generated to require splitting into more than one well. 
This observation required confirmation that T cells rather than B cells were 
proliferating, since CpG is a strong mitogen of B cells. This was confirmed by a 
CD19 and CD11c Dump Channel, which verified that even in these wells the 
percentage of CD19+ or CD11c+ cells was 10% at the most and usually 5% or less 
(Appendix 1, Supplementary Figure 17). For this reason we continued to be 
particularly interested in the comparison between the GMDC and GMDC+B cell 
groups as no enhanced fold expansion was observed in any other 10-day-primed 
group. 
 
4.4.7 Lysate-loaded APCs Induce TCM and TEM T Cell Phenotypes  
By Day 10 sufficient numbers of live lysate-primed CD8+ T cells were often 
unavailable for phenotyping, and even fewer remained by Day 20. No CD4+ T cells 
survived 10-day priming. However we were able to harness the power of Flow 
Cytometry which allows analysis of rare cell populations to assess what changes in 
phenotype could be observed between naïve and Day-10 lysate-primed CD8+ T cells.  
Three observations were measured wherever possible despite the difficulties in 
obtaining three robust repeats, 
 
The naïve CD4+ and CD8+ T cells were unexpectedly found to have very low 
expression of CD28 a key co-stimulatory molecule in the CD28/CTLA4/B7 
(CD80/CD86) pathway. CD28 is known to be critical in the priming of antigen-
specific CD4 T cells, however, in line with findings from other studies that showed 
CD28-independent CD8+ T cell priming214–216, our lysate-primed CD8+CD28- T cells 
were able to proliferate in response to OVA antigen. In accordance with these other 
studies, antigen-specific lysate-primed T cells were observed, as evidenced by T cell 
proliferation and IFN-γ responses, and the lack of CD28 did not affect the generation 
of memory T cells, albeit possibly at lower frequencies. 
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Loss of CD27 in fully differentiated effector T cells may be responsible for, or 
contribute to, CD8+ T cell impaired expansion and survival after ACT69. In three 
consecutive clinical trials that yielded 49 – 72% response rates, the number of 
CD8+CD27+ cells was highly correlated with the persistence of adoptively 
transferred TILs112. Therefore it was encouraging to observe 40% and 50% CD27 
expression respectively in CD8+ T cells primed by oxidized lysate-loaded GMDC and 
GMDC+B cell. Interestingly, while these CD27 expression levels were lower than 
those recorded in the MΦ, DC+MΦ, Bc+MΦ or Triple combination-primed groups, in 
our hands this did not correlate with reduced in vivo function, as will be discussed in 
Chapter 5. 
 
Our naïve T cells were CD28- and, unsurprisingly, did not show upregulation of 
CD28 in response to priming with lysate. Romero and colleagues have shown 
heterogenicity of CD27 and CD28 expression in human CD8+ T cells and suggested 
that stepwise loss of both molecules characterised T cell differentiation217. They 
grouped TEM cells into four subsets on the basis of CD27CD28 expression: 
EM1 (CD27+CD28+), EM2 (CD27+CD28−), EM3 (CD27−CD28−) and 
EM4(CD27−CD28+) On this basis our cells would fall into the EM2 subset which they 
describe as producing characteristic effector mediators. The late-stage effector CD27-
CD28- group are further differentiated and have undergone further rounds of division 
than the CD27+CD28- group.  
 
CD44 is a molecule that is expressed at low levels on naïve T cells and upregulated in 
response to antigen exposure. Compared with naïve levels we observed an 
approximate tripling in the expression of CD44 in CD8+ T cells in response to 
priming with OVA-loaded GMDC. The response to oxidised lysate-loaded GMDC 
generated similar levels of CD44 to the OVA-primed cells in two out of three 
experiments. No differences were observed between the GMDC and GMDC+B cell-
primed groups. 
 
When assessing the functionality of the CD62L molecule, Gattinoni and colleagues 
reported that CD62LHI subset had superior anti-tumour properties in vivo compared to 
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the CD62LLO subset69. Interestingly, CD62L positivity returned an opposite trend to 
that of CD44, with OVA-, ox-L+GMDC- and ox-L+GMDC+B cell-primed T cells 
displaying lower levels than CD8+ T cells primed by other APCs. And in bi-variate 
CD44+CD62L analysis the GMDC+OVA-, GMDC+ox-L- and GMDC+Bc+ox-L-
primed CD8+ T cells had lower percentages of double positive cells compared to cells 
primed with M1 MΦs or the other APCs or APC combinations. Thus we were able to 
successfully generate CD8+ TEM cells, but fewer TCM. However, in the GMDC and 
GMDC+B cell-primed groups the percentage of naïve or TSCM(CD62L+CD44-) cells 
was also lower (Figure 60, Figure 61), suggesting that the GMDC and GMDC+B cell 
combination were able to activate more T cells in response to lysate antigens. In 
addition CD62L+ cells are classified as early effector cells, as opposed to the effector 
cells which lose CD62L expression69, therefore it may be that these cells retained an 
early effector phenotype such as have been described as being more effective in 
ACT109,218,219. The lower percentages of TCM generated by the GMDC and GMDC+B 
cell combination, which primed superior CD8+ T cell responses, may reflect higher 
levels of IL-2 production in these co-cultures, however IL-2 was not measured. 
 
Upregulation of PD-1 would not have been an unexpected response to the ‘self-
antigens’ found in the lysate since PD-1 upregulation is a means of regulating 
autoimmune responses and promoting self-tolerance. However no increases in PD-1 
were observed on CD8+ T cells in response to ox-L (Appendix 1, Supplementary 
Figure 33) and overall levels of PD-1 remained <3%, indicating that priming with 
oxidized lysate was not inducing significant levels of T cell exhaustion. 
 
No upregulation of CD122 was observed in any lysate-primed CD8+ T cells. The lack 
of CD122 was of some concern given that CD122 upregulation should be observed on 
TEFF and TCM cells, thus its absence implies lack of differentiation. Although CD122 
upregulation is transient on TEFF therefore its lack may be due to the timing of the 
observation. CD8+CD122+PD-1+ cells have been reported to be TREGs, whereas 
CD8+CD122+PD-1- cells were true memory cells220,221. Thus despite the lack of 
CD122, the absence of PD-1 on these lysate-primed cells points to a lack of 
regulatory function, which would be a desireable feature in cells destined for ACT.  
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Likewise, no upregulation of the IL-7 receptor CD127 was observed, suggesting a 
lack of memory phenotype. Sensitivity to IL-7 and IL-2 instills in TCM a greater 
capacity than TEM to persist in vivo and a greater proliferative potential, thus rendering 
them more efficient mediators in anti-tumour immunity. CD8+CD127-/LO cells have 
been assigned to the short-lived effector category222. Thus the lack of CD127 was 
concerning due to its implications of IL-7 insensitivity in these cells, which implies 
reduced persistence and memory differentiation in vivo.  
 
Overall these data demonstrated that priming CD8+ T cells with undefined tumour 
antigens in the form of oxidized tumour lysate leads to the formation of T cells with 
an appropriate phenotype for use in ACT for cancer. 
 
With regards to the aims of this chapter, these results established that when oxidized 
lysate is used to prime CD8+ T cells, the GMDC+B cell combination resulted in 
significantly greater T cell proliferation than GMDC alone. No statistically significant 
increases in IFN-γ, or TNF-α or IL-10, were observed in CD8+ T cells primed with 
soluble or oxidised lysate-loaded GMDC+B cell compared to GMDC alone. Less IL-
12 was measured in the GMDC and GMDC+B cell-primed groups compared to other 
APC-primed T cells and the GMDC and GMDC+B cell-primed CD8+ T cells also 
clustered together in terms of their TCM and TEM phenotypes at Day 10.  
 
Taken together these data supported our hypothesis in that the combination of a 
GMDC and a B cell might represent an enhanced method of priming CD8+ T cells 
with oxidized lysate antigens, We therefore examined whether these enhancements 
would translate into an improved effector function by consequently examining the in 
vivo cytotoxic capacity of these cells. 
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Cytotoxic Function of  
Lysate-Primed T cells 
5.1 Introduction 
Adoptive cell therapy with activated T cells has proven to be the most promising 
approach for the treatment of advanced melanoma1–8. In the clinic, the capacity of 
tumour-specific cells to release IFN-γ and to kill the patients’ tumor cells in vitro 
have been the primary criteria used to select cells for adoptive transfer to cancer 
patients9–11. While some clinical success has been reported with the use of these 
cells12,13, an association between immune assay response and patient antitumour 
response has not been clearly established for most current in vitro measurements of 
cellular immune responses14,15. This could be due to the use of peripheral blood T 
cells, which may not be the optimal source of TAA-reactive T cells, since cytolytic 
CTLs in peripheral blood are rare and require multiple rounds of expansion prior to 
lysis testing which may introduce artefacts14,16,17. In one study regression was observed 
in two patients in the absence of in vitro CTL lysis14,18, thus there remains a 
disconnect between the in vitro capacities of tumour-specific T cells and their in vivo 
efficacy. 
 
An inverse relationship between in vitro effector function and in vivo antitumor 
efficacy has been noted in several studies9,11,19–21 and retrospective analyses of ACT in 
melanoma patients demonstrate that in vivo effectiveness is not predicted by these in 
vitro criteria. Objective clinical responses are not always observed after adoptive 
transfer of IFN-γ producing, cytolytic tumor-specific CD8+ lymphocytes11,19,20. 
Gattinoni notes that “Specifically IFN-γ release and cytotoxicity 
were negatively correlated with in vivo antitumor efficacy”9. We had observed IFN-γ 
production in our lysate-primed T cells and therefore wished to know if these in vitro 
capabilities would transfer to a tumour antigen-specific response in vivo. 
 
Activated CD4+ and CD8+ T cells are essential to the regression of established 
cancers, whether individually, or in concert. Both CD4+ and CD8+ CTLs display 
direct and indirect cytotoxic functions. Clinical work using APC-activated T cells has 
5 
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focused largely on the use of DCs as the APC and tumour associated peptides as the 
source of antigen. A number of clinical trials have been conducted, in various cancer 
types, using undefined antigens in the form of tumour lysate, all utilising a DC as the 
APC22–32. While B cells are entering the clinic as a viable alternative APC to DCs33, 
we are not aware of any clinical trials that have utilized B cells or MΦs to present 
lysate antigens to T cells. 
 
We had identified that our lysate-primed CD8+ T cells were able to proliferate in 
response to the presentation of oxidised lysate by GMDC+B cells. We had also 
demonstrated that lysate antigen-primed CD8+ T cells produced IFN-γ, particularly in 
response to priming by GMDC or GMDC+B cell. Oxidised lysate-primed CD8+ T 
cells also displayed TEM and TCM phenotypes in varying proportions, according to the 
APC(s) that had presented the lysate antigens. Thus these lysate antigen-primed T 
cells displayed the potential for some clonal expansion, and cytotoxic functions based 
on their phenotype and ability to produce IFN-γ. It has been observed in a murine 
adoptive cell therapy model that more-differentiated cells are less effective in vivo9 so 
we were interested to assess the in vivo effectiveness of our lysate-primed cells. 
 
Since in vitro results do not necessarily reflect what occurs in vivo we examined 
whether our IFN-γ-producing TEM and TCM cells would deliver cytolytic functions in 
vivo by measuring the ability of lysate-primed T cells to lyse peptide-pulsed target 
cells in vivo.  
 
Work in our laboratory34 and others has demonstrated the importance of the TCM 
phenotype, particularly CD62L positivity, in the anti-cancer response35–37. A study to 
identify the characteristics of transferred CD8+ T lymphocytes that are effective in 
vivo versus cells with impaired in vivo function identified that less differentiated, 
early effector T cells proliferated more vigorously both in vitro and in vivo9. However, 
while both CD62LLO and CD62LHI cells both proliferated well in vitro, only the 
CD62LHI group produced superior in vivo antitumor results. These cells preferentially 
homed to the lymph nodes, where it was demonstrated that they interacted with 
tumour-antigen-bearing APC to bring about eradication of established tumours.  
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It had been proposed that TCM and TEM are not necessarily discrete subsets, but rather 
form part of a linear differentiation continuum that proceeds from naïve to effector to 
TEM to TCM37. However an interesting study published in 2015 that analysed the 
transcriptional profiles of differentiating T cells revealed an unexpected step-wise 
progression that followed a TN è TCM è TEM è TEFF pattern38. Rather than more 
differentiated, this puts TCM cells as less-differentiated cells than TEFF and may help to 
explain their superior abilities in ACT35, particularly in light of Gattinoni’s 
observation of an inverse correlation between in vitro full effector differentiation and 
in vivo effectiveness9. Having identified that the lysate-primed CD8+ T cells 
displayed TCM and TEM subpopulations we proceeded to assess their effector functions.  
 
We investigated the ability of anti-OVA CD4+ or CD8+ T cells that had been primed 
with lysate-loaded GMDC or GMDC+B cell to kill OVA peptide-loaded target cells 
in vivo after adoptive transfer into wild type mice. At the time of conducting the in 
vivo cytotoxicity assays M1 MΦs, along with the combination of DC+MΦ, Bc+MΦ 
and the triple combination, had been eliminated as being less effective than a GMDC 
alone or the GMDC+B cell combination and therefore these APCs and APC 
combinations were not tested. 
 
The optimal characteristics of the ideal T cell for ACT for cancer remain to be defined 
and we were interested to examine whether or not the CD62L status, or TEM to TCM 
ratio, of our lysate-primed T cells prior to injection correlated with in vivo killing, 






The aim of the studies in this chapter was to assess the in vivo functional capacity of 
CD8+ T cells primed with lysate-derived tumour antigens. The ex vivo T cell response 
to re-stimulation with a lysate-loaded GMDC or GMDC+B cell was also examined. 
We hypothesized that priming T cells with GMDC+B cell would result in enhanced in 
vivo cytotoxicity of target cells compared with a GMDC alone. We also hypothesized 
that re-stimulating ex vivo tumour-draining lymph node-derived cells with the 
combination of GMDC+B cell would result in enhanced expansion of these cells 
compared with a GMDC alone.  
 
To address these hypotheses the following objectives were undertaken: 
1. Determine the in vivo cytotoxic response of adoptively transferred T cells 
primed by lysate-loaded GMDC versus GMDC+B cell  
 
2. Determine the fold expansion and T cell phenotype that results from 
restimulating ex vivo tumour-draining lymph node-derived cells with GMDC 




5.3.1 Adoptively Transferred T Cells Primed With Lysate-Loaded 
Dendritic Cells+B cells Display Enhanced In Vivo Cytotoxicity 
Our in vitro results indicated that the GMDC+B cell combination might yield a 
superior anti-tumor response based on slight increases in proliferation and IFN-γ 
production, but not in vitro cytotoxicity (Appendix 1, Supplementary Figures 31, 32). 
Therefore the GMDC+B cell combination was compared against GMDC alone in the 
in vivo cytotoxicity response. The effector T cells were generated as usual by co-
culture with lysate-loaded GMDC or GMDC+B cell. Target cells were pulsed with 
SIINFEKL or OVA323-339 peptide, or left unpulsed as a control against non-specific 
killing. Peptide-loaded target cells were stained with fluorescent dyes and i.v. injected 
into wild type mice. The following day a 50/50 mix of CD4+ and CD8+ effector T 
cells primed by either soluble lysate- or oxidised lysate-loaded GMDCs or lysate-
loaded GMDC+B cells was adoptively transferred by i.v. injection. Twenty-four 
hours after transfer the spleens were harvested and killing of the peptide-loaded 
targets assessed by Flow Cytometry. 
 
Figure 63 shows the gating strategy and raw phenotype data of GMDC+B cell soluble 
lysate, GMDC oxidised lysate and GMDC+B cell oxidised lysate-primed CD8+ T 
cells. Raw data for CD4+ T cells is found in Appendix 1, Supplementary Figure 33. 
In the first experiment sufficient cells were generated for injection only and not for 
phenotyping. In the second experiment sufficient cells were generated by 
GMDC+soluble lysate-priming for injection however insufficient cells remained for 
assessment of T cell phenotype therefore T cell phenotype data is only available for 
the GMDC+Bc+s-L, GMDC+ox-L and GMDC+Bc+ox-L groups (Figure 63). 
Summary data is shown in Appendix 1, Supplementary Figure 34. T cell viability in 
the GMDC oxidised lysate groups was consistently greater than 40% whereas 
viability in the GMDC+B cell groups was considerably lower at 20-30%. The 
phenotype of these cells was only measured once and so these results are discussed in 
Appendix 1 Section 7.33. 
  
 shows the results of CD8+ T cell-mediated lysis from two independent in vivo 
cytotoxicity experiments. In both experiments, 100% lysis was achieved in the OVA-
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primed T cells. Unexpectedly, in both experiments, 100% lysis also occurred in the 
mice that were injected with PBS instead of effector cells as a negative control. In the 
APC-primed T cells identical killing trends were observed in both experiments.  
 
Twenty-four hours after transfer of targets 49% of SIINFEKL-pulsed cells were 
eliminated by GMDC+soluble lysate-primed CD8+ T cells. The percentage of cells 
lysed increased to 61% for GMDC+Bc+soluble lysate-primed CD8+ T cells. Lysis 
was higher again in the GMDC+oxidised lysate-primed CD8+ T cells (84%), and the 
greatest cell lysis, 95%, was achieved in the GMDC+Bc+oxidised lysate-primed 
group. 
 
Transferred CD4+ effector cells appeared to elicit no killing in either experiment 
(Appendix 1, Supplementary Figure 35). Unexpectedly the number of unpulsed cells 
was less than the number of OVA323-339 peptide-pulsed cells in both experiments, 
which resulted in negative lysis values, a biological impossibility. The trend of fewer 
target cells in the GMDC+B cell primed CD4+ groups compared to the GMDC 
groups was the same as CD8+ T cells but does not alter the fact that these results do 
not demonstrate killing by CD4+ T cells due to the negative values. 
 
Negative binomial regression, which accounts for an over-dispersed Poisson 
distribution was used to compare the number of live SIIN and OVA-323-339-pulsed cells 
that remained after 24 hours in vivo in mice that had received adoptively transferred 
lysate-primed effector T cells. The model included terms for the groups and adjusted 
for the number of cells collected. Although no adjustment was made for multiple 
comparisons it should be noted that all the p values were <0.001 therefore these 





   
 304 
   
Figure 62 Gating strategy & raw data showing phenotype of adoptively transferred T cells. Immature Day 
6 C57/BL6 BMDC, +/- spleen-derived B cells, were pulsed overnight with whole OVA protein (50 µg/mL) and 
soluble lysate or Oxidised lysate (1:1 ratio tumor cell to APC). The following day CD4+ and CD8+ T cells were 
added to the APCs (10:1) and co-cultured for 3 or 4 days. Cells were harvested for injection into CD57BL/6 
mice and surplus cells were analysed for phenotype by Flow Cytometry. Cells were labeled with FVS450 (BD 
Biosciences) dead cell exclusion dye and mABs against CD3, CD4, CD8, CCR7, CD154 (CTLA4), CD27, 
CD28, CD44, CD62L, CD122, CD127 and PD-1. Cells were fixed in 4% paraformaldehyde and stored at 4°C 
overnight prior to collection on a Gallios. Data shown is from 1 of 2 experiments. A) T cells primed with 
GMDC+B cell+soluble lysate B) T cells primed with GMDC+oxidised lysate C) T cells primed with GMDC+B 





Figure 63 Gating strategy and raw data showing loss of SIIN-pulsed T cells in in vivo cytotoxicity assays. Day 6 
C57BL/6 GMDC and spleen-derived B cells were prepared as previously described. APCs were pulsed overnight with whole 
OVA protein (50 µg/mL) and soluble or oxidised lysate (1:1 ratio tumor cell to APC). The following day CD4+ and CD8+ T 
cells were added to the APCs (10:1) and co-cultured for 3 days. Effector cells were resuspended at 1 x 107 c/mL in sterile 
DPBS and 200 μL injected per mouse. The following day C57BL/6 splenocytes were pulsed for 3 hours with SIINFEKL or 
OVA323-339 peptide or left unpulsed. The 3 groups of target cells were dyed with CFSEHI (25 μM), CFSELO (2.5 μM) and 
VPD450 (10 μM) respectively. Dye-labelled cells were resuspended at 50 e 6 c/mL in DPBS and equal volumes of the target 
populations mixed together. 200 μL per mouse (10 e 6 target cells; 3.33 e 6 per target per mouse) were i.v. injected. 24-hours 
after adoptive transfer mice were sacrificed and splenocytes prepared for acquisition by Flow Cytometry. Cells were labeled 
with live/dead NIR dead cell exclusion dye, fixed in 4% paraformaldehyde and stored at 4°C overnight prior to collection on 







































In Vivo Cytotoxicity SIINFEKL-Peptide Pulsed Cells
0.1262
**
Results of 2 separate experiments. Error bars = s.e.m. 
Stats: Student's Unpaired t test; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001
***
****
Figure 64 Priming T cells with Oxidised lysate results in greater in vivo cytotoxicity by CD8+ effector 
cells than soluble lysate and the combination of lysate-loaded GMDC+B cell is superior to GMDC 
alone. Immatur  Day 6 C57/BL6 BMDC, +/- spleen-derived B cells, were pulsed overnight with whole 
OVA protein (50 µg/mL) and soluble lysate or oxidised lysate (1:1 ratio tumor cell to APC). The following 
day CD4+ and CD8+ T cells were added to the APCs (10:1) and co-cultured for 3 or 4 days. Lysate-primed 
effector T cells were i.v. injected into CD57BL/6 mice. The following day C57BL/6 target splenocytes 
were incubated with SIINFEKL peptide (1 μg/mL), OVA323-339 peptide (5 μg/mL), or left unpulsed. Target 
cells were labeled 25 μM CFSE (CFSEHI), 2.5 μM CFSE (CFSELO) or 10 μM VPD450 and mixed together 
for injection into recipient mice (1/3 each SIIN-pulsed, OVA323-339-pulsed and unpulsed). Legend: each 
symbol represents a single mouse; (n = 3-7 per group). **p <0.01, ***p<0.001 and **** P <0.0001 
(Negative binomial regression). Data are from 2 independent experiments. Error bars = s.e.m.  
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5.3.2 Ex Vivo Re-stimulation of Tumour Draining Lymph Node Cells 
The final data of this thesis pertains to the attempt to restimulate cells isolated from 
the tumour draining lymph nodes (tu dLN) of B16.OVA tumour-bearing mice. Single 
cell suspensions were created from the dLNs and the cells frozen for later use. 
Cryopreserved cells were recovered from liquid nitrogen storage and allowed to 
recover overnight prior to co-culture with lysate-loaded GMDC or GMDC+B cells.  
In addition to IL-2, IL-7, IL-15 and IL-21, anti-CD28 was included in the medium in 
an attempt to augment the tumour-specific T cells’ fold expansion. Including α-CD28 
with the T cells provides extra costimulation for the antigen-specific T cells but will 
not drive non-specific proliferation, as α-CD3 will do.  
 
We also experimented with the use of mABs against CTLA-4 and PD-1 as an 
indicator of whether these checkpoint inhibitors might be useful in augmenting the 
response of ex vivo-derived cells restimulated with lysate tumour antigens. Those 
observations are discussed in Appendix 1, Section 7.33. 
 
Cell conditioned media was analysed by ELISA for the presence of IFN-γ and IL-12. 
Consistent with the in vitro results in Chapter 4 (Chapter 4, Figures 16 and 17), these 
preliminary observations showed a pattern of increased IFN-γ (Figure 65A) and 
decreased IL-12 (Figure 8B) in the GMDC+B cell groups compared to the GMDC-
primed cells.   
 
In cells treated with checkpoint blockade mABs, cytokine production was strongly 
decreased in mAB-treated groups compared with cells not exposed to mABs (Figure 
8C). 
 
Due to the low numbers of cells that were recovered we were unable to test more than 
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Figure 65 IFN-γ  production is increased, while IL-12 production is decreased, in one set of tumour 
draining lymph node cultures re-stimulated with oxidised lysate-loaded GMDC+B cell. Wild type 
C57BL/6 mice were injected with 50,000 B16.OVA cells and sacrificed when tumours reached 150 mm2. 
Tumour draining lymph nodes were excised, single cell suspensions prepared and the cells cryopreserved 
for future use. Cryopreserved cells were retrieved from liquid nitrogen, thawed and allowed to rest 
overnight prior to adding to lysate-loaded APCs at a ratio of 10:1, +/- α-PD-1 and α-CTLA-4 as indicated. 
Cells were cultured for 10 days and fed no less than every other day. Cell conditioned media were 
harvested, stored at -20° and analysed by anti-IFN-γ and anti-IL-12 ELISA. Insufficient cells were 
obtained to test more than 2 conditions.in any given experiment. GMDC+s-L and GMDC+Bc+s-L were 
compared in one experiment. GMDC+ox-L and GMDC+Bc+ox-L were compared in one experiment. Each 
column in the lower graph shows the result from one experiment. 
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5.4 Discussion 
5.4.1 In vivo Cytotoxicity  
The in vitro data discussed in Chapter 4 demonstrated that the combination of 
GMDC+B cell resulted in enhanced T cell proliferation and IFN-γ production when 
compared with GMDC alone – particularly in oxidised lysate-primed CD8+ T cell 
responses. Our in vivo cytotoxicity data corroborated those results with highly 
significant improvements in target cell lysis by CD8+ T cells primed with GMDC+B 
cell as opposed to a GMDC alone. In line with Chiang’s findings39–41, oxidized lysate 
also proved more effective as an antigen source than soluble fraction lysate in vivo. 
However, our data demonstrated that the T cell response to oxidized lysate was 
enhanced to an even greater degree when presented by the combination of GMDC+B 
cell.  
 
In order for self-antigens to be used as anti-tumour targets tolerance must be 
overcome. Oxidation provides an effective means of increasing the immunogenicity 
of poorly immunogenic molecules40,42–45. It is interesting to note that the production of 
reactive oxygen species, including hypochlorous acid and hydrogen peroxide, by 
neutrophils is one cooperative strategy used between the innate and adaptive immune 
systems44.  
 
IL-12 production by DCs has been used as a measure of improved immunogenicity of 
oxidized tumour lysate46. In this study IL-12 production in lysate-loaded APC cell 
cultures was noted to increase in response to oxidised lysate. However in APC-T cell 
cultures the IL-12 levels decreased in response to oxidized lysate compared to the 
soluble fraction of freeze-thaw lysate. Nonetheless, in vivo the oxidized lysate-primed 
CD8+ T cells outperformed CD8+ T cells primed with soluble fraction lysate (Figure 
64Figure 2). This result is in line with another study which also found a negative 
correlation between the IL-12 response and the in vivo anti-tumor response when 
apoptotic-necrotic lysate-loaded DC were used as the APC47. Thus increased IL-12 
does not always correspond to an improved anti-tumor response and more must be 
done to understand this mechanism of action. The authors of the aforementioned 
study concluded that the anti-tumour response was unconnected to the IL-12-
dependent mechanisms and that therefore other non-DC immune cells in the starting 
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bone marrow-derived, GM-CSF-stimulated APC population were involved. In this 
present study I hypothesise that the reduced levels of IL-12 may be due to the IL-12 
being consumed by the more activated T cells in the oxidised lysate groups.  
 
Work by Constant et al provides one possible explanation as to why the GMDCs in 
this study could competently prime CD4+ and CD8+ T cells with peptides, but were 
less efficient with lysate, which comprises numerous different proteins.  They 
demonstrated that the type of antigen, peptide versus protein, was important. DCs can 
efficiently present peptide to naïve CD4+ T cells but are poor presenters of the same 
antigen in its protein form48,49. Using μMT KO mice, which lack B cells, they showed 
impaired priming against protein, but not peptide antigens. The presence of B cells 
was required for DCs to prime with protein antigen. In vivo uptake experiments 
demonstrated preferential uptake of peptide antigens by DC, while B cells took up 
protein antigens.  Both DC and activated B cells express the costimulatory molecules 
essential for effective T cell priming and in vivo protein-primed B cells showed 
upregulation of CD80 and CD8648. We did not observe upregulation of these 
molecules in response to in vitro loading with lysates. However our CD80, CD86 data 
are in vitro results and may not reflect the in vivo situation as studied by Constant et 
al. 
 
Kleindienst and Brocker50 used a transgenic mouse model in which B cells or DCs, or 
both, expressed MHC Class II. They showed that DCs alone are sufficient to prime 
naïve T cells in vivo after immunization with a peptide antigen. Interestingly, on their 
own neither naïve nor activated B cells could activate naïve CD4+ T cells, however if 
DCs were present B cells supported and enhanced CD4+ T cell priming. In our hands 
there was a significant increase in the MFI of MHC-II on both B cells and GMDC in 
response to soluble lysate but only B cells upregulated MHC-II in response to 
oxidised lysate. However the absolute MFI values were greater on B cells than 
GMDC, which reflects an increased capacity for presenting lysate proteins to naïve 
CD4+ T cells.  
 
B cells express clonal, antigen-specific surface immunoglobulins (Ig) that stimulate 
antigen uptake51–54. Antigen taken up by B cell surface Ig is processed and presented 
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on MHC Class II55. While early studies indicated that B cells induced TH2 responses 
and did not activate TH1 cells56–60 Shirota et al argued showed that B cells could 
efficiently take up and present peptides to TH cells, as long as the antigen was 
conjugated to CpG. In addition CpG-activated B cells produced IL-12 in quantities 
sufficient to drive a TH1 response61. Importantly for this thesis, Shirota and colleagues 
demonstrated that CpG-activated B cells achieved this irrespective of the antigen 
specificity of the surface Ig. In other words, the antigen uptake occurred in an antigen 
non-specific manner, a feature that was previously believed to be a characteristic of 
DCs and MΦs.  
 
It has been demonstrated that antigen-specific B cells can cross-present antigen62,63. In 
this study we used B cells that were not specific for the model antigen OVA, which 
begs the question, how can these non-OVA-specific B cells enhance the CD8+ T cell 
response? The non-classical MHC-I, which is conserved in mice64, may provide the 
answer. In 2013 Goodridge and colleagues described a novel extracellular cross-
presentation mechanism, which may explain the ability of non-professional APCs to 
cross-present MHC-I-restricted peptides to CTLs, despite their reduced intracellular 
cross-presentation machinery compared to DCs65. During presentation of endogenous 
antigen and the cross presentation of exogenous antigen acquired proteins are 
degraded into 8-10 amino acid sequences in the proteasome. In the ER these epitopes 
are loaded onto MHC-I by the chaperones TAP and tapasin for delivery to the plasma 
membrane, where they can be recognised by CTL TCRs. It was previously believed 
that MHC-I molecules required peptide binding to form stable complexes for delivery 
to the surface. However it is now known that during activation lymphoid and myeloid 
cells also upregulate empty MHC-I in an open conformation (MHC-I OC)64,66–68. In 
addition HLA-F, one of the non-classical MHC-molecules in humans, is upregulated 
in a peptide-free format, and this open conformation HLA-F binds MHC-I OC on 
activated lymphocytes and monocytes66,67. They discovered that HLF-F assists loading 
of peptides into MHC-I in B cells. HLA-F and MHC-I-expressing B cells took up 
native proteins and polypeptides. HLA-F and MHC-I dissociated in the lysosome 
where further protein processing and binding of peptides to MHC-I occurred. Finally, 
on presentation of viral or tumour antigen by these B cells, CTLs lysed the antigen-
specific B cells. Importantly TAP and tapasin were not required in this pathway, 
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which also exists in activated HLA-F-expressing CTLs, and presents the intriguing 
notion of self-presentation in inflammatory settings68. Interestingly the external 
binding to HLA-F and MHC-I required denatured protein, such as may be found in 
oxidized lysate. HLA-F has a murine ortholog meaning that this scenario is not 
impossible in mice also. 
 
Wykes et al and others have also demonstrated that DC can transfer native antigen to 
naïve B cells to stimulate antibody production in T-dependent and T-independent 
manners69–71. Kushnir et al showed initiation of DC-B cell clusters within 1 hour 
which persisted for up to 48 hours indicative of significant inter-cellular interactions72. 
Wykes points out that since DCs can be a source of antigen for B cells, which can 
then upregulate CD40L, and given that DCs and B cells can form stable clusters, the 
B cells are likely to receive CD40 cross-talk from the DCs. In addition, since DCs can 
induce B cell proliferation independent of CD40, Wykes proposed that this would 
result in B cell clonal expansion prior to T cell interaction and increase the likelihood 
that antigen-specific B cells would encounter an antigen-specific T cell73,74. In the 
context of this study this mechanism seems less likely since B cells and DCs formed 
less than 10% of the 72-hour proliferation population, thus little B cell expansion had 
occurred. 
 
Work by Gattinoni et al9 addressed the issue that is currently faced in the clinic, 
namely, that whereas less-differentiated T cells are more effective in vivo the ex vivo 
expansion of small precursor frequencies into high numbers of tumour-specific T cells 
for adoptive transfer necessarily forces T cell differentiation. By comparing T cells 
expanded in the presence of IL-2 with T cells expanded in the presence of IL-15 they 
observed less differentiation and superior in vivo anti-tumour efficacy in the IL-15-
expanded group. The observation that less-differentiated effector cells are more 
effective in the anti-tumour response has been corroborated by work in our 
laboratory34, therefore we used Day 4 primed T cells for the first in vivo cytotoxicity 
assay and Day 3 cells for the second assay. We expanded our lysate-loaded APC-
primed T cells in the presence of IL-2 for the first 24 hours only, but retained IL-15 in 
the cell culture medium until the cells were harvested for transfer. The phenotype of 
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these cells resembled a mix of early effector and effector cells, with relatively low 
percentages of TCM.  
 
We used Day 3 lysate-primed T cells for the second assay due to the significant 
reduction in T cell numbers after longer periods in culture, which resulted in 
insufficient cell numbers for injection. Previous work has demonstrated that memory-
like T cells develop 1 day after antigen encounter, but optimally after 3 days75. 
Therefore in order to have sufficient quantities of cells to inject we reasoned that Day 
3 cells would suffice.  
 
Work in the Busch lab has demonstrated that transfer of just one antigen-specific 
naïve CD8+ T cell resulted in retrieval of clonally expanded cells following 
immunization76. Taken together these data from the Busch76 and Restifo9 labs argue 
that the extremely high numbers of T cells currently utilized in ACT may not 
necessarily be required, and that fewer, less-differentiated, tumour-specific T cells 
may be sufficient to achieve tumour regression. Though whether fewer lysate-primed 
T cells would be sufficient to overcome immune suppression in cancer-bearing mice 
or cancer patients remains to be tested in animal models, or in the clinic. 
 
Insufficient cells remained for phenotyping in the first in vivo assay therefore 
phenotype data only exists for the cells used in the second in vivo assay. While this 
single observation can be commented on, no conclusions can be drawn and therefore 
these results are discussed in Appendix 1, Section 8.35. However it is interesting to 
compare these 3 day-primed cells with the 10-day primed cells. Only slight 
differences were observed between the phenotypes of T cells generated by priming 
with GMDC+Bc+soluble lysate, GMDC+oxidised lysate and GMDC+Bc+oxidised 
lysate (Figure 62). Our cells did not fall neatly into the definitions outlined by Restifo 
et al9.  Instead of an early effector, effector or late effector phenotype our cell 
populations displayed a phenotype that demonstrated a mix of CD62LHI (indicative of 
naïve or TCM) CCR7LO (indicative of early effector or effector cells) CD27HI (TN to 
early effector). No correlations were observed between CD62L positivity and in vivo 
effectiveness as the difference in the percentage of cells positive for CD62L between 
GMDC+Bc+soluble lysate-primed T cells and GMDC+Bc+oxidised lysate-primed T 
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cells was slight (83 and 77% respectively). No CD62L data exists for T cells primed 
with soluble lysate-loaded GMDC alone as, due to lower numbers in this group these 
cells could only be stained with two of three panels. 
 
CD44 is an indicative marker for effector memory T cells and is expressed at a lower 
level on naïve T cells compared to memory T cells77,78. Cells that are double positive 
for CD62L and CD44 are not addressed in Restifo’s schematic, however this 
combination is also used to identify TCM cells. The proportion of TCM between 
GMDC+Bc+soluble lysate and GMDC+Bc+oxidised lysate was very similar (26 and 
29% respectively) and these small differences are unlikely to be statistically 
significant. Tumour trials would also be required to ascertain if these differences have 
a significant impact on T cell ability to control tumour growth. However the three 
populations resulting from bi-variate analysis of CD44 and CD62L point toward a 
mix of TEM, TCM, the recently named memory stem cells (TSCM)85,86 and early effectors.  
The left to right spread of CD62L positivity in particular points to a mix of TSCM and 
early effectors.  
 
CD127, also known as IL-7 receptor α (IL-7Rα), is expressed by most resting T cells 
and downregulated following T cell activation. Long-living T cells are characterized 
by constitutive CD127 expression79,80. The CD127HIGH population has been shown in 
adoptive cell transfer experiments to represent long living T central memory (TCM) 
cells, especially when combined with CD62LHIGH status88. The combination of CD122 
and CD127 are used to assess survival potential and responsiveness of cells to 
homeostatic cytokine signaling in vivo. Cells that are negative for CD122 display 
unresponsiveness to IL-2, which is indicative of reduced long-term persistence in 
vivo. In the same manner cells that are negative for CD127 display unresponsiveness 
to IL-7, which is also indicative of reduced long-term persistence in vivo. Our lysate-
primed cells were CD127-CD122-, which suggests that they might not be ideal 
candidates for ACT. Their usefulness would need to be further analysed by 
assessment of in vivo persistence after ACT.  
 
Finally, overexpression of inhibitory receptors such as PD-1 is one indicator of T cell 
exhaustion (reviewed in 81) and high PD-1 expression correlates with impaired T cell 
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function82. PD-1 negativity indicates that these cells do not appear to be exhausted by 
priming with lysates. Although one study has shown that very low PD-1 expression 
can be sufficient to inhibit T cell expansion, TNF-α and IL-2 production81. 
 
As a final comment, in both in vivo experiments, while 100% lysis was achieved in 
the OVA-primed T cells, 100% lysis also occurred in the mice that were treated with 
PBS. Therefore these results remain preliminary until minimal lysis can be achieved 
in PBS-treated negative controls. However the fact that a treatment-dependent result, 
as opposed to 100% lysis, was observed in the four APC-primed T cell groups, points 
to a technical error rather than a failure of the assay. We are yet to ascertain the source 
of this technical error. 
5.4.3 Ex Vivo Re-stimulation of Tumour Draining Lymph Node Cells 
While the analysis of in vitro-priming of T cells by various APCs can shed light on 
whether or not multiple APCs may play a role in in vivo priming, ultimately clinicians 
have no control over this aspect of their patients’ treatment.  Patients arrive at the 
clinic with cancer-primed T cells that are ineffective. Thus the clinician’s role is to re-
activate these T cells against the patients’ tumour, or to re-educate them to recognise 
the patient’s tumour. While our studies are still far from the clinic setting, re-
stimulation of ex vivo-derived tumour draining lymph node cells is a more clinically 
relevant scenario. 
 
The conditions under which the ex vivo-derived cells were cultured are clearly still far 
from optimal as evidenced by the low fold expansion and poor viability of these cells 
after 10 days in culture. An improved approach may be to attempt to coordinate the 
retrieval of tumour draining lymph node cells with the culture of the APCs, such that 
freshly isolated lymph node cells may be added directly to lysate-loaded APCs 
without the cryopreservation step. This will result in higher starting lymph node cell 
numbers, which will allow analysis of multiple parameters, instead of one parameter 
at a time. Alternatively, a study discovered after these experiments were completed, 
utilised anti-CD3 and anti-CD40 mABs to stimulate the T cells, B cells and DCs in 
the ex vivo tumour dLN cells92. Removal of either B cells or DCs significantly 
diminished the anti-tumour responses of the tumour dLN cells highlighting the 
importance of antigen presentation and CD40 stimulation. We used anti-CD28 only in 
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our tumour dLN cells and an improvement would be to compare the response of both 
anti-CD40 and anti-CD28 engagement.  
 
While acknowledging the highly preliminary nature of these data, an interesting 
pattern of increased IFN-γ and reduced IL-12 production was observed in these cells 
when re-stimulated with GMDC+B cell (Figure 65). This result correlates with the 
pattern of increased IFN-γ and reduced IL-12 observed in lysate-loaded GMDC+B 
cell T cell co-cultures. These data contrast with that of Li et al who observed 
increased IL-12, and inhibited IL-4, in their anti-CD3+anti-CD40-stimulated tumour 
dLN cells92. As stated above we would like to repeat these experiments using anti-
CD28 and anti-CD40 to compare the response to anti-CD28 alone and to Li’s anti-
CD3+anti-CD40 combination. 
 
The upregulation of CTLA4 is important in T cell anergy. If the high level of T cell 
death is due to GMDCs killing off self-reactive T cells then blocking T cell inhibition 
with monoclonal antibodies against CTLA4 may result in a reduction of T cell death, 
as well as anergy. Our preliminary attempts to test this theory demonstrated a small 
increase in fold expansion over cells treated with α-PD-1 (Figure 3), and an apparent 
synergy when α-CTLA-4 and α-PD-1 were both used. However, this small 
synergistic increase did not result in greater fold expansion than when cells were 
primed with GMDC+Bc+oxidised lysate+ α-CD28. Therefore these preliminary 
results suggest that the inclusion of α-PD-1 and α-CTLA-4 yield no additional 
benefit. 
 
Taken together these in vitro, in vivo and ex vivo results continue to lend weight to the 
argument for the use of oxidised lysate antigens in stimulating an anti-tumour 
response. They also demonstrate that an improvement in CTL-mediated killing can be 
achieved when CD8+ T cells are primed with lysate-loaded GMDC+B cell as 
opposed to a GMDC alone, particularly oxidized lysate.  
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Discussion of Results & Future 
Directions 
“only a fraction of patients treated with currently available immunotherapies respond to them. The 
challenge now is to figure out how to unleash and strengthen the power of the immune response to turn 
more non-responders into responders” 
AACR 2015 Report, CRI website 
http://cancerresearch.org/news-publications/our-blog/april-2015/aacr-2015-report-from-day-5 
6.1 Results 
The overarching aim of this thesis was to enhance adoptive cell therapy for cancer. 
DCs are currently in clinical use for ACT for cancer, however despite some notable 
successes, robust and consistent tumour regressions remain elusive. Thus some 
investigators are turning to alternative APCs as potential adjuncts in cancer 
immunotherapy. Several populations of APC can individually activate an anti-tumour 
T cell response, but they may also act in concert to achieve this. Therefore we 
examined the three professional APCs, DCs, MΦs and B cells for their ability to 
present lysate tumour antigens to T cells, individually and in combination. 
 
Previous work with soluble freeze-thaw lysate had yielded low T cell proliferation. 
We therefore manipulated the potentially immunosuppressive lysate to make the 
antigens more immunogenic and compared the APC response to loading with soluble 
and oxidised lysate. GMDCs upregulated CD40 in response to oxidised lysate, while 
B cells upregulated CD86. MHC-II was only upregulated on B cells in response to 
LPS&CpG rather than lysate. 
  
We hypothesised that the use of two or more APC would yield an augmented T cell 
response to lysate tumour antigens. We used a model system in which B16 tumour 
cells have been engineered to express ovalbumin. The high frequency of antigen-
specific T cells in this model allows assessment of both MHC Class II-mediated 
CD4+ and MHC Class I-mediated CD8+ T cell responses following priming by 
GMDC,. M1 MΦ and B cells. Following lysate exposure DC upregulated CD40 and 
B cells upregulated CD86. MHC-II was upregulated on B cells in response to 
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LPS&CpG. Combining GMDC+B cells resulted in enhanced IL-12 production after 
oxidised lysate loading. 
 
We next examined whether combining APCs would augment the T cell response to 
presentation of lysate antigen and discovered that the combination of GMDC+B cell 
resulted in increased proliferation and IFN-γ production in CD8+, but not CD4+, T 
cells compared with a GMDC alone. Finally, in vivo cytotoxicity assays demonstrated 
the superior cytotoxicity of CD8+ T cells primed by GMDC+B cells over a GMDC 
alone. 
 
We compared the ability of two kinds of lysate to generate a T cell response and 
found that oxidized lysate resulted in better T cell viability, enhanced CD8+ T cell 
proliferation and in vivo killing compared with soluble lysate, particularly when 
GMDC+B cell presented the oxidised lysate antigens. Oxidised lysate did not increase 
IFN-γ production in CD8+ T cell cultures. 
 
Our results support the hypothesis that different APCs possess different roles in the 
priming of CD8+ T cell responses against lysate tumour antigens and that has 
implications for the design and administration of APC-mediated ACT for cancer. 
6.2 The Problem: DCs Presenting Defined Peptides Do Not 
Consistently Yield Durable T Cell Responses 
The numbers of DCs recovered from cancer patients are lower than from healthy 
volunteers, and monocyte-derived DC generation ex vivo can also be diminished 
(reviewed in1). Removal of primary tumours can result in significant recovery of DC 
numbers2–4, however DCs still only represent less than 1% of circulating leukocytes5. 
Moreover, since ex vivo tumour experienced DC function may be impaired their use is 
avoided by the use of GM-CSF+IL-4 to generate DCs from monocyte precursors. 
However the limited response to monocyte-derived DC-mediated ACT has forced the 
immunotherapy community to re-visit the use of naturally occurring blood DCs6.  
 
Much work has been done showing that the tumour microenvironment can be highly 
immunosuppressive. Cytokines secreted by pancreatic carcinoma cells have resulted 
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in a tolerogenic DC phenotype7 and in melanoma constitutive activation of the B-RAF 
signal path promotes excessive production of the DC suppressing factors IL-10, IL-6 
and VEG-F8. Tumour glycoproteins such as MUC-1 and CEA have been observed to 
interact with DC-SIGN, leading to antigenic retention in early endosomal 
compartments, which inhibited effective processing and presentation9. Additionally, 
MUC-1, a potent chemoattractant for iDC, also suppresses IL-12 production by 
DCs10.  
 
DCs from mice in late stage cancer expressed higher levels of PD-L1 along with high 
arginase activity. These data correlate with DCs observed in human ovarian cancer. 
Tumour-derived PGE2 and mature TGF-β1 induced the up-regulation of PD-L1 in 
immunocompetent DCs causing their T cell suppressive activity. The final sentence of 
Scarlett’s abstract summarises by saying: “… we … show that aggressive cancer 
progression after a comparatively long latency period is primarily driven by the 
mobilization of immunosuppressive microenvironmental leukocytes, rather than loss 
of tumour immunogenicity”11. 
 
Thus, despite the DCs impressive antigen presenting credentials, in the cancer patient 
the growing tumour often negatively impacts this professional APC, which is critical 
to mounting an anti-tumour response, rendering the DC unable to effectively perform 
the task for which it is so exquisitely designed. 
 
6.3 A Potential Solution: Combine GMDC +B cell During Antigen 
Presentation 
B cells possess many of the same biological attributes as DC, including high MHC 
expression and antigen-specific T cell-differentiating cytokine profiles. These reasons, 
along with their relative ease of use makes them an alternative to DCs in 
immunotherapy12,13. Autologous B cells vastly outnumber DCs and can be readily 
isolated from patient blood14, and further expanded by CD40L activation. Monocyte-
differentiated DCs are significantly lower in number than B cells to begin with, and 
are not so easily expanded as required for multiple transfers in therapeutic 
schedules15–17. Reinfused B cells migrate to lymph tissue, the principal site of T cell 
 324 
activation and, depending on their antigenic load, can avoid CTL-mediated 
destruction, which can plague antigen delivery by infused DCs. In the LNs B cells can 
deliver antigen to follicular DCs which in turn present antigen to CD8+ CTLs and TCM 
cells17. Indeed novel ways to enhance antigen-non-specific uptake by B cells are 
already being explored18. 
 
The key finding of this thesis is that the combination of GMDC+B cell yields an 
improved T cell response, in vitro and in vivo, over GMDC alone presenting oxidised 
lysate-derived antigens. DC-B cell cooperation has been observed in other 
investigations. Dubois et al published in vitro evidence in 199719 and 1999 of direct 
DC-B cell CD40L-CD40 interaction20. In 2000 Wyckes and Macpherson showed that 
CD40 on DC was important for B cell survival but not proliferation21. Other studies 
have shown DC-B cell clustering in vivo and that DC can increase B cell proliferation. 
For this reason it was important to show that in the DC+B cell +T cell co-cultures it 
was T cell proliferation that was occurring, not just B cell proliferation. A flow 
cytometric dump channel showed that in most cases less than 10% of the cells in the 
culture were CD11c+ or CD19+ demonstrating that it was T cells and not B cells or 
DCs that were proliferating. 
 
Clinical studies by Nielsen and colleagues have identified that CD20+ TILs with an 
atypical CD27 negative phenotype, in conjunction with CD8+ TILS, correlate with 
favourable prognoses in ovarian cancer22. Interestingly Nielsen’s findings did not 
show a link with increased levels of serum antibodies against tumour antigens, 
indicating this effect was not antibody mediated. This was despite the B cells being of 
the IgG type and therefore having undergone somatic hypermutation and class 
switching. These activated B cells were acting in a manner independent of the 
antibodies they were secreting. While in the Nielsen study patient serum antibodies 
did not correlate with protection, this is not always the case.  
 
Other studies have reported correlations between serum antibody levels and tumour 
responses23. Valmori et al did not directly observe whether or not the B cells and T 
cells interacted, but they did use CpG as an adjuvant to a peptide vaccine therapy and 
noted that this was a potent activator of B cells. They proposed that these B cells may 
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support long-term persistence of CD8+ CTLs, and that their lymphotoxin and 
cytokines may positively affect both local (tertiary) lymphoid structures and T cell 
polarization24. Others have also reported on the short lifespan of antigen-presenting 
DCs as being a limiting factor in their T cell stimulating capacity and that this is an 
aspect that needs further investigation25. Moseman et al have also reported on the 
lymphotoxin-mediated role of B cells in protection against VSV infection26. 
Lymphotoxin activation of MΦs, not the adaptive antibody response, was required. 
Our results argue for a role in the CTL adaptive response as improvements were 
observed in the CD8+ but not CD4+ groups, and it is CD4+ T cells, not CD8+ T cells 
that are involved in antibody production by B cells27. Analysis of the AB response 
was not conducted in this study, though samples have been stored for analysis of anti-
OVA antibodies in the cell supernatants.  
 
The current dogma of DC, CD4+, B cell activation is that DCs become activated by 
the uptake of antigen, activate CD4+ T cells, which then activate B cells. While this 
thesis doesn’t argue against this dogma, it argues that the order of the steps can be 
manipulated, and the immune response enhanced, if the B cells are activated at the 
same time as the DCs, rather than relying on B cells to be activated by DC-activated T 
cells.  
 
Wang also argues that there are multiple paths for activation of naive CD8+ T cells 
and other sources of CD4-independent help28,29. “CD8+ T cells can provide self-help 
if they are present at a sufficiently high precursor frequency. The important variable 
is the total number of T cells responding.” Whether Wang’s studies present a 
physiologically relevant scenario, or an artifact of in vitro studies with artificially high 
numbers of T cells remains to be verified. 
 
6.3.1 The CpG Factor 
In 2002 Shirota et al challenged the notion that B cells lack antigen non-specific 
capture, priming of naïve T cells and TH1 induction capacity30. Theirs was the first 
study to demonstrate that when OVA antigen was conjugated to CpG, B cells 
assumed the same functional capacity as DCs. Unconjugated CpG was utilised as an 
immune stimulant in our study, yet we also observed significant increases in MHC-II 
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on B cells in response to LPS&CpG, demonstrating increased antigen presentation 
capacity in the lysate+LPS&CpG-loaded B cells. 
 
Another intriguing example of CpG-mediated anti-tumour effects is a study that found 
that intratumoural injection of the TLR9 agonist CpG along with anti-OX40L and/or 
anti-CTLA4 antibodies, to eliminate TREGs in the tumour microenvironment, initiated 
a systemic anti-tumour response and long-lasting protection in mice31. Conversely, 
systemic delivery of antibodies and CpG ODNs had an immediate anti-tumour effect 
but mice later relapsed. The study authors attributed the results to the depletion of 
TREGs by mABs but in light of the results of this thesis, it seems plausible that the anti-
tumour effect observed in the intratumoural injection groups arose from the effects of 
damaged tumour cells being exposed to activated DCs and B cells in the tumour 
which were able to more effectively prime the CTLs. 
 
In a similar vein, Brok and colleagues reported that in situ cryoablation, another 
scenario that induces a form of in situ tumour lysate, accompanied by CpG, resulted 
in an enhanced anti-tumour response32. They also only assessed the DCs, which they 
found were more effective in this scenario, however it is likely that CpG enhanced the 
B cell function also. 
6.3.2 CD40-CD40L Connections 
Immunological dogma says that priming of CD8+ CTLs usually requires “help” from 
activated CD4+ T cells. Yet it has been known since 1998 that ligation of CD40L 
with CD40 can replace CD4+ T helper cell priming of helper-dependent CTLs33. 
CD40-CD40L interactions can take place between APC and CD8+ T cells and 
signaling through CD40 on APCs can replace CD4+ ‘help’34. 
 
Mamula and Janeway pointed out that early studies in mice whose B cell development 
was suppressed from birth, had defective T cell proliferation that could be rescued 
with antigen-specific B cells, suggesting an important role for B cells in the T cell 
response to antigen35. The MHC II-restricted CD4+ T cell levels of these B cell-
deficient mice were normal, showing that B cells are required for particular aspects of 
CD4+ T cell priming. These authors proposed a model in which DC present primarily 
high affinity peptides to CD4+ T helper cells via MHC II. These CD4 TH cells, 
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primed against immunodominant peptides, then activate antigen-specific B cells 
inducing costimulatory capacity in B cells, probably principally via the CD40L-CD40 
interaction. The activated B cells are then able to act as APCs that can initiate naïve T 
cell responses. More recent studies have also demonstrated that DCs primarily prime 
against tight-binding, high affinity peptides while MΦs broaden the T cell response 
by presenting more loosely binding epitopes36. Thus both B cells and MΦs have the 
potential to assist DCs in widening the adaptive response against the full range of 
tumour antigens found in tumour lysate. 
 
Wykes et al demonstrated a direct DC-B cell interaction, independent of T cells, that 
was able to initiate antibody production37. They showed that DC could retain native 
antigen, as opposed to processing it and presenting it as peptides on MHC, and that 
DC could transfer this native antigen to B cells in vivo. In 2008 and 2014 Harvey et al 
reported on their findings that human B cells transfer BCR-captured antigen to MΦs 
and DCs via Scavenger Receptor A on MΦs, resulting in MΦs and DCs acquiring 
more antigen in the presence of B cells than in their absence38,39. Scavenger Receptor 
A had previously been assigned a role in DC ‘nibbling’ – a process whereby they 
capture antigen from live cells40. Harvey has now shown that human DC can also 
‘nibble’ membrane-bound BCR-antigen complexes from B cells. While DCs tend to 
present and cross-present high affinity peptides on MHC II and MHC I respectively, 
is it possible that nibbling antigen complexes from B cells is another way for 
increasing the amount of peptide presented? Albeit possibly only the high affinity 
peptides? This hypothesis could be tested by comparing the uptake of antigen and the 
level of surface MHC-bound specific peptides on DC cultured with B cells in the 
presence and absence of specific inhibitors of DC ‘nibbling’ 
 
As an alternative mechanism to B cells cross-presenting the lysate peptides on MHC-I 
Shultz suggests that B cells could act as accessory cells for CD8+ T cell activation by 
way of their IL-1 or IL-6 production48. Klarnet et al discovered that a subset of CD8+ 
CTLs produced IL-2 and that this production was IL-1α-mediated41. These T cells 
may be critical in the anti-tumour response as they don’t require CD4+ T helper cells 
to become activated but rather respond to IL-1α via their IL-1 receptors. The 
interaction of IL-1α with IL-1 receptors on these tumour antigen-specific CTLs is 
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necessary for IL-2 production, which then acts in an autocrine and paracrine manner 
to stimulate proliferation of both the IL-2 producing and non-IL-2 producing CD8+ T 
cells. In this scenario, IL-1α-producing B cells would play an important role in 
CD8+CTL activation in environments where tumour antigen-specific CD4+ T cells 
are lacking. IL-1 was not measured in this study thus we currently have no evidence 
to support this theory. 
 
6.3.3 A proposed model 
Based on the data from this study and the observations of other investigators the 
following scenario is proposed to explain how the combination of oxidised lysate-
loaded GMDC+B cell enhances the CD8+ T cell response to tumour antigens.  
• DCs and B cells acquire and process lysate antigens 
• Mutual antigen transfer occurs: DCs present and/or transfer undegraded 
antigen to B cells42,43 and B cells transfer antigen to DCs39  
• Costimulatory CD40 is induced on DC by oxidised lysate; CD86 is 
upregulated on B cells by oxidised lysate; and CpG&LPS upregulates MHC-II 
on B cells 
• B cells become competent APCs capable of initiating naïve T cell responses 
 
• As yet unidentified cell-cell or cytokine mediated interactions between DCs 
and B cells induces IL-12 production by DCs, and possibly by B cells 
• Elevated levels of IL-12 provide the critical third signal (over and above 
Signals 1 and 2) for optimal CD8+ IFN-γ production and effector function44 
6.4 Challenges  
6.4.1 OVA-Specific Effects? 
OVA is a metal-binding transport protein that can bind to many other proteins. 
Zinkernagel has questioned whether this is a special property of OVA which may 
have given rise to some of the OVA-mediated immune responses observed and 
suggests this needs to be further explored45. With regards to this study OVA is utilised 
as an imitation tumour antigen to allow the CD4+ and CD8+ T cell response to be 
explored. However it is recognised that OVA-specific effects may be at play in this 
model system, which may not readily translate to a truly undefined lysate setting. 
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OVA is an immunodominant foreign antigen while tumour antigens are altered self 
antigens. While B16.OVA provides a useful tool for proof of principle studies, these 
studies need to be taken into an ‘altered self’ setting. A more clinically relevant 
scenario would be to generate tumour-specific T cells in tumour-bearing WT mice. 
The tumours could be surgically excised from the mice, to mimic a patient biopsy. 
Undefined lysate could be created from the ‘biopsies’ and loaded onto APCs for re-
stimulation of T cells from tumour-bearing mice. Reinfusion of these T cells into mice 
who have had tumours excised would mimic ACT in a patient. These mice could be 
monitored to evaluate whether these T cells can prevent the return of tumours.   
6.4.2 A Dendritic Cell By Any Other Name 
There is controversy surrounding the relationship of DCs with the mononuclear 
phagocyte system (MPS). Significant overlaps of function and marker expression in 
bone marrow- and monocyte-derived cells makes the demarcation of DC from MΦ 
difficult, especially in non-lymphoid tissue. 
 
On the basis of a large meta-analysis of multiple public domain gene expression array 
datasets Mabbot et al found that BMDC, cultured in GM-CSF, identified clearly as 
phagocytes and were distinct from isolated lymphoid tissue DC that showed low 
expression of phagocytic genes. They suggested that a better delineation between 
these two cells would be to call them phagocytic APCs (antigen-presenting MΦs) and 
non-phagocytic APCs (classical DCs)46. Hume has also questioned the identification 
of DCs and MΦs on the basis of surface markers47,48 and makes the point (personal 
email correspondance, May 2015) that antigen presentation is a function, not a cell 
type. 
 
When this study commenced the prevailing consensus was that GM-CSF-
differentiated bone marrow APCs were considered a model for dendritic cells. By the 
end of this study the tide of opinion had turned toward calling these cells GM-CSF-
stimulated antigen-presenting cells and the consensus is that they represent a type of 
antigen-presenting MΦ, not a DC. Under this logic the APCs studied in this project 
could all be considered MΦs and thus it remains to be seen how a Flt-3 ligand-
differentiated cell (i.e. a “true” DC) stacks up against these cells. Unfortunately due to 
the timing of these developments, this question remains to be answered. 
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6.4.3 Further Optimisation of T Cell Numbers 
Not unlike the situation in the clinic, we experienced difficulties obtaining T cell 
numbers high enough for phenotyping the cells used in in vivo studies. This problem 
has to be addressed, probably through further optimisation of the growth conditions to 
encourage the T cells to keep expanding. This may be achieved by the inclusion of 
anti-CD28 +/- anti-CD3 mABs to stimulate explansion of all the clones that are 
generated with the priming. Alternatively, the use of protease inhibitors in the lysate 
may be responsible for the low T cell numbers and so comparison of the T cell 
response to lysate made with and without these inhibitors should be made. 
 
Nonetheless Stemberger et al showed that diverse effector and memory subsets can 
develop from a single naïve CD8+ precursor using in vivo ACT of a single, antigen-
specific naïve CD8+ T cell49. In vivo TEM proliferate poorly, despite having rapid 
effector function, while TCM expand rapidly but have delayed effector function. 
TEM are small in number out in the periphery but if they encounter their cognate 
antigen they’re very powerful. Thus the quality of these cells may be more important 
than the quantity. 
 
On the other hand TCM in the lymphoid organs will rapidly expand to generate 
overwhelming T cell numbers as well as exerting effector functions once they reach 
the peripheral site of infection or tumour. In other words though small in number the 
TEM attempt to hold the problem at bay while the TCM get activated and come to the 
rescue with superior numbers. Applying this to the clinic, it is possible that in future 
we may see effective ACT achieved with a combination of smaller numbers of highly 
specific and highly effective TEM and larger numbers of TCM. The intriguing work of 
Busch and Schumacher with minimal T cell numbers in the bacterial infection and 
allo-HST settings49–53 highlights an opportunity for testing low dose T cell numbers in 
ACT for cancer.  
 
6.4.4 How to Overcome T cell ‘Stunning’ in the Face of Tumour Lysate 
A 2008 study reported that very few peptide-MHC complexes were necessary for the 
induction of full-fledged T cell activation and effector differentiation54. They observed 
a “Goldilocks effect” in which the amount of antigen had to be not too much, nor too 
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little, but “just right” for optimal T cell activation. They observed that: “T cells 
rapidly formed tight stable contacts with DCs presenting large numbers of cognate 
pMHC complexes. However, T cells did not engage in immediate tight contacts with 
DCs with low antigen densities; instead, they accumulated signals through hours of 
signal integration during serial encounters with many DCs until sufficient antigenic 
stimulation enabled the transition from phase one to phase two” (stable T cell-DC 
interactions). 
 
So, if a group of DCs arrive in the lymph nodes bearing a significant amount of 
antigen, the phase 1 ‘sampling’ of antigen timing to reach a critical threshold, will be 
shorter, and continuation to phase 2 and activation faster, than if DCs bearing smaller 
amounts of antigen arrive in the LN. This is due to the serial sampling taking longer 
to reach critical activation threshold, not unlike bacterial quorum sensing. 
 
This is relevant to cancer because APCs are less likely to arrive with large amounts of 
tumour antigen, but rather more likely to arrive with small amounts of cancerous 
antigen over a longer period of time. This could help explain why T cells are not 
interested in the tumour antigens – because there is insufficient antigen to reach 
activation threshold. The T cell sees its cognate antigen but due to the lack of 
sufficient signal integration to form a ‘quorum’ the T cell passes to anergy instead of 
activation. Therefore in ACT its critical to get the right amount of antigen.  
 
In this study our APC:T cell ratio was 1:10 so the density of APCs was likely 
adequate. However the number of peptide-MHC complexes per APC (ie MHC-SIIN) 
in the lysates may be too low and may be the limiting factor in determining overall 
antigen dose. Experiments to assess the number of peptide-MHC complexes on the 
surface of the lysate-loaded APCs may yield further insights for the presentation of 
lysate TAAs. 
6.5 Limitations 
For many of these assays using tumour lysates, a similarly prepared lysate from the non-OVA 
expressing B16F10 cells would have been an excellent negative control. We used the irrelevant 
melanoma peptide gp100 as the negative control, since the OVA transgenic mice should only bind 
OVA peptides, not gp100 or any other peptide in the lysate. In hindsight, including the B16 parental 
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line as a further control would have controlled for unexpected non-specific binding, and thus this is a 
limitation of these assays. 		
Considering that  our overall aim was the improvement of adoptive cell therapy for cancer, the value of 
this thesis would have had more impact if we had demonstrated evidence of enhanced tumor regression 
or clearance by DC+B cell-primed T cells in a preclinical tumour model. The in vitro work was 
necessary to provide a rationale for which combination(s), if any, were worth trying in expensive, time-
consuming in vivo trials. Unfortunately infections in the mice colony for a significant period of the 
thesis tenure resulted in significant delays due to the need for many repeats. Many experiments had 
proliferation in untreated wells rendering the entire experiment invalid. This proliferation was not due 
to contamination or experimental technique as other students and staff had the same issue. The 
unfortunate outcome was that planned tumor trials were unable to be conducted within the time frame. 
To build on the results of this thesis, another lab member is currently conducting trials of oxidized 
lysate in a pre-clinical model of colorectal cancer. Planning is also well underway to conduct trials 
comparing oxidized lysate presented by DC+B cells in a xenograft model of human brain tumors at 
Children’s National Medical Centre in Washington DC. It is hoped that the groundwork laid by this 
thesis will prove fruitful in future trials. 
6.6 Future Directions 
6.6.1 Tumour Trials 
Rolf Zinkernagel has written: “The difference between “what is possible under any 
experimental condition” versus “what happens physiologically” is a crucial 
distinction”45.  While the results of our in vivo cytotoxicity assays are promising, 
further in vivo data in the form of tumour trials is required to assess the ability of T 
cells primed with GMDC+B cell presenting lysate antigens to eliminate established 
tumours and to resist tumour challenge. In particular, as mentioned above, the use of 
truly undefined lysate antigens from tumour-bearing mice would represent a 
significant step toward clinical applicability should the same observations of 
increased tumour control by T cells primed by oxidised lysate—loaded GMDC+B 
cells hold true. 
 
T cell degeneracy and promiscuity55 make it reasonable to assume that when APCs are 
pulsed with lysate from tumour cells, in addition to the highly peptide-specific TCR-
p-MHC interactions, there will also be lower affinity interactions with other p-MHC 
complexes, generating a broader repertoire of T cell responses to other unidentified 
TAAs in the lysate. Tumour antigen expression is not only unique to each patient, it is 
also highly heterogeneous within the tumour tissue down to the single cell level56,57, 
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resulting in immune activity against multiple TAAs within the patient56,58,59. Thus T 
cell degeneracy and promiscuity combined with tumour heterogeneity further argues 
for the choice of lysate as opposed to a limited range of defined antigens as the TAA 
source in ACT for cancer.  
 
6.6.2 Which is the Best DC? 
Most clinical studies use in vitro-generated monocyte-derived DCs as opposed to the 
less populous peripheral blood DCs60. The most recent edition of Clinical and 
Translational Immunology reported on the Tenth Human Leukocyte Differentiation 
Antigen (HLDA) Workshop, in which the authors state: “To date, the use of 
monocyte-derived DCs has failed to provide strong clinical data to argue that these 
should be the cells of choice”6,61. Optimal parameters, including which is the superior 
DC for activating anti-tumour T cells, is ongoing so the full potential of DC-mediated 
immunomodulation may be realized. Repeating these experiments using tumour 
biopsy-derived material and peripheral blood DCs may be enlightening. As would 
repeating the experiments using Flt3L-generated DCs, which more closely resemble 
lymphoid CD8+ DCs. 
 
Interestingly, Gérard and colleagues found that T cell-T cell interactions had a 
stronger impact on T cell expansion and effector memory balance than DC-T cell 
interactions62. Scarlett et al showed a DC-mediated immune response that transitioned 
from elimination to escape during tumour development11. These two reports have a 
strong bearing on this study since they demonstrate opposite ends of the DC-T cell 
interaction spectrum and highlight both the DC-T cell relationship as well as the 
importance of T cell-T cell and other cellular contacts during T cell maturation.  
 
The APC-T cell contact is obviously critical in initiating the T cell response, but then 
its importance may be lessened during T cell maturation. However, as tumourigenesis 
proceeds the DC-T cell interaction comes back into the limelight as the DCs lose anti-
tumour reactivity in response to tumour-produced PGE2 and TGF-β1, reducing CD8+ 
T cell proliferation and production of IFN-γ and granzyme-B, thus eliminating their 
tumour-eradicating faculties. Since, in the Scarlett model, the tumour retained 
immunogenicity11, is it possible that during the immunoediting process a second APC 
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could step in at this point to reignite the T cells? Why are DC so responsive to PGE2 
and TGF-β1? Are other APCs more resistant to the immunosuppressive effects of 
PGE2 and TGF-β1?  
 
Perhaps TAA-specific B cells in the splenic germinal centres, whose proximity to the 
T cell zone facilitates their priming of naïve CD4+ T cells, could step in to take up 
where the DCs have left off? Confirmation of the existence of cytotoxic CD4+ T 
cells63 has shed light on the importance of CD4+ T cells in the anti-tumour response, 
and as such their relationship with B cells may also prove to be important in tumour 
elimination since B cells are required for protection against certain tumours64,65. 
 
6.6.3 Enhanced Definition of Optimal GMDC and B Cell Activation and 
Lysate Loading 
The decision to load GMDC+B cell with lysates plus activation stimuli overnight 
serendipitously enabled enhanced B cell activation, which allowed the cooperative 
effects of the GMDC+B cell combination to be observed. However, further 
optimization of GMDC and B cell activation is required. A superior scenario may 
involve pulsing GMDC overnight with lysate, followed by 4 hours of activation 
stimuli. For the B cells pulsing overnight with activation stimuli prior to adding 
lysates would be a better approach. The two optimally activated cells would then be 
combined immediately prior to the addition of the T cells. In this manner the T cell 
enhancing properties of this combinatorial approach may be further augmented. 
 
However this optimization must be changed for translation into human cells since 
human DCs do not express TLR9 and human B cells do not express TLR4 thus in all 
likelihood this combination of immune stimulants will not work in the human setting. 
The combination of CD40L and CpG induces IL-12 production from human B cells66 
while the combination of CD40L and monophosphoryl lipid A (MPL-A) triggers 
synergistic increases in IL-12 in human DCs compared with either agonist alone67. 
Further examination of CD40L, CpG and MPL-A in the activation of lysate-loaded 
GMDC+B cell is warranted. 
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6.6.4 Broaden Analysis of APC-Mediated Tumour Responses to Include B 
cells & MΦs 
In 2011 Beatty and colleagues reported on a clinical trial in which anti-CD40 mABs 
plus gemcitabine chemotherapy were tested in a small cohort of pancreatic ductal 
adenocarcinoma (PDA) patients68. Gemcitabine therapy was used prior to delivery of 
the mAB to enhance tumour antigen presentation by APCs. The CD40 mABs were 
used for their T cell-stimulating properties and tumour regressions were observed in 
some patients. In testing the mechanism of action in a mouse model they 
unexpectedly discovered that tumour regression required MΦs, but not T cells or 
gemcitabine. CD40-activated MΦs rapidly infiltrated tumours, lysed tumour cells and 
mediated tumour stroma destruction, demonstrating MΦ-mediated, T cell-
independent elimination of these tumours. The role of B cells was not examined in 
this study but it would be interesting to explore given the work with CD40-activated 
B cells which showed MΦ transfer of antigen to B cells38,69, B cell transfer of antigen 
to DCs39 and tumour regression15,70. 
 
Examples abound of the utility of CpG in the anti-tumour setting71–76. However in the 
majority of cases the reactions of only two immune cells are observed: the DCs and 
the T cells. I pose the question, have the B cell responses been investigated in these 
approaches? Were the tumour regressions really CD4+-mediated? Did they look at 
CD8+ T cells? B cells as professional APCs is a paradigm shift in thinking for 
immunotherapists but perhaps one we need to consider. 
 
Or alternatively, could the combination of CD169+ MΦs77–79 and in situ-generated 
“tumour lysate” be harnessed to stimulate TAA-specific T cells in the face of DC 
immunosuppression? CD169+CD11c+ MΦs, carrying out their general scavenging 
function, bind phosphatidyl serine (PS) on the surface of dead cells entering the LN 
via lymph flow. These MΦs phagocytose the apoptotic cells and cross-present antigen 
to CD8+ T cells80. Therefore killing tumour cells in vivo i.e. in vivo-generation of 
tumour lysate, may be useful due to dead cells flowing into the lymph nodes and 
spleen via lymph and blood flow, where CD169+CD11c+ MΦs can engulf them. This 
rapid process sees cells arriving in the LNs within hours. DCs in the area of the lysed 
tumour cells will also collect antigen and migrate back to the LNs to present antigen 
to T cells. These DCs start arriving within days, a much slower process. However, if 
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these DCs are insufficiently activated due to immune-suppressive factors in the 
tumour environment, or due to the fact that tumour cells are self cells, then cross-
presentation of these antigens will not lead to a robust anti-tumour T cell result, but 
rather T cell anergy or immune tolerance to these antigens. Thus the combination of 
in situ tumour lysate may activate the clinical potential for a response by CD169+ 
MΦs. 
6.6.5 Re-think MΦs In Cancer Immunotherapy: MΦs in the Driving Seat 
Cancer has been described as a smouldering, unhealing wound81. Thus it is 
unsurprising that tumour-promoting MΦs secrete large quantities of growth-
promoting ornithine in an attempt to “heal the wound”. Tumour-protective MΦs, on 
the other hand, produce large quantities of nitric oxide (NO)82, just as they do when 
fulfilling their anti-pathogen role83,84. Thus the key to harnessing the MΦs tumour-
fighting capacity may lie in defining the conditions that switch MΦs from tumour-
promoting arginine production85 to tumour protective NO production86. It is already 
known that TGF-β is one of the key cytokines regulating this balance between NO 
and ornithine, with TGF-β inhibiting NO production87–94. MΦs do not require T or B 
adaptive immune cells to become activated68,95,96, thus directing the MΦ response may 
result in efficient anti-tumour T cell outcomes. 
This simple proposition will nonetheless require fine regulation since NO suppresses 
tumour growth but also suppresses CTLs97–100. Thus overproduction of NO by MΦs 
inhibits the beneficial T cell response against tumours and refined clinical control will 
be required to focus their nitric oxide synthase activities toward producing just 
enough NO to be toxic to tumours but not so much that it suppresses activity of TILs. 
Even so, manipulating MΦ activities toward the required disease-suppressing role, 
rather than eliminating them altogether, may represent the more useful approach.  
 
A mechanistic explanation for the loss of response to lysate in LPS+CpG activated 
MΦs may lie in the downregulation of IRAK-4. This phenomenon has been 
implicated in LPS- and CpG DNA-induced tolerance in macrophages101. Modulation 
of the MΦ inflammatory response to lysate via IRAK phosphorylation and 
degradation has not been conducted on our cells, but represents an intriguing option 
for future analysis. 
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6.6.6 Manipulating the Combined CD4+ CD8+ T Cell Response To Lysate 
Antigens 
The results of this study suggest that CD4+ T cells on their own may not be useful in 
the lysate setting. However certain experiments hinted at possible synergies with the 
CD4+CD8+ combinations. Studies in our lab and others102 point to the requirement 
for both CD4+ and CD8+ T cells in the effective eradication of cancer – particularly 
in melanoma. Therefore future studies could include examining how the CD4+ T cell 
response could be more successfully included. For example, previous work has shown 
that defined antigen can be used to activate both CD4+ and CD8+ T cells. Therefore 
would priming CD4+ T cells with defined peptide(s), and CD8+ T cells with lysate 
lysate peptides, augment the CD8+ activity and increase T cell memory compared 
with using CD8+ T cells alone? 
6.6.7 Bringing Other Players Into The Game 
The role of immune cells other than DC, B cells and MΦs play is currently being 
more appreciated. The work of Dranoff and colleagues in 1993 hinted at this when 
they observed massive infiltration of “immature dividing monocytes, granulocytes 
(predominantly eosinophils) and activated lymphocytes” at the vaccination site in 
mice vaccinated with B16.OVA cells engineered to express GM-CSF in which a 
strong anti-tumour response was seen103.   
 
A furtherance of this current study would be to include neutrophils 
(polymorphonuclear cells; PMNs) in the analysis, for example, DC+PMN. Recent 
work is focusing on the anti-tumour activity of PMNs, natural killer (NK) and NK T 
cells. Darcy and colleagues found in a mouse model of breast cancer that depletion of 
PMNs or NK cells or CD8+ T cells was detrimental to the anti-tumour response 
showing that both the adaptive and innate arms of the immune system are involved104. 
Another study showed that murine PMNs can act as professional APCs capable of 
directing a TH1 and TH17 response105. We are aware that these cells could also be 
important in the anti-tumour immune response however time constraints did not allow 
this project to look at the impact of PMNs, NK or NK T cells, however future study 
could include these cells. It is recognised of course that while these innate cells may 
be useful in the induction of tumour killing they will never be utilised as cell-based 
therapies on their own since they do not induce immune memory. The advantage of 
 338 
including innate immune cells will only lie in their augmentation of the adaptive, 
memory-inducing response. 
6.6.8 Mechanisms of Action 
We began preliminary investigations of the mechanisms of action with two 
inconclusive experiments assessing the MHC-I response on lysate-loaded APCs (data 
not shown). Further investigations into how the combination of GMDC+B cell 
improves the T cell response could include analysis of the CD40, CD80 and CD86 
responses on the APCs. For example calcium flux, which has been shown to be 
important for the efficiency of costimulation106. Analysis of the calcium flux in lysate-
loaded GMDCs versus B cells versus when the two APCs are co-cultured during 
lysate loading may reveal differences between the cells and differences when these 
two cells are interacting during lysate antigen loading. Analysis of signaling pathways 
with inhibitors may also give insight into which pathways are being activated, or not 
activated, while gene expression profiles will do the same for gene activation. The 
DeMAND method of genome-wide analysis of network perturbation is utilised to 
identify targets, effectors and activity modulators of small-molecule compounds107. 
This method clarifies mechanism of action proteins based on global dysregulation of 
their molecular interactions and could equally be applied to the analysis of alterations 
in lysate-loaded APC networks compared to un-loaded controls, or lysate-primed T 
cells compared to un-primed controls.  
6.6.9 Does the GMDC+B Cell Augmentation of the CD8+ T Cell Response 
Hold True For Lysate Colorectal Cancer Antigens? 
“There has been limited study of DC vaccines in the adjuvant setting after resection 
of metastatic tumours in general, and colorectal cancer in particular”108 
In addition to our position as world leaders on the melanoma “scoreboard”, Australia 
and New Zealand also have the highest rates of colorectal cancer (CRC) in the world. 
Laparoscopic resection of CRC combined with polychemotherapeutic regimens such 
as fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) or fluorouracil, leucovorin, 
and irinotecan (FOLFIRI) are the current standard of care for CRC. Chemotherapy in 
metastatic CRC seeks primarily to prolong survival but is not curative109. Targeted 
monoclonal antibodies (mAB) may also be included, examples of which include 
bevacizumab, which slows angiogenesis by inhibiting vascular endothelial growth 
factor A [VEGF-A].  
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Currently around 50% of all CRC cases will progress to advanced metastatic disease 
leading to death in most patients109. While many ACT studies have been carried out in 
melanoma, little work on ACT for CRC has been undertaken to date. Since our aim 
was ultimately to translate the work of this thesis into human colon carcinoma studies 
are already underway in our laboratory to transfect the MC38 murine colon carcinoma 
cell line to express membrane bound OVA and utilise this cell line as a source of 
tumour lysate. 
6.7 Concluding Remarks 
The most important finding from this study was that combining GMDCs and B cells, 
could augment the CD8+ T cell response to oxidised tumour lysate antigens. In the 
same way that combination immunotherapies are currently favoured for cancer 
treatment, the results of this thesis suggest that combinations of APC should be 
considered in ACT for cancer in the future.  
 
I propose that the following road map (M.A.P.) for APC-mediated ACT may 
represent a better approach: 
• MANIPULATE MΦs: direct their arginine substrate to the NOS path to 
promote an M1 phenotype  
• ACTIVATE B cells: use CD40L+CpG to enhance IL-12 production, which 
drives TH1 differentiation and results in strong IFN-γ production from these 
cells 
• POTENTIATE DCs: combining DCs with these appropriately activated B 
cells and/or MΦs may result in more effective antigen presentation by DCs 
 
In recognition of the current dogma which states that B cells can’t activate CD8+ T 
cells I leave the reader with the words of Nobel laureate Ralph Zinkernagel, Professor 
of Experimental Immunology at the University of Zurich: 
“In biology, particularly in immunology, nothing is impossible” 
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Appendix 1, Supplementary Data 










Supplementary Figure 1 B16.OVA melanoma cell line is not contaminated with Mycoplasma. B16OVA 
cells that had been grown for at least three subcultures without antibiotics were harvested, resuspended in PBS 
and stored at -20°C until DNA extraction. DNA was extracted using Purelink DNA Mini-kit from Invitrogen 
(Cat:K1820-01) according to the manufacturer’s instructions. The DNA concentration was measured via 
NanoDrop, and diluted to 10 ng/µL in miliQ water. The primers used amplified DNA from highly conserved 
regions of the 16SrRNA gene, which do not detect eukaryotic DNA or bacteria closely related to Mycoplasmas. 
Lane 1, 100-bp DNA ladder; lane 2, negative control (mQ); lane 3, positive control; lane 4, half dilution of DNA 
sample (13 ng/µL); lane 5, one third dilution of DNA sample (8.7 ng/µl). 
 
7.2 MHC-I-SIIN is Not Expressed By B16F10 Cells and Is Expressed at Low 
Levels on B16.OVA cells 
 
 
Supplementary Figure 2 No MHC-I-SIIN is expressed on the surface of B16F10 cells. B16.OVA and 
B16F10 cells were cultured as described under B16OVA cells in Materials & Methods. Geneticin was not added 
to B16F10 cultures. Following 5 hours incubation with Brefeldin A cells were stained with antibodies to H-2Kb 
bound to SIINFEKL conjugated to PE. Cells were fixed with 2% paraformaldehyde, stored overnight at 4°C and 
acquired the following day on a Gallios Flow Cytometer. Data was analysed on FlowJo version 9. 
Representative dot plots of B16.OVA and B16F10 cells after Brefeldin A treatment. Representative data from 












7.3 Protein Concentrations in Tumour Lysates 
Supplementary Table 1 Protein concentrations in tumor lysates 
BATCH AVERAGE PROTEIN 
CONCENTRATION 
METHOD USED TO 
ASSAY PROTEIN 
CONCENTRATION 
TL1 Unreliable results ND 
TL2 9.38 mg/mL ND 
TL3 9.49 mg/mL ND 
TL4 Not measured  
TL5 13.22 mg/mL ND 
TL6 13.29 mg/mL ND 
TL7 11.6 mg/mL ND 
TL8 8.92 mg/mL ND 
TL9 16.97 mg/mL BCA 
TL10 10.48 mg/mL BCA 
The protein content of each batch of tumor lysate (TL) was assessed by NanoDrop™ (ND; 
ThermoFisher Scientific Inc) where 1 A280 = 1 mg/mL, or by BCA Assay as specified in the 
Table.  
7.4 Sample B16.OVA Oxidation Raw Data 
Supplementary Figure 3 shows sample raw data of the dose-dependent death of HOCl-





Supplementary Figure 3 B16.OVA cells display concentration-dependent levels of live, apoptotic and 
dead cells after HOCl-mediated cell death. B16.OVA cells were harvested and resuspended in varying 
doses of HOCl as indicated in the figure. After 1 hour at 37°C cells were labeled with PI and acquired on a 
Gallios Flow Cytometer within 1 hour. Data was analysed and graphed with FlowJo software. 
Representative data from multiple independent experiments. US: Unstained; PI: propidium iodide. 
50 μM 90 μM 
US cells 20 μM 
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7.5 Three Non-Melanoma Cell Lines Require Different HOCl Concentrations to 
















7.6 Unactivated GMDC, IL4DC and MΦ Morphology & Phenotypes 
The different magnifications below best illustrate the differences between the cell cultures. 
IL4DCs and MΦs at 40X show the difference in cell size and cell numbers, which were 
always much lower in MΦ cultures compared to DCs. DCs at 10X shows the global view of 
the DC clusters which were much smaller in MΦ cultures and not obvious at 10X 
magnification, therefore that image was not shown. Finally, GMDC at 100X gives a close-up 
of one of the clusters seeding off into the medium. These clusters are present to a greatly 
reduced degree in MΦ cultures. This difference can be observed between the DC 100X and 


























































Supplementary Figure 4 Three cell lines require different HOCl concentrations to achieve 95% 
cell death by oxidation. The colon carcinoma cell line MC38, the human monocytic leukaemia cell 
line THP-1 and the murine lung epithelial tumour cell line TC1 were incubated for 1 hour at 37°C in 
the HOCl concentrations indicated. Cells were washed, labelled with PI and acquired by Flow 
Cytometry within the hour. Cell death aws measured by the percentage of PI positive cells. Data was 





























GMDC D4, 10X GMDC D6, 100X 
IL4DC D5, 40X M1 MΦ D10, 40X 
Supplementary Figure 5 GMDC, IL4DC and MΦ  populations differ in their gross morphological characteristics,and 
CD206 expression but are all negative for CD135 and CD169. Bone marrow-derived precursor cells were incubated for 10 
days in GM-CSF (5 ng/mL)+IL-3 (5 ng/mL)+FCS10% (MΦ); 6 days in GM-CSF (20 ng/mL)+FCS (5%) (GMDC); or 6 days in 
GM-CSF (20 ng/mL)+IL-4 (10 ng/mL)+FCS (5%) (IL4DC). Cell cultures were imaged prior to harvest. A) Top left: D6 
unactivated GMDC 10X magnification showing typical pattern of background adherent and semi-adherent cells along with non-
adherent cells seeding off into culture medium. A) Top right: D6 GMDC 100X magnification showing typical immature GMDC 
population with background adherent cells and smaller, round, non-adherent clusters seeding off. A) Bottom left: D5 unactivated 
IL4DC 40X magnification showing 60 μM diameter large clear cells among the smaller immature dendritic cells. A) Bottom 
right: D10 unactivated M1 MΦ 40X magnification, showing firmly adherent, rounded and elongated cells. Example images 
from representative experiments. B) Cells were harvested, stained with dead cell exclusion dye and labeled with fluorophore-
conjugated antibodies against a range of common DC and MΦ identifying markers: CD11c, MHC-II, F4/80, CD115, CD135, 
CD8α; as well as the costimulatory markers CD40, CD80 and CD86. Cells were fixed with 4% paraformaldehyde, stored 
overnight at 4°C and collected the following day on a Gallios Flow Cytometer (Beckman Coulter). Data were analysed on 
FlowJo Version X and graphed in Prism. Summary data showing the mean ± s.e.m of six (GMDC, IL4DC) and four (MΦ) 
independent experiments. Statistically significant differences were calculated by Kruskal-Wallis one-way ANOVA by ranks 






















CD135 on Bone Marrow-Derived Dendritic Cells +/- IL4 versus 
Bone Marrow-Derived Macrophages
Results of 4 separate experiments;
Stats = unpaired Student's t-test; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 






















CD206 on Bone Marrow-Derived Dendritic Cells versus 
Bone Marrow-Derived Macrophages
Results of 9 separate experiments (DC) & 9 separate experiments (Mφ);
Stats = unpaired Student's t-test; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
























CD169 on Bone Marrow-Derived Dendritic Cells versus 
Bone Marrow-Derived Macrophages
Results of 10 separate experiments (DC) & 8 separate experiments (Mφ);
Stats = unpaired Student's t-test; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
Error bars = mean with s.e.m.
B 
 350 
7.7 Antibody Panels Used To Assess GMDC, IL4DC and MΦ Response to Lysates 
Supplementary Supplementary Table 2 Antibody panels used in experiments to assess GMDC, IL4DC 



































































Supplementary Figure 6 Gating Strategy Used in MΦ Phenotype Analysis. D10 M1 MΦ were prepared as 
previously described. Cells were stained with Live/Dead exclusion dye  and Fc receptor block followed by surface 
molecule staining with the following monoclonal antibodies: MHC-II-FITC, CD11c-BV421, CD135-PE, CD169-
PE, CD115-PE, F4/80-PE, CD40-APC, CD206-BV421, CD80-BV421. Antibody-stained cells were washed twice 
and fixed in 4% paraformaldehyde. Cells were stored overnight at 4°C and acquired the following day on a 
Gallios Flow Cytometer. 5 e 4 - 1 e 5 cells were collected per sample wherever possible. The gating strategy 
consisted of doublet exclusion followed by dead cell exclusion and then gating on the cells of interest using 
unstained cells and single stained cells as negative gating controls. Data was analysed and graphed in FlowJo 
software Version X. Representative data from numerous independent experiments. 
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7.9 Media Alters M1 MΦ Surface Phenotype but Bacteriological Petri Dishes 
Have No Impact 
We compared M1 MΦs grown in RPMI and IMDM on tissue culture plates (TCP) and 
bacteriological petri dishes (BP) (Supplementary Figure ). There was no difference in the 
expression of F4/80, or any other marker measured, on cells grown on TCPs versus BPs. 
However the RPMI medium had a strong negative impact on the levels of this marker. Even 
though the downregulation of F4/80 was not statistically significant when analysed by either 
Mann Whitney U test or one-way ANOVA, we elected to use IMDM to avoid downregulation 
of F4/80. 
 
CD40 was higher on TCP than on BP in both IMDM and RPMI. However CD40 was only 
























Supplementary Figure 7 Bone marrow macrophages downregulate F4/80 when cultured in 
RPMI. Day 10 M1 MΦs cultured in RPMI or IMDM on tissue culture plates (TCP) or sterile 
bacteriological (non-tissue culture-treated) plates (BP) were harvested, stained with dead cell exclusion 
dye and labeled with mABs against MHC-II, CD11c, Ly6C, F4/80, CD169, CD40, CD11b and Flt3 
(CD135). Antibody-stained cells were washed twice, fixed in 4% paraformaldehyde, and stored 
overnight at 4°C. Cells were collected the following day on a Gallios Flow Cytometer. 3 e 4 cells were 
collected in each sample. The gating strategy consisted of doublet exclusion followed by dead cell 
exclusion and then gating on the cells of interest using unstained cells and single stained cells as 
negative gating controls. Data was analysed on FlowJo software Version X and graphed in Prism. 
Summary data of two independent experiments. CD40 and Flt3 were only measured in the second 
experiment. Error bars = mean + s.e.m.  
Unactivated Macrophage Phenotype
IMDM vs RPMI






































7.10 GMDC, M1 MΦ and B Cell Response to Activation Stimuli 
Various APC activation stimuli are in current use in bench studies and clinical trials around 
the world1–9. To determine the best parameters for activating these APCs their responses to 
different combinations and concentrations of the cytokine interferon gamma (IFN-γ) and 
two TLR agonists, CpG or LPS were tested (Supplementary Figure 6). Supplementary Table 
3 shows the concentrations and combinations of these three immune stimuli that were 
compared for their ability to upregulate MHC-II, CD40, and CD80 on GMDCs, M1 MΦs and 
B cells. It has been noted that these LPS concentrations are high, however they were chosen 
based on previous studies in the literature. 
 
Supplementary Table 3 Immune stimuli combinations and Doses Tested on GMDCs, M1 MΦs and B Cells 
IFN-γ  LPS CpG 
10 U/mL 1 μg/mL _ 
50 U/mL 5 μg/mL _ 
100 U/mL 10 μg/mL _ 
50 U/mL 100 μg/mL _ 
_ 1 μg/mL 0.3 μg/mL 
_ 5 μg/mL 0.03 μg/mL 
_ 10 μg/mL 0.5 μg/mL 
_ 50 μg/mL 3 μg/mL 
_ 100 μg/mL 6 μg/mL 
10 U/mL _ 0.5 μg/mL 
50 U/mL _ 3 μg/mL 
100 U/mL _ 5 μg/mL 
 
A stimulant concentration titration experiment was carried out on GMDCs. The combinations 
of LPS+CpG and LPS+IFN-γ yielded no statistically significant increases in the percentage of 
GMDC positive for CD40, CD80 or MHC-II (Supplementary Figure 6a). This contrasted with 
the IFN-γ+CpG combination, which reduced MHC-II, CD40 and CD80 expression. For M1 
MΦs none of the activators tested stimulated any increase in CD40 or MHC-II and 
downregulation of CD80 occurred in the presence of all stimulant doses when compared with 
UT (Supplementary Figure 6b). Finally these combinations were also assessed on B cells in 
one pilot experiment, which yielded small, non-statistically significant increases in CD40 but 
no response by CD80. Thus no one combination was ideal for any of these APCs. The triple 
combination of IFN-γ+CpG+LPS was tested on GMDCs only and results were identical to 
those of the other combinations.  
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It was not noted at the time of analysing these experiments that the MHC-II on UT GMDCs 
was lower than normal while the MHC-II and CD40 on UT B cells was higher than normal 
(Supplementary Figure 6c). 
 
At the time the results of these experiments were incorrectly analysed leading to the erroneous 
conclusion that LPS was the common stimulating factor for GMDC and MΦs, whereas the 
combinations of LPS+CpG and IFN- γ +CpG enhanced the B cell response. Later reanalysis 
after the experiments were concluded is shown in Supplementary Figure 6. These results 
show that none of these cytokine TLR combinations resulted in upregulation of MHC-II, 
CD40 or CD80.  
 
However, the TH1/TH2 cytokine response elicited by these stimuli was also evaluated in one 
LegendPlex (BioLegend, USA) assay (Supplementary Figure 10). The combinations of 
LPS+CpG and IFN- γ+CpG elicited the highest IFN-γ and TNF-α responses from GMDC, B 
cell and M2 MΦs. M2 MΦs were inadvertently analysed by bead array instead of M1 MΦs 
and we did not have access to a further bead array at that time, thus this data set does not exist 
for M1 MΦs.  
 
We observed no difference between these stimuli in the activation response of the M1 MΦs. 
The inclusion of IFN-γ appeared important for GMDC activation while CpG appeared to be 
required for B cell activation but the IFN-γ+CpG combination yielded a very poor 
costimulatory marker response for GMDCs. Therefore based on the surface molecule 
response, as analysed at the time, and LegendPlex cytokine data, the combination of LPS and 
CpG was chosen as the APC activator for future experiments. However it is acknowledged 






























Conclusion: This data was incorrectly analysed at the time leading to the erroneous conclusion that
the inclusion of CpG was important for B cell activation, when in fact, despite insufficient repeats & insufficient data 
for statistical analysis, the IFN-y+LPS combination displayed slight increases in MHC-II, CD40 & CD80 in both DCs 
& B cells, though not Macs. The triple adjuvant combination was only tested in M1 Macs in Dec 2015 (data not 




LPS (1 ug/mL)+CpG (0.3 ug/mL)
LPS (5 ug/mL)+CpG (0.03 ug/mL)
LPS (10 ug/mL)+CpG (0.5 ug/mL)
IFN-y (10U/mL)+CpG (0.5 ug/mL)
IFN-y (50U/mL)+CpG (3 ug/mL)
IFN-y (100U/mL)+CpG (5 ug/mL)


























LPS (1 ug/mL)+CpG (0.3 ug/mL)
LPS (5 ug/mL)+CpG (0.03 ug/mL)
LPS (10 ug/mL)+CpG (0.5 ug/mL)
IFN-y (10U/mL)+CpG (0.5 ug/mL)
IFN-y (50U/mL)+CpG (3 ug/mL)
IFN-y (100U/mL)+CpG (5 ug/mL)
Conclusion: This data was incorrectly analysed at the time leading to the erroneous conclusion that
the inclusion of CpG was important for B cell activation, when in fact, despite insufficient repeats & no
statistical analysis, the IFN-y+LPS combination displayed slight increases in MHC-II, CD40 & CD80 across all three
APCs. The triple adjuvant combination was never tested.
UT





























LPS (1 ug/mL)+CpG (0.3 ug/mL)
LPS (5 ug/mL)+CpG (0.03 ug/mL)
LPS (10 ug/mL)+CpG (0.5 ug/mL)
IFN-y (10U/mL)+CpG (0.5 ug/mL)
IFN-y (50U/mL)+CpG (3 ug/mL)
IFN-y (100U/mL)+CpG (5 ug/mL)





Supplementary Figure 8 GMDC, M1 Macrophage and B cell responses to immune stimuli concentrations. 
A)Day 6 bone marrow-derived GMDC, B) Day 10 bone marrow-derived macrophages and C) B cells were prepared 
as previously described and pulsed overnight with the immune stimuli concentrations described in the legend. Cells 
were harvested, stained with dead cell exclusion dye and mABs against the surface markers MHC-II, CD40 and 
CD80. Cells were fixed with 4% paraformaldehyde, st red overnight at 4° C and cquired the following day by 
Gallios Flow Cy om ter. Dat  were analysed on Flow Jo Version X and graphed in Prism. Summary data of 1 
(GMDC & B cell) and 3 (M1 MΦ) experiments are shown. Error bars = mean +/- s.e.m.  
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7.11 M2 MΦ Response to Activation Stimuli 
On M2 MΦs all doses of IFN-γ+LPS yielded statistically significant upregulation of CD40 
and CD80 compared with UT (Supplementary Figure 9). All doses of LPS+CpG also 
significantly upregulated CD40 and CD80 molecules on M2 MΦ though to a lesser degree 
than IFN-γ+LPS. The combination of IFN-γ+CpG stimulated no increase in CD40 or CD80 
on MΦs as compared to the UT cells. No differences were seen in the percentage of M2 MΦs 
positive for MHC-II or CD169, nor was there any change in the MHC-II MFI in response to 








Supplementary Figure 9 M2 macrophage responses to activation stimuli. Day 10 bone marrow-derived 
precursor cells were prepared as previously described and pulsed overnight with the immune stimuli concentrations 
described in the legend. Cells were harvested, stained with dead cell exclusion dye and mABs against the surface 
markers MHC-II, CD40 and CD80. Cells were fixed with 4% paraformaldehyde, stored overnight at 4° C and 
acquired the following day by Gallios Flow Cytometer. Data were analysed on Flow Jo Version X and graphed in 
Prism. Summary data of 3 experiments are shown. Error bars = mean +/- s.e.m.  

































   
   
   
   







LPS (1 ug/mL)+CpG (0.3 ug/mL)
LPS (5 ug/mL)+CpG (0.03 ug/mL)
LPS (10 ug/mL)+CpG (0.5 ug/mL)
LPS (50 ug/mL)+CpG (3 ug/mL)
LPS (100 ug/mL)+CpG (6 ug/mL)
IFN-y (10U/mL)+CpG (0.5 ug/mL)
IFN-y (50U/mL)+CpG (3 ug/mL)
IFN-y (100U/mL)+CpG (5 ug/mL)
Conclusions: IFN-y+LPS gives best increase in MHC-II MFI and %+ve of CD40 on BMMφs
Similar results are obtained for CD80 with IFNy+LPS or LPS+CpG
IFN-y+CpG is not effective
Interestingly none of these Th1-polarising adjuvants are effective in raising CD169 levels on 
M2 Mφs indicating a shift in phenotype which may be expected to have functional 
consequences
The lack of increase in MHC-II expression or MFI is concerning as it indicates lack of Th1
polarisation. It will be important to verify Th1/Th2 cytokine response.
Results of 3 separate experiments;
Stats = unpaired Student's t-test; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
Error bars = mean with s.e.m.
UT

























LPS (1 ug/mL)+CpG (0.3 ug/mL)
LPS (5 ug/mL)+CpG (0.03 ug/mL)
LPS (10 ug/mL)+CpG (0.5 ug/mL)
LPS (50 ug/mL)+CpG (3 ug/mL)
LPS (100 ug/mL)+CpG (6 ug/mL)
IFN-y (10U/mL)+CpG (0.5 ug/mL)
IFN-y (50U/mL)+CpG (3 ug/mL)
IFN-y (100U/mL)+CpG (5 ug/mL)
Conclusions: IFN-y+LPS gives best increase in MHC-II MFI and %+ve of CD40 on BMMφs
Similar results are obtained for CD80 with IFNy+LPS or LPS+CpG
IFN-y+CpG is not effective
Interestingly none of these Th1-polarising adjuvants are effective in raising CD169 levels on 
M2 Mφs indicating a shift in phenotype which may be expected to have functional 
consequences
The lack of increase in MHC-II expression or MFI is concerning as it indicates lack of Th1
polarisation. It will be important to verify Th1/Th2 cytokine response.
Results of 3 separate experiments;
Stats = unpaired Student's t-test; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
Error bars = mean with s.e.m.
UT
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7.12 Legendplex Analysis of Th1/Th2 Cytokine Response to Activation Stimuli 
We analysed the cell culture conditioned media (supernatants) of GMDC, B cells and M2 
MΦs cultured overnight with the adjuvants described on the x axes in Supplementary Figure 
10. Supernatants were analysed by LegendPlex bead array for the presence of the two TH1 
cytokines, IFN-γ and TNF-α and the two TH2 cytokines, IL-4 and IL-10. Based on these data, 
the surface molecule responses and the T cell proliferation responses LPS+CpG were chosen 










































































































































































































Th1 & Th2 Cytokine Production in OT-I T Cell Co-Culture Supernatants 



































































































































































Th1 & Th2 Cytokine Production in OT-I T Cell Co-Culture Supernatants 


































































































































































Th1 & Th2 Cytokine Production in OT-I T Cell Co-Culture Supernatants 






Supplementary Figure 10 GMDC, B cells and M2 Macrophage Cytokine Responses Differ Between 
Adjuvant Types. GMDC, M2 MΦs and B cells were prepared as previously described. APCs were pulsed 
overnight with the adjuvant concentrations described on the x axes. Cell culture supernatants were stored at 
-20°C prior to analysis by LegendPlex bead array on a Gallios Flow Cytometer. The data was analysed on 
Legendplex softwared and graphed in Prism. Summary data of 1 experiment are shown. Error bars = mean 
with s.e.m. of triplicate readings. 
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7.13 GMDC, IL4DC and MΦ Activation Response To Soluble & Oxidised lysates 
DCs and MΦs vary in size and granularity and therefore auto fluorescence. For this reason 
these cells were acquired using different voltages. Thus while direct comparisons of MFI 
cannot be drawn between DCs and MΦs in the manner shown in these graphs the aim of these 
experiments was to assess the response of the individual APCs to the lysates. Given that no 
change in the MFI of CD40 was recorded for MΦs (Supplementary Figure 11) it was deemed 
unnecessary to directly compare the results between MΦs and the two DCs. A significant 
change in CD80 MFI was observed for both IL4DCs and MΦs therefore we could have 
directly compared the change of this molecule between GMDC, IL4DC and MΦs. However 
in both cases these significant fold increases only related to the difference between untreated 
and positive control-treated cells thus calculation of this fold change was also deemed 
unnecessary since the change merely acted as a biological control rather than a result per se. 
In no instance did the median fluorescence intensity of MHC-II, CD40, CD80 or CD86 



























  Supplementary Figure 11 GMDC, IL4DC and MΦ Vary In Their CD80 Response to s-L and ox-L. 
GMDC, M1 MΦs and B cells were prepared as previously described. APCs were pulsed overnight with soluble 
or oxidised lysate (1:1 ratio tumour cell:APC), LPS (1 μgmL) and CpG (0.3 μg/mL). After 24 hours cells were 
prepared for Flow Cytometric analysis of CD80 expression on the three APCs in response to s-L and,ox-L +/- 
LPS & CpG. Summary data of 4 independent experiments,. Statistically significant differences were calculated 
using the Kruskal-Wallis test followed by Dunn’s test, without Bonferroni correction. * p<0.05; ** p<0.01; *** 


































































CD80 MFI on Lysate-Pulsed
GM-CSF-stimulated Bone Marrow-Derived Cells (GM-DCs), 
GM-CSF+IL-4-stimulated Bone Marrow-Derived Cells (IL-4 DCs) 
& GM-CSF+IL-3-stimulated Bone Marrow-Derived Cells (BMMφ)
Results of 4 separate experiments;
Stats = unpaired Student's t-test compared with UT; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 




7.14 CD40 and CD80 Are Not Upregulated on B Cells in Response to Soluble or 
Oxidised Lysate Plus Activation Stimuli 
In contrast to MHC-II and CD86 (Chapter 3, Figure 13) neither CD40 nor CD80 percent 
positivity, nor MFI, increased significantly in response to any lysate plus activation stimuli 























































































CD80 % +ve B Cell Response to lysates +adjuvants Dec 2015
Supplementary Figure 12 The percentage of B Cells positive for CD40 or CD80 does not increase 
in response to s-L or ox-L plus activation stimuli. Splenic B cells were isolated by magnetic bead 
separation. B cells were pulsed overnight with s-L and ox-L (1:1 ratio tumour cell:APC) + LPS (1 
μg/mL) & CpG (0.3 μg/mL) as indicated on the x axes. The day after lysate loading cells were prepared 
for Flow Cytometric analysis of antigen presentation and costimulatory molecule expression in response 
to s-L and ox-L. Summary data of 3 independent experiments. Statistical analysis was not required. Error 



















































































CD40 % +ve B Cell Response to lysates + adjuvants Dec 2015


































































































































































CD40 MFI B Cell Response to lysates +adjuvants Dec 2015
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7.15 No Difference Is Observed In the Amount of IL-12 Produced by IL4DCs 
Compared to GMDCs 
The APC populations were compared for their ability to produce IL-12 in response to the two 
tumour lysates (Chapter 3, Figure 37). After 24 and 48 hours exposure to soluble lysate and 
oxidised lysate in the presence or absence of LPS & CpG cell conditioned media were 
collected and stored at -20°C for analysis by anti-IL-12 ELISA.  
 
GMDC, M1 MΦs and IL4DC all produced small amounts of IL-12 in response to soluble 
lysate (5.7 ng/mL, 9.7 ng/mL and 2 ng/mL respectively) (Supplementary Figure 13). 
Differences between the APCs were not statistically significant. All three APCs also produced 
IL-12 in response to oxidised lysate, however GMDC and M1 MΦs produced more IL-12 (11 
ng/mL and 8 ng/mL respectively) than IL4DC (4.4 ng/mL; p<0.05). There was no difference 
in IL-12 production between soluble lysate- and oxidised lysate-loaded APCs. 
  
Supplementary Figure 13 IL4DCs do not produce more IL-12 than GMDCs in response to lysate loading. 
GMDC, M1 MΦs and B cells were prepared as previously described. APCs were pulsed overnight with s-L and 
ox-L (1:1 ratio tumour cell:APC) +/- LPS+CpG. After 24 and 48 hours cell conditioned media (supernatants) 
were collected and stored at -20°C. Supernatants were analysed by anti-IL-12 ELISA. Observations from 1 
(IL4DC+B cell), 3 (IL4DC+s-L; IL4DC+ox-L) and 4 (remaining bars) independent experiments showing IL-12 
production after 48 hours exposure to s-L and ox-L +/- LPS+CpG. Statistically significant differences were 










































































IL-12 Production By GMDC, Mφ & IL4DC or DC+Bc at 24 & 48 hrs (CFSE+)
Results of at least 3 separate experiments; stats= Student's unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;
error bars = mean with s.e.m;
IL-12 production is greatest in GMDC, Mac & IL4DC stimulated with HOClwFTL, not sFTL;
The addition of LPS+CpG greatly increases IL-12 production by GMDC, M1 Mac & IL4DC cf lysate alone; 
in GMDCs, IL4DCs and M1 Macs there is no difference between LPS&CpG-treated & LPS&CpG+lysate-treated therefore this effect is due to LPS&CpG alone. However 
the addition of B cells lifts the IL-12 response beyond that of LPS&CpG alone. This does not occur in IL4DCs.
The addition of B cells appears to increase IL-12 production in GMDC+sFTL & GMDC+HOClwFTL cf GMDC alone;
The addition of B cells= no advantage with sFTL-loaded IL4DC;
HOClwFTL stimulates more IL-12 from GMDCs than sFTL, but not from Macs or IL4DC;
Mac+Bc was unfortunately not tested..
*
 361 
7.16 Lysate-loaded APC Do Not Express IDO 
It has been shown that DCs expressing indoleamine 2,3-dioxygenase (IDO) can suppress 
antigen-specific T-cell responses by killing T cells or inhibiting T-cell proliferation10–12. We 
tested IDO expression by DCs and found no difference in the median fluorescence intensity of 
IDO-1 between UT and lysate-treated cells (Supplementary Figure 14). These data combined 
with the extremely low numbers of B220+ cells in the co-cultures (data not shown) mean that 


























































IDO-1 DC & Mφ Resp To sFTL vs HOCl-wFTL 
Supplementary Figure 14 DCs and macrophages do not upregulate IDO-1 in response to soluble or 
oxidised lysate. Bone marrow-derived GMDC and MΦ were generated as previously described. 50,000 
APCs were pulsed overnight with s-L and ox-L (1:1 ratio tumour cell:APC) and LPS+CpG. After 24 hours 
cells were harvested, stained with live/dead exclusion dye, labeled with mABs against surface CD11c, fixed, 
permeabilised and labeled with mABs against intracellular IDO-1. Cells were stored overnight at 4°C and 
acquired by Gallios Flow Cytometer the next day. Data were analysed on FlowJo Version 10 and graphed in 
Prism . Summary data showing median fluorescence intensity of anti-IDO-1 after 24 hour exposure to s-L and 
ox-L or IFN-γ. Error bars = mean ± s.e.m of 3 independent experiments. UT: untreated. 
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Supplementary Figure 16 Gating strategy used in GMDC+B cell-T cell proliferation co-cultures. GMDCs 
and B cells were prepared as previously described. APCs were pulsed with whole OVA protein [50 µg/mL], or 
tumor lysate [6:1]) for 24 hours and co-cultured with CFSE-labeled CD4+ or CD8+ OT T cells, or both. Cells 
were harvested at 72 hours, stained with dead cell exclusion dye, and labeled with mABs against anti-CD19-PE 
anti-CD11c-PE (dump), anti-CD8α-APC, anti-CD3-PerCPCy5.5. Cells were fixed with 4% paraformaldehyde, 
stored overnight at 4°C and collected the following day on a Gallios Flow Cytometer. Data was analysed and 
graphed in FlowJo Version X. Dead cells (Live/Dead+) were gated out, followed by gating out of CD19+ and 
CD11c+ cells. Gating on CD3+CD8+ (or CD3+CD4+) double positive cells was used for assessment of T cell 
proliferation at 72 hours. Proliferation was expressed as the percentage of cells that had reduced fluorescence 
compared with untreated cells. Day 0 CFSE-stained cells, unstained cells and single stain control cells were used 
in every experiment to set gates. Representative data from numerous experiments. 
Supplementary Figure 15 Flow cytometry gating strategy for assessment of T cell purity. CD8+ and 
CD4+ T cells were isolated by positive or negative selection magnetic beads (AutoMACS Pro, Miltenyi 
Biotech), labeled with live cell exclusion dye (VPD450, BD Biosciences) and incubated with mABs against 
the surface markers CD8, CD3, CD27, CD28, CD44, CD62L, CD69, CD122 and CD127. Cells were fixed 
in 4% paraformaldehyde, stored overnight at 4°C and analysed the next day on a Gallios (Beckman 
Coulter). Fluorescence Minus One and unstained autofluorescence controls were used to guide the setting 
of positive and negative gates. Representative data from 15 independent experiments. 
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7.19 Tumour Lysate Dose Titrations 
B16.OVA tumour lysate contains OVA protein and therefore the peptide sequences 
recognised by the T cell receptors of OVA transgenic mice should be presented on MHC 
molecules after processing by APC. To identify which concentration of tumour lysate would 
generate the best T cell proliferation we pulsed GMDCs overnight with different volumes of 
tumour lysate. The following day VPD-450-labeled T cells were added to the lysate-pulsed 
APCs and after 72 hours the cells were analysed by Flow Cytometry for their proliferative 
response. The B16.OVA cells were resuspended at 2.4 x 107 c/mL prior to freeze-thaw lysis. 
Therefore 5 μL of lysate equated to the contents of approximately 1.2 x 105 lysed tumour 
cells. Unsorted splenocytes were cultured with the GMDCs at a ratio of 5 T cells to 1 GMDC. 
With whole freeze-thaw lysate no differences were seen between lysate doses and the 
proliferation stimulated with whole FTL was much lower overall - 18% for 10 μL of soluble 
lysate compared with 3%, 3% and 7% for 10, 20 and 50 μL of whole freeze-thaw lysate lysate 
respectively (Supplementary Figure 17).  
 
In one experiment 5 μL soluble lysate was insufficient to stimulate T cell proliferation, 10 μL 
stimulated T cell proliferation and 20 μL inhibited proliferation. In a repeat of this experiment 
10 μL of sFTL again yielded the highest T cell proliferation, with 20 μL and 50 μL reducing 
proliferation in a dose-dependent manner.  
 
We also compared lysate made with tumour cells that had been incubated in the protein 
transport inhibitor Brefeldin A for 1 hour or 5 hours (Supplementary Figure 18). The first 
experiment returned no difference between these two lysates and the second yielded 34% 
proliferation for cells that had been Brefeldin A-treated for 5 hours, compared with 21% 
proliferation for cells that had been incubated in Brefeldin A for 1 hour. We reasoned that this 
second experiment made more sense and used 10 μL of 5-hour Brefeldin A-treated soluble 
lysate in future experiments. No dose response was seen between lysate doses in OT-II CD4+ 






























































































































Supplementary Figure 17 Ten 10 μL of 5-hour Brefeldin-A-treated soluble freeze thaw lysate 
stimulates optimal CD8+ T cell proliferation. Day 6 C57/BL6 GMDC, were pulsed overnight with 
whole OVA protein (50 - 100 µg/mL) and the B16.OVA s-L doses indicated. The following day the APC 
were pulsed with SIINFEKL peptide (2 µg/mL) for at least 4 hours prior to addition of unsorted, VPD-
labeled OT-I splenocytes at a ratio of 10 T cells:1 DC. 72 hours later proliferation was assessed by Flow 
Cytometry (Fortessa LSR). No statistically significant differences were recorded. Error bars = s.e.m of 2-3 
experiments carried out in duplicate or triplicate. 
Supplementary Figure 18 Tumour cells treated with Brefeldin A for 5 hours stimulate stronger CD8+ T 
cell proliferation than tumour cells treated with Brefeldin A for 1 hour. Day 6 C57/BL6 GMDC, were 
pulsed overnight with whole OVA protein (50 µg/mL) and the lysates of B16.OVA s-L from cells treated with 
Brefeldin A for 1 hr or 5 hrs prior to freeze-thaw lysis, at the doses indicated. The following day the APC 
were pulsed with SIINFEKL peptide (2 µg/mL) for at least 4 hours prior to addition of unsorted, VPD-labeled 
OT-I splenocytes at a ratio of 10 T cells:1 DC. 72 hours later proliferation was assessed by Flow Cytometry 
(Fortessa LSR). No statistically significant differences were recorded.  Error bars = s.e.m of 1 experiment plated 
in triplicate and carried out in tandem (2 identical plates). 
Expt 1a.1-6 DCs as Antigen Pr senting Cells 
For Proliferation of OT-I T Cells 
























































Student's paired T-test. * P < 0.05. ** P < 0.005, *** P < 0.0001. Error bars = s.e.m 
of triplicates of 2 plates
Background is higher than usual. Take background off TL result for more 
realistic TL result
 365 
7.20 CD8+ T Cell Proliferation Is Observed After 72 Hour Incubation with 
Lysate-Loaded GMDCs But Not with MΦs or B cells 
To verify the optimal time point for harvesting undefined antigen-primed T cells we assessed 
proliferation at 24, 48 and 72-hours (Supplementary Figure 19). Initial experiments indicated 
that significant CD8+ T cell proliferation in response to soluble lysate could sometimes be 
achieved when priming with GMDCs (Supplementary Figure 19A). However the level of 
response was usually more moderate and overall CD8+ proliferation averaged approximately 
20%. Initial experiments also indicated that CD4+ T cells could proliferate in response to 
undefined lysate antigens (Supplementary Figure 19B). However these early data could not be 
reproduced and Supplementary Figure 19C shows the CD4+ T cell response that was 
consistently observed throughout remaining experiments.  
 
Supplementary Figure 19D and E show the lack of CD4+ and CD8+ T cell proliferation in 
response to soluble lysate-loaded M1 MΦs. Supplementary Figure 19F and G show the lack 























































Expts 1a.3-1,2,3: MΦs as Antigen Presenting Cells 
For Proliferation of CD3+CD4+  OT-II T Splenocytes
in response to B16OVA tumor lysate 

















































































48 hrs 72 hrs24 hrs
Student's paired T-test. * P < 0.05. ** P < 0.005, *** P < 0.001, **** P < 0.0001. 
Error bars = s.e.m of 3 separate experiments carried out in triplicate
Expts 1a.3-1,2,3: MΦs as Antigen Presenting Cells 
For Proliferation of CD3+CD8+ OT-I Splenocytes 
in response to B16OVA tumor lysate 











































































48 hrs 72 hrs24 hrs
Student's unpaired T-test. * P < 0.05. ** P < 0.005, *** P < 0.001, **** P < 0.0001. 
Error bars = s.e.m of 3 separate experiments carried out in triplicate
Expt 1a.1-9 DCs as Antigen Presenting Cells 
For Proliferation of OT-I T Cells 






































































Student's paired T-test. * P < 0.05. ** P < 0.005, *** P < 0.0001. Error bars = s.e.m 
of triplicates









































































Expt 1a1-9 DC OT-II 24,48,72 hrs Reanalysed Dec 2015
















































Supplementary Figure 19 Optimal CD8+ and CD4+ T cell proliferation response to cognate antigen is 
observed at 72 hours. Bone marrow-derived precursor cells were incubated for 6 days in GM-CSF (20 
ng/mL)+FCS (5%) (GMDC) and 10 days in GM-CSF (5 ng/mL+10% FCS (M1 MΦ). B cells were freshly 
isolated from C57BL/6 spleens by magnetic bead isolation (AutoMACS Pro). 4 x 104 APCs were pulsed 
overnight with the soluble fraction of freeze-thaw lysate (sTL) (6:1 ratio tumour cell:APC) or whole OVA 
protein (50 µg/mL). The following morning 2 µg/mL SIIN peptide was added for at least 4 hours prior to the 
addition of VPD450-stained OT-I splenocytes (10 T cell:1 DC). After 72 hours cells were stained with dead 
cell exclusion dye, labeled with mABs to surface markers and fixed in 2% paraformaldehyde. Cells were 
stored overnight at 4°C and collected the following day on an LSR Fortessa Flow Cytometer. Data was 
analysed on FlowJo Software version 9 and graphed in Prism...Summary data of T cell proliferation after 72 
hours exposure to sFTL-loaded GMDC, M1 MΦ or B cells. The results of 1 representative experiment, plated 
in triplicate are shown for each APC. Statistically significant differences were assessed by Kruskal-Wallis 
one-way ANOVA followed by Dunn’s post test with Bonferroni correction.  p<0.05;. Error bars = mean ± 
s.e.m.   
Expt 1a.2-2 B Cells as Antigen Presenting Cells 
For Proliferation of OT-II T Cells 





















































Student's paired T-test. * P < 0.05. ** P < 0.005, *** P < 0.0001. Error bars = mean with SD of triplicates

















48 hrs 72 hrs
Expt 1a.2-2 B Cells as Antigen Presenting Cells 
For Proliferation of OT-I T Cells 




































































7.21 SIINFEKL Response Is Consistently Low Across Different SIINFEKL 
Sources 
 The CD8+ T cell response to SIINFEKL peptide was lower than expected and so we 
compared the GMDC-primed T cell response to our SIINFEKL and to the SIINFEKL of three 
other independent labs (Supplementary Figure 20). There was no concentration-response to 
different doses of SIINFEKL (2, 4, 8, 10 μg/mL; data not shown) and no differences in the 
response to SIINFEKL from the four different sources indicating that the source of the low 
response did not lie in our batch of SIINFEKL  
 
  
Supplementary Figure 20 The source of low CD8+ T cell response to SIINFEKL peptide did not lie with 
our batch of SIINFEKL. Day 6 GMDC were loaded with SIINFEKL peptide (2,μg/mL) was added for 4 hours 
prior to the addition of unsorted, Violet Proliferation Dye-labeled OT-I splenocytes (10:1 ratio T cells to DC). 72 
hours later the cultures were dyed with dead cell exclusion dye and labeled with mABs against CD11c, CD3 and 
CD8. Cells were fixed in 2% PFA, stored overnight and proliferation assessed by Flow Cytometry the following 
day on an LSR Fortessa Flow Cytometer. Flow data was analysed on FlowJo software V9 and graphed in Prism 
Summary data of 1 experiment, 2 plates plated in triplicate. Path: our laboratory’s SIINFEKL; Pharm, MW and 
RK correspond to independent laboratories sources of SIINFEKL. 
Expt 1a.1-8 DCs as Antigen Presenting Cells 
For Proliferation of OT-I T Cells 























































7.22 Activated Soluble Lysate-Loaded GMDCs Induce Less CD8+ Proliferation 
Than Unactivated GMDCs 
 When compared to Figure 43 in Chapter 4 we observed that GMDC loaded overnight with 
sFTL and LPS&CpG stimulate less CD4+ and CD8+ proliferation than GMDCs loaded with 
sFTL alone (Supplementary Figure 21). The GMDC continued to induce an approximately 3 
fold proliferation over UT cells (p<0.05 when calculated using Mann Whitney U test; ns 
when differences between the 3 groups are assessed by Kruskal-Wallis followed by 
Bonferroni-adjusted Dunn’s post test). That the reduction in proliferation could be attributable 
to the use of LPS&CpG was not recognized at the time. Nonetheless, the addition of 












Supplementary Figure 21 GMDCs pulsed overnight with sFTL and activation stimuli induce less CD8+ 
T cell proliferation than lysate-loaded GMDCs alone. Day 6 GMDC, prepared as described previously. 5 x 
104 GMDCs were pulsed overnight with lysate (6:1 tumour cell:APC) or OVA protein (50 μg/mL). The 
following morning the irrelevant melanoma peptide gp100 and OVA257-264 peptide (SIINFEKL) or OVA329-337 
peptide were added 4 hours prior to the addition of 0.5 x 106 Violet Proliferation Dye 450-labelled CD4+ or 
CD8+ T cells. 72 hours later cells were stained with dead cell discrimination dye and labeled with mABs 
against CD11c, CD3 and CD8. Cells were fixed in 2% paraformaldehyde and stored overnight at 4°C and 
analysed the following day on an LSR Fortessa Flow Cytometer. Flow data was analysed on FlowJo software 
V9 and graphed in Prism. Summary data of the mean of 4 independent experiments. Statistical differences 
were assessed by Kruskal-Wallis test followed by Dunn’s post test with Bonferroni correction. ** p<0.01.. 

































Results of 3 expts  Error bars = s.e.m. Stats: Student's unpaired t-test; *p<0.05
Stimulation of OT-I T cells In Response to DCs pulsed O/N 
with sFTL B16OVA Tumor Lysate+adjuvants
**
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7.23 Activated B cells Stimulate More T Cell Proliferation Than Unactivated B 
Cells 
We compared the T cell stimulatory capacity of immature B cells loaded with lysate and that 
of B cells activated for 24 hours with CpG prior to the addition of lysate. Unactivated lysate-
loaded B cells were unable to stimulate CD4+ or CD8+ T cell proliferation (Supplementary 
Figure 22). No improvement in CD4+ or CD8+ proliferation was observed in CpG-loaded B 
cell groups.   
 
The addition of CpG to the lysate yielded no significant increases in T cell proliferation over 
UT, lysate-loaded or OVA-primed groups, thus these results were interpreted to mean there 
was no advantage to using activated B cells for presenting lysate antigen and experiments 
were continued for some time using unactivated B cells. This may explain the delay in seeing 




Supplementary Figure 22 Activating B cells with CpG alone does not stimulate greater CD4+ or CD8+ T 
cell proliferation than unactivated B cells. Freshly isolated C57/BL6 splenocytes were labeled with anti-CD43 
magnetic beads and B cells isolated by AutoMACS Pro. The negative fraction was loaded with soluble freeze-
thaw lysate (5.0 x 105 cells/well) and/or CpG (2 μg/mL) overnight and the following day unsorted, Violet 
Proliferation Dye-labeled OT-I or OT-II splenocytes were added to the B cells at a ratio of 10 T cells to 1 B cell. 
72 hours later the cultures were stained with dead cell exclusion dye and labelled with mABs against CD19, CD3, 
CD8 or CD4. Cells were fixed in 2% PFA, stored overnight and proliferation assessed by Flow Cytometry the 
following day on a Gallios Flow Cytometer.. Flow data was analysed on FlowJo software V9 and graphed in 
Prism. Statistically significant differences were calculated using Kruskal-Wallis followed by Dunn’s test with 
Bonferroni adjustment. *p<0.05. Summary data of 1 experiment showing the mean +/- the s.e.m of triplicates. 
Activated vs Unactivated B Cells as Antigen Presenting Cells 
For Proliferation of OT-I (L) & OT-II (R) T Cells 






















































Student's unpaired T-test. * P < 0.05. ** P < 0.005, *** P < 0.0001. Error bars = m an with SD of triplicates













7.24 T Cells Vary in Their Viability Response To Soluble and Oxidised lysates 
During the 72-hour proliferation assays we observed large reductions in the viability of both 
CD4+ and CD8+ T cells primed with APCs loaded with either lysate (Supplementary Figure 
23 ). The one exception to this observation was the viability of CD8+ T cells primed by 
oxidised lysate-loaded MΦs. Consistent with the excellent viability of MΦs loaded with both 
lysates (Figure 36), T cells primed by oxidised lysate-loaded MΦs showed the best overall 
viability (Supplementary Figure 23 ). 
 
The viability of CD4+ and CD8+ T cells primed by soluble lysate-loaded M1 MΦs was 
higher than the viability of T cells primed by GMDC+s-L (CD4+: 73% versus 24% 
respectively; CD8+: 62% versus 28% respectively).  
 
The combination of an M1 MΦ with a GMDC showed a trend toward rescued viability in 
both CD4+ and CD8+ T cell cultures compared with GMDC alone. When CD8+ T cells were 
primed with GMDC loaded with s-L, live T cells constituted only 22% of the population 
compared with 53% in GMDC+MΦ+s-L-primed samples. The same trend was seen oxidized 
lysate groups with 32% live T cells in the GMDC-primed samples versus 64% in the 
GMDC+MΦ-primed wells. The same pattern of viability rescue in the GMDC+MΦ groups 
was observed in the CD4+ T cells. However none of these differences were statistically 
significant. There was no difference in viability observed between GMDC-primed and 
GMDC+Bc-primed samples. 
 
CD4+ and CD8+ T cells primed by lysate-loaded IL4DC showed the worst viability overall. 
Experiments using IL4DCs combined with other APCs were only conducted twice due to the 
overall low viability. Therefore, while there was a general trend of the lowest live cells in 
soluble lysate groups, nothing statistically significant can be calculated. Given that the 
viability of IL4DC-primed T cells was so low we discontinued the evaluation of these APCs. 
 
Together these data demonstrate a negative effect of these lysates on T cell viability, 
particularly when presented by GMDC or GMDC+B cells. It has been suggested that the use 
of protease inhibitors during lysate generation may be responsible for the negative impact on 
the T cells. However it was assumed that the small volumes of lysate would not contain 
sufficient protease inhibitors to impact the T cells significantly and so comparison of lysate 
+/- protease inhibitors was not conducted during this project. Given that Chiang et al do not 





   
Supplementary Figure 23 CD4+ and CD8+ OT-I T Cells Viability Response to Presentation of soluble and 
oxidised lysate by Different APCs. Bone marrow-derived precursor cells were prepared as previously described. 
APCs were pulsed overnight with s-L and ox-L (1:1 ratio tumour cell:APC) and LPS+CpG. The following day CD4+ 
and CD8+ cells were isolated from spleens of OT-I mice by AutoMACS Pro (Miltenyi Biotech) negative selection 
bead separation and stained with CFSE prior to being added to the lysate-pulsed APCs at a ratio of 1 T cell:10 APCs. 
After 72 hours cells were stained with dead cell exclusion dye (Fixable Viability Stain 450, BD Biosciences), labeled 
with mABs to surface markers and fixed in 4% paraformaldehyde. Cells were stored overnight at 4°C and collected the 
next day on a Gallios Flow Cytometer. Data was analysed on FlowJo version X and graphed in Prism..Summary data 
of T cell viability after 72 hours exposure to s-L and ox-L. Results of two (IL4DC) and three (GMDC, MΦ B cell) 
independent experiments. Statistically significant differences were assessed by Kruskal-Wallis test followed by 















































































































































OT-II T Cell VIABILITY After Presentation of 
Soluble Freeze-Thaw Lysate or
Oxidised Whole Freeze-Thaw Lysate 
by Different APCs  
Results of 4 separate experiments; Stats: Sudents unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;
error bars = mean with s.e.m;














































































































































































OT-I T Cell VIABILITY After Presentation of 
Soluble Freeze-Thaw Lysate or
Oxidised Whole Freeze-Thaw Lysate 
by Different APCs  
Results of 2-4 separate experiments; Stats: Sudents unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;
error bars = mean with s.e.m;
APC and Lysate Used To Stimulate T cells
HOCl-wFTL less toxic to GMDC than sFTL
Macrophages less affected by lysate than 
GMDC
Adding in a Mac reduces overall cell death 
in GMDC+Mac or IL4DC+Mac cultures
IL4DC more susceptible to lysate-induced 
death than GMDC
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7.24.1 Lysate-Loaded APCs Reduce T Cell Viability  
CD4+ and CD8+ T cell viability was higher in oxidised lysate-primed T cells than soluble 
lysate-primed T cells (Supplementary Figure 23). This result contrasted with GMDC viability, 
which dropped strikingly when GMDC were pulsed with oxidised lysate+LPS&CpG. IL4DC-
primed T cell viability was significantly lower than that of GMDC-primed T cells. These 
results paralleled the reduced IL4DC viability compared to GMDC when loaded with lysate. 
Thus, while the oxidised lysate had a negative impact on GMDC and IL4DC viability T cell 
viability was consistently higher when T cells were primed with oxidised lysate-loaded APC. 
We therefore continued to evaluate its usefulness. 
 
With the exception of MΦs there were only small differences in viability between CD8+ T 
cells primed with soluble or oxidised lysate irrespective of which APC(s) presented the 
lysate-derived antigens. There were, however, differences in the number of live T cells 
depending on which APC(s) presented the lysate-derived antigens. GMDC alone and 
GMDC+Bc yielded the lowest numbers of live T cells and these numbers were similar 
between these two lysate groups. A small improvement in T cell viability was observed in the 
triple combination group but the best viability occurred in the MΦ and GMDC+MΦ groups. 
 
We observed that by Day 3 lysate-primed T cells were in clumps of dead or dying cells and 
large numbers of cells had disappeared (Appendix 1, Supplementary Figure 23), presumably 
phagocytosed by the APCs as part of homeostatic clonal deletion of autoreactive T cells13 or 
as a result of activation induced cell death (AICD)14. Lysate contains a mixture of TAAs and 
self antigens. In the periphery self-antigen is presented on DCs and other non-professional 
APCs such as Lymph Node Stromal Cells (LNSCs)15. For activation of lymphocytes to occur, 
both antigen and costimulatory ‘second’ signals must be present. Absence of either will result 
in failure of lymphocyte activation and self-antigens presented to auto-reactive T cells in the 
periphery will result in T cell anergy or deletion via AICD mechanisms. T cell activation 
causes upregulation of the death receptor Fas (CD95) and its ligand Fas-ligand (Fas-L) 
resulting in cell suicide and sororicide16. AICD forms part of normal homeostatic peripheral 
tolerance mechanisms against self reactive mature T cells and is induced by repeated 
antigenic stimulation, such as may be found in our lysate-loaded APC-T cell co-cultures14. 
Only activated T cells are sensitive to this form of apoptotic death, which is enhanced by IL-2 
and is Fas-dependent.  
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One reason for reduced T cell viability in our samples may be the induction of AICD by 
APCs via Fas-FasL-mediated pathways.  Freshly isolated CD8+FasL+ murine lymphoid DC 
have been shown to induce apoptosis in activated CD4+ T cells17. The DCs in our study were 
CD8 negative however another study demonstrated FasL+CD8- DC also induced AICD 
showing that CD8 expression may be unrelated to this function18. The expression of Fas or 
FasL on the T cells or APCs was not assessed, therefore we cannot ascribe the cause of death 
to Fas-FasL-mediated signaling. But it remains a biologically plausible explanation. 
 
Tumour-infiltrating MΦs have been shown to strongly induce apoptosis in activated CD8+ T 
cells via MΦ-associated TNF and Nitric oxide (NO). However we saw the lowest T cell death 
in our MΦ-stimulated samples. In addition the conditioned cell media from all our samples 
were negative for TNF-α. Thus it is unlikely that TNF-α played a role in the T cell death. 
Nitric oxide (NO) plays a dual role in immuno-pathologies19 and immune-mediated defense 
against micro-organisms20. It is known that high dose NO inhibits IL-12 production in MΦs 
whereas low dose NO enhances differentiation of murine TH1 cells21. Given that we saw 
excellent levels of IL-12 expression across GMDC-, MΦ- and IL4DC-lysate-primed T cells 
(Figure 17, Figure 16) it is also unlikely that NO was responsible for the T cell death. 
 
The use of chemotherapy to reduce tumour burden prior to ACT restores the CTL’s ability to 
overcome the tumour. These effects have been ascribed to the combination of de-bulking by 
direct chemotherapeutic tumour killing, as well as CTL activation by the dead and dying 
tumour cells22 and the reduction in circulating TREGS23. In this study the deletion and 
inactivation of CTLs was clearly seen in in vitro assays in which the APCs had been pulsed 
with soluble lysate. The APCs were clearly able to process and present TAA as evidenced by 
their ability to stimulate T cell proliferation. However after 72 hours the T cell proliferation 
ceased and the T cells appeared ‘stunned’ and began to die off. Proliferation did not cease and 
die-off did not occur in T cells activated by APCs pulsed with OVA protein. This points to a 
failure, not at the level of antigen presentation but at the level of T cell function post-antigen 
presentation. Something in the lysate switches off the CTLs, or, the immune environment 
induced by presentation of lysate antigens induces a T cell-destructive milieu. In a study by 
Prato and colleagues they state that “it is still unclear whether CTL inactivation occurs as a 
result of recognition of cognate Ag or is mediated by soluble factors acting in a non-antigen–
specific fashion”24. This current study does not clarify that issue and we recognise the need for 
dissection of the pathways involved in T cell activation to identify at what point, and by what 
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mechanisms, the CTLs are deactivated. We also recognise the need for comparison of lysates 
generated with and without protease inhibitors to ascertain their impact on T cell ‘stunning’. 
 
The hypothesis of APC phagocytosis of lysate-primed T cells could be tested by an uptake 
assay in which T cells are stained with CFSE prior to culturing with APCs, harvested on Day 
2 of co-culture and gated on CFSE+CD11c+MHC-II+CD3- cells. If the theory is correct two 
populations should be observed: a larger population of CFSE+CD11c+MHC-II+CD3- cells 
and a much smaller fraction of proliferating, TAA-reactive CFSE+CD3+ T cell. This assay 
would provide a proxy method for quantifying the percentage of potentially tumour-reactive T 
cells in the cultures. These T cells could potentially also be tested with soluble peptide MHC 
tetramers to confirm true tumour reactivity.  
 
To summarise, striking differences in both APC viability and T cell viability were noted 
between the two types of lysate. Despite the higher cell death in oxidised lysate-loaded APCs 
we continued to compare the response to the two lysates because of the improved viability in 
the T cells primed with oxidised lysate-loaded APCs.  
 
As a final comment on the low T cell numbers, interesting work in the Busch and Schumacher 
labs has demonstrated that as few as one T cell can yield the diverse range of cells that are 
required for an effective immune response25–28. Furthermore Busch et al have evaluated a 
lower limit of antigen-specific T cells required for protective immunity in a mouse model of 
bacterial infection  as well as preliminary human data in the stem cell transplantation setting29. 
They reported that as few as 1-100 CD62LHI CD8+ T cells proliferated, differentiated into 
different subpopulations and conferred immunity. Other groups have argued the case for 
observing physiologically relevant doses of T cells and demonstrated that seeding as few as 
∼10–50 TCR-transgenic T cells, which constitute a fraction of the endogenous repertoire, 
allowed vigorous proliferation and analysis of TCR-transgenic cells after infection in a 
scenario representing normal physiology for any individual TCR30. These observations bear 
important relevance to ACT for cancer with its current requirement of high numbers of TAA-
specific T cells. While the low numbers of viable T cells generated in this study were 
disappointing, the high numbers that have been used in clinical trial to date may not 
necessarily be required – though this hypothesis remains to be tested. Nevertheless, despite 
the less than ideal T cell proliferation we were able to generate an in vivo response with these 
lysate antigen-primed T cells. Thus the quality of the cells generated may be more important 
than the quality. 
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7.25 Supporting Long Term In Vitro Culture of T Cells 
The choice of exogenous cytokines in growth media is an important factor for directing the 
outcome of anti-tumour immune responses. Highly regulated cytokines are important for for 
driving differentiation of different T cell subsets from their uncommitted precursors as well as 
for supporting naïve and antigen-experienced T cell survival.  
 
Lysate had a negative effect on both APC and T cell viability. We therefore evaluated IL-2, 
IL-7, IL-15 and IL-21 by carrying out concentration titrations to verify if they would have any 
improvement on viability or fold expansion of lysate-primed CD4+ or CD8+ T cells. During a 
personal discussion Professor Susanne Heinzel (Walter and Eliza Hall Institute, 10.7.15) 
mentioned that high cytokine doses are needed to see a good T cell response. For this reason 
we chose the 10-100 ng/mL range for our concentration titrations. Supplementary Table 4 
shows the cytokine concentration titrations examined. 
 
The combination of IL-7, IL-15 and IL-21 has been shown to preferentially expand 
CD8+CD44+CD62L+ central memory T cells (TCM) in ACT for murine melanoma31. 
Therefore we compared the proliferation of lysate-primed T cells cultured in the doses of IL-
2, IL-7, IL-15 and IL-21specified in Supplementary Table 4. 
 
Supplementary Table 4 Cytokine Dose Titrations 
IL-2 
2 ng/mL 2 ng/mL 2 ng/mL 2 ng/mL 
IL-7 
10 ng/mL 20 ng/mL 50 ng/mL 100 ng/mL 
IL-15 
10 ng/mL 20 ng/mL 50 ng/mL 100 ng/mL 
IL-21 
10 ng/mL 20 ng/mL 50 ng/mL 100 ng/mL 
GM-CSF 
5 ng/mL 5 ng/mL 5 ng/mL 5 ng/mL 
 
IL-2 was added for the first 24 to 48 hours only as previous work from our laboratory showed 
that prolonged IL-2 led to activation induced cell death (AICD)32. GM-CSF was also included 
in the T cell medium as GM-CSF-differentiated DCs can die when GM-CSF is removed from 
the culture medium33, therefore we wished to eliminate GM-CSF-starvation-induced DC 
death as a confounding variable. Also GM-CSF has been used successfully as an adjunct in 
human trials of immunotherapy for cancer due to its effects on DCs which skew T cells 
toward Th1 responses34–36. 
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No improvement in fold expansion was observed with any of these cytokines (Supplementary 
Figures 24, 25). The “fold expansion” was far too low to be considered fold expansion per se, 
but slight, dose-dependent improvements in viability were observed.  
 
The 100 ng/mL of IL-7, IL-15 and IL-21 was the only dose that trended toward an 
improvement in FE/viability for CD8+ T cells primed by IL4DC pulsed with s-L compared 
with 10 ng/mL (Supplementary Figure 24). There was no concentration-dependent 
improvement in FE/viability for T cells primed by IL4DC loaded with ox-L. 
 
The “fold expansion” doubled from 0.002 at the 10 ng/mL dose to 0.005 for the 100 ng/mL 
dose in sFTL-loaded GMDC-primed CD8+ T cells. For T cells primed by GMDC loaded with 
HOCl-wFTL 100 ng/mL of these cytokines also generated the highest FE/viability (0.011 FE 
compared with 0.0025 FE for 10 ng/mL) (Supplementary Figure 25). However this data had a 
very wide response range (0.003 to 0.02). We continued with the 100 ng/mL dose in order to 





















Supplementary Figure 24 CD8+ T cells primed by IL4DCs loaded with soluble lysate show no 
concentration-dependent improvements in viability when cultured for 10 days with IL7, IL-15 and 
IL-21. IL4DCs were prepared as previously described and pulsed overnight with s-L and ox-L (1:1 ratio 
tumour cell:APC) and LPS+CpG. The following day CD8+ cells were isolated from spleens of OT-I 
mice by AutoMACS Pro negative selection bead separation and added to the lysate-pulsed APCs at a 
ratio of 1 T cell:10 APCs. After 10 days live cells were counted by Trypan Blue exclusion. Results were 
graphed in Prism. Summary data of T cell fold expansion after days co-culture with s-L and ox-L-loaded 
APCs.  Results of three independent experiments. No statistically significant differences were calculated. 
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Supplementary Figure 25 CD8+ T cells primed by GMDCs loaded with s-L and ox-L show no 
concentration-dependent improvements in viability when cultured for 10 days with IL7, IL-15 and 
IL-21. GMDCs were prepared as previously described and pulsed overnight with s-L and ox-L (1:1 ratio 
tumour cell:APC) and LPS+CpG. The following day CD8+ cells were isolated from spleens of OT-I mice 
by AutoMACS Pro negative selection bead separation and added to the lysate-pulsed APCs at a ratio of 1 T 
cell:10 APCs. After 10 days live cells were counted by Trypan Blue exclusion. Results were graphed in 
Prism. Summary data of T cell fold expansion after days co-culture with s-L and ox-L-loaded APCs.  
Results of three independent experiments. No statistically significant differences were calculated. Error 
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7.26 The Combination of B Cell+MΦ Does Not Induce Greater Fold Expansion of 
CD8+ T Cells Than GMDC Alone When Restimulating OVA-Primed Cells 
We attempted to re-stimulate OVA-primed CD8+ T cells with the same or different APC(s). 
In our hands OVA-primed CD8+ T cell proliferation was variable, and usually less than that 
observed by others in our lab and in other groups. Therefore limited data also exists for OVA-
primed and re-stimulated CD8+ T cells (Supplementary Figure 26). In contrast to the oxidised 
lysate-primed and re-stimulated CD8+ T cells, the combination of B cell+MΦ during re-
stimulation resulted in an enhanced fold expansion of OVA-primed and restimulated CD8+ T 
cells, irrespective of which APC(s) had primed the T cells. This was the case in every group 
except the GMDC-primed T cells, which saw the greatest fold expansion in cells primed and 
restimulated with a GMDC. Conversely, CD8+ T cells primed by a GMDC presenting whole 
OVA protein and restimulated by the Bc+MΦ combination presenting OVA protein resulted 
in the lowest fold expansion. In the OVA-primed CD8+ T cells priming with a GMDC and 
restimulating with a GMDC yielded the greatest fold expansion. In no group was 
restimulation with the Bc+MΦ combination able to induce greater fold expansion than 
restimulation with a GMDC alone. However this experiment was only successfully conducted 



















































































































































































































































































































KOP4 D20 OT-I T cell Fold Expansion 
(Male & Female)
Supplementary Figure 26 Irrespective of which APC(s) are used to prime CD8+ T cells, the combination of 
B cell+MΦ has a positive effect on the expansion of restimulated CD8+ T cells, except where T cells have 
been primed by an OVA-pulsed GMDC. GMDC, M1 MΦs and B cells were prepared as previously described. 
5.0 x 105 individual APCs, or combinations thereof, were pulsed overnight with whole OVA protein (50 µg/mL), 
and LPS+CpG. The following day CD8+ T cells were isolated by magnetic bead negative selection and added to 
APCs (10:1 Tcell:APC). APCs and T cells were co-cultured for 10 days. T cells were counted and re-stimulated 
with OVA-pulsed APCs as indicated on the x-axis. Cells were cultured for a further 10 days and fold expansion 
assessed by counting live cells under Trypan Blue dead cell exclusion staining. Results were graphed in Prism. 
Summary data of 1 experiment.. 
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Supplementary Figure 27 Flow cytometry gating strategy for assessment of phenotype in naïve CD4+ and 
CD8+ T cells. A) CD4+ and B) CD8+ T cells were isolated by negative selection magnetic beads (AutoMACS 
Pro), labeled with live cell exclusion dye and incubated with mABs against the surface markers CD8, CD27, 
CD28, CD44, CD62L, CD69, CD122 and CD127. Cells were fixed in 4% paraformaldehyde, stored overnight at 
4°C and acquired the next day on a Gallios Flow Cytometer. Data was analysed and graphed in FlowJo Version 
X. The quadrant markers for bivariate dot plots were set based on unstained autofluorescence controls and verified 




7.28 Gating Strategy and Raw Data of Day 10 Primed CD8+ T Cell Phenotype 
  
Supplementary Figure 28 Sample raw data of Day 10 oxidised lysate-primed CD8+ T cells. Day 6 GMDC and 
freshly isolated B cells were prepared as previously described. 1 x 105 GMDC or 0.5 x 105 GMDC and 0.5 x 105 B 
cells were pulsed overnight with whole OVA protein (50 µg/mL) and B16.OVA oxidised lysate (1:1 ratio tumor cell 
to APC) plus LPS&CpG. The following day freshly isolated OT-II and OT-I splenocytes were labeled with CD4 and 
CD 8 negative selection bead cocktails respectively and sorted by AutoMACS Pro and plated with lysate-loaded 
APCs (10:1 ratio, T cell to APC). APCs and T cells were co-cultured for 10 days with fresh media and cytokines 
being replaced every 2 days. The resultant CD8+ T cells were stained with dead cell exclusion dye (FVS450) and 
labeled with mABs against the surface molecules CD3, CD8, CD27, CD28, CD44, CD122, CD127, PD-1, CD62L 
and CD69. Labeled cells were fixed in 4% PFA, stored overnight at 4°C and collected the following day on a 
Gallios Flow Cytometer. Data was analysed and graphed in FlowJo VX Software. Representative data of 7 
independent experiments. 
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7.29 Phenotype of T Cells Primed with Lysate-loaded APCs  
Wherever possible within the liminations of this technically challenging assay we assessed the 
phenotype of T cells primed with lysate tumour antigens. Supplementary Figure 29 shows the 
summary data that could be obtained. While results for OVA-primed T cells could be 
obtained, despite methodology modifications, sufficient live lysate-primed T cells for 
phenotyping were not always available at Day 10. Lysate-primed CD8+ T cells were 
consistently negative for CD28, PD-1, CD122 and CD127 We observed up to 13% expression 
of CD127 on naïve CD8+ T cells and we compared two different anti-CD127 antibodies on 
different fluorophores. Therefore it does not appear that the low expression of CD127 on 
lysate-primed T cells was due to issues with the antibody. We also compared three different 
antibodies conjugated to two different fluorophores for CD28 to eliminate antibody binding 
as the issue for the non-existent CD28. Other students in our lab have experienced the same 
issues with CD122 expression therefore, once again we were satisfied that the problem was 
not with the antibody. Due to the lack of data and variability in results insufficient data is 

















































































































KOP4 D10 Primed T cell Phenotype CD27 
Restifo (2005) reported MFI for CD27, CD62L, CD69, CD44, not % +ve
Make graph of MFI as well
Make graph comparing naive MFI with D10 (& D20) MFI to show change from
naive to "early effector" to "effector" phenotype 
Early effectors do better in ACT than fully differentated effectors
Loss of CD27 in fully differentiated effector T cells may be responsible for/
contribute to CD8+ T cell impaired expansion & survival after ACT (Restifo, 2005)
Note reduced CD27 on DC & DC+Bc-primed T cells. CD27 is higher on Mφ, DC

























































































KOP4 D10 Primed T cell Phenotype CD62L 
Restifo (2005) reported MFI for CD27, CD62L, CD69, CD44, not % +ve
Make graph of FI as well
Restifo, 2005: CD62LHI subset have superior anti-tumor properties. Interestingly, the T cells in this graph with the 
highest CD62L all have Mφs in the mix (DC+Mφ (OVA & lysate primed), Mφ, BcMφ & Triple
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 Supplementary Figure 29 Day 10 CD8+ T cells primed by oxidized lysate-loaded APCs do not 
express CD28, PD-1, CD122 or CD127. GMDC, M1 MΦs and spleen-derived B cells, or 
combinations thereof, were prepared as previously described and pulsed overnight with whole OVA 
protein (50 µg/mL), B16.OVA ox-L (1:1 tumour cell:APC) and LPS+CpG. The following day CD8+ 
T cells were isolated by magnetic bead negative selection (AutoMACS Pro), co-cultured with APCs 
for 10 days and then harvested for phenotype analysis. Cells were stained with dead cell exclusion 
dye and labeled with mABs against the surface molecules CD8, CD27, CD28, CD44, CD69, CD122, 
CD127, CD62L and PD-1. Cells were fixed with 4% paraformaldehyde, stored overnight at 4°C and 
acquired on a Gallios Flow Cytometer the following day. Data was analysed in FlowJo Version X 




















































































KOP4 D10 Primed T cell Phenotype CD28 
Restifo (2005) reported MFI for CD27, CD62L, CD69, CD44, not % +ve
Make graph of MFI as well
Make graph comparing naive MFI with D10 (& D20) MFI to show change from
naive to "early effector" to "effector" phenotype 
Early effectors do better in ACT than fully differentated effectors
Loss of CD27 in fully differentiated effector T cells may be responsible for/
contribute to CD8+ T cell impaired expansion & survival after ACT (Restifo, 2005)
Note reduced CD27 on DC & DC+Bc-primed T cells. CD27 is higher on Mφ, DC




















































































KOP4 D10 Primed T cell Phenotype CD69 
Restifo (2005) reported MFI for CD27, CD62L, CD69, CD44, not % +ve
Make graph of MFI as well
Make graph comparing naive MFI with D10 (& D20) MFI to show change from
naiv  t  "early effector" to "effector" phenotype 
Early effectors do better in ACT than fully differentated effectors
Loss of CD27 in fully differentiated effector T cells may be responsible for/
contribute to CD8+ T cell impaired expansion & survival after ACT (Restifo, 2005)
Note reduced CD27 on DC & DC+Bc-primed T cells. CD27 is higher on Mφ, DC
























































































KOP4 D10 Primed T cell Phenotype CD44 
Restifo (2005) reported MFI for CD27, CD62L, CD69, CD44, not % +ve





















































































KOP4 D10 Primed T cell Phenotype CD122 
Restifo (2005) reported MFI for CD27, CD62L, CD69, CD44, not % +ve
Make graph of MFI as well
Make graph comparing naive MFI with D10 (& D20) MFI to show change from
naive to "early effector" to "effector" phenotype 
Early effectors do better in ACT than fully differentated effectors
Loss of CD27 in fully differentiated effector T cells may be responsible for/
contribute to CD8+ T cell impaired expansion & survival after ACT (Restifo, 2005)
Note reduced CD27 on DC & DC+Bc-primed T cells. CD27 is higher on Mφ, DC



















































































KOP4 D10 Primed T cell Phenotype PD-1 
Restifo (2005) reported MFI for CD27, CD62L, CD69, CD44, not % +ve
Make graph of MFI as well
Make graph comparing naive MFI with D10 (& D20) MFI to show change from
naive to "early effector" to "effector" phenotype 
Early effectors do better in ACT than fully differentated effectors
Loss of CD27 in fully differentiated effector T cells may be responsible for/
contribut  t  CD8+ T cell impaired expansion & survival after ACT (Restifo, 2005)
Note reduced CD27 on DC & DC+Bc-primed T cells. CD27 is higher on Mφ, DC





















































































KOP4 D10 Primed T cell Phenotype CD127 
Restifo (2005) reported MFI for CD27, CD62L, CD69, CD44, not % +ve
Make graph of MFI as well
Make graph comparing naive MFI with D10 (& D20) MFI to show change from
naive to "early effector" to "effector" phenotype 
Early effectors do better in ACT than fully differentated effectors
Loss of CD27 in fully differentiated effector T cells may be res onsible for/
contribute to CD8+ T cell impaired expansion & survival after ACT (Restifo, 2005)
Note reduced CD27 on DC & DC+Bc-primed T cells. CD27 is higher on Mφ, DC
+Mφ & Triple-primed cells
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7.30 Optimal IL-12 Levels Are Observed at 24-48 hours  
Lysate-loaded APCs and CD4+ or CD8+ T cells were co-cultured for 72 hours and 
conditioned cell media removed for anti-IL-12 ELISA assays at 24, 48 and 72 hours. 
Supplementary Figure 30 shows summary data of one set of data from one representative 
experiment taken at 24, 48 and 72 hour time points, demonstrating the elevated IL-12 levels at 





7.31 In Vitro Cytotoxicity 
DCs loaded with freeze-thaw lysate of medullary thyroid carcinoma have demonstrated 
tumour cell cytotoxicity after in vitro restimulation37. Having demonstrated that combinations 
of GMDC+B cell can stimulate improved CD8+ T cell proliferation and IFN-γ production we 
evaluated whether or not combined APCs were superior to GMDCs in their capacity to 




























































































































































































































IL-12 Production By DC, Mφ, B cell or Combinations Thereof
 in CD4+ T-Cell Co-Culture Supernatants at 24, 48 and &2 hrs (CFSE+)
Results of 1 experiment; stats= Student's unpaired t-test; *p<0.05; **p<0.01; ***p<0.001;
error bars = mean with s.e.m;
IL-12 production is gre t st between 24-48 hrs and drops off thereafter;
No improvement in IL-12 production when a B cell isadded;
At 48 hrs HOClwFTL induces more IL-12 than sFTL
Supplementary Figure 30 Optimal IL-12 levels are observed at 24-48 hours of APC-T cell co-cultures Day 
6 GMDC, Day10 M1 MΦs and freshly isolated splenic B cells, or combinations thereof, were pulsed overnight 
with whole OVA protein (50 µg/mL) and sFTL or Ox-L (1:1 ratio tumor cell to APC). LPS (1 μg/mL) and CpG 
(0.3 μg/mL) were added at the same time as the lysates. The following morning, CFSE-labeled CD4+ or CD8+ 
T cells were added (10:1 ratio, T cell to APC). APCs and T cells were co-cultured for 72 hours and conditioned 
cell media removed at 24, 48 and 72 hours. Supernatants were stored at -20°C for assessment by anti-IL-12 
ELISA. Results were analysed in Excel and graphed in Prism. .Summary data of 1 experiment showing 






Effector T cells were generated by co-culture with soluble lysate-loaded APCs. These 
experiments were conducted prior to the work with oxidised lysate and were not repeated with 
oxidised lysate. Target B16.OVA cells were stained with VPD450 and allowed to form a 
monolayer prior to the addition of the effector T cells.  
 
In B16.OVA tumor samples with no added cytotoxic T lymphocytes (CTLs) the survival 
ranged from 96 – 97% across all samples, as expected (Supplementary Figures 31, 32). Each 
group of lysate-primed CD4+ and CD8+ effector T cells demonstrated ratio-dependent 
increases in cytotoxicity as the ratio of effector cells to tumor cells was increased from 0.1:1 
to 2:1.  
 
In the CD4+ T cell tests maximal killing (1% survival; range 0.5%-2%) was observed in the B 
cell-primed samples while 5% survival was observed in GMDC cell-primed samples (range 
1%-7%). No differences were observed between the MΦ, DC+MΦ, DC+B cell, Bc+MΦ or 
groups (4%, 5%, 5% and 4% respectively). The Triple Combination survival was the highest 
on 9%. The differences between B cell-primed T cell killing and the DC+MΦ and Triple 
combination groups were statistically significant (p=0.013 and 0.015 respectively). 
Differences were assessed by negative bionomial regression that accounted for Poisson over-
dispersion.  
 
B cell-primed cells also generated maximal cytotoxicity in CD8+ T cells (6% survival). This 
was significantly lower than GMDC alone (17% survival; p=0.018). Once again no difference 
was observed between MΦ-primed T cells (20% survival) or the double combination groups 
of DC+MΦ, DC+Bc and B cell+MΦ (21%, 20% and 19% respectively). And as with the 
CD4+ T cells survival in the Triple combination group was lower than in the double 
combinations on 12%. In the MΦ and combination-primed groups killing was significantly 
lower than that achieved by B cell-primed T cells (p=0.003 or less).  
 
In these assays lysis of B16.F10 cells was compared as a control against non-specific lysis. 
However the level of B16.F10 killing was virtually identical to that of B16.OVA cells 
suggesting that either the B16.F10 cells were incorrectly labeled, or the lysis observed was 
non-specific.   
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Supplementary Figure 31 B cells presenting lysate antigens demonstrate a trend toward inducing 
increased in vitro cytotoxicity in CD4+ T cells compared with GMDCs. Day 6 GMDCs, Day 10 M1 M
Φs and splenic B cells (or combinations thereof) were pulsed overnight with freeze-thaw lysate and co-cultured 
for 72 hours with OT-II T cells. B16.OVA cells were labelled with VPD450 proliferation dye, and allowed to 
form a monolayer before the effector T cells were added to the tumor cells for 6 hours. The cells were harvested, 
stained with propidium iodide and analysed by Flow Cytometry. Alternatively cells were stained with dead cell 
exclusion dye, fixed in 2% paraformaldehyde and stored overnight at 4°C prior to collection on a Gallios Flow 
Cytometer. Data was analysed on FlowJo Version 9 and graphed in Prism. Statistically significant differences 
were calculated using negative binomal regression. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 as compared 
































































Supplementary Figure 32 B cells presenting lysate antigens demonstrate a trend toward inducing 
increased in vitro cytotoxicity in CD8+ T cells. Day 6 GMDCs, Day 10 M1 MΦs and splenic B cells (or 
combinations thereof) were pulsed overnight with freeze-thaw lysate and co-cultured for 72 hours with OT-I T 
cells. B16.OVA cells were labelled with VPD450 proliferation dye, and allowed to form a monolayer before the 
effector T cells were added to the tumor cells for 6 hours. The cells were harvested, stained with propidium iodide 
and analysed by Flow Cytometry. Alternatively cells were stained with dead cell exclusion dye, fixed in 2% 
paraformaldehyde and stored overnight at 4°C prior to collection on a Gallios Flow Cytometer. Data was analysed 
on FlowJo Version 9 and graphed in Prism. Statistically significant differences were calculated using negative 
binomal regression. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 as compared to B cell+TL. Error bars = mean 































































7.31.1 Discussion of In Vitro Cytotoxicity 
We attempted to assess the in vitro cytotoxic capacity of unsorted splenocytes primed with 
DCs, MΦs B cells and combinations of these three APCs using the VITAL assay. These 
experiments were conducted in the first year of this thesis, graphed and and analysed at that 
time. Re-analysis of these experiments immediately prior to submission of this thesis revealed 
that these experiments had not been conducted according to the methods described by 
Hermans et al38. Hermans et al  plated peptide-loaded and control cells in the same well. We 
plated B16.OVA targets separately to B16F10 controls. Thus the analysis employed by 
Hermans had to be modified accordingly. The results graphed in this thesis are the 
percentages of surviving cells, as opposed to the adjusted specific lysis calculated in the 
Hermans method. Thus these data ideally needs to be repeated according to the Hermans 
method so that specific lysis can be calculated. Nonetheless distinct ratio-specific responses 
were observed and significant levels of cytotoxicity were achieved with the lysate-primed 
cells. Interestingly, in both the CD4+ and CD8+ T cell groups the greatest cytotoxicity was 
achieved by soluble lysate-loaded B cell-primed T cells. 
 
These assays were carried out using unactivated APCs, prior to our experiments with 
activation stimuli or oxidized lysate. They have not been conducted with activated or oxidised 
lysate-loaded APCs. While interesting, it is redundant in light of the in vivo cytotoxicity 
results to assess whether greater killing is achieved by activated, oxidised lysate-loaded 
GMDC+B cells. 
 
We initially followed the method developed by Hermans et al that employs propidium iodide 
(PI) to assess the level of tumor cell killing by cytotoxic T cells38. While conducting these 
assays we experimented with using a dead cell exclusion dye and fixing the cells prior to 
analysis on a Flow Cytometer. This proved to be a more useful method than analysing cell 
death with PI, which requires flow cytometric analysis within the hour and is not practical on 
large sample sizes. The new method makes the assay more flexible as fixed cells can be 
stored for analysis at a later time point. This improved method reduces artefacts that may be 
introduced by the delay in harvesting tumour targets in the final wells compared to the initial 
wells when analysing high numbers of samples. It also reduces artefacts introduced by the 
delay in collecting cells which have PI left sitting on them for longer periods than the first 
tubes. The cells can be stained almost simultaneously with dead cell exclusion dye, as 
opposed to the PI method where PI must be added only shortly prior to collection to avoid 
false positives.  
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In CD4+ and CD8+ T cells we observed the same degree of killing of the B16F10 negative 
control cells as was observed in the 2:1 CTL:tumour cell ratio groups. This is indicative of 
non-specific cell killing, which may be cytokine mediated.  
 
A limitation of the VITAL Assay includes the fact that, in contrast to the method described by 
Hermans in which only T cells were added to the tumour targets, we were not able to isolate T 
cells from T cell+APC co-culture wells. We merely harvested all non-adherent cells and 
added them to the tumour monolayers. For this reason, and the fact that the assays were 
conducted using unsorted splenocytes rather than isolated T cells, our T cell numbers will be 
less accurate. This may explain the wide error bars in these data, as well as the minimal 
differences in killing between groups. An improved method, in addition to using isolated T 
cells instead of unsorted splenocytes, may be to use magnetic beads that attach to DCs, B cells 
and MΦs but not T cells. If the plate were rested on a magnetic block during T cell harvest, 
this would reduce the number of non-T cells collected and added to the tumour targets. While 
these results show the same trend as that of Hermans T cell only method, namely increased 
cytotoxicity with increasing CTL:tumor ratio these data do not support antigen-specific 
killing by the lysate-loaded T cells. 
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7.32 Raw Data for Lysate-Primed CD4+ T Cells Used in In Vivo Cytotoxicity 









7.33 Summary Data of Effector T Cell Phenotypes Used In Vivo Cytotoxicity 
Assays 
No difference was observed in the TCM (CD62L+CD44+) subset between T cells primed with 
GMDC+Bc+soluble lysate and GMDC+Bc+oxidised lysate (26 and 29% respectively) 
(Supplementary Figure 34). Minor differences were observed in the percentage of cells 
displaying a TEM phenotype (GMDC+Bc+soluble lysate: 15%; GMDC+Bc+oxidised lysate: 
22%) suggestive of different responses to the two lysates. However no conclusions can be 
drawn from one experiment. Likewise the small differences in percentages of naïve or T stem 
cell memory phenotypes (GMDC+Bc+soluble lysate: 57%; GMDC+Bc+oxidised lysate: 
48%) remain as one off observations.  
 
Small increases were observed in the percentages of both CD8+ and CD4+ T cells positive for 
CCR7 when primed with GMDC+oxidised lysate. CD8+ T cells primed with GMDC+B 
cell+soluble lysate were 2.3% positive for CCR7, 3.3% positive when primed with GMDC+B 
cell+oxidised lysate and 6.3% positive when primed with GMDC+oxidised lysate. CD4+ T 
cells demonstrated the same pattern with an approximate doubling of CCR7 positivity in the 
GMDC+oxidised lysate group (GMDC+B cell+soluble lysate: 5.35%; GMDC+B 
cell+oxidised lysate: 5.85%; GMDC+oxidised lysate: 10.5%).  
 
CD27 and CD44 expression was lower on CD4+ T cells than CD8+ T cells and consistent 
with previous experiments all cells exhibited high expression of CD62L.  
 
CTLA4 percentages were less than 2% across all samples, however, once again the 
GMDC+oxidised lysate group showed an approximate doubling compared to the other two 
groups. PD-1 was consistently low (5% or less) and CD28, CD122 and CD127 were absent 
from these cells, as they had been in previous assays.  
 
Supplementary Figure 33 Gating strategy and raw data showing phenotypes of lLysate-primed CD4+ T 
cells used in In Vivo cytotoxicity assays. Day 6 C57BL/6 GMDC, +/- spleen-derived B cells, were pulsed 
overnight with whole OVA protein (50 µg/mL) and soluble lysate or oxidised lysate (1:1 ratio tumor cell to 
APC)+LPS (1 μg/mL) & CpG (0.3 μg/mL).. The following day CD4+ and CD8+ T cells were added to the 
APCs (10:1) and co-cultured for 3 or 4 days. Cells were harvested for injection into CD57BL/6 mice and 
surplus cells were analysed for phenotype by Flow Cytometry. Cells were labeled with FVS450 (BD 
Biosciences) dead cell exclusion dye and mABs against CD3, CD4, CD8, CCR7, CD154 (CTLA4), CD27, 
CD28, CD44, CD62L, CD122, CD127 and PD-1. Cells were fixed in 4% paraformaldehyde and stored at 4°C 
overnight prior to collection on a Gallios. Data shown is from 1 of 2 experiments. A) T cells primed with 
GMDC+B cell+soluble lysate B) T cells primed with GMDC+oxidised lysate C) T cells primed with GMDC+B 
cell +oxidised lysate. 
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In the only group that we can directly compare with 10-day lysate-primed cells (GMDC+ox-
L) CD44 and CD27 was lower CD62L higher on these 3-day-primed cells. These differences 


















































Phenotype of DC+Bc+s-L-primed effector CD8+ T cells for IVC2



















































Phen type of DC+Bc+ox-L-primed effector CD8+ T cells for IVC2



































































































































































































Phenotype of DC+Bc+ox-L-primed effector CD4+ T cells for IVC2
GMDC+ox-L 
Supplementary Figure 34 Summary phenotype data of CD4+ and CD8+ effector T cells used in in vivo 
cytotoxicity assays. Day 6 C57BL/6 GMDC, +/- spleen-derived B cells, were pulsed overnight with whole OVA 
protein (50 µg/mL) and soluble lysate or oxidised lysate (1:1 ratio tumor cell to APC)+LPS (1 μg/mL) & CpG 
(0.3 μg/mL). The following day CD4+ and CD8+ T cells were added to the APCs (10:1) and co-cultured for 3 or 
4 days. Cells were harvested for injection into CD57BL/6 mice and surplus cells were analysed for phenotype by 
Flow Cytometry. Cells were labeled with FVS450 (BD Biosciences) dead cell exclusion dye and mABs against 
CD3, CD4, CD8, CCR7, CD154 (CTLA4), CD27, CD28, CD44, CD62L, CD122, CD127 and PD-1. Cells were 
fixed in 4% paraformaldehyde and stored at 4°C overnight prior to collection on a Gallios. Data shown is from 1 
of 2 experiments. A) T cells primed with GMDC+B cell+soluble lysate B) T cells primed with GMDC+oxidised 


















































Supplementary Figure 35 No in vivo cytotoxicity is observed by CD4+ T cells. Day 6 C57BL/6 
GMDC, +/- spleen-derived B cells, were pulsed overnight with whole OVA protein (50 µg/mL) and 
s-L or ox-L (1:1 ratio tumor cell to APC) )+LPS (1 μg/mL) & CpG (0.3 μg/mL). The following 
day CD4+ and CD8+ T cells were added to the APCs (10:1) and co-cultured for 3 or 4 days. Lysate-
primed effector T cells were i.v. injected into CD57BL/6 mice. The following day C57BL/6 target 
splenocytes were incubated with SIINFEKL peptide (1 μg/mL), OVA323-339 peptide (5 μg/mL), or left 
unpulsed. Target cells were labeled 25 μM CFSE (CFSEHI), 2.5 μM CFSE (CFSELO) or 10 μM 
VPD450 and mixed together for injection into recipient mice (1/3 each SIIN-pulsed, OVA323-339-
pulsed and unpulsed). Legend: each symbol represents a single mouse; (n = 3-7 per group). **p 
<0.01, ***p<0.001 and **** P <0.0001 (Student’s unpaired t-test). Data are from 2 independent 
experiments. Error bars = s.e.m.  
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7.35 Ex Vivo Expansion of Tumour Draining Lymph Node Cells 
Once a cancer is established T cell control mechanisms have become impaired. The T cells 
may retain the capacity to recognise the tumour, as demonstrated by ex vivo expansion of 
tumour-specific T cells from patients, however tumor escape mechanisms may gain control 
over the immune response and in the tumour microenvironment the T cells are rendered 
ineffective. In the clinic the DC is the APC of choice for restimulating ex vivo derived TAA-
specific patient T cells. Activation of naïve T cells in vitro is achieved more easily than 
activation of T cells from tumour bearing hosts whose T cells often display markers of 
exhaustion and are susceptible to AICD. Moreover generation of peptide-specific CTLs from 
patients is complex, time-consuming and laborious39. The isolation of tumour-reactive T cells 
is not easily achieved in all melanoma patients, nor is their ex vivo expansion to 
therapeutically useful numbers always attainable. TIL therapy can be even more difficult in 
non-melamona patients40. This is one of the reasons for the uses of alternative tumour-reactive 
T cells such as TCR-modified and CAR T cells. We used a murine model to mimic a 
clinically relevant scenario in which we obtained cells from the draining LNs of a tumour-
bearing host and undertook a preliminary comparison of the ability of GMDC and GMDC+ B 
cell to restimulate these ex vivo-derived cells.  
 
Fold expansion in these experiments was minimal and due to the low numbers of cells 
obtained from each tumour-bearing moue each condition was only tested once. Therefore no 
conclusions can be drawn from these results until they are repeated – preferably with 
improved methods that results in significantly greater fold expansion. 
 
The use of α-PD-1 or α-CTLA4 reduced FE even further compared to cells restimulated 
without checkpoint inhibitors (Supplementary Figure 36). However once again no 
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Fold Expansion GMDC v GMDC+Bc
Supplementary Figure 36 Single observations of fold expansion in tumour-draining lymph node cells 
+/- mABs against PD-1 and CTLA4. Wild type C57BL/6 mice were injected with 50,000 B16.OVA cells 
and sacrificed when tumours reached 150 mm2. Tumour draining lymph nodes were excised, single cell 
suspensions prepared and the cells cryopreserved for future use. Cryopreserved cells were retrieved from 
liquid nitrogen, thawed and allowed to rest overnight prior to adding to lysate-loaded APCs at a ratio of 
10:1. Cells were cultured for 10 days with feeding taking place no less than every other day. Cells were 
harvested and counted for fold expansion by Trypan Blue exclusion. Sufficient cells were harvested to test 
one condition per 3-4 tumour-bearing mice therefore each column is the result from 1 of 7 independent 
experiments. 
 397 
7.36 Statistical Analysis of In Vivo Cytotoxicity Data 
Negative binomial regression, which accounts for an over-dispersed Poisson distribution, was 
used to compare the number of live SIIN and OVA-323-339-pulsed cells that remained after 24 
hours in vivo in mice that had received adoptively transferred lysate-primed effector T cells. 
The model included terms for the groups and adjusted for the number of cells collected. 
Although no adjustment was made for multiple comparisons it should be noted that all the p 
values were <0.000 therefore these results are highly unlikely to be due to chance. 
7.36.1 Negative Binomial Regression Analysis of SIINFEKL-Pulsed Target Cell Lysis 
sum cfsehisiincells 
 
     Variable |        Obs        Mean    Std. Dev.       Min        Max 
-------------+--------------------------------------------------------- 
cfsehisiin~s |         31    812.3871    766.1442         18       2215 
 
. nbreg cfsehisiincells b5.group, exp(unpulsed) irr 
 
Fitting Poisson model: 
 
Iteration 0:   log likelihood = -1173.2933   
Iteration 1:   log likelihood = -992.03972   
Iteration 2:   log likelihood = -987.97669   
Iteration 3:   log likelihood = -987.95935   
Iteration 4:   log likelihood = -987.95935   
 
Fitting constant-only model: 
 
Iteration 0:   log likelihood = -238.40137   
Iteration 1:   log likelihood = -237.20897   
Iteration 2:   log likelihood = -237.20876   
Iteration 3:   log likelihood = -237.20876   
 
Fitting full model: 
 
Iteration 0:   log likelihood = -225.17312  (not concave) 
Iteration 1:   log likelihood =  -208.9186   
Iteration 2:   log likelihood = -197.82067   
Iteration 3:   log likelihood = -193.45411   
Iteration 4:   log likelihood = -192.85388   
Iteration 5:   log likelihood = -192.85283   
Iteration 6:   log likelihood = -192.85283   
 
 
Negative binomial regression          Number of obs  =         31 
                                                 LR chi2(5)         =      88.71 
Dispersion     = mean                    Prob > chi2       =     0.0000 
Log likelihood = -192.85283        Pseudo R2          =     0.1870 
 
---------------------------------------------------------------------------------------------------------------- 
cfsehisiin~s |        IRR    Std. Err.      z     P>|z|     [95% Conf. Interval] 
-------------+------------------------------------------------------------------------------------------------- 
       group  | 
          1   |   54.15918    13.54218    15.96    0.000      33.17678    88.41173 
          2   |   40.67912    10.17332    14.82    0.000      24.91708    66.41192 
          3   |   17.33085    4.339188    11.39    0.000      10.60966     28.3099 
          4   |   5.515192    1.387944     6.79    0.000      3.367818    9.031763 
          6   |   .9243781    .2616743    -0.28    0.781      .5307503    1.609937 
              | 
       _cons  |   .0094875   .0020018   -22.08   0.000     .0062741    .0143465 
ln(unpulsed) |          1  (exposure) 
-------------+----------------------------------------------------------------------------------------------- 
    /lnalpha |  -2.230603   .2675437                     -2.754979   -1.706227 
-------------+----------------------------------------------------------------------------------------------- 
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       alpha |   .1074636   .0287512                      .0636104    .1815496 
------------------------------------------------------------------------------------------------------------- 
LR test of alpha=0: chibar2(01) = 1590.21              Prob >= chibar2 = 0.000 
 
. lincom 1.group-2.group, eform 
 ( 1)  [cfsehisiincells]1.group - [cfsehisiincells]2.group = 0(GMDC+sFTL vs GMDC+Bc+sFTL) 
------------------------------------------------------------------------------------------------------------- 
cfsehisiin~s |     exp(b)   Std. Err.         z    P>|z|     [95% Conf. Interval] 
-------------+----------------------------------------------------------------------------------------------- 
         (1) |   1.331375   .2527206     1.51   0.132     .9177535    1.931412 
 
. lincom 1.group-3.group, eform 
 ( 1)  [cfsehisiincells]1.group - [cfsehisiincells]3.group = 0 (GMDC+sFTL vs GMDC+HOClwFTL) 
------------------------------------------------------------------------------------------------------------- 
cfsehisiin~s |     exp(b)   Std. Err.         z      P>|z|     [95% Conf. Interval] 
-------------+----------------------------------------------------------------------------------------------- 
         (1) |   3.125016   .5943684     5.99   0.000     2.152566    4.536785 
 
. lincom 1.group-4.group, eform 
 ( 1)  [cfsehisiincells]1.group - [cfsehisiincells]4.group = 0 (GMDC+sFTL vs GMDC+Bc+HOClwFTL) 
------------------------------------------------------------------------------------------------------------- 
cfsehisiin~s |     exp(b)   Std. Err.       z        P>|z|     [95% Conf. Interval] 
-------------+----------------------------------------------------------------------------------------------- 
         (1) |   9.819999   1.884309    11.91   0.000     6.741845    14.30356 
 
. lincom 1.group-6.group, eform 
 ( 1)  [cfsehisiincells]1.group - [cfsehisiincells]6.group = 0 (GMDC+sFTL vs PBS) 
------------------------------------------------------------------------------------------------------------- 
cfsehisiin~s |     exp(b)   Std. Err.      z          P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         (1) |   58.58986    13.5674    17.58   0.000      37.2146    92.24259 
 
. lincom 2.group-3.group, eform 
 ( 1)  [cfsehisiincells]2.group - [cfsehisiincells]3.group = 0 (GMDC+Bc+sFTL vs GMDC+HOClwFTL) 
------------------------------------------------------------------------------------------------------------- 
cfsehisiin~s |     exp(b)   Std. Err.        z        P>|z|     [95% Conf. Interval] 
-------------+----------------------------------------------------------------------------------------------- 
         (1) |   2.347209   .4465646     4.48   0.000      1.61662    3.407971 
 
. lincom 2.group-4.group, eform 
 ( 1)  [cfsehisiincells]2.group - [cfsehisiincells]4.group = 0 (GMDC+Bc+sFTL vs GMDC+Bc+HOClwFTL) 
------------------------------------------------------------------------------------------------------------- 
cfsehisiin~s |     exp(b)   Std. Err.        z        P>|z|     [95% Conf. Interval] 
-------------+----------------------------------------------------------------------------------------------- 
         (1) |   7.375831   1.415723    10.41   0.000     5.063265    10.74463 
 
. lincom 2.group-6.group, eform 
 ( 1)  [cfsehisiincells]2.group - [cfsehisiincells]6.group = 0 (GMDC+Bc+sFTL vs PBS) 
------------------------------------------------------------------------------------------------------------- 
cfsehisiin~s |     exp(b)   Std. Err.        z        P>|z|     [95% Conf. Interval] 
-------------+----------------------------------------------------------------------------------------------- 
         (1) |   44.00702   10.19259    16.34   0.000     27.94942     69.2901 
 
. lincom 3.group-4.group, eform 
 ( 1)  [cfsehisiincells]3.group - [cfsehisiincells]4.group = 0 (GMDC+HOClwFTL vs GMDC+Bc+HOClwFTL) 
------------------------------------------------------------------------------------------------------------- 
cfsehisiin~s |     exp(b)   Std. Err.        z       P>|z|     [95% Conf. Interval] 
-------------+----------------------------------------------------------------------------------------------- 
         (1) |   3.142383   .6043249     5.95   0.000     2.155564    4.580968 
 
. lincom 3.group-6.group, eform 
 ( 1)  [cfsehisiincells]3.group - [cfsehisiincells]6.group = 0 (GMDC+HOClwFTL vs PBS) 
------------------------------------------------------------------------------------------------------------- 
cfsehisiin~s |     exp(b)   Std. Err.        z        P>|z|     [95% Conf. Interval] 
-------------+----------------------------------------------------------------------------------------------- 




 . lincom 3.group -5.group, eform   ( 1)  [cfsehisiincells]3.group - [cfsehisiincells]5b.group = 0 (GMDC+HOClwFTL vs GMDC+OVA) 
 ----------------------------------------------------------------------------------------------------  cfsehisiin~s  |     exp(b)       Std. Err.        z         P>|z|     [95% Conf. Interval]  -------------+------------------------------------------------------------------------------------- 
          (1)  |   17.43849   1.650077    30.21   0.000     14.48658    20.99191  
 
	
7.36.2 Negative Binomial Regression Analysis of OVA323-339-Pulsed Target Cell Lysis 
sum vpd450ovaiipcells    
    Variable |        Obs        Mean    Std. Dev.       Min        Max  -------------+---------------------------------------------------------  vpd450ovai~s |         31     6033.29    1280.342       3118       9005  
  . nbreg vpd450ovaiipcells b5.group, exp(unpulsed) irr    
Fitting Poisson model:  Iteration 0:   log likelihood = -252.27203    Iteration 1:   log likelihood = -252.26399   
 Iteration 2:   log likelihood = -252.26399      Fitting constant-only model: 
 Iteration 0:   log likelihood = -300.36388    Iteration 1:   log likelihood = -247.66715    Iteration 2:   log likelihood =  -246.1204   
 Iteration 3:   log likelihood =  -245.8812    Iteration 4:   log likelihood = -245.88095    Iteration 5:   log likelihood = -245.88095   
   Fitting full model:  
Iteration 0:   log likelihood = -231.55316    Iteration 1:   log likelihood = -208.07264    Iteration 2:   log likelihood = -206.26215    
 Iteration 3:   log likelihood = -205.79948    Iteration 4:   log likelihood = -205.79796     
Iteration 5:   log likelihood = -205.79796        Negative binomial regression                 Number of obs      =         31  
                                                 LR chi2(5)         =      80.17  Dispersion     = mean                           Prob > chi2        =     0.0000  Log likelihood = -205.79796                Pseudo R2          =     0.1630 
   ---------------------------------------------------------------------------------------------------    vpd450ovai~s |        IRR      Std. Err.           z         P>|z|     [95% Conf. Interval] 
 -------------+------------------------------------------------------------------------------------         group  |            1   |   1.253654   .0276089    10.26   0.000     1.200693    1.308951 
            2   |    1.20825   .0266041      8.59    0.000     1.157216    1.261535              3   |     1.1241    .0247726       5.31    0.000      1.07658    1.173717            4   |   1.061771   .0235287     2.70    0.007     1.016643    1.108903 
           6   |   .8852598   .0214371    -5.03    0.000     .8442253    .9282889                |         _cons  |    1.46274   .0263761    21.09   0.000     1.411947    1.515361 
 ln(unpulsed) |          1      (exposure)  -------------+------------------------------------------------------------------------------------  
    /lnalpha  |  -7.123038   .3088993                            -7.728469   -6.517606  -------------+------------------------------------------------------------------------------------         alpha  |   .0008063   .0002491                            .0004401    .0014772  
------------------------------------------------------------------------------  LR test of alpha=0: chibar2(01) = 92.93                Prob >= chibar2 = 0.000     
 
 . lincom 1.group-2.group, eform  
  ( 1)  [vpd450ovaiipcells]1.group - [vpd450ovaiipcells]2.group = 0 (GMDC+sFTL vs GMDC+Bc+sFTL)   ------------------------------------------------------------------------------  




 . lincom 1.group-3.group, eform   ( 1)  [vpd450ovaiipcells]1.group - [vpd450ovaiipcells]3.group = 0 (GMDC+sFTL vs GMDC+HOClwFTL) 
 ------------------------------------------------------------------------------  vpd450ovai~s |     exp(b)   Std. Err.      z    P>|z|     [95% Conf. Interval]  -------------+---------------------------------------------------------------- 
          (1) |   1.115252   .0199611     6.09   0.000     1.076807    1.155069 
  
 . lincom 1.group-4.group, eform   ( 1)  [vpd450ovaiipcells]1.group - [vpd450ovaiipcells]4.group = 0 (GMDC+sFTL vs GMDC+Bc+HOClwFTL) 
 ------------------------------------------------------------------------------  vpd450ovai~s |     exp(b)   Std. Err.      z    P>|z|     [95% Conf. Interval]  -------------+---------------------------------------------------------------- 
          (1) |    1.18072   .0213089     9.20   0.000     1.139685    1.223232 
  
 . lincom 1.group-6.group, eform   ( 1)  [vpd450ovaiipcells]1.group - [vpd450ovaiipcells]6.group = 0 (GMDC+sFTL vs PBS)  
------------------------------------------------------------------------------  vpd450ovai~s |     exp(b)   Std. Err.      z    P>|z|     [95% Conf. Interval]  -------------+----------------------------------------------------------------  
         (1) |   1.416142   .0290621    16.95   0.000     1.360312    1.474264 
   
 . lincom 2.group-3.group, eform     
( 1)  [vpd450ovaiipcells]2.group - [vpd450ovaiipcells]3.group = 0 (GMDC+Bc+sFTL vs GMDC+HOClwFTL)  ------------------------------------------------------------------------------  vpd450ovai~s |     exp(b)   Std. Err.      z    P>|z|     [95% Conf. Interval]  
-------------+----------------------------------------------------------------           (1) |    1.07486    .019233     4.03   0.000     1.037818    1.113225 
 
 
 . lincom 2.group-4.group, eform   ( 1)  [vpd450ovaiipcells]2.group - [vpd450ovaiipcells]4.group = 0 (GMDC+Bc+sFTL vs GMDC+Bc+HOClwFTL) 
 ------------------------------------------------------------------------------  vpd450ovai~s |     exp(b)   Std. Err.      z    P>|z|     [95% Conf. Interval]  
-------------+----------------------------------------------------------------           (1) |   1.137957   .0205327     7.16   0.000     1.098417    1.178921 
  
 . lincom 2.group-6.group, eform   ( 1)  [vpd450ovaiipcells]2.group - [vpd450ovaiipcells]6.group = 0 (GMDC+Bc+sFTL vs PBS) 
 ------------------------------------------------------------------------------  vpd450ovai~s |     exp(b)   Std. Err.      z    P>|z|     [95% Conf. Interval]  -------------+---------------------------------------------------------------- 
           (1) |   1.364854    .028002    15.16   0.000      1.31106    1.420855 
 
 
 . lincom 3.group-4.group, eform  
 ( 1)  [vpd450ovaiipcells]3.group - [vpd450ovaiipcells]4.group = 0 (GMDC+HOClwFTL vs GMDC+Bc+HOClwFTL)  ------------------------------------------------------------------------------  vpd450ovai~s |     exp(b)   Std. Err.      z    P>|z|     [95% Conf. Interval]  
-------------+----------------------------------------------------------------           (1) |   1.058702   .0191273     3.16   0.002      1.02187    1.096863 
  
 
 . lincom 3.group-6.group, eform   
 ( 1)  [vpd450ovaiipcells]3.group - [vpd450ovaiipcells]6.group = 0 (GMDC+HOClwFTL vs PBS)  ------------------------------------------------------------------------------  vpd450ovai~s |     exp(b)   Std. Err.      z    P>|z|     [95% Conf. Interval]  
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